<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006391" GROUP_ID="SCHIZ" ID="588605021509502862" MERGED_FROM="" MODIFIED="2012-10-02 11:41:57 +0100" MODIFIED_BY="Claire Irving" REVIEW_NO="80" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.4">
<COVER_SHEET MODIFIED="2012-10-02 11:41:57 +0100" MODIFIED_BY="Claire Irving">
<TITLE>Benzodiazepines for schizophrenia</TITLE>
<CONTACT MODIFIED="2012-10-02 11:41:57 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="13468438652653628973110207120503" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Markus</FIRST_NAME><LAST_NAME>Dold</LAST_NAME><POSITION>Psychiatry resident</POSITION><EMAIL_1>markus.dold@lrz.tu-muenchen.de</EMAIL_1><EMAIL_2>markus.dold@lrz.tum.de</EMAIL_2><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Ismaninger Straße 22</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140-6466</PHONE_1><FAX_1>+49-89-4140-6431</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-10-02 11:41:57 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="13468438652653628973110207120503" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Markus</FIRST_NAME><LAST_NAME>Dold</LAST_NAME><POSITION>Psychiatry resident</POSITION><EMAIL_1>markus.dold@lrz.tu-muenchen.de</EMAIL_1><EMAIL_2>markus.dold@lrz.tum.de</EMAIL_2><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Ismaninger Straße 22</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140-6466</PHONE_1><FAX_1>+49-89-4140-6431</FAX_1></ADDRESS></PERSON><PERSON ID="7E028C0382E26AA200C1C7C465D3B6B4" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Chunbo</FIRST_NAME><LAST_NAME>Li</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>chunbo_li@yahoo.com</EMAIL_1><EMAIL_2>chunbo_li@163.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Biological Psychiatry</DEPARTMENT><ORGANISATION>Shanghai Mental Health Centre, Shanghai Jiao Tong University School of Medicine</ORGANISATION><ADDRESS_1>600 Wan Ping Nan Road</ADDRESS_1><CITY>Shanghai</CITY><ZIP>200030</ZIP><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 21 64387250 ext 3243</PHONE_1><FAX_1>+86 21 64387986</FAX_1></ADDRESS></PERSON><PERSON ID="628CAF3782E26AA20077BCD5710C6076" ROLE="AUTHOR"><FIRST_NAME>Magdolna</FIRST_NAME><LAST_NAME>Tardy</LAST_NAME><EMAIL_1>Magdolna.Tardy@lrz.tu-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY></ADDRESS></PERSON><PERSON ID="F1C23B5C82E26AA20178986B46DBBF8C" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Vesal</FIRST_NAME><LAST_NAME>Khorsand</LAST_NAME><POSITION>Oberärztin</POSITION><EMAIL_1>vesal_k@yahoo.de</EMAIL_1><ADDRESS><DEPARTMENT>Gynäkologisch-geburtshilfliche Abteilung</DEPARTMENT><ORGANISATION>Kreisklinik München Pasing</ORGANISATION><ADDRESS_1>Steinerweg 1</ADDRESS_1><CITY>München</CITY><ZIP>81241</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 (0) 89 8 40 14 40</PHONE_1><FAX_1>+49 (0) 89 84 05 94 91</FAX_1></ADDRESS></PERSON><PERSON ID="19546" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Donna</FIRST_NAME><LAST_NAME>Gillies</LAST_NAME><POSITION>Senior Researcher</POSITION><EMAIL_1>Donna_Gillies@wsahs.nsw.gov.au</EMAIL_1><ADDRESS><ORGANISATION>Western Sydney and Nepean Blue Mountains Local Health Districts - Mental Health</ORGANISATION><ADDRESS_1>Cumberland Hospital</ADDRESS_1><ADDRESS_2>Locked Bag 7118</ADDRESS_2><CITY>Parramatta</CITY><ZIP>2150</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 9840 3510</PHONE_1><FAX_1>+61 2 9840 3707</FAX_1></ADDRESS></PERSON><PERSON ID="D3501EE082E26AA20080535F42019853" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Stefan</FIRST_NAME><LAST_NAME>Leucht</LAST_NAME><POSITION>Oberarzt</POSITION><EMAIL_1>Stefan.Leucht@lrz.tu-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140 ext: 4249</PHONE_1><FAX_1>+49-89-4140-4888</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-06-28 10:04:49 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="6" MONTH="7" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="21" MONTH="2" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="13" MONTH="10" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2012-09-03 15:44:17 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-09-03 15:44:17 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="6" YEAR="2012"/>
<DESCRIPTION>
<P>Three further studies are included (<LINK REF="STD-Ma-2006" TYPE="STUDY">Ma 2006</LINK>, <LINK REF="STD-Wang-2000" TYPE="STUDY">Wang 2000</LINK>, <LINK REF="STD-Xuan-2007" TYPE="STUDY">Xuan 2007</LINK>) and 24 studies have been added to the "excluded studies table". The text has been rewritten and every included trial assessed with the 'Risk of bias' tool. The main findings did not change substantially.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-06-27 12:59:57 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="6" YEAR="2012"/>
<DESCRIPTION>
<P>Substantive update: conclusions not changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-10-08 13:58:35 +0100" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Freistaat Bayern</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>German Ministry of Health, German Research Network on Schizophrenia, funded by the German Federal Ministry of Education and Research (grant 01GI933x)</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-10-02 11:03:47 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-09-27 11:38:44 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-04-24 19:15:46 +0100" MODIFIED_BY="[Empty name]">Benzodiazepines for schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2012-09-27 11:38:44 +0100" MODIFIED_BY="[Empty name]">
<P>Antipsychotic drugs are the primary method of treatment for people suffering from mental illness. However, many people with mental health problems do not respond well to antipsychotics which often are very good at treating positive symptoms (e.g. hearing voices or seeing things), but not so good for negative symptoms (e.g. loss of emotions, inactivity). In addition, antipsychotics can sometimes cause debilitating side effects such as movement disorders, weight gain, sleepiness and dizziness. If someone does not respond well to traditional antipsychotic drugs, psychiatrists are faced with the choice of switching to a different type of drug that may work better on its own; or adding a new drug or drugs to supplement the original antipsychotic drug treatment.</P>
<P>Benzodiazepines can be taken alone or in combination with more traditional antipsychotic drugs. They cause sedation, calmness and relax the muscles, so are helpful in calming down agitated people with anxiety, sleep problems, seizures, alcohol withdrawal and acute mental health problems.</P>
<P>This review found 34 studies with 2657 people. It compared benzodiazepines when used alone as the only medication or when used in combination with another drug for people with schizophrenia. Information from the 34 studies was generally poor, incomplete and badly reported. The 34 studies were of short duration and were small in size. The review suggests that there is little evidence to support the use of benzodiazepines either alone or in combination. However, benzodiazepines do have sedative properties that can calm people down and help them become less agitated for short periods of time. More research, particularly involving benzodiazepines as add-on treatment used in combination with traditional antipsychotic drugs, is required. </P>
<P>This plain language summary has been written by Benjamin Gray, Service User and Service User Expert, Rethink Mental Illness, Email: ben.gray@rethink.org.                          </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-09-03 15:48:53 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2012-04-30 08:27:23 +0100" MODIFIED_BY="[Empty name]">
<P>Because of the high number of people with schizophrenia not responding adequately to monotherapy with antipsychotic agents, the evidence regarding the efficacy and safety of additional medication was examined in a number of clinical trials. One approach to this research question was the use of benzodiazepines, as monotherapy as well as in combination with antipsychotics.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-04-30 08:27:14 +0100" MODIFIED_BY="[Empty name]">
<P>To determine the efficacy, acceptability, and tolerability of benzodiazepines in people with schizophrenia and schizophrenia-like psychoses.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-06-27 13:01:16 +0100" MODIFIED_BY="[Empty name]">
<P>In February 2011, we updated the literature search of the previous version of this systematic review (last search March 2005). We searched the trial register of the Cochrane Schizophrenia Group (containing methodical searches of BIOSIS, CINAHL, Dissertation abstracts, EMBASE, LILACS, MEDLINE, PSYNDEX, PsycINFO, RUSSMED, Sociofile, supplemented with hand searching of relevant journals and numerous conference proceedings). Additionally, we inspected references of all identified studies for further relevant studies and contacted authors of relevant publications in order to obtain missing data from existing trials. We applied no language restrictions.<BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-06-27 13:01:58 +0100" MODIFIED_BY="[Empty name]">
<P>We included all randomised controlled trials comparing benzodiazepines (as monotherapy or as adjunctive agent) with antipsychotic drugs or placebo for the pharmacological management of schizophrenia and/or schizophrenia-like psychoses.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-09-03 15:44:17 +0100" MODIFIED_BY="[Empty name]">
<P>Review authors (MD and CL) analysed independently the new references of the update-search referring to the inclusion criteria. MD and CL extracted all data from the included trials. <BR/>
<BR/>For dichotomous outcomes we calculated risk ratios (RR) and their 95% confidence intervals (CI). We analysed continuous data by using mean differences (MD) and their 95% CI. We assessed each pre-selected outcome from the included trials with the risk of bias tool.<BR/>
</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-09-03 15:48:53 +0100" MODIFIED_BY="[Empty name]">
<P>The 2011 update search yielded three further randomised controlled trials. The review currently includes 34 studies with 2657 participants. Most studies were characterised by a small sample size, short duration, and incomplete outcome data reporting.</P>
<P>Benzodiazepine monotherapy is compared with placebo in eight trials. The proportion of participants with no clinically important response did not significantly differ between those given benzodiazepines or placebo (N = 382, 6 RCTs, RR 0.67 CI 0.44 to 1.02). The results from the various rating scales applied to assess global and mental state were inconsistent.</P>
<P>Fourteen studies examined benzodiazepine monotherapy in comparison with antipsychotic monotherapy. Clinically important treatment response assessment revealed no statistically significant difference between the study groups (30 minutes: N = 44, 1 RCT, RR 0.91 CI 0.58 to 1.43; 60 minutes: N = 44,1 RCT, RR 0.61 CI 0.20 to 1.86; 12 hours: N = 66, 1 RCT, RR 0.75 CI 0.44 to 1.30; pooled short-term studies: N = 112, 2 RCTs, RR 1.48 CI 0.64 to 3.46). Desired sedation occurred significantly more often among participants in the benzodiazepine group than in the antipsychotic group at 20 and 40 minutes. No significant between-group differences could be identified for global and mental state or occurrence of adverse effects.</P>
<P>Twenty trials compared benzodiazepine augmentation of antipsychotics with antipsychotic monotherapy. Referring to clinically important response, statistically significant improvement could be demonstrated only for the first 30 minutes of augmentation treatment (30 minutes: 1 RCT, N = 45, RR 0.38 CI 0.18 to 0.80; 60 minutes: N = 45,1 RCT, RR 0.07 CI 0.00 to 1.13; 12 hour: N = 67,1 RCT, RR 0.85 CI 0.51 to 1.41; pooled short-term studies: N = 511, 6 RCTs, RR 0.87 CI 0.49 to 1.54). Analyses of the global and mental state yielded no between-group differences except for desired sedation at 30 as well as 60 minutes (30 minutes: N = 45, 1 RCT, RR 2.25 CI 1.18 to 4.30; 60 minutes: N = 45, 1 RCT, RR 1.39 CI 1.06 to 1.83).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-09-03 15:44:17 +0100" MODIFIED_BY="[Empty name]">
<P>There is currently no convincing evidence to confirm or refute the practise of administering benzodiazepines as monotherapy or in combination with antipsychotics for the pharmacological treatment of schizophrenia and schizophrenia-like psychosis. Low-quality evidence suggests that benzodiazepines are effective for very short-term sedation and could be considered for calming acutely agitated people with schizophrenia. Measured by the overall attrition rate, the acceptability of benzodiazepine treatment appears to be adequate. Adverse effects were generally poorly reported. High-quality future research projects with large sample sizes are required to clarify the evidence of benzodiazepine treatment in schizophrenia, especially regarding long-term augmentation strategies.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-10-02 11:02:51 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-09-03 15:44:17 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2012-09-03 15:44:17 +0100" MODIFIED_BY="[Empty name]">
<P>Schizophrenia is a chronic and disabling psychiatric disorder. It afflicts approximately one per cent of the population worldwide with little gender differences. Schizophrenia ranks among the seven most frequent causes listed by the WHO for loss of years of life due to disability (<LINK REF="REF-WHO-2001" TYPE="REFERENCE">WHO 2001</LINK>). Its typical manifestations are "positive" symptoms such as fixed, false beliefs (delusions) and perceptions without cause (hallucinations), "negative" symptoms such as apathy and lack of drive, disorganisation of behaviour and thought, and catatonic symptoms such as mannerisms and bizarre posturing (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>). The degree of suffering and disability is considerable with 80% to 90% of those affected not working (<LINK REF="REF-Marvaha-2004" TYPE="REFERENCE">Marvaha 2004</LINK>) and up to 10% dying by suicide (<LINK REF="REF-Tsuang-1978" TYPE="REFERENCE">Tsuang 1978</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2012-09-03 15:44:17 +0100" MODIFIED_BY="[Empty name]">
<P>Benzodiazepines are mainly characterised by their sedative and muscle-relaxing properties. Therefore, these compounds are traditionally used for the pharmacotherapy of anxiety disorders, sleep disorders, seizures, and alcohol withdrawal. In schizophrenia, the administration of benzodiazepines can be considered to sedate and calm agitated people with acute schizophrenic episodes (<LINK REF="REF-Leucht-2011" TYPE="REFERENCE">Leucht 2011</LINK>). The adverse effects that are experienced most frequently are drowsiness, dizziness, problems with concentration, and "paradoxical effects" including irritability, impulsivity as well as seizures. Rare, but very severe adverse effects of benzodiazepines are respiratory depression/arrest in short-term treatment and, more commonly, the risk of dependence in case of long-term medication.</P>
<P>Benzodiazepines are often classified according to their elimination half-live (e.g. short-acting with less than six hours and long-acting with more than 24 hours).</P>
</INTERVENTION>
<THEORY MODIFIED="2012-03-25 11:57:38 +0100" MODIFIED_BY="[Empty name]">
<P>The mechanism of action of benzodiazepines is characterised by enhanced activity of the inhibiting neurotransmitter GABA (gamma-aminobutyric acid). The GABA-A receptor in the synapsis of neurons has specific receptors for benzodiazepines. Interaction of benzodiazepines with these receptors results in a hyperpolarisation through increased opening of chloride ion channels (increase of the membrane potential). These molecular alterations result in an enhancement of GABA-A receptor activity followed by decline of the excitability of neurons. All in all, these mechanisms cause the calming effects of the benzodiazepines due to reduced synaptic communication between neurons (<LINK REF="REF-Benkert-2011" TYPE="REFERENCE">Benkert 2011</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2012-09-03 15:44:17 +0100" MODIFIED_BY="[Empty name]">
<P>Antipsychotic drugs can be regarded as core treatment for both, acute and long-term treatment of schizophrenia (<LINK REF="REF-Falkai-2005" TYPE="REFERENCE">Falkai 2005</LINK>; <LINK REF="REF-Falkai-2006" TYPE="REFERENCE">Falkai 2006</LINK>). The effectiveness of antipsychotics in schizophrenia could be demonstrated in a wide range of randomised controlled trials (<LINK REF="REF-Leucht-2009" TYPE="REFERENCE">Leucht 2009</LINK>). But many people with schizophrenia do not achieve full remission of symptoms despite adequate antipsychotic drug treatment. At the present time, clozapine is considered as gold standard in the case of treatment-resistance (<LINK REF="REF-Essali-2009" TYPE="REFERENCE">Essali 2009</LINK>), but due to its risk profile (especially in terms of agranulocytosis), most guidelines recommend clozapine administration only after non-response to at least two adequate trials with different other antipsychotic compounds (<LINK REF="REF-Leucht-2011" TYPE="REFERENCE">Leucht 2011</LINK>). However, many individuals with psychoses fail to respond satisfactorily to conventional treatment with first- and second-generation antipsychotics, and clinicians are often faced with the choice of switching to alternate types of medication, or augmenting existing antipsychotics with other drugs or treatment options.</P>
<P>Therefore, the evaluation of additive therapeutic strategies in the presence of remaining relevant schizophrenic symptoms has high clinical relevance. Over the last forty years a variety of adjunctive treatment options have been evaluated concerning effectiveness in the treatment of schizophrenia (<LINK REF="REF-Christison-1991" TYPE="REFERENCE">Christison 1991</LINK>). In this context, the administration of various compounds such as carbamazepine (<LINK REF="REF-Leucht-2007a" TYPE="REFERENCE">Leucht 2007a</LINK>), lithium (<LINK REF="REF-Leucht-2007b" TYPE="REFERENCE">Leucht 2007b</LINK>), benzodiazepines, beta-blockers (<LINK REF="REF-Cheine-2001" TYPE="REFERENCE">Cheine 2001</LINK>) and valproate (<LINK REF="REF-Schwarz-2008" TYPE="REFERENCE">Schwarz 2008</LINK>) were examined in people with psychosis refractory to antipsychotic monotherapy. Additionally to the pharmacological approaches, other somatic therapy strategies such as electroconvulsive therapy have also been evaluated for people with schizophrenia (<LINK REF="REF-Tharyan-2005" TYPE="REFERENCE">Tharyan 2005</LINK>).</P>
<P>In this systematic review we examine the role of benzodiazepines in the treatment of schizophrenia. Companion reviews of our work-group have examined the anticonvulsant carbamazepine (<LINK REF="REF-Leucht-2007a" TYPE="REFERENCE">Leucht 2007a</LINK>), lithium (<LINK REF="REF-Leucht-2007b" TYPE="REFERENCE">Leucht 2007b</LINK>) and valproate (<LINK REF="REF-Schwarz-2008" TYPE="REFERENCE">Schwarz 2008</LINK>) as sole or adjunctive treatment for schizophrenia. In contrast to this systematic review, another Cochrane review examined the effectiveness of benzodiazepines in acute psychoses irrespective of the underlying diagnosis (<LINK REF="REF-Gillies-2005" TYPE="REFERENCE">Gillies 2005</LINK>), while we only included studies on schizophrenia and related disorders.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-09-03 15:44:17 +0100" MODIFIED_BY="[Empty name]">
<P>To review the effectiveness of benzodiazepines for the treatment of schizophrenia and schizophrenia-like psychoses, including examining whether:</P>
<UL>
<LI>benzodiazepines monotherapy is an effective treatment option for schizophrenia and schizophrenia-like psychoses; and</LI>
<LI>benzodiazepine augmentation of antipsychotic medication is an effective treatment for the same illnesses.</LI>
</UL>
</OBJECTIVES>
<METHODS MODIFIED="2012-09-26 10:08:00 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-09-03 15:44:17 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2012-09-03 15:44:17 +0100" MODIFIED_BY="[Empty name]">
<P>We only included studies that randomly assigned participants with schizophrenia or related disorders. We excluded quasi-randomised studies such as those using allocation by day of the week, date of birth, alternate allocation. This decision is based on the evidence of a strong relationship between allocation concealment and direction of effect (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>).</P>
<P>If a trial was described as "double-blind", but randomisation was not explicitly mentioned, we implied that the study was randomised and assessed the inclusion of the trial in a sensitivity analysis. If there was no substantive difference within primary outcomes (see <LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>) when these "implied randomisation" studies were added, then we included these in the final analysis. If there was a substantive difference, we only analysed clearly randomised trials and described the results of the sensitivity analysis in the text.</P>
<P>Where people were given additional medications within the treatment group receiving benzodiazepines, we only included data if the adjunct treatment was evenly distributed between groups and it was only the medication with benzodiazepines that was randomised.</P>
<P>Randomised cross-over studies were eligible, but only data up to the point of first cross-over were used to avoid biases due to carry-over effects of the treatments (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-09-03 15:44:17 +0100" MODIFIED_BY="[Empty name]">
<P>We included people with the main diagnosis of schizophrenia and other types of schizophrenia-like psychoses (e.g. schizophreniform, schizoaffective, or delusional disorders), irrespective of the diagnostic system applied. There is no clear evidence that the schizophrenia-like psychoses are caused by fundamentally different disease processes or require different treatment approaches (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>). In accordance with the general strategy of the Cochrane Schizophrenia Group (<LINK REF="REF-Adams-2011" TYPE="REFERENCE">Adams 2011</LINK>), we also included studies that had used other diagnostic criteria than those of the International Statistical Classification of Diseases and Related Health Problems (ICD) and the Diagnostic and Statistical Manual of Mental Disorders (DSM). These diagnostic criteria are not meticulously used in clinical routine either, so broader inclusion criteria will enhance generalisability and representativeness. Trials randomising people with schizophrenia were included without restrictions concerning age, gender, and comorbidities.</P>
<P>To be included, at least 50% of the participants within a trial had to have a schizophrenic syndrome, or the results exclusively regarding the participants with schizophrenia were provided by the authors.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-09-03 15:44:17 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Benzodiazepine alone.</LI>
<LI>Placebo (or no intervention).</LI>
<LI>Benzodiazepine in combination with any antipsychotic treatment: any dose.</LI>
<LI>Antipsychotic treatment (any dose).</LI>
<LI>Antipsychotic treatment (any dose) in combination with placebo (or no intervention).</LI>
</OL>
<P>Benzodiazepines could be applied in any dose and any route of administration (e.g. oral tablets, oral liquids, intramuscular injections, or intravenous injections).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-06-27 13:38:17 +0100" MODIFIED_BY="[Empty name]">
<P>We grouped all outcomes by time - ultra short term (up to 24 hours), short term (up to 12 weeks), medium term (13 to 26 weeks) and long term (over 26 weeks).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-06-27 13:38:17 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. No clinically important response to treatment.</HEADING>
<P>We defined this as less than 50% reduction from the baseline value of a rating scale such as the "Positive and Negative Syndrome Scale" (PANSS; <LINK REF="REF-Kay-1987" TYPE="REFERENCE">Kay 1987</LINK>) or the "Brief Psychiatric Rating Scale" (BPRS; <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) because validation studies have shown that this definition is clinically meaningful (<LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>; <LINK REF="REF-Leucht-2005b" TYPE="REFERENCE">Leucht 2005b</LINK>; <LINK REF="REF-Leucht-2006" TYPE="REFERENCE">Leucht 2006</LINK>). If these data were not available, we used the definition provided in the included studies.</P>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-06-19 13:42:26 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Leaving the study early</HEADING>
<P>1.1 Leaving the study early due to any reason (as a measure of overall acceptability)<BR/>1.2 Leaving the study early due to adverse effects (as a measure of overall tolerability)<BR/>1.3 Leaving the study early due to inefficacy of treatment (as a measure of overall efficacy)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Global state</HEADING>
<P>2.1 Average score/change of the global state<BR/>2.2 Relapse - as defined by each of the studies</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Mental state</HEADING>
<P>3.1 No clinically significant improvement of the general mental state - as defined by each of the studies<BR/>3.2 Average score/change of the general mental state<BR/>3.3 No clinically significant response in terms of anxiety - as defined by each of the studies<BR/>3.4 Average score/change of anxiety<BR/>3.5 No clinically significant response in terms of positive symptoms - as defined by each of the studies<BR/>3.6 Average score/change of positive symptoms<BR/>3.7 No clinically significant response in terms of negative symptoms - as defined by each of the studies<BR/>3.8 Average score/change of negative symptoms<BR/>3.9 No clinically significant response in terms of depressive symptoms - as defined by each of the studies<BR/>3.10 Average score/change of depressive symptoms<BR/>3.11 No clinically significant response in terms of manic symptoms - as defined by each of the studies<BR/>3.12 Average score/change of manic symptoms<BR/>3.13 Number of participants with clinically desired sedation<BR/>3.14 Average score/change of vigilance</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Behaviour</HEADING>
<P>4.1 General behaviour<BR/>4.2 Specific behaviours<BR/>4.2.1 Social functioning<BR/>4.2.2 Aggression against self, others, or property</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Service utilisation</HEADING>
<P>5.1 Days in hospital<BR/>5.2 Change in hospital status</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6. Adverse effects</HEADING>
<P>6.1 General adverse effects - total number of patients with adverse effects<BR/>6.2 Specific adverse effects</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7. Economic outcomes</HEADING>
<P>7.1. Average change in total cost of medical and mental health care<BR/>7.2. Total indirect and direct costs</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-06-27 13:14:11 +0100" MODIFIED_BY="[Empty name]">
<P>No language restriction was applied to avoid the problem of "language bias" (<LINK REF="REF-Egger-1997b" TYPE="REFERENCE">Egger 1997b</LINK>).</P>
<ELECTRONIC_SEARCHES MODIFIED="2012-06-27 13:14:11 +0100" MODIFIED_BY="[Empty name]">
<P>The search methods for this 2011 update are documented below, for previous searches see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>
<B>Cochrane Schizophrenia Group Trials Register (February 2011)</B>
</P>
<P>We searched the register using the phrases:</P>
<P>[*abecarnil* OR *adinazolam* OR *AHN 086* OR *alpidem* OR *alprazolam* OR *anthramycin* OR *arfendazam* OR *azepam* OR *bentazepam* OR *benzodiazepine* OR *bretazenil* OR *bromazepam* OR *brotizolam* OR *CGS 20625* OR *CGS 8216* OR *CGS 9895* OR *CGS 9896* OR *chlordiazepoxide* OR *ciclotizolam* OR *ciprazafone* OR *clobazam* OR *clonazepa* OR *clotiazepam* OR *CP 32961* OR *DBCE* OR *devazepide* OR *dextofisopam* OR *diazepam* OR *dikaliumclorazepat* OR *divaplon* OR *dulozafone* OR *ELB 139* OR *emapunil* OR *endixaprine* OR *eszopiclone* OR *etizolam* OR *FG 7142* OR *flumazenil* OR *flunitrazepam* OR *flurazepam* OR *flutazoram* OR *GABA* OR *gedocarnil* OR *girisopam* OR *imidazenil* OR *JL 13* OR *KC 5944* OR *L 365260* OR *lorazepam* OR *lormetazepam* OR *lorzafone* OR *magnesium* OR *MCC* OR *medazepam* OR *metaclazepam* OR *midazolam* OR *nerisopam* OR *nitrazepam* OR *nordazepam* OR *oxazepam* OR *pazinaclone* OR *PBCC* OR *perlapine* OR *pinasepam* OR *pipequaline* OR *Pirenzepine* OR *PK 11195* OR *prazepam* OR *premazepam* OR *quazepam* OR *radequinil* OR *reclazepam* OR *ricasetron* OR *rilmazafone* OR *Ro 15-4513* OR *Ro 19-5686* OR *Ro 5-4864* OR *sarmazenil* OR *SL 75102* OR *SR 95195* OR *suriclone* OR *temazepam* OR *tiagabine* OR *timelotem* OR *tofisopam* OR *tracazolate* OR *trepipam* OR *triazolam* OR *triflubazam* OR *Y 23684* OR *zaleplon* OR *zalospirone* OR *ZAPA* OR *ZK 90798* OR *ZK 91296* OR *ZK 93423* OR *zolam* OR *zolpidem* OR *zopiclone* in interventions of STUDY]</P>
<P>This register is compiled by systematic searches of major databases, hand searches and conference proceedings (http://szg.cochrane.org/cochrane-schizophrenia-group-specialised-register).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-10-12 08:04:42 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Reference searching</HEADING>
<P>We inspected the references of all identified studies for further relevant studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Personal contact</HEADING>
<P>We contacted the first/corresponding author of each included study for information regarding unpublished trials and for missing information.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-09-26 10:08:00 +0100" MODIFIED_BY="[Empty name]">
<P>Methods used in data collection and analysis for this update are documented below, for previous methods please see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.<BR/>
</P>
<STUDY_SELECTION MODIFIED="2012-09-04 08:36:47 +0100" MODIFIED_BY="[Empty name]">
<P>Review authors MD and CL inspected all abstracts of studies identified as above and identified potentially relevant reports. In addition, to ensure reliability, MT and SL inspected a random sample of these abstracts, comprising 10% of the total. Where disagreement occurred this was resolved by discussion, or if there was still doubt, the full article was acquired for further inspection. The full articles of relevant reports were acquired for reassessment and carefully inspected for a final decision on inclusion (see <LINK TAG="SELECTION_CRITERIA" TYPE="SECTION">Criteria for considering studies for this review</LINK>). Once the full articles were obtained, in turn MD and CL inspected all full reports and independently decided whether they met the inclusion criteria. MD and CL were not blinded to the names of the authors, institutions, or journal of publication. Where difficulties or disputes arose, we asked author SL for help and if it was impossible to decide, we added these studies to those awaiting assessment and contacted the authors of the papers for clarification.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-09-05 14:31:56 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Extraction</HEADING>
<P>Review authors MD and CL extracted data from all included studies. In addition, to ensure reliability, MT independently extracted data from a random sample of these studies, comprising 10% of the total. Again, any disagreement was discussed, decisions documented and, if necessary, we contacted the authors of studies for clarification. With remaining problems, SL helped to clarify issues and these final decisions were documented. We extracted data presented only in graphs and figures whenever possible but included the data only if two review authors independently had the same result. We attempted to contact authors through an open-ended request in order to obtain missing information or for clarification whenever necessary. If studies were multicentre, wherever possible, we extracted data relevant to each component centre separately.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Management</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Forms</HEADING>
<P>We extracted data on standard simple forms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Endpoint versus change data</HEADING>
<P>There are advantages of both endpoint and change data. Change data can remove a component of between-person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint) which can be difficult to conduct in unstable conditions such as schizophrenia. We decided primarily to use endpoint data, and only use change data if the former were not available. We combined endpoint and change data in the analysis as we used mean differences (MD) rather than standardised mean differences (SMD) throughout (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3 Skewed data</HEADING>
<P>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we applied the following standards to all data before inclusion:<BR/>
<BR/>(a) data from studies of at least 200 participants were entered in the analysis irrespective of the following rules, because skewed data pose less of a problem in large studies;<BR/>(b) endpoint data: when a scale starts from the finite number zero, we subtracted the lowest possible value from the mean, and divided this by the standard deviation. If this value was lower than one, it strongly suggested a skew and the study was excluded. If this ratio was higher than one but below two, there is suggestion of skew. We entered the study and tested whether its inclusion or exclusion substantially changed the results. If the ratio was larger than two the study was included, because skew is less likely (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>; <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).<BR/>(c) change data: when continuous data are presented on a scale which includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. We entered the study, because change data tend to be less skewed and because excluding studies would also lead to bias, because not all the available information was used.</P>
<P>In case of skewness we displayed the data in an 'other data table' and did not calculate effect sizes. These tables can be found within the section "data analysis".</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4 Common measure</HEADING>
<P>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5 Conversion of continuous to binary</HEADING>
<P>Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into "clinically improved" or "not clinically improved". It can be generally assumed that if there is a reduction less than 50% in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or the PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), this could be considered as "No clinically significant response" (<LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>; <LINK REF="REF-Leucht-2005b" TYPE="REFERENCE">Leucht 2005b</LINK>). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6 'Summary of findings' table</HEADING>
<P>We used the GRADE approach to interpret findings (<LINK REF="REF-Sch_x00fc_nemann-2008" TYPE="REFERENCE">Schünemann 2008</LINK>) and used GRADE profiler (<LINK REF="REF-GRADE-Profiler" TYPE="REFERENCE">GRADE Profiler</LINK>) to import data from RevMan 5 (<LINK REF="REF-Review-Manager-_x0028_RevMan_x0029_" TYPE="REFERENCE">Review Manager (RevMan)</LINK>) to create 'Summary of findings' tables. These tables provide outcome-specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient-care and decision making. We selected the following main outcomes for inclusion in the summary of findings table.</P>
<SUBSECTION>
<HEADING LEVEL="6">1. No clinically important response to treatment</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2. Acceptability of treatment</HEADING>
<UL>
<LI>leaving the study early due to any reason</LI>
<LI>leaving the study early due to adverse effects (tolerability of treatment)</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3. Desired sedation/tranquillisation</HEADING>
<UL>
<LI>number of participants tranquillised at endpoint of the study (ultra short term)</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-09-03 15:44:17 +0100" MODIFIED_BY="[Empty name]">
<P>Three review authors (MD, CL, MT) worked independently to assess risk of bias by using criteria described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) to measure trial quality. This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting, and other biases. We did not include studies in this systematic review if sequence generation was inadequate.</P>
<P>If the raters disagreed, the final rating was made by consensus, with the involvement of another member of the review group (SL). Where inadequate details of randomisation and other characteristics of trials were provided, we contacted the authors of the studies in order to obtain further information. Non-concurrence in quality assessment was reported, but if disputes arose as to which category a trial was to be allocated, again, resolution was made by discussion.</P>
<P>The level of risk of bias was noted in both, the text of the review and in the <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-09-03 15:44:17 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Dichotomous data</HEADING>
<P>For binary outcomes, we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Continuous data</HEADING>
<P>For continuous outcomes, we estimated mean differences (MDs) between groups with their 95% confidence intervals (CIs).</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2012-09-03 15:44:17 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Cluster trials</HEADING>
<P>Studies increasingly employ "cluster randomisation" (such as randomisation by clinician or practice) but analysis and pooling of clustered data pose problems. Firstly, authors often fail to account for intra-class correlation (ICC) in clustered studies, leading to a "unit of analysis" error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>; <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>If clustering had not been accounted for in primary studies, we planned to present data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. If in subsequent versions of this review we include cluster trials, we will seek to contact first authors of studies to obtain ICCs for their clustered data and will adjust for this by using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we will present these data as if from a non-cluster randomised study but adjust for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a "design effect". This is calculated using the mean number of participants per cluster (m) and the ICC [Design effect = 1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC is not reported it will be assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>If cluster studies had been appropriately analysed taking into account ICCs and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Cross-over trials</HEADING>
<P>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are very likely in severe mental illness, we only used data of the first phase of cross-over studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Studies with multiple treatment groups</HEADING>
<P>Where a study involves more than two treatment arms, if relevant, the additional treatment arms were presented in comparisons. If data are binary these were simply added and combined within the two-by-two table. If data were continuous, we combined data following the formula in section 7.7.3.8  (Combining groups) of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>. Where the additional treatment arms were not relevant, we did not reproduce these data.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2012-09-03 15:44:17 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Overall loss of credibility</HEADING>
<P>At some degree loss of follow-up, data must lose credibility (<LINK REF="REF-Xia-2009" TYPE="REFERENCE">Xia 2009</LINK>). The loss to follow-up in randomised schizophrenia trials is often considerable calling the validity of the results into question. Nevertheless, it is unclear what degree of attrition leads to a high degree of bias. We did not exclude data from trials on the basis of the percentage of participants completing them. We, however, used the 'Risk of bias' tool described above to indicate potential bias when more than 25% of the participants left the studies prematurely, when the reasons for attrition differed between the intervention and the control group, and when no appropriate imputation strategies were applied.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Dichotomous data</HEADING>
<P>Data were presented on a "once-randomised-always-analyse" basis, assuming an intention-to-treat (ITT) analysis. If the authors applied such a strategy, we used their results. If the original authors presented only the results of the per-protocol or completer population, we assumed that those participants lost to follow-up would have had the same percentage of events as those who remained in the study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Continuous data</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 General</HEADING>
<P>Intention-to-treat was used when available. We anticipated that in some studies, in order to perform an ITT analysis, the method of last observation carried forward (LOCF) would be employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<LINK REF="REF-Leon-2006" TYPE="REFERENCE">Leon 2006</LINK>). Therefore, where LOCF data were used in the analysis, it was indicated in the review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Standard deviations</HEADING>
<P>If standard deviations(SDs) were not reported, we first tried to obtain the missing values from the authors. If not available, where there were missing measures of variance for continuous data, but an exact standard error (SE) and confidence intervals (CIs) available for group means, and either 'P' value or 't' values available for differences in mean, we can calculate them according to the rules described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>): When only the SE is reported, SDs are calculated by the formula SD = SE * square root (n). Chapters 7.7.3 and 16.1.3 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) present detailed formulae for estimating SDs from P values, t or F values, CIs, ranges or other statistics. If these formulae did not apply, we calculated the SDs according to a validated imputation method which is based on the SDs of the other included studies (<LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study&#8217;s outcome and thus to lose information.</P>
</SUBSECTION>
</SUBSECTION>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-09-03 15:44:17 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Clinical heterogeneity</HEADING>
<P>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations. When such situations or participant groups arose, these were fully discussed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Methodological heterogeneity</HEADING>
<P>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods. When such methodological outliers arise these were fully discussed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Statistical heterogeneity</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Visual inspection</HEADING>
<P>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Employing the I<SUP>2</SUP> statistic</HEADING>
<P>Heterogeneity between studies was investigated by considering the I<SUP>2 </SUP>method alongside the Chi<SUP>2</SUP> P value. The I<SUP>2 </SUP>provides an estimate of the percentage of inconsistency thought to be due to chance (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The importance of the observed value of I<SUP>2 </SUP>depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. P value from Chi<SUP>2</SUP>  test, or a confidence interval for I<SUP>2</SUP>). An I<SUP>2 </SUP>estimate greater than or equal to around 50% accompanied by a statistically significant Chi<SUP>2</SUP> statistic, was interpreted as evidence of substantial levels of heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). When substantial levels of heterogeneity were found in the primary outcomes, we explored reasons for heterogeneity (see <LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-09-03 15:44:17 +0100" MODIFIED_BY="[Empty name]">
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<LINK REF="REF-Egger-1997a" TYPE="REFERENCE">Egger 1997a</LINK>). These are described in Section 10 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects. We did not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar sizes. In other cases, where funnel plots are possible, we sought statistical advice in their interpretation.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-09-03 15:44:18 +0100" MODIFIED_BY="[Empty name]">
<P>We understand that there is no closed argument for preference for use of fixed-effect or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random-effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage concerning the random-effects model. It puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose random-effects model for all analyses but additionally we investigated the use of a fixed-model approach in sensitivity analyses for the primary outcomes.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-09-03 15:44:18 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Investigation of heterogeneity</HEADING>
<P>If inconsistency was high, this was reported. First, we investigated whether data had been entered correctly. Second, if data were correct, the graph was visually inspected and outlying studies were successively removed to see if heterogeneity was restored. For this review, we decided that should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, data were presented. If not, data were not pooled and issues discussed. We know of no supporting research for this 10% cut off but are investigating use of prediction intervals as an alternative to this unsatisfactory state.</P>
<P>When unanticipated clinical or methodological heterogeneity was obvious, we simply stated hypotheses regarding these for future reviews or versions of this review. We did not perform further analyses.</P>
</SUBSECTION>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-09-03 15:44:18 +0100" MODIFIED_BY="[Empty name]">
<P>All sensitivity analyses were only applied for the primary outcome.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Implication of randomisation</HEADING>
<P>We aimed to include trials in a sensitivity analysis if they were described in some way as implied randomisation. For the primary outcomes, we included these studies in sensitivity analyses and if there were no substantive differences when the implied randomised studies were added to those with better description of randomisation, then all data were employed from these studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Implication of non double-blind trials</HEADING>
<P>We aimed to assess the exclusion of trials that were not double-blind in a sensitivity analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Fixed versus random-effects models</HEADING>
<P>All data were synthesised using a random-effects model, however, we also calculated data for the primary outcome using a fixed-effect model to evaluate whether the greater weights assigned to larger trials with greater event rates, altered the significance of the results compared with the more evenly distributed weights in the random-effects model.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-10-02 11:02:51 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-09-03 15:44:18 +0100" MODIFIED_BY="[Empty name]">
<P>Please also see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>, and <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2012-09-03 15:44:18 +0100" MODIFIED_BY="Heather Maxwell">
<P>The initial search strategy identified more than 180 citations, of which about 100 were clearly unrelated to the topic of this review. We obtained and inspected 82 articles. Forty-one studies were excluded and a further three studies are awaiting assessment. Overall 31 studies were included.</P>
<P>The update search in February 2011 yielded 80 further references of which 34 were potentially relevant and were regarded more closely. Three of these reports were included (<LINK REF="STD-Wang-2000" TYPE="STUDY">Wang 2000</LINK>; <LINK REF="STD-Ma-2006" TYPE="STUDY">Ma 2006</LINK>; <LINK REF="STD-Xuan-2007" TYPE="STUDY">Xuan 2007</LINK>) and 24 studies were excluded and the reasons for exclusion documented in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table. One citation could be a further relevant randomised trial (<LINK REF="STD-Davis-2008" TYPE="STUDY">Davis 2008</LINK>), but due to insufficient information it had to be classified as awaiting assessment. We have written to the corresponding author. Six references retrieved in the update search were reports of studies that had been already included in the first version of this review (a flowchart of the systematic literature search is provided in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).<BR/>
<BR/>This systematic review now includes 34 studies while 66 reports are listed in the excluded studies table and four studies are still awaiting assessment.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2012-09-03 15:44:18 +0100" MODIFIED_BY="Heather Maxwell">
<P>The 34 included studies were published between 1962 and 2007. Most of the studies were published in English, four in Chinese (<LINK REF="STD-Wang-2000" TYPE="STUDY">Wang 2000</LINK>; <LINK REF="STD-Wang-2003" TYPE="STUDY">Wang 2003</LINK>; <LINK REF="STD-Ma-2006" TYPE="STUDY">Ma 2006</LINK>; <LINK REF="STD-Xuan-2007" TYPE="STUDY">Xuan 2007</LINK>) and one study in German (<LINK REF="STD-Marneros-1979" TYPE="STUDY">Marneros 1979</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">2.1 Methods</HEADING>
<P>All studies were randomised ("implied randomisation" in case of <LINK REF="STD-Marneros-1979" TYPE="STUDY">Marneros 1979</LINK>) and most used double-blind-blind methodology. For further details please see sections below on allocation and blinding.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2 Study design</HEADING>
<P>Thirty studies had a parallel group design, whereas four were designed as cross-over studies (<LINK REF="STD-Holden-1968" TYPE="STUDY">Holden 1968</LINK>; <LINK REF="STD-Lingjaerde-1979" TYPE="STUDY">Lingjaerde 1979</LINK>; <LINK REF="STD-Lingjaerde-1982" TYPE="STUDY">Lingjaerde 1982</LINK>; <LINK REF="STD-Nishikawa-1982" TYPE="STUDY">Nishikawa 1982</LINK>). No trial employed a cluster randomisation. Regarding dealing with missing data, many studies did not clearly indicate which analysis method was applied. Some stated the use of a completers-only analysis, whereas, no trial report mentioned a last observation carried forward (LOCF) approach.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.3 Duration</HEADING>
<P>In 25 studies the benzodiazepines were administered over a short-term period from one to 10 weeks (N = 25), in seven studies over an ultra short-term period - up to 24 hours, and in two studies (<LINK REF="STD-Cheung-1981" TYPE="STUDY">Cheung 1981</LINK>; <LINK REF="STD-Nishikawa-1982" TYPE="STUDY">Nishikawa 1982</LINK>) over a long-term period (from 18 months to three years).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.4 Participants</HEADING>
<P>The 34 studies included a total of 2657 people. The number of people included in each study ranged from 12 (<LINK REF="STD-Nestoros-1982" TYPE="STUDY">Nestoros 1982</LINK>) to 301 (<LINK REF="STD-TREC_x002d_Rio-2003" TYPE="STUDY">TREC-Rio 2003</LINK>). Nineteen studies included only persons with schizophrenia or schizophrenia-like psychosis. The applied diagnostic criteria varied to a considerable degree because the studies were carried out at different times during a period of 45 years. Fifteen studies additionally included people with other diagnoses. They were included because at least 50% of the trial sample had a diagnosis of schizophrenia or schizophrenia-like psychosis. There was one exception to this rule. <LINK REF="STD-Azima-1962" TYPE="STUDY">Azima 1962</LINK> included 184 persons of which only 22 were diagnosed with schizophrenia or schizophrenia-like psychosis, but the data used in this analysis exclusively refer to the 22 people with schizophrenia or schizophrenia-like psychosis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.5 Setting</HEADING>
<P>Eighteen trials included exclusively inpatients, five trials randomised outpatient participants. One study included both, inpatients and outpatients (<LINK REF="STD-Lingjaerde-1979" TYPE="STUDY">Lingjaerde 1979</LINK>), and another trial was conducted in an emergency room (<LINK REF="STD-TREC_x002d_Rio-2003" TYPE="STUDY">TREC-Rio 2003</LINK>). There was no information regarding the setting available for the remaining nine trials examined in this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.6 Interventions</HEADING>
<P>Seven studies compared benzodiazepine as a sole agent with placebo and 13 trials compared benzodiazepines with antipsychotic drugs both given as monotherapy. Twenty included studies examined the effects of benzodiazepines as add-on medication to antipsychotic compounds. Diazepam (N = 7) and chlordiazepoxide (N=7) were the most frequently administered benzodiazepines followed by clonazepam (N = 6) and lorazepam (N = 5). Other benzodiazepines such as alpidem, alrazolam, camazepam, estazolam, flunitrazepam, and midazolam were given in only a few cases. Dose of medication varied due to the duration of the studies and due to the mode of administration (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
<P>The most often administered antipsychotic drug was haloperidol (N = 13) followed by chlorpromazine (N = 4). Occasionally fluphenazine, thioridazine or risperidone were given. Some studies did not indicate the antipsychotic used, but it was stated that the dose of the antipsychotic agents was kept constant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.7 Outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.7.1 No clinically important response to treatment</HEADING>
<P>The primary outcome criteria "no clinically important response to treatment" was reported only by a limited number of the included studies (16 trials).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.7.2 Rating scales</HEADING>
<P>Different rating scales were used to assess clinical response and adverse effects. Details of scales that provided usable data are shown below. Reasons for exclusion of data from other instruments are given under "outcomes" in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<SUBSECTION>
<HEADING LEVEL="6">2.7.2.1 Global state</HEADING>
<P>
<U>2.7.2.1.1 Clinical Global Impression - CGI </U>(<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>A rating instrument commonly used in studies on schizophrenia that enables clinicians to quantify severity of illness and overall clinical improvement during therapy. A seven-point scoring system is usually used with low scores indicating decreased severity and/or greater recovery. <LINK REF="STD-Chouinard-1993" TYPE="STUDY">Chouinard 1993</LINK> and <LINK REF="STD-Foster-1997" TYPE="STUDY">Foster 1997</LINK> reported data from this scale.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2.7.2.2 Mental state</HEADING>
<P>
<U>2.7.2.2.1 Agitated Behaviour Scale - ABS </U>(<LINK REF="REF-Corrigan-1989" TYPE="REFERENCE">Corrigan 1989</LINK>)<BR/>This is a 14-item scale used for monitoring agitation levels. This scale has been applied in emergency department settings. The means and standard deviations for the total score and subscale scores are based on samples of persons with traumatic brain injury treated during the acute phases of recovery on an inpatient rehabilitation unit. A prospective sample of all participants with brain injuries, regardless of whether they were demonstrating agitation, revealed an overall mean ABS score of 21.01 and a standard deviation of 7.35 (<LINK REF="REF-Corrigan-1989" TYPE="REFERENCE">Corrigan 1989</LINK>). <LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK> used this scale.</P>
<P>
<U>2.7.2.2.2 Brief Psychiatric Rating Scale - BPRS </U>(<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>)<BR/>A brief rating scale used to assess the severity of a range of psychiatric symptoms, including psychotic symptoms. The scale has 18 items, and each item can be defined on a seven-point scale varying from "not present" (1) to "extremely severe" (7). Scoring goes from 18 -126. <LINK REF="STD-Barbee-1992" TYPE="STUDY">Barbee 1992</LINK>; <LINK REF="STD-Minervini-1990" TYPE="STUDY">Minervini 1990</LINK>; <LINK REF="STD-Foster-1997" TYPE="STUDY">Foster 1997</LINK>; <LINK REF="STD-Wang-2000" TYPE="STUDY">Wang 2000</LINK>; <LINK REF="STD-Ma-2006" TYPE="STUDY">Ma 2006</LINK> and <LINK REF="STD-Xuan-2007" TYPE="STUDY">Xuan 2007</LINK> reported data from the BPRS scale. <LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK> selected eleven psychosis/anxiety items (hostility, suspiciousness, uncooperativeness, unusual thought content, disorganised conceptualisation, hallucinatory behaviour, grandiosity, anxiety, excitement, tension and mannerisms/posturing) and termed this modified version the MBPRS.</P>
<P>
<U>2.7.2.2.3 Inpatient Multidimensional Psychiatric Scale - IMPS </U>(<LINK REF="REF-Lorr-1962" TYPE="REFERENCE">Lorr 1962</LINK>)<BR/>A rating scale used to assess the severity of a range of psychiatric symptoms. Higher scores indicate more symptoms. Further details could not be obtained. <LINK REF="STD-Chouinard-1993" TYPE="STUDY">Chouinard 1993</LINK> reported data from this scale.<BR/>
<BR/>
<U>2.7.2.2.4 Malamud-Sands Scale - MMS</U> (<LINK REF="REF-Malamud-1947" TYPE="REFERENCE">Malamud 1947</LINK>)<BR/>The scale consists of 19 items which can be divided into three major groups. The first seven comprise behavior items that can be directly observed at the time when the patient is interviewed. The next four are functions which are also objectively observable but which are based on the continuous observations by ward personnel during 24 hours which are reported to the rating psychiatrist. The third group comprises eight functions which can be evaluated only on the basis of an interview and on communication with the participants themselves. Only <LINK REF="STD-Merlis-1962" TYPE="STUDY">Merlis 1962</LINK> provided data from this scale.</P>
<P>
<U>2.7.2.2.5 Positive and Negative Symptom Scale - PANSS</U> (<LINK REF="REF-Kay-1987" TYPE="REFERENCE">Kay 1987</LINK>)<BR/>A 30-item scale used to assess the severity and range of general, positive and negative symptoms in schizophrenia. Each item is defined on a seven-point severity scale from absent (1) to extreme (7). Scoring goes from 30 -210. <LINK REF="STD-Wang-2003" TYPE="STUDY">Wang 2003</LINK> used this scale.</P>
<P>
<U>2.7.2.2.6 Scale for the Assessment of Negative Symptoms - SANS</U> (<LINK REF="REF-Andreasen-1989" TYPE="REFERENCE">Andreasen 1989</LINK>)<BR/>This six-point scale contains a global rating of the following negative symptoms: alogia, affective blunting, avolition-apathy, anhedonia-associality and attention impairment. Higher scores indicate more symptoms. <LINK REF="STD-Barbee-1992" TYPE="STUDY">Barbee 1992</LINK> reported data from this scale.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2.7.2.3 Behaviour</HEADING>
<P>
<U>2.7.2.3.1 Nurses Observation Scale for Inpatient Evaluation - NOSIE</U> (<LINK REF="REF-Honigfeld-1965" TYPE="REFERENCE">Honigfeld 1965</LINK>)<BR/>An 80-item scale with items rated on a five-point scale from zero (not present) to four (always present). Ratings are based on behaviour over the previous three days. The seven headings are social competence, social interest, personal neatness, cooperation, irritability, manifest psychosis and psychotic depression. The total score ranges from zero to 320 with high scores indicating a poor outcome. <LINK REF="STD-Chouinard-1993" TYPE="STUDY">Chouinard 1993</LINK> reported data from this scale.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2.7.2.4 Adverse effects</HEADING>
<P>
<U>2.7.2.4.1 Simpson Angus Scale - SAS</U> (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>)<BR/>This 10-item scale, with a scoring system of zero to four for each item, measures drug-induced parkinsonism, a short term drug-induced movement disorder. A low score indicates low levels of parkinsonism. <LINK REF="STD-Foster-1997" TYPE="STUDY">Foster 1997</LINK> used this scale.</P>
<P>
<U>2.7.2.4.2 Treatment Emergent Symptom Scale/Form - TESS/F</U> (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>This checklist assesses a variety of characteristics for each adverse effects, including severity, relationship to the drug, temporal characteristics (timing after a dose, duration and pattern during the day), contributing factors, course, and action taken to counteract the effect. Symptoms can be listed a priori or can be recorded as observed by the investigator. <LINK REF="STD-Ma-2006" TYPE="STUDY">Ma 2006</LINK> reported data from this scale.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2.7.3 Missing outcomes</HEADING>
<P>The primary outcome criteria "No clinically important response to treatment" was incompletely reported by the included studies. Special aspects, as for example, aggression and manic symptoms, were evaluated only by very few studies. Again, behaviour and adverse effects were incompletely reported. No data were available for economic consequences of treatment.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-09-03 15:44:18 +0100" MODIFIED_BY="Heather Maxwell">
<P>Sixty-five studies were excluded and displayed in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table. The reasons for exclusion were that the participants were not randomised (N = 22), the randomisation procedure was inappropriate (N = 4), or in case of adjunct treatment it was not only the medication with benzodiazepines that was randomised (N = 15). Further reasons were that the studies did not include a placebo or non-intervention group (N = 3), they were designed as cross-over studies with unusable data of the first cross-over phase (N = 2), case reports (N = 3), reviews (N = 2), did not report numbers in each group (N = 3), or the participants with schizophrenia and/or schizophrenia-like psychosis were less than 50% of the trial sample and data were not provided separately for people with schizophrenia (N = 7), or no diagnosis was indicated (N = 4).</P>
<SUBSECTION>
<HEADING LEVEL="3">Studies awaiting assessment</HEADING>
<P>We contacted the authors of two cross-over studies (<LINK REF="STD-Maculans-1964" TYPE="STUDY">Maculans 1964</LINK>; <LINK REF="STD-Ungvari-1999" TYPE="STUDY">Ungvari 1999</LINK>) to obtain data from the first cross-over phase. We also contacted a further first author (<LINK REF="STD-Salzman-1991" TYPE="STUDY">Salzman 1991</LINK>) to clarify initial group size and missing standard deviation. We have not yet received feedback from these authors. Another trial is currently awaiting assessment after the update search (<LINK REF="STD-Davis-2008" TYPE="STUDY">Davis 2008</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing studies</HEADING>
<P>We found no ongoing studies.</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-09-03 15:44:18 +0100" MODIFIED_BY="[Empty name]">
<P>For graphical representations of our judgements of risk of bias please refer to <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. Full details of judgements are provided in the risk of bias tables of the included studies.</P>
<ALLOCATION MODIFIED="2012-09-03 15:44:18 +0100" MODIFIED_BY="[Empty name]">
<P>The participants of three studies (<LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>; <LINK REF="STD-Dorevitch-1999" TYPE="STUDY">Dorevitch 1999</LINK>; <LINK REF="STD-TREC_x002d_Rio-2003" TYPE="STUDY">TREC-Rio 2003</LINK>) were assigned by a table of random numbers and two trials were balanced for each group of six participants (<LINK REF="STD-Minervini-1990" TYPE="STUDY">Minervini 1990</LINK>; <LINK REF="STD-Morphy-1986" TYPE="STUDY">Morphy 1986</LINK>). These trials were classified as having a "Low risk of bias" in the quality score ranking. No further details on the randomisation method were available in 24 studies. Three trials stated at least to have used a "stratified randomisation procedure" (<LINK REF="STD-Hanlon-1969" TYPE="STUDY">Hanlon 1969</LINK>; <LINK REF="STD-Hanlon-1970" TYPE="STUDY">Hanlon 1970</LINK>; <LINK REF="STD-Carpenter-1999" TYPE="STUDY">Carpenter 1999</LINK>,) and in one study the randomisation procedure was based on a lottery (<LINK REF="STD-Wang-2000" TYPE="STUDY">Wang 2000</LINK>). In one publication, no randomisation was mentioned (<LINK REF="STD-Marneros-1979" TYPE="STUDY">Marneros 1979</LINK>). Because the trial was described as "double-blind" we implied that the study was randomised. All these 31 studies were given the quality score "Unclear risk of bias".<BR/>
</P>
<P>Regarding concealment of allocation, only one study provided enough information to permit judgement of "Low risk of bias" in the quality score (<LINK REF="STD-TREC_x002d_Rio-2003" TYPE="STUDY">TREC-Rio 2003</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2012-09-03 15:44:18 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Performance-Bias:</B> Most of the included studies were declared as "double-blind". In 10 of these, the trial authors provided no further information concerning the mechanism of blinding ("Unclear risk of bias"), while 16 provided information to allow judgement with "Low risk of bias" in the quality tool. Most of these trials used identical capsules for blinding. Two studies (<LINK REF="STD-Wyant-1990" TYPE="STUDY">Wyant 1990</LINK>; <LINK REF="STD-Ma-2006" TYPE="STUDY">Ma 2006</LINK> ) were described as single-blind without further information ("Unclear risk of bias") and six studies (<LINK REF="STD-Garza_x002d_Trevino-1989" TYPE="STUDY">Garza-Trevino 1989</LINK>; <LINK REF="STD-Stevens-1992" TYPE="STUDY">Stevens 1992</LINK>; <LINK REF="STD-Wang-2000" TYPE="STUDY">Wang 2000</LINK>; <LINK REF="STD-Wang-2003" TYPE="STUDY">Wang 2003</LINK>; <LINK REF="STD-TREC_x002d_Rio-2003" TYPE="STUDY">TREC-Rio 2003</LINK>; <LINK REF="STD-Xuan-2007" TYPE="STUDY">Xuan 2007</LINK>) were not blinded (classified as "High risk of bias").</P>
<P>
<B>Detection-Bias:</B> 19 publications did not provide enough information to allow classification of high or low risk of bias. In 11 trials, we assessed a "Low risk" for a detection-bias, while four studies appeared to have a "High risk" regarding this bias (<LINK REF="STD-Garza_x002d_Trevino-1989" TYPE="STUDY">Garza-Trevino 1989</LINK>; <LINK REF="STD-Wang-2000" TYPE="STUDY">Wang 2000</LINK>; <LINK REF="STD-Wang-2003" TYPE="STUDY">Wang 2003</LINK>; <LINK REF="STD-Xuan-2007" TYPE="STUDY">Xuan 2007</LINK>). The open studies of <LINK REF="STD-Stevens-1992" TYPE="STUDY">Stevens 1992</LINK> and <LINK REF="STD-TREC_x002d_Rio-2003" TYPE="STUDY">TREC-Rio 2003</LINK> were blinded for the assessment of the main outcome and therefore classified as "Low risk of bias".</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2012-09-03 15:44:18 +0100" MODIFIED_BY="[Empty name]">
<P>The overall-attrition (participants who left the trials early for any indication) was low (&lt; 10%) in 27 trials (rated as "Low risk of bias" with the exception of the study by <LINK REF="STD-Kurland-1966" TYPE="STUDY">Kurland 1966</LINK> that was characterised by highly different attrition rates in the intervention- and control group and therefore classified as "Unclear risk of bias") and moderate (10% to 25%) in five studies (<LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK>; <LINK REF="STD-Hanlon-1969" TYPE="STUDY">Hanlon 1969</LINK>; <LINK REF="STD-Marneros-1979" TYPE="STUDY">Marneros 1979</LINK>; <LINK REF="STD-Lingjaerde-1982" TYPE="STUDY">Lingjaerde 1982</LINK>; <LINK REF="STD-Stevens-1992" TYPE="STUDY">Stevens 1992</LINK>). Moderate attrition was judged as "Unclear risk of bias" because the trial authors of these studies did not provide sufficient information to judge if the analysis methods were appropriate to deal with the missing data. In two trials the attrition could be considered as high (&gt; 25%) (<LINK REF="STD-Gundlach-1966" TYPE="STUDY">Gundlach 1966</LINK>; <LINK REF="STD-Lerner-1979" TYPE="STUDY">Lerner 1979</LINK>) (rated as "High risk of bias"). Thirteen studies reported the number of participants leaving the study early due to adverse effects and 11 studies reported the number of participants leaving the study early due to inefficacy of treatment. In most of the publications the trial authors used a completers-analysis.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2012-09-03 15:44:18 +0100" MODIFIED_BY="[Empty name]">
<P>The outcome-data reporting was incomplete in 22 studies (rated as "High risk of bias"). In several instances the data had to be estimated from figures which led to imprecision. Ten trials appeared to be free of selective reporting and were rated with "Low risk of bias" in the quality score, although in many of these publications the reporting of adverse effects was incomplete.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2012-09-03 15:44:18 +0100" MODIFIED_BY="[Empty name]">
<P>Only three studies seemed to be free of other potential sources of bias and were assigned a "Low risk of bias" (<LINK REF="STD-Cheung-1981" TYPE="STUDY">Cheung 1981</LINK>; <LINK REF="STD-Barbee-1992" TYPE="STUDY">Barbee 1992</LINK>; <LINK REF="STD-TREC_x002d_Rio-2003" TYPE="STUDY">TREC-Rio 2003</LINK>). In 25 studies the risk of bias was considered as "unclear" due to a lack of available information in the publications. Thus, there was insufficient information to assess whether an important risk of bias exists. Two trials were characterised through extreme baseline imbalances regarding the different study groups (<LINK REF="STD-Azima-1962" TYPE="STUDY">Azima 1962</LINK>; <LINK REF="STD-Foster-1997" TYPE="STUDY">Foster 1997</LINK>). Other reasons for rating "High risk of bias" are provided in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-10-02 11:02:51 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. COMPARISON 1: BENZODIAZEPINES AS SOLE TREATMENT versus PLACEBO AS SOLE TREATMENT</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1.1 Primary outcome: No clinically important response to treatment</HEADING>
<P>Six short-term studies (<LINK REF="STD-Azima-1962" TYPE="STUDY">Azima 1962</LINK>, <LINK REF="STD-Gundlach-1966" TYPE="STUDY">Gundlach 1966</LINK>, <LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK>, <LINK REF="STD-Merlis-1962" TYPE="STUDY">Merlis 1962</LINK>, <LINK REF="STD-Minervini-1990" TYPE="STUDY">Minervini 1990</LINK>, <LINK REF="STD-Nestoros-1982" TYPE="STUDY">Nestoros 1982</LINK>) reported the number of participants without a clinically significant response to treatment. Combining the data of these trials demonstrated no significant difference in favour of any treatment modality (N = 382, 6 RCTs, RR 0.67 CI 0.44 to 1.02). The I² value of 62% and the significant heterogeneity test (P = 0.02) indicated a substantial level of heterogeneity. The included long-term studies did not provide data for the primary outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2 Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.2.1 Leaving the study early</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">1.2.1.1 Leaving the study early due to any reason</HEADING>
<P>Eight studies contributed data to this outcome. Seven studies were short term and one was long term. In the short-term studies there was no statistically significant difference between participants treated with benzodiazepines and placebo (N = 417, 7 RCTs, RR 0.89 CI 0.57 to 1.38) and in the long-term trial, no participant left the trial early (<LINK REF="STD-Nishikawa-1982" TYPE="STUDY">Nishikawa 1982</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">1.2.1.2 Leaving the study early due to adverse effects</HEADING>
<P>Three short-term studies (<LINK REF="STD-Merlis-1962" TYPE="STUDY">Merlis 1962</LINK>; <LINK REF="STD-Minervini-1990" TYPE="STUDY">Minervini 1990</LINK>; <LINK REF="STD-Nestoros-1982" TYPE="STUDY">Nestoros 1982</LINK>) indicated the reason for premature discontinuation was due to adverse effects. As there no one left early in either group, the risk ratio could not be estimated. The same holds true for the only long-term study (<LINK REF="STD-Nishikawa-1982" TYPE="STUDY">Nishikawa 1982</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">1.2.1.3 Leaving the study early due to inefficacy of treatment</HEADING>
<P>Again, four trials (<LINK REF="STD-Merlis-1962" TYPE="STUDY">Merlis 1962</LINK>; <LINK REF="STD-Minervini-1990" TYPE="STUDY">Minervini 1990</LINK>; <LINK REF="STD-Nestoros-1982" TYPE="STUDY">Nestoros 1982</LINK>; <LINK REF="STD-Nishikawa-1982" TYPE="STUDY">Nishikawa 1982</LINK>) stated the number of participants leaving the study early was due to inefficacy of treatment. No attrition was observed.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.2 Global state</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">1.2.2.1 Relapse</HEADING>
<P>Two trials reported relapse rates after one year, one short-term study (<LINK REF="STD-Carpenter-1999" TYPE="STUDY">Carpenter 1999</LINK>) and one long-term study (<LINK REF="STD-Nishikawa-1982" TYPE="STUDY">Nishikawa 1982</LINK>). We found no significant difference between the treatment and placebo groups in both trials (short term: N = 35, 1 RCT, RR 0.67 CI 0.36 to 1.23; long term: N = 23, 1 RCT, RR 1.00 CI 0.85 to 1.18).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.3 Mental state</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">1.2.3.1 General: BPRS and MMS scale</HEADING>
<P>
<LINK REF="STD-Merlis-1962" TYPE="STUDY">Merlis 1962</LINK> analysed the number of participants unimproved or worse according to the BPRS and the MMS total scores. There were no significant differences between groups, neither in terms of the BPRS (N = 60,1 RCT, RR 1.00 CI 0.39 to 2.53), nor in terms of the MMS (N = 60,1 RCT, RR 0.90 CI 0.52 to 1.57). In contrast to the dichotomous data, we found that the mean BPRS scores at three weeks favoured benzodiazepines compared with placebo on a statistically significant level (<LINK REF="STD-Minervini-1990" TYPE="STUDY">Minervini 1990</LINK>, N = 66,1 RCT, MD -17.60 CI -22.61 to -12.59).</P>
<P>1.2.3.2 Specific: anxiety symptoms (TSRS and HAM-A scale)<BR/>Two studies rated anxiety (<LINK REF="STD-Gundlach-1966" TYPE="STUDY">Gundlach 1966</LINK>; <LINK REF="STD-Minervini-1990" TYPE="STUDY">Minervini 1990</LINK>) with special scales. <LINK REF="STD-Gundlach-1966" TYPE="STUDY">Gundlach 1966</LINK> used the TSRS at six weeks and found no evidence for significant group difference (N = 39,1 RCT, RR 1.16 CI 0.63 to 2.15). <LINK REF="STD-Minervini-1990" TYPE="STUDY">Minervini 1990</LINK> employed the HAM-A rating scale at three weeks and reported a significant advantage in favour of the treatment group. However, data were skewed and could therefore only be displayed in an "other data table".</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.4 Adverse effects</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">1.2.4.1 General: total number of participants with adverse effects</HEADING>
<P>Only <LINK REF="STD-Gundlach-1966" TYPE="STUDY">Gundlach 1966</LINK> analysed how many participants experienced at least one adverse effect. The difference between the two groups was statistically significant (N = 100,1 RCT, RR 1.44 CI 1.02 to 2.04, number needed to harm (NNTH) 5 CI 3 to 50) with more participants in the benzodiazepine group suffering from adverse effects than in the placebo group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">1.2.4.2 Specific adverse effects</HEADING>
<P>
<U>1.2.4.2.1 Anorexia</U>
<BR/>
<LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK> reported on anorexia. No participant experienced this adverse effect (N = 122,1 RCT, RR not estimable).</P>
<P>
<U>1.2.4.2.2 Autonomic reactions</U>
<BR/>
<LINK REF="STD-Gundlach-1966" TYPE="STUDY">Gundlach 1966</LINK> observed 13 participants in the benzodiazepine group and seven participants in the placebo group with autonomic reactions such as flushing or dry mouth. The difference did not reach statistical significance (N = 100,1 RCT, RR 1.71 CI 0.75 to 3.93).</P>
<P>
<U>1.2.4.2.3 Cardiovascular reactions, depression and dryness of mouth</U>
<BR/>
<LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK> reported on cardiovascular reactions, depression and dryness of mouth, but no participant in neither group experienced these adverse effects (N = 122,1 RCT, RR not estimable).</P>
<P>
<U>1.2.4.2.4 Energy level</U>
<BR/>Two studies (<LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK>; <LINK REF="STD-Gundlach-1966" TYPE="STUDY">Gundlach 1966</LINK>) examined changes in energy level. We found no significant difference regarding an increase in energy level between groups (N = 222, 2 RCTs, RR 0.62 CI 0.02 to 22.78). An I² value of 69% was assessed and the Chi<SUP>2</SUP> test<SUP> </SUP>indicated a P value of P = 0.07.<BR/>For the pooled results of both trials, significantly more participants with a decrease in energy level in the benzodiazepine group than in the control group were identified (N = 222, 2 RCTs, RR 2.18 CI 1.38 to 3.43, NNTH 5 CI 3 to 25).</P>
<P>
<U>1.2.4.2.5 Gastrointestinal reactions</U>
<BR/>Three studies (<LINK REF="STD-Gundlach-1966" TYPE="STUDY">Gundlach 1966</LINK>; <LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK>; <LINK REF="STD-Minervini-1990" TYPE="STUDY">Minervini 1990</LINK>) indicated the numbers of participants experiencing gastrointestinal reactions on the prescribed study medication, but no significant difference between the groups could be identified (3 RCTs, N = 288, RR 0.99 CI 0.29 to 3.37).</P>
<P>
<U>1.2.4.2.6 Headache</U>
<BR/>Regarding headache, there was no significant difference between benzodiazepines and placebo (<LINK REF="STD-Gundlach-1966" TYPE="STUDY">Gundlach 1966</LINK>; <LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK>) (N = 222, 2 RCTs, RR 0.75 CI 0.20 to 2.81).</P>
<P>
<U>1.2.4.2.7 Insomnia</U>
<BR/>In <LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK> only one participant in the placebo group complained about insomnia (N = 122,1 RCT, RR 1.14 CI 0.05 to 27.28).</P>
<P>
<U>1.2.4.2.9 Movement disorder</U>
<BR/>Two studies (<LINK REF="STD-Azima-1962" TYPE="STUDY">Azima 1962</LINK>; <LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK>) investigated the occurrence of movement disorders and we found participants in the benzodiazepine group experienced significantly more ataxia compared to the placebo group (N = 144, 2 RCTs, RR 8.18 CI 1.35 to 49.74, NNTH not significant). <LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK> also reported on EPS in general, but no participant in either group experienced this adverse effect (N = 122,1 RCT, RR not estimable).</P>
<P>
<U>1.2.4.2.10 Sedation</U>
<BR/>Altogether, in two studies (<LINK REF="STD-Minervini-1990" TYPE="STUDY">Minervini 1990</LINK>; <LINK REF="STD-Nestoros-1982" TYPE="STUDY">Nestoros 1982</LINK>) only one participant in the pooled benzodiazepine group suffered from extreme sedation (N = 78, 2 RCTs, RR 3.00 CI 0.15 to 61.74).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.3 Sensitivity analyses</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.3.1 Implication of randomisation</HEADING>
<P>We aimed to conduct a sensitivity analysis in terms of the primary outcome when a trial was not clearly stated to be randomised but described as "double-blind". This affects no study which contributed data to this comparison. Therefore, the sensitivity analysis was not undertaken.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.2 Implication of non double-blind trials</HEADING>
<P>No non-double blind trial was included in the pooled data-analysis of the primary outcome.Therefore, no sensitivity analysis was conducted.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.4 Fixed and random effects</HEADING>
<P>When using a fixed-effect model to analyse the data for the primary outcome, we assessed a statistically significant superiority of benzodiazepines compared with placebo (N = 382, 6 RCTs, RR 0.66 CI 0.5 to 0.8) accompanied by a substantial level of heterogeneity (I² = 62%, heterogeneity test: P = 0.02).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.5 'Summary of findings' table</HEADING>
<P>The results of three outcomes - no clinically important response to treatment, leaving the study early due to any reason, and leaving the study early due to adverse effects - were considered more closely in a 'Summary of findings' table (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). The judgements derived from this instrument were used for the discussion section of the review (see <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK> - <LINK TAG="SUMMARY_OF_RESULTS" TYPE="SECTION">Summary of main results</LINK>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. COMPARISON 2: BENZODIAZEPINES versus ANTIPSYCHOTICS</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">2.1 Primary outcome: No clinically important response to treatment</HEADING>
<P>Focussing on global clinical response only four studies (<LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>; <LINK REF="STD-Garza_x002d_Trevino-1989" TYPE="STUDY">Garza-Trevino 1989</LINK>; <LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK>; <LINK REF="STD-Merlis-1962" TYPE="STUDY">Merlis 1962</LINK>) evaluated the number of participants who experienced no clinically significant response to treatment. <LINK REF="STD-Garza_x002d_Trevino-1989" TYPE="STUDY">Garza-Trevino 1989</LINK> investigated the participants after 30 and 60 minutes, <LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK> after 12 hours, <LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK> after two weeks, and <LINK REF="STD-Merlis-1962" TYPE="STUDY">Merlis 1962</LINK> after four weeks. We found no significant differences between groups (30 minutes: N = 44,1 RCT, RR 0.91 CI 0.58 to 1.43; 60 minutes: N = 44,1 RCT, RR 0.61 CI 0.20 to 1.86; 12 hours: N = 66,1 RCT, RR 0.75 CI 0.44 to 1.30; pooled short-term studies: N = 112, 2 RCTs, RR 1.48 CI 0.64 to 3.46). In summary, no significant evidence was found to suggest that one agent was superior to the other.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2 Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.2.1 Leaving the study early</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">2.2.1.1 Leaving the study early due to any reason</HEADING>
<P>Thirteen studies indicated the number of participants leaving the study early due to any reason. Seven studies were ultra short term, four were short term, and two were long-term studies. In neither group was the difference between the medication with benzodiazepines and antipsychotics significant (ultra short: N = 514, 7 RCTs, RR 0.67 CI 0.33 to 1.36; short term: N = 161, 4 RCTs, RR 0.65 CI 0.27 to 1.56; long term: N = 63, 2 RCTs, 2 RCTs, RR 5.00 CI 0.26 to 96.13).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2.2.1.2 Leaving the study early due to adverse effects</HEADING>
<P>Regarding attrition due to adverse terms in three studies of the ultra short-term category (<LINK REF="STD-Lerner-1979" TYPE="STUDY">Lerner 1979</LINK>; <LINK REF="STD-TREC_x002d_Rio-2003" TYPE="STUDY">TREC-Rio 2003</LINK>; <LINK REF="STD-Wyant-1990" TYPE="STUDY">Wyant 1990</LINK>), no statistically significant difference was found between benzodiazepines and antipsychotics (N = 351, 3 RCTs, RR 13.00 CI 0.78 to 216.39). Only <LINK REF="STD-Merlis-1962" TYPE="STUDY">Merlis 1962</LINK> and <LINK REF="STD-Nishikawa-1982" TYPE="STUDY">Nishikawa 1982</LINK> reported on leaving early due to adverse effects in the short and long term, respectively, but again, no significant differences could be detected between the pooled results of the intervention and control groups (short term: N = 60,1 RCT, RR not estimable; long term: N = 33,1 RCT, RR not estimable).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2.2.1.3 Leaving the study early due to inefficacy of treatment</HEADING>
<P>Additionally, there were no significant differences in terms of premature discontinuation due to inefficacy of treatment in either category (ultra short term: N = 311, 2 RCTs, RR not estimable; short term: N = 76, 2 RCTs, RR 0.33 CI 0.02 to 7.14; long term: N = 33,1 RCT, RR not estimable).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2.2 Global state</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">2.2.2.1 CGI severity score</HEADING>
<P>Three studies (<LINK REF="STD-Chouinard-1993" TYPE="STUDY">Chouinard 1993</LINK>; <LINK REF="STD-Foster-1997" TYPE="STUDY">Foster 1997</LINK>; <LINK REF="STD-Lerner-1979" TYPE="STUDY">Lerner 1979</LINK>) reported on the mean CGI severity score at endpoint as a measure of the participants' global state. <LINK REF="STD-Foster-1997" TYPE="STUDY">Foster 1997</LINK> assessed one and four hours, <LINK REF="STD-Chouinard-1993" TYPE="STUDY">Chouinard 1993</LINK> two hours, and <LINK REF="STD-Lerner-1979" TYPE="STUDY">Lerner 1979</LINK> four, and 24 hours. <LINK REF="STD-Foster-1997" TYPE="STUDY">Foster 1997</LINK> revealed a statistically significant superiority of benzodiazepines at one hour (N = 37, 1 RCT, MD -0.67 CI -1.09 to -0.25) but not at four hours (N = 37, 1 RCT, MD -0.62 CI -1.36 to 0.12). The data at two hours (<LINK REF="STD-Chouinard-1993" TYPE="STUDY">Chouinard 1993</LINK>), four hours (<LINK REF="STD-Lerner-1979" TYPE="STUDY">Lerner 1979</LINK>), and 24 hours (<LINK REF="STD-Lerner-1979" TYPE="STUDY">Lerner 1979</LINK>) were skewed and could only be displayed in an "other data table".</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2.2.2.2 Relapse</HEADING>
<P>Relapse was reported by <LINK REF="STD-Carpenter-1999" TYPE="STUDY">Carpenter 1999</LINK> at four weeks, and by <LINK REF="STD-Cheung-1981" TYPE="STUDY">Cheung 1981</LINK> and <LINK REF="STD-Nishikawa-1982" TYPE="STUDY">Nishikawa 1982</LINK> at one year or longer. There was no significant between-group difference in the short-term study (N = 33, 1 RCT, RR 0.84 CI 0.43 to 1.66) as well as in the pooled overall result of the two long-term studies (N = 63, 2 RCTs, RR 2.02 CI 0.37 to 11.04). With an I² value of 83% and a significant heterogeneity test (P = 0.01), the heterogeneity between the two long-term studies (<LINK REF="STD-Cheung-1981" TYPE="STUDY">Cheung 1981</LINK>; <LINK REF="STD-Nishikawa-1982" TYPE="STUDY">Nishikawa 1982</LINK>) was substantial.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2.3 Mental state</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">2.2.3.1 General: BPRS, MBPRS and MMS scale</HEADING>
<P>
<LINK REF="STD-Merlis-1962" TYPE="STUDY">Merlis 1962</LINK> reported on the number of participants without an improvement in general mental state using the BPRS and the MMS scale, but the data from both scales were not significantly different between groups (BPRS: N = 60,1 RCT, RR 2.5 CI 0.6 to 10.3; MMS: N = 60,1 RCT, RR 1.3 CI 0.6 to 2.1). <LINK REF="STD-Foster-1997" TYPE="STUDY">Foster 1997</LINK> and <LINK REF="STD-Lerner-1979" TYPE="STUDY">Lerner 1979</LINK> evaluated the general mental state by mean BPRS total score at one hour (<LINK REF="STD-Foster-1997" TYPE="STUDY">Foster 1997</LINK>), four hours (<LINK REF="STD-Lerner-1979" TYPE="STUDY">Lerner 1979</LINK>; <LINK REF="STD-Foster-1997" TYPE="STUDY">Foster 1997</LINK>), and 12 to 24 hours (<LINK REF="STD-Lerner-1979" TYPE="STUDY">Lerner 1979</LINK>). Because of skewness the 12 to 24-hour data by <LINK REF="STD-Lerner-1979" TYPE="STUDY">Lerner 1979</LINK> were displayed in an 'other data table' (see <LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK>). <LINK REF="STD-Foster-1997" TYPE="STUDY">Foster 1997</LINK> showed wide confidence intervals without a statistically significant difference between groups (N = 37, 1 RCT: one hour MD -3.26 CI -10.7 to 4.1; four hours MD -1.73 CI -9.6 to 6.1). <LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK> rated the mean MBPRS scores at one and 12 hours. One-hour data were statistically significant favouring the control group (N = 66,1 RCT, MD 6.00 CI 0.68 to 11.32). Twelve-hour data were not significantly different (N = 66,1 RCT, MD 1.00 CI -4.32 to 6.32).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2.2.3.2 Specific: manic symptoms (IMPS subscore)</HEADING>
<P>Because of skewness data by <LINK REF="STD-Chouinard-1993" TYPE="STUDY">Chouinard 1993</LINK> could only be displayed in an "other data table".</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2.2.3.3 Specific: sedation</HEADING>
<P>Three studies (<LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>; <LINK REF="STD-Garza_x002d_Trevino-1989" TYPE="STUDY">Garza-Trevino 1989</LINK>; <LINK REF="STD-TREC_x002d_Rio-2003" TYPE="STUDY">TREC-Rio 2003</LINK>) evaluated sedation at 20 minutes (<LINK REF="STD-TREC_x002d_Rio-2003" TYPE="STUDY">TREC-Rio 2003</LINK>), 30 minutes (<LINK REF="STD-Garza_x002d_Trevino-1989" TYPE="STUDY">Garza-Trevino 1989</LINK>), 40 minutes (<LINK REF="STD-TREC_x002d_Rio-2003" TYPE="STUDY">TREC-Rio 2003</LINK>), 60 minutes (<LINK REF="STD-Garza_x002d_Trevino-1989" TYPE="STUDY">Garza-Trevino 1989</LINK>; <LINK REF="STD-TREC_x002d_Rio-2003" TYPE="STUDY">TREC-Rio 2003</LINK>), 120 minutes (<LINK REF="STD-TREC_x002d_Rio-2003" TYPE="STUDY">TREC-Rio 2003</LINK>), and 12 hours (<LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>). The results at 20 minutes showed a statistically significant superiority of benzodiazepines (N = 301, 1 RCT, RR 1.32 CI 1.16 to 1.49, number needed to benefit (NNTB) 5 CI 3 to 8). The results of <LINK REF="STD-Garza_x002d_Trevino-1989" TYPE="STUDY">Garza-Trevino 1989</LINK> at 30 minutes were not significant but showed a trend similar to the results of <LINK REF="STD-TREC_x002d_Rio-2003" TYPE="STUDY">TREC-Rio 2003</LINK> at 20 minutes (N = 44,1 RCT, RR 1.17 CI 0.53 to 2.59). At 40 minutes, we again found a significant superiority of benzodiazepines in terms of sedation compared to antipsychotic drugs (N = 301, 1 RCT, RR 1.13 CI 1.04 to 1.23, NNTB 9 CI 6 to 33). However, sedation at 60 minutes was not significantly different (N = 345, 2 RCTs, RR 1.07 CI 1.00 to 1.15). Also, no significant difference was found at 120 minutes in <LINK REF="STD-TREC_x002d_Rio-2003" TYPE="STUDY">TREC-Rio 2003</LINK> (N = 301, 1 RCT, RR 1.04 CI 0.98 to 1.10). The 12-hour data of the study by <LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK> were equivocal (N = 66,1 RCT, RR 0.75 CI 0.44 to 1.30). <LINK REF="STD-Chouinard-1993" TYPE="STUDY">Chouinard 1993</LINK> examined sedation with the mean CGI sedation score at two hours. We could not reveal any significant between-group difference (N = 16, 1 RCT, MD 0.10 -0.98 to 1.18).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2.4 Behaviour</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">2.2.4.1 General: modified NOSIE score</HEADING>
<P>
<LINK REF="STD-Chouinard-1993" TYPE="STUDY">Chouinard 1993</LINK> reported on general behaviour at 2 hours using the NOSIE scale. The data were skewed and could therefore only be displayed in the "other data table".</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2.2.4.2 Specific: aggression</HEADING>
<P>Aggression data were reported (<LINK REF="STD-TREC_x002d_Rio-2003" TYPE="STUDY">TREC-Rio 2003</LINK>) at different times with three criteria: Needing restraints within two hours, needing additional tranquillising drugs at two hours, and any episode of aggression at 24 hours. None of these items revealed any significant differences between groups (needing restraints, N = 301, 1 RCT, RR 0.82 CI 0.55 to 1.22); (any episode of aggression, N = 301, 1 RCT, RR 1.12 CI 0.78 to 1.62); (needing additional drugs, N = 301, 1 RCT, RR 0.28 CI 0.06 to 1.34). <LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK> reported on aggression using the mean ABS score at one and at 12 hours. There were no significant differences between groups (mean ABS at one hour, N = 66, 1 RCT, MD 4.00 CI -1.32 to 9.32; mean ABS at 12 hours, N = 66, 1 RCT, MD 3.00 CI -2.32 to 8.32).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2.5 Service utilisation</HEADING>
<P>
<LINK REF="STD-TREC_x002d_Rio-2003" TYPE="STUDY">TREC-Rio 2003</LINK> documented how many participants were still in hospital after two weeks of pharmacotherapy. There was no statistically significant between-group difference between benzodiazepine and antipsychotic treated participants (N = 301, 1 RCT, RR 0.96 CI 0.77 to 1.18).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2.6 Adverse effects</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">2.2.6.1 General: total number of patients with adverse effects</HEADING>
<P>Two studies (<LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>; <LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK>) analysed how many participants experienced at least one adverse effects without verifying any statistically significant difference between the study groups (N = 118, 2 RCTs, RR 0.73 CI 0.45 to 1.17).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2.2.6.2 Specific adverse effects</HEADING>
<P>
<U>2.2.6.2.1 Anorexia</U>
<BR/>In <LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK>, two participants in the antipsychotic drug group suffered from anorexia. The between-group difference was not significant (N = 52, 1 RCT, RR 0.19 CI 0.01 to 3.69).</P>
<P>
<U>2.2.6.2.2 Cardiovascular reactions</U>
<BR/>Only <LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK> reported on the rate of cardiovascular reactions in the two treatment groups, but no statistically significant difference was found (N = 52, 1 RCT, RR 0.19 CI 0.01 to 3.69).</P>
<P>
<U>2.2.6.2.3 Energy level</U>
<BR/>
<LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK> observed six participants in the benzodiazepine group and 10 participants in the antipsychotic group with a decrease in energy level (N = 52, 1 RCT, RR 0.56 CI 0.24 to 1.30). Also the outcome of "increase in energy level" was equivocal (N = 52, 1 RCT, RR 0.93 CI 0.06 to 14.03).</P>
<P>
<U>2.2.6.2.4 Depression</U>
<BR/>Only <LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK> reported on depression without revealing any significant difference between the two study groups ( N = 52, 1 RCT, RR 0.19 CI 0.01 to 3.69).</P>
<P>
<U>2.2.6.2.5 Dizziness</U>
<BR/>In <LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>, benzodiazepines did not produce more dizziness than antipsychotics (N = 66, 1 RCT, RR 1.13 CI 0.25 to 5.19).</P>
<P>
<U>2.2.6.2.6 Dryness of mouth</U>
<BR/>Two studies (<LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK>; <LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>) examined dryness of mouth. We could not identify any significant difference between groups (N = 118, 2 RCTs, RR 1.36 CI 0.35 to 5.33).</P>
<P>
<U>2.2.6.2.7 Gastric reactions, headache and insomnia</U>
<BR/>In <LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK>, no participant suffered from gastric reactions or insomnia (N = 52, 1 RCT, RR not estimable). Two participants in the antipsychotic group experienced a headache, but data were not statistically significant (N = 52, 1 RCT, RR 0.19, CI 0.01 to 3.69).</P>
<P>
<U>2.2.6.2.8 Movement disorder</U>
<BR/>Altogether, three studies provided information regarding movement disorders (<LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>; <LINK REF="STD-Foster-1997" TYPE="STUDY">Foster 1997</LINK>; <LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK>). These included reports referring to the movement disorders ataxia (<LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK>; <LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>), dystonia (<LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>), parkinsonism (<LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>), slight dysarthria (<LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>), tremor (<LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>), and extrapyramidal adverse effects (EPS) in general (<LINK REF="STD-Foster-1997" TYPE="STUDY">Foster 1997</LINK>; <LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK>) without revealing any statistically significant between-group differences: ataxia (ultra short term: N = 66, 1 RCT, RR 2.26 CI 0.22 to 23.71; short term: N = 52, 1 RCT, RR 0.31 CI 0.030 to 2.78), dystonia (N = 66, 1 RCT, RR 0.16, CI 0.02 to 1.24), parkinsonism (N = 66, 1 RCT, RR 0.16 CI 0.01 to 2.99), slight dysarthria (N = 66, 1 RCT, RR 0.56 CI 0.11 to 2.87), tremor (N = 66,1 RCT, RR 0.56 CI 0.05 to 5.93), and EPS in general (ultra short term: N = 37,1 RCT, RR not estimable; short term: N = 52, 1 RCT, RR 0.19 CI 0.01 to 3.69). <LINK REF="STD-Chouinard-1993" TYPE="STUDY">Chouinard 1993</LINK> evaluated movement disorders with the mean "Parkinsonism Total Score" and the mean "Tardive Dyskinesia Score" at two hours. The data were skewed and could therefore only be displayed in the "other data table". <LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK> and <LINK REF="STD-Foster-1997" TYPE="STUDY">Foster 1997</LINK> reported on the use of antiparkinson medication, but we found no significant difference between groups (N = 103, 2 RCTs, RR 0.50 CI 0.17 to 1.47).</P>
<P>
<U>2.2.6.2.9 Respiratory depression</U>
<BR/>In the relatively large trial by <LINK REF="STD-TREC_x002d_Rio-2003" TYPE="STUDY">TREC-Rio 2003</LINK> only one participant with benzodiazepine medication suffered from respiratory depression (N = 301, 1 RCT, RR 2.98 CI 0.12 to 72.58).</P>
<P>
<U>2.2.6.2.10 Sedation</U>
<BR/>Extreme sedation (<LINK REF="STD-Foster-1997" TYPE="STUDY">Foster 1997</LINK>) was equivocal between groups (N = 37, 1 RCT, RR 1.76 CI 0.33 to 9.364).</P>
<P>
<U>2.2.6.2.11 Seizure</U>
<BR/>In <LINK REF="STD-TREC_x002d_Rio-2003" TYPE="STUDY">TREC-Rio 2003</LINK>, one participant in the antipsychotic group experienced a seizure, but data did not reach a statistically significant level (N = 301, 1 RCT, RR 0.33 CI 0.01 to 8.06).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.3 Sensitivity analyses</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.3.1 Implication of randomisation</HEADING>
<P>Because all trials that contributed data to the primary outcome were clearly stated to be randomised, the reason for performing the preplanned sensitivity analysis was not given. Therefore, sensitivity analysis was not undertaken.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3.2 Implication of non double-blind trials</HEADING>
<P>No non-double blind trials were included in the pooled data-analysis of the primary outcome.Therefore, no sensitivity analysis was conducted.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.4 Fixed and random effects</HEADING>
<P>Using a fixed-effect model to analyse the data for the primary outcome did not alter the main findings (statistically significant between-group differences) in the relevant comparisons (fixed-effect model: 30 minutes: N = 44, 1 RCT, RR 0.91 CI 0.58 to 1.43; 60 minutes: N = 44, 1 RCT, RR 0.61 CI 0.20 to 1.86; 12 hours: N = 66, 1 RCT, RR 0.75 CI 0.44 to 1.30; pooled short-term studies: N = 112, 2 RCTs, RR 1.58 CI 0.68 to 3.67).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.5 'Summary of findings' table</HEADING>
<P>The results of four outcomes - no clinically important response to treatment, leaving the study early due to any reason, leaving the study early due to adverse effects, and desired sedation - were considered more closely in a 'Summary of findings' table (see <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). The judgements derived from this instrument were used for the discussion section of the review (see <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK> - <LINK TAG="SUMMARY_OF_RESULTS" TYPE="SECTION">Summary of main results</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. COMPARISON 3: ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS versus PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">3.1 Primary outcome: No clinically important response to treatment</HEADING>
<P>Data concerning the primary outcome were reported by eight studies at different time points. The number of participants failing to achieve clinically important response to treatment was provided for the study duration of 30 minutes (<LINK REF="STD-Garza_x002d_Trevino-1989" TYPE="STUDY">Garza-Trevino 1989</LINK>), 60 minutes (<LINK REF="STD-Garza_x002d_Trevino-1989" TYPE="STUDY">Garza-Trevino 1989</LINK>), 12 hours (<LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>), and three weeks or longer (<LINK REF="STD-Guz-1972" TYPE="STUDY">Guz 1972</LINK>; <LINK REF="STD-Hanlon-1969" TYPE="STUDY">Hanlon 1969</LINK>; <LINK REF="STD-Hanlon-1970" TYPE="STUDY">Hanlon 1970</LINK>; <LINK REF="STD-Lingjaerde-1982" TYPE="STUDY">Lingjaerde 1982</LINK>; <LINK REF="STD-Morphy-1986" TYPE="STUDY">Morphy 1986</LINK>; <LINK REF="STD-Xuan-2007" TYPE="STUDY">Xuan 2007</LINK>). Only the results at 30 minutes showed a statistically significant superiority of the benzodiazepine augmentation (30 minutes: N = 45, 1 RCT, RR 0.38 CI 0.18 to 0.80, NNTH 2, CI 2 to 7. Neither 60 minutes data (N = 45, 1 RCT, RR 0.07 CI 0.00 to 1.13), 12 hour data (N = 67, 1 RCT, RR 0.85 CI 0.51 to 1.41) nor three weeks or longer data were statistically significant (N = 511, 6 RCTs, RR 0.87 CI 0.49 to 1.54). Regarding the pooled results of the six short-term studies substantial heterogeneity - represented through a significant heterogeneity test (P = 0.008) and an I² value of 68% - must be considered.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.2 Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.2.1 Leaving the study early</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">3.2.1.1 Leaving the study early due to any reason</HEADING>
<P>Nineteen studies contributed to the outcome "number of participants leaving the study early" due to any reason. Three studies fell in the ultra short term and 16 studies fell in the short-term category. In the ultra short-term studies, no participant in either group left the study early (N = 140, 3 RCTs, RR not estimable). Short-term studies revealed a slight trend towards higher attrition rates in the intervention group (antipsychotics plus benzodiazepines), but the difference was not statistically significant (N = 1045, 16 RCTs, RR 1.36 CI 0.81 to 2.30).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3.2.2.2 Leaving the study early due to adverse effects</HEADING>
<P>Assessing the number of participants with premature termination of treatment due to adverse effects did not reveal any significant difference between the benzodiazepine augmentation group and the control group (N = 415, 6 RCTs, RR 3.24 CI 0.68 to 15.45).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3.2.2.3 Leaving the study early due to inefficacy of treatment</HEADING>
<P>The between-group difference was not statistically significant concerning the number of participants leaving the study early due to inefficacy of treatment (N = 347, 6 RCTs, RR 0.76 CI 0.17 to 3.42).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2.3 Global state</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">3.3.1 CGI severity score</HEADING>
<P>
<LINK REF="STD-Lingjaerde-1982" TYPE="STUDY">Lingjaerde 1982</LINK> applied the mean CGI severity score for the evaluation of the global state, but the data were skewed and could therefore only be displayed in an "other data" table.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2.4 Mental state</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">3.2.4.1 General (BPRS, MBPRS and PANSS scale)</HEADING>
<P>Five studies examined the participants' general state at different time points and using different scales. In <LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK> there were no statistically significant between-group differences in mean MBPRS scores at one hour (N = 67,1 RCT, MD -4.00 CI -9.51 to 1.51) and at 12 hours (N = 67, 1 RCT, MD 2.00 CI -3.27 to 7.27). In <LINK REF="STD-Barbee-1992" TYPE="STUDY">Barbee 1992</LINK> mean BPRS scores at three days favoured significantly the control group (N = 28, 1 RCT, MD 6.81 CI 0.32 to 13.30) but not at one hour ( N = 28, 1 RCT, MD -3.11 CI -8.86 to 2.64), 24 hours (N = 28, 1 RCT, MD 0.01 CI -7.28 to 7.28), and two days (N = 28, 1 RCT, MD 2.00 CI -3.86 to 7.86). In <LINK REF="STD-Wang-2003" TYPE="STUDY">Wang 2003</LINK>, we found no significant difference in terms of PANSS total scores at two weeks (N = 80, 1 RCT, MD -6.20 CI -12.55 to 0.15) and in <LINK REF="STD-Stevens-1992" TYPE="STUDY">Stevens 1992</LINK> there was no significant difference in terms of percentage BPRS reduction at 28 days (N = 61, 1 RCT, MD -4.50 CI -14.93 to 5.93). In the same way the difference between the mean BPRS total score of the two study groups were statistically not significant in <LINK REF="STD-Xuan-2007" TYPE="STUDY">Xuan 2007</LINK> at eight weeks (N = 97, 1 RCT, MD -3.20 Cl -6.54 to 0.14).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3.2.4.2.1 Specific: anxiety symptoms (HAM-A score)</HEADING>
<P>
<LINK REF="STD-Morphy-1986" TYPE="STUDY">Morphy 1986</LINK> analysed anxiety with the mean HAM-A score at endpoint and <LINK REF="STD-Guz-1972" TYPE="STUDY">Guz 1972</LINK> with the mean HAM-A change score from baseline to endpoint. The data of both studies were skewed and could therefore only be presented in an "other data" table.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3.2.4.2.2 Specific: negative symptoms (SANS score)</HEADING>
<P>
<LINK REF="STD-Barbee-1992" TYPE="STUDY">Barbee 1992</LINK> assessed negative symptoms using the mean SANS score at endpoint and found a slight superiority of the control group. Again, the data were skewed and could only be displayed in an "other data" table.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3.2.4.2.3 Specific: sedation</HEADING>
<P>Sedation data were reported by <LINK REF="STD-Garza_x002d_Trevino-1989" TYPE="STUDY">Garza-Trevino 1989</LINK> and <LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>. In the benzodiazepine augmentation group of <LINK REF="STD-Garza_x002d_Trevino-1989" TYPE="STUDY">Garza-Trevino 1989</LINK>, significantly more participants were tranquillized at 30 minutes (N = 45, 1 RCT, RR 2.25 CI 1.18 to 4.30, NNTB 2 CI 2 to 7) and at 60 minutes (N = 45, 1 RCT, RR 1.39 CI 1.06 to 1.83, NNTB 3 CI 2 to 11) in comparison to the control group. In <LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>, we found no significant difference in terms of participants who were asleep at 12 hours (N = 67, 1 RCT, RR 0.85 CI 0.51 to 1.41).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2.5 Behaviour</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">3.2.5.1 Specific: aggression</HEADING>
<P>Aggression data were reported in two studies (<LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>; <LINK REF="STD-Dorevitch-1999" TYPE="STUDY">Dorevitch 1999</LINK>). <LINK REF="STD-Dorevitch-1999" TYPE="STUDY">Dorevitch 1999</LINK> documented the number of participants needing restraints within 120 minutes but nobody needed sanctions (N = 28, 1 RCT, RR not estimable). <LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK> evaluated aggression with the mean ABS score at one and at 12 hours, but there was no statistically significant between-group difference measurable (one hour: N = 67, 1 RCT, MD -3.00 CI -8.27 to 2.27; 12 hours: N = 67, 1 RCT, MD 0.00 CI -5.27 to 5.27).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2.6 Service use</HEADING>
<P>Only one study examined service utilisation (<LINK REF="STD-Barbee-1992" TYPE="STUDY">Barbee 1992</LINK>) and reported on the number of participants who were still in hospital after three days without identifying any significant difference (N = 28, 1 RCT, RR 0.90 CI 0.54 to 1.50).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2.7 Adverse effects</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">3.2.7.1 General: total number of participants with adverse effects, TESS score</HEADING>
<P>Two studies (<LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>; <LINK REF="STD-Kurland-1966" TYPE="STUDY">Kurland 1966</LINK>) indicated the total number of participants experiencing at least one adverse effect. We found no statistically significant differences between groups (N = 151, 2 RCTs, RR 0.91 Cl 0.54 to 1.53). In the same way, we found no significant difference regarding the TESS score which was reported in <LINK REF="STD-Ma-2006" TYPE="STUDY">Ma 2006</LINK> (N = 120,1 RCT, MD 0.61 Cl -0.42 to 1.64).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3.2.7.2 Spectfic adverse effects</HEADING>
<P>
<U>3.2.7.2.1 Anorexia</U>
<BR/>Only one participant in the control group of <LINK REF="STD-Guz-1972" TYPE="STUDY">Guz 1972</LINK> suffered from anorexia, a non-significant difference (N = 60,1 RCT, RR 0.33 CI 0.01 to 7.87).</P>
<P>
<U>3.2.7.2.2 Allergic reaction</U>
<BR/>
<LINK REF="STD-Kurland-1966" TYPE="STUDY">Kurland 1966</LINK> reported the occurrence of allergic reactions. There was no significant difference between both study arms detectable (N = 84,1 RCT, RR 1.36 CI 0.24 to 7.75).</P>
<P>
<U>3.2.7.2.3 Blurred vision</U>
<BR/>
<LINK REF="STD-Guz-1972" TYPE="STUDY">Guz 1972</LINK> and <LINK REF="STD-Kurland-1966" TYPE="STUDY">Kurland 1966</LINK> evaluated the number of participants in each group that experienced blurred vision. In <LINK REF="STD-Guz-1972" TYPE="STUDY">Guz 1972</LINK>, one participant in the combination group experienced blurred vision and in <LINK REF="STD-Kurland-1966" TYPE="STUDY">Kurland 1966</LINK>, one participant in the control group. Therefore, no statistically significant difference could be assessed (N = 144, 2 RCTs, RR 0.96 CI 0.10 to 9.04).</P>
<P>
<U>3.2.7.2.4 Cardiovascular reaction</U>
<BR/>Combining the results of <LINK REF="STD-Guz-1972" TYPE="STUDY">Guz 1972</LINK> and <LINK REF="STD-Kurland-1966" TYPE="STUDY">Kurland 1966</LINK> regarding cardiovascular reactions, no significant difference between groups could be identified (N = 144, 2 RCTs, RR 1.53 CI 0.19 to 12.11).</P>
<P>
<U>3.2.7.2.5 Chills</U>
<BR/>One trial (<LINK REF="STD-Kurland-1966" TYPE="STUDY">Kurland 1966</LINK>), described that chills did not occur in either group (N = 84,1 RCT, RR not estimable).</P>
<P>
<U>3.2.7.2.6 Confusion, depression and diarrhoea</U>
<BR/>
<LINK REF="STD-Guz-1972" TYPE="STUDY">Guz 1972</LINK> found no significant difference between the intervention and control groups concerning confusion (N = 60, 1 RCT, RR 0.33 CI 0.01 to 7.87), depression (N = 60,1 RCT, RR 1.00 CI 0.07 to 15.26), and diarrhoea (N = 60, 1 RCT, RR 3.00 CI 0.13 to 70.83).</P>
<P>
<U>3.2.7.2.7 Dizziness</U>
<BR/>Dizziness was reported in four trials (<LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>; <LINK REF="STD-Lingjaerde-1982" TYPE="STUDY">Lingjaerde 1982</LINK>; <LINK REF="STD-Ma-2006" TYPE="STUDY">Ma 2006</LINK>; <LINK REF="STD-Pujalte-1994" TYPE="STUDY">Pujalte 1994</LINK>) occurring in 18 participants in the pooled intervention group and nine participants in the pooled control group. This difference did not reach statistical significance for all four studies (N = 257, 4 RCTs, RR 1.96 CI 0.88 to 4.37), but only investigating the three short-term studies revealed a significant between-group difference (N = 190, 3 RCTs, RR 2.58 CI 1.1 to 6.2; NNTH not significant).</P>
<P>
<U>3.2.7.2.8 Drowsiness</U>
<BR/>In <LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK> and <LINK REF="STD-Kurland-1966" TYPE="STUDY">Kurland 1966</LINK> the pooled between-group difference was not statistically significant in terms of drowsiness (N = 151, 2 RCTs, RR 0.52 CI 0.13 to 2.05).</P>
<P>
<U>3.2.7.2.9 Dryness of mouth</U>
<BR/>Four studies (<LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>, <LINK REF="STD-Guz-1972" TYPE="STUDY">Guz 1972</LINK>, <LINK REF="STD-Kurland-1966" TYPE="STUDY">Kurland 1966</LINK>, <LINK REF="STD-Lingjaerde-1982" TYPE="STUDY">Lingjaerde 1982</LINK>) reported on dryness of mouth and we found no significant difference between groups (N = 269, 4 RCTs, RR 1.63 CI 0.38 to 6.97).</P>
<P>
<U>3.2.7.2.10 Excitation</U>
<BR/>
<LINK REF="STD-Guz-1972" TYPE="STUDY">Guz 1972</LINK> documented one participant with excitation in the control group (N = 60, 1 RCT, RR 0.33, CI 0.01 to 7.87).</P>
<P>
<U>3.2.7.2.11 Gastrointestinal reaction</U>
<BR/>In <LINK REF="STD-Kurland-1966" TYPE="STUDY">Kurland 1966</LINK> there was no significant difference between groups concerning gastrointestinal reaction (N = 84, 1 RCT, RR 0.30 CI 0.01 to 7.25).</P>
<P>
<U>3.2.7.2.12 Headache</U>
<BR/>Combining the results of <LINK REF="STD-Kurland-1966" TYPE="STUDY">Kurland 1966</LINK> and <LINK REF="STD-Lingjaerde-1982" TYPE="STUDY">Lingjaerde 1982</LINK> did not reveal any significant between-group difference (N = 142, 2 RCTs, RR 0.78 CI 0.04 to 14.93).</P>
<P>
<U>3.2.7.2.13 Increased salivation and insomnia</U>
<BR/>
<LINK REF="STD-Guz-1972" TYPE="STUDY">Guz 1972</LINK> and <LINK REF="STD-Kurland-1966" TYPE="STUDY">Kurland 1966</LINK> evaluated the occurrence of increased salivation (N = 144, 2 RCTs, RR 1.98 CI 0.26 to 14.91) and insomnia (N = 144, 2 RCTs, RR 1.50 CI 0.41 to 5.44), without revealing any statistically significant between-group difference.</P>
<P>
<U>3.2.7.2.14 Lactation</U>
<BR/>In <LINK REF="STD-Kurland-1966" TYPE="STUDY">Kurland 1966</LINK> the between-group difference was not statistically significant in terms of lactation (N = 84, 1 RCT, RR 0.30 CI 0.01 to 7.25).</P>
<P>
<U>3.2.7.2.15 Movement disorder</U>
<BR/>We found no significant difference in terms of specific movement disorders such as ataxia (<LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>; <LINK REF="STD-Guz-1972" TYPE="STUDY">Guz 1972</LINK>), dystonia (<LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>; <LINK REF="STD-Kurland-1966" TYPE="STUDY">Kurland 1966</LINK>), parkinsonism (<LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>; <LINK REF="STD-Guz-1972" TYPE="STUDY">Guz 1972</LINK>; <LINK REF="STD-Kurland-1966" TYPE="STUDY">Kurland 1966</LINK>) slight dysarthria (<LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>; <LINK REF="STD-Lingjaerde-1982" TYPE="STUDY">Lingjaerde 1982</LINK>), or tremor (<LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>; <LINK REF="STD-Guz-1972" TYPE="STUDY">Guz 1972</LINK>). Summarizing the three short-term studies (<LINK REF="STD-Barbee-1992" TYPE="STUDY">Barbee 1992</LINK>; <LINK REF="STD-Hanlon-1969" TYPE="STUDY">Hanlon 1969</LINK>; <LINK REF="STD-Stevens-1992" TYPE="STUDY">Stevens 1992</LINK>), significantly fewer participants in the benzodiazepine augmentation group received antiparkinson medication at least once (N = 215, 3 RCTs, RR 0.74 CI 0.61 to 0.90; NNTH not significant).</P>
<P>
<U>3.2.7.2.16 Restlessness</U>
<BR/>In <LINK REF="STD-Guz-1972" TYPE="STUDY">Guz 1972</LINK> and <LINK REF="STD-Lingjaerde-1982" TYPE="STUDY">Lingjaerde 1982</LINK>,, six participants in the benzodiazepine augmentation group and five participants in the control group suffered from restlessness, a non-significant difference (N = 118, 2 RCTs, RR 1.16 CI 0.40 to 3.36).</P>
<P>
<U>3.2.7.2.17 Sensory disturbances</U>
<BR/>Sensory disturbances were reported by <LINK REF="STD-Kurland-1966" TYPE="STUDY">Kurland 1966</LINK>. The difference between the groups was not statistically significant (N = 84, 1 RCT, RR 0.91 CI 0.06 to 14.06).</P>
<P>
<U>3.2.7.2.18 Sleep disorder</U>
<BR/>There was no statistically significant between-group difference in the one trial which reported on sleep disorders (<LINK REF="STD-Lingjaerde-1982" TYPE="STUDY">Lingjaerde 1982</LINK>, N = 58, 1 RCT, RR 0.41 CI 0.02 to 9.60).</P>
<P>
<U>3.2.7.2.19 Somnolence</U>
<BR/>We found reports of somnolence (<LINK REF="STD-Guz-1972" TYPE="STUDY">Guz 1972</LINK>; <LINK REF="STD-Lingjaerde-1982" TYPE="STUDY">Lingjaerde 1982</LINK>) which was significantly higher in the benzodiazepine augmentation group than in the control group (N = 118, 2 RCTs, RR 3.30 CI 1.04 to 10.40, NNTH 8 CI 5 to 50).</P>
<P>
<U>3.2.7.2.20 Vomiting</U>
<BR/>
<LINK REF="STD-Guz-1972" TYPE="STUDY">Guz 1972</LINK> reported the numbers of participants experiencing vomiting, but no significant difference between the study groups could be detected (N = 60, 1 RCT, RR 3.00 CI 0.13 to 70.83).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.3 Sensitivity analysis</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.3.1 Implication of randomisation</HEADING>
<P>We aimed to conduct a sensitivity analysis in terms of the primary outcome when a trial was not clearly stated to be randomised but described as "double-blind". In this comparison, this affects the study of <LINK REF="STD-Marneros-1979" TYPE="STUDY">Marneros 1979</LINK>. Because this trial did not provide any data that were included in the meta-analytic calculations measuring the primary outcome; this sensitivity analysis was not undertaken.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3.2 Implication of non double-blind trials</HEADING>
<P>In terms of the evaluation of an augmentation of antipsychotics with benzodiazepines there was one open trial included in the pooled data-analysis of the primary outcome (<LINK REF="STD-Xuan-2007" TYPE="STUDY">Xuan 2007</LINK>). Removing this trial did not convert the results in terms of statistically significant between-group differences.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.4 Fixed and random effects</HEADING>
<P>Using a fixed-effect model to analyse the data for the primary outcome did not alter the main findings (statistically significant between-group differences) in the relevant comparisons (fixed-effect model: 30 minutes: N = 45, 1 RCT, RR 0.37 CI 0.18 to 0.80; 60 minutes: N = 45, 1 RCT, RR 0.07 CI 0.00 to 1.13; 12 hours: N = 67, 1 RCT, RR 0.85 CI 0.51 to 1.41; pooled short-term studies: N = 511, 6 RCTs, RR 0.96 CI 0.72 to 1.27).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.5 'Summary of findings' table</HEADING>
<P>The results of four outcomes - no clinically important response to treatment, leaving the study early due to any reason, leaving the study early due to adverse effects, and desired sedation - were considered more closely in a 'Summary of findings' table (see <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>). The judgements derived from this instrument were used for the discussion section of the review (see <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK> - <LINK TAG="SUMMARY_OF_RESULTS" TYPE="SECTION">Summary of main results</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Publication bias</HEADING>
<P>Due to the small number of included trials providing usable data concerning the primary outcome, we did not perform a funnel plot analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Investigation of heterogeneity</HEADING>
<P>Statistical tests revealed substantial levels of heterogeneity (defined by an I<SUP>2 </SUP>estimate greater than or equal to around 50% accompanied by a statistically significant Chi<SUP>2</SUP> test) in the outcomes "No clinically important response to treatment" (Comparison 1. and 3.) and relapse rates (Comparison 2.), but we did not identify clear reasons explaining this heterogeneity. As the number of trials and participants is still low for the individual outcomes, some of this heterogeneity may be due to chance alone. Regarding the outcome "relapse", the different duration of the trials could be a possible reason for the high heterogeneity.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-09-03 15:44:18 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2012-09-03 15:44:18 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">General</HEADING>
<P>It is common practise to use benzodiazepines for a variety of purposes in schizophrenia including anxiety, agitation, disruptive behaviour, motor disturbances, and sometimes for the augmentation of antipsychotic drugs to alleviate positive symptoms. Analysing 34 randomised controlled trials with a total number of 2657 participants, we found no supportive evidence for this widespread clinical practice, except for short-term sedation of agitated schizophrenic persons.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">1. COMPARISON 1: BENZODIAZEPINES AS SOLE TREATMENT versus PLACEBO AS SOLE TREATMENT</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1.1 No clinically important response to treatment</HEADING>
<P>Based on the data of six short-term studies, we found no evidence supporting the general use of benzodiazepines as monotherapy to improve symptomatology in people with schizophrenia. Study participants randomised to benzodiazepines alone did not differ significantly from those given placebo in achieving clinically important response to treatment. Statistically significant heterogeneity in the pooled results led to an overestimate of treatment effect with the fixed-effect model that was not evident when the (more appropriate) random-effects model was applied to pool data for this outcome.</P>
<P>The fact that a statistically significant difference in favour of benzodiazepine treatment occurred in the sensitivity analysis when applying a fixed-effect model can be attributed to the substantial level of heterogeneity between the single trials contributing data to this comparison.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2 Leaving the study early</HEADING>
<P>About 15% of participants (64 out of 440) left the study early due to any reason. Since there was no statistically significant between-group difference, monotherapy with benzodiazepines may be generally acceptable for people with schizophrenia. Analysing specific reasons for leaving the studies early, adverse effects or inefficacy of treatment, we also observed no significant differences between benzodiazepines and placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.3 Relapse rate</HEADING>
<P>Because two small trials (<LINK REF="STD-Carpenter-1999" TYPE="STUDY">Carpenter 1999</LINK>; <LINK REF="STD-Nishikawa-1982" TYPE="STUDY">Nishikawa 1982</LINK>) revealed no significant difference in relapse rates between the study groups, it can be concluded that for relapse prevention benzodiazepines are not an appropriate alternative to antipsychotic drugs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.4 Mental state</HEADING>
<P>Results regarding the participants' mental state were rarely reported and difficult to interpret because different scales were used. Whereas one small study (<LINK REF="STD-Merlis-1962" TYPE="STUDY">Merlis 1962</LINK>), found no significant difference in terms of the number of participants with an improvement of general mental state, <LINK REF="STD-Minervini-1990" TYPE="STUDY">Minervini 1990</LINK> (who analysed the mean BPRS after three weeks) found benzodiazepines to be significantly superior to placebo. Although <LINK REF="STD-Minervini-1990" TYPE="STUDY">Minervini 1990</LINK> claimed that all participants were in remission and their psychotic symptoms "controlled" and that they were all not receiving antipsychotics, the mean BPRS score was quite high for such a condition (mean BPRS about 67). In addition, the data were derived from only one study and thus need replication. Therfore, we advise caution in the interpretation of this result.<BR/>
<BR/>Again, very limited data were available for specific aspects of the mental state and no statistically significant outcome data were revealed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.5 Adverse effects</HEADING>
<P>The incomplete reporting of adverse effects considerably limits the interpretation of these outcomes. There were significantly more participants treated with benzodiazepines who suffered from any adverse effects, but this result was based on only one study (<LINK REF="STD-Gundlach-1966" TYPE="STUDY">Gundlach 1966</LINK>). Again, based on very limited data, benzodiazepines decreased the participants' energy level more often than placebo. This finding can be explained by the sedating properties of benzodiazepines. Benzodiazepines were also associated with more ataxia than placebo.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. COMPARISON 2: BENZODIAZEPINES versus ANTIPSYCHOTICS</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">2.1 No clinically important response to treatment</HEADING>
<P>Only four studies including 222 participants reported on the number of participants with a failure to achieve clinically important response to treatment, and no significant difference was found. Compared with placebo (Comparison 1.), the results of this examination (benzodiazepine versus antipsychotic monotherapy) do not support the general use of benzodiazepines as sole agents in people with schizophrenia and related disorders.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2. Leaving the study early</HEADING>
<P>Overall 44 out of 738 participants (6 %) terminated the studies prematurely with no statistical significant difference between benzodiazepines and antipsychotics, both given as sole agents. This result was consistent irrespective of the trial duration (ultra short, short, or long term). When specific reasons for leaving the studies early - adverse effects or inefficacy of treatment - were indicated, again there was no significant difference between groups. This result was quite surprising as it could be assumed that more participants in the antipsychotic group discontinued due to adverse effects and more participants in the benzodiazepine group due to inefficacy of treatment, at least in longer-term studies. Because the total number of participants discontinuing the studies was generally few, there may have been a lack of statistical power and larger trials are needed to assess these outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.3 Global state</HEADING>
<P>One study found a superiority of benzodiazepines compared to placebo analysing the mean CGI severity score at one hour (<LINK REF="STD-Foster-1997" TYPE="STUDY">Foster 1997</LINK>). This difference may be caused by the more sedating effects of antipsychotic drugs, but it requires a replication, especially since the superiority vanished in the study at four hours.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.4 Relapse rate</HEADING>
<P>There was no difference in terms of relapse rates both for the short-term and long-ter studies, but the occurrence of high heterogeneity limits the interpretation of the results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.5 Mental state</HEADING>
<P>Only four studies analysed the general mental state measured by different scales and only one trial could verify a significant difference in favour of antipsychotics at one hour. Thus, the results were not consistent and further studies comparing benzodiazepines with antipsychotics are needed.<BR/>
<BR/>Sedation as a desired treatment effect was more prevalent among the participants receiving benzodiazepines than antipsychotics. Nevertheless, a statistically significant difference was only found at 20 minutes and at 40 minutes but not at 30 minutes, 60 minutes, 120 minutes, and 12 hours. Again, more studies are required to replicate this finding.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.6 Behaviour</HEADING>
<P>Neither general nor specific aspects of behaviour such as aggression showed any significant superiority between any group. Again, the analysis was limited by the fact that only two trials reported usable data on behaviour.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.7 Service utilisation</HEADING>
<P>The only outcome on service utilisation analysed was the number of participants who were still in hospital after two weeks. There was no significant difference in the only study that contributed to this comparison.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.8 Adverse effects</HEADING>
<P>There was no significant difference between benzodiazepines and antipsychotic drugs neither in terms of "any adverse effect" nor in terms of the specific adverse effects anorexia, cardiovascular reactions, change in energy level, depression, dizziness, dryness of mouth, gastric reactions, headaches, insomnia, movement disorders, respiratory depression, extreme sedation, and seizure. Again, since only four studies (<LINK REF="STD-Battaglia-1997" TYPE="STUDY">Battaglia 1997</LINK>; <LINK REF="STD-Foster-1997" TYPE="STUDY">Foster 1997</LINK>; <LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK>; <LINK REF="STD-TREC_x002d_Rio-2003" TYPE="STUDY">TREC-Rio 2003</LINK>) provided data for these outcomes, no firm conclusion can be drawn.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. COMPARISON 3: ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS versus PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 No clinically important response to treatment</HEADING>
<P>The addition of benzodiazepines to antipsychotics may improve the global state of people with schizophrenia for a very short time frame.This finding was statistically significant at 30 minutes, but the difference diminished over time. For the results at one and 12 hours as well as for the short-term trials, the analyses failed to identify any significant between-group differences. Again, the sedating and anxiolytic properties of benzodiazepines may contribute to this short-term effect. The results of the short-term studies are limited by substantial heterogeneity between the included trials.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.2 Leaving the study early</HEADING>
<P>In this comparison 56 out of 1185 participants (5%) discontinued the regular study phase early. There was no significant difference between groups, neither in terms of leaving early for any reason nor for inefficacy of treatment or for adverse effects, suggesting an equal acceptability of benzodiazepine augmentation compared with that of taking antipsychotics alone or combined with placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.3 Mental state</HEADING>
<P>Few studies presented data on the mental state. Various scales and various assessment times were used which may in part explain why the results were very inconsistent with some studies showing a superiority of antipsychotic monotherapy whereas, others showed a reversed trend. No firm conclusion can be drawn on the basis of the available data. The very little data on anxiety and on negative symptoms were skewed and thus, could not be used in analysis. Sedation as a desired treatment effect was reported by two studies at different time points. At 30 and 60 minutes significantly more participants in the benzodiazepine augmentation group were sedated than in the control group. At 12 hours this effect was not reproducible. Again, the sedating effect of benzodiazepines is the only one that could be found relatively consistently in this systematic review, but due to the small sample size more evidence is necessary.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.4 Behaviour</HEADING>
<P>Only two ultra short-term studies reported on aggression using different criteria. Neither measure showed any difference between groups, but it is surprising how few studies evaluated this important outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.5 Service utilisation</HEADING>
<P>Only one study (<LINK REF="STD-Barbee-1992" TYPE="STUDY">Barbee 1992</LINK>), reported on how many participants were still in hospital after three days and did not find a significant difference between groups. The interpretation of this outcome is again hampered by the small number of participants included.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.6 Adverse effects</HEADING>
<P>The reporting of adverse effects was very sparse. Only two studies (N = 151) reported on the number of participants with at least one adverse effect and found no significant difference between the benzodiazepine plus antipsychotic group and the control group. In the same way the TESS score, assessed in only one study (N = 120), revealed no significant between-group difference. There was also no significant difference in terms of anorexia, allergic reaction, blurred vision, cardiovascular reaction, chills, confusion, depression, diarrhoea, drowsiness, dryness of mouth, excitation, gastrointestinal reaction, headache, increased salivation, insomnia, lactation, movement disorders, restlessness, sensory disturbances, sleep disorder and vomiting. Significantly more participants in the benzodiazepine augmentation group experienced somnolence and dizziness when analysing only the short-term studies. Nevertheless, if there are any consistent effects of benzodiazepines that could be detected by this review, then it was the sedating characteristics of benzodiazepines. These properties can be used therapeutically, but benzodiazepines must be carefully dosed to avoid respiratory depression. In this context, it should be considered that sedation in agitated schizophrenic people can be also achieved by combining high-potency with low-potency antipsychotics (<LINK REF="REF-Leucht-2011" TYPE="REFERENCE">Leucht 2011</LINK>). Fewer participants in the benzodiazepine augmentation group received antiparkinson medication. It is possible that benzodiazepines alleviate extrapyramidal adverse effects of antipsychotic drugs. As adverse effects were generally poorly reported, future research projects are needed to assess this aspect of treatment.</P>
</SUBSECTION>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-07-28 16:03:03 +0100" MODIFIED_BY="[Empty name]">
<P>Some limitations regarding this systematic review must be considered, e.g. the trials were usually characterised by small sample sizes and the outcomes were often incompletely reported thus not allowing their inclusion in the meta-analytic calculations. As a result of variability in the trial designs and different outcome scales being applied, pooling the results was often impossible. One reason for this diversity is that the trials were carried out during a very long period from 1962 to 2007.<BR/>
<BR/>There is an important distinction between no evidence for an effect (as is the case in this review) and evidence that there is no effect. Thus, no firm conclusions on the efficacy and tolerability of benzodiazepines for schizophrenia can be drawn. Further adequate trials are required to clarify this research question.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2012-09-03 15:44:18 +0100" MODIFIED_BY="[Empty name]">
<P>All included trials were randomised and most of them were double-blind, but details were often not presented. Therefore, it appears unclear whether the studies were adequately randomised, whether treatment allocation was really concealed, and whether sufficient blinding could be assured over the whole trial period. In 27 out of 34 studies the overall attrition was classified as low (&lt;10%). Within this context, it should be considered that many of these trials were characterised by a short trial duration. Some studies evaluated only a time frame fewer than 24 hours. Only 12 trials were judged to be free of selective reporting, and there were studies with other problems such as extreme baseline imbalances etc. Based on the GRADE approach the quality of the evidence can be regarded as low or very low (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2012-09-03 15:44:18 +0100" MODIFIED_BY="[Empty name]">
<P>A priori we decided to pool all benzodiazepines in this systematic review. This could be probably a potential bias because benzodiazepines differ in terms of potency and speed of metabolism and elimination. Additionally, the route of administration (oral or parenteral) could probably limit the comparability of the trials results.</P>
<P>The decision to pool all studies irrespective of the administered antipsychotic drug (Comparison 2. and 3.) is justified for efficacy related outcomes because most antipsychotics are characterised by comparable effectiveness (<LINK REF="REF-Leucht-2009" TYPE="REFERENCE">Leucht 2009</LINK>). The pooling of the antipsychotic compounds seems to be more problematic for adverse effects because antipsychotic drugs differ to a large extent in this regard. Thus, any differences in Comparison 2. and 3. in terms of adverse effects cannot be generalised to all antipsychotic compounds.</P>
<P>The study search was largely based on the trial register of the Cochrane Schizophrenia Group (<LINK REF="REF-Adams-2011" TYPE="REFERENCE">Adams 2011</LINK>). This is largely made up of searches of published literature. It is possible that there are unpublished studies we are not aware of and the possibility of a publication bias must be regarded.</P>
<P>We have chosen to use the random-effects model for our meta-analytic calculations to consider variability between the included studies. This technique does emphasise the results from smaller trials and it is these studies that are likely to be most prone to bias. Within this context, it must be accounted that applying a fixed-effect model instead of a random-effects approach in a sensitivity analysis of the primary outcome converted non-significant results to significant between-group difference in Comparison 1. (benzodiazepine monotherapy versus placebo).</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2012-09-03 15:44:18 +0100" MODIFIED_BY="[Empty name]">
<P>We are aware of one Cochrane review investigating the utilisation of benzodiazepines in acute psychosis irrespective of the underlying diagnosis (<LINK REF="REF-Gillies-2005" TYPE="REFERENCE">Gillies 2005</LINK>). Thus, this review differs from the present one which evaluated only trials that included people with the main diagnosis of a schizophrenia and other types of schizophrenia(-like) psychoses (e.g. schizophreniform, schizoaffective, or delusional disorders). As in this review, <LINK REF="REF-Gillies-2005" TYPE="REFERENCE">Gillies 2005</LINK> concluded that the findings were insufficient to derive evidence-based treatment recommendations.</P>
<P>Our meta-analytic findings support the advice of international treatment guidelines which recommend explicitly antipsychotic monotherapy as first-line medication for the management of schizophrenia (e.g. <LINK REF="REF-Falkai-2005" TYPE="REFERENCE">Falkai 2005</LINK>; <LINK REF="REF-Falkai-2006" TYPE="REFERENCE">Falkai 2006</LINK>; <LINK REF="REF-Lehman-2004" TYPE="REFERENCE">Lehman 2004</LINK>; <LINK REF="REF-NICE-2009" TYPE="REFERENCE">NICE 2009</LINK>). Due to their well established sedating properties, the administration of benzodiazepines should be considered primarily for the short-term management of acutely highly agitated patients with schizophrenia but not for the medium and long term pharmacological treatment of schizophrenia and schizophrenia-like psychosis.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-09-03 15:44:18 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2012-09-03 15:44:18 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. For clinicians</HEADING>
<P>Although benzodiazepines are very frequently used in clinical practise, we found, apart from short-term sedation, no empirical evidence to support their widespread use. At best, benzodiazepines may effectively be used to calm or sedate people with schizophrenia in the ultra short term with an acute episode of a schizophrenic disorder. This systematic review is unable to quantify the effects of benzodiazepines for other outcomes that benzodiazepines are commonly used for in clinical practise such as reducing anxiety or improving positive symptoms of schizophrenia and related disorders.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. For people with schizophrenia</HEADING>
<P>People with schizophrenia should know that benzodiazepines may help them to calm down during exacerbations of the disorder and that their use for this indication is not associated with a high number of adverse effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. For managers and policy makers</HEADING>
<P>This systematic review provides evidence that benzodiazepines main indication of benzodiazepines in schizophrenia (sedation of acute agitated people with schizophrenia) is supported by this systematic review. No evidence is available for the effectiveness of the general prescription of benzodiazepines in schizophrenia.</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-06-19 15:15:42 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. General</HEADING>
<P>Any future trials should respect standards of measuring outcomes and of reporting trial data in order to enhance the comparability of study results (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>). Therefore, the updated version of the CONSORT Statement should be considered (<LINK REF="REF-Schulz-2010" TYPE="REFERENCE">Schulz 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Specific</HEADING>
<P>Benzodiazepines are very frequently prescribed in the treatment of schizophrenia. It is therefore sobering how poorly their efficacy and safety have been examined up to date in randomised controlled research projects. We suggest to conduct further trials on benzodiazepines, especially as "add-on" medication to antipsychotic drugs, to evaluate a potential alleviation of the positive symptoms of schizophrenia.</P>
</SUBSECTION>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-10-02 11:03:47 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank Profs. and Drs. Carpenter, Cheung, Huf, Lingjaerde, Mauri, Minervini, and Ungvari for their reply to our letters or for sending us their original patient data. We would like to acknowledge the contribution of Anja Volz who helped with data extraction and writing of the report in previous versions of the review. We also wish to thank Samantha Roberts, Mark Fenton and Judy Wright for the trial searching and the editorial base of the Cochrane Schizophrenia Group for their continuous help.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-09-28 13:42:07 +0100" MODIFIED_BY="[Empty name]">
<P>Markus Dold: received travel payment from Janssen-Cilag.<BR/>Magdolna Tardy: none to declare.<BR/>Chunbo Li: none to declare.<BR/>Vesal Khorsand: none to declare.<BR/>Donna Gillies: none to declare.<BR/>Stefan Leucht: has received honoraria for consulting/advisory boards from Alkermes, BristolMyersSquibb, EliLilly, Janssen, Johnson&amp;Johnson, Medavante, Roche, lecture honoraria from AstraZeneca, BristolMyersSquibb, EliLilly, EssexPharma, Janssen, Johnson&amp;Johnson, Lundbeck Institute, Pfizer, SanofiAventis, and EliLilly has provided medication for a trial with SL as the primary investigator.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-09-26 10:08:35 +0100" MODIFIED_BY="[Empty name]">
<P>Markus Dold: study selection, data extraction, statistical analyses, writing of the report (updated version of the review).<BR/>Magdolna Tardy: study selection, data extraction (updated version of the review).<BR/>Chunbo Li: study selection, data extraction (updated version of the review).<BR/>Vesal Khorsand: protocol development, data extraction (previous version of the review).<BR/>Donna Gillies: data extraction (previous version of the review).<BR/>Stefan Leucht: protocol development, checking study selection and data extraction, writing of the report (previous and updated version of the review).</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-09-05 14:32:19 +0100" MODIFIED_BY="[Empty name]">
<P>In difference to the previous version of this systematic review we did not intend to include continuous data from rating scales only if a.) the psychometric properties of the measuring instrument have been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>); and b.) the measuring instrument has not been written or modified for that particular trial.</P>
<P>In this updated systematic review we calculated the number needed to treat to provide benefit /to induce harm statistic (NNTB/H), and its 95% confidence interval (CI) as the inverse of the risk differences for statistically significant results.</P>
<P>We did not aim to calculate the standardised mean differences (SMDs) as effect size measures.</P>
<P>Contrary to our statements in the previous version of this systematic review, we did not exclude trials because of unclear allocation concealment.</P>
<P>In this updated systematic review we decided to display skewed data in an 'other data table' and did not calculate effect sizes. These tables can be found within the section "data analysis".</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-10-02 11:35:33 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-10-02 11:35:33 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-10-02 11:29:40 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Azima-1962" MODIFIED="2012-07-26 13:39:54 +0100" MODIFIED_BY="[Empty name]" NAME="Azima 1962" YEAR="1962">
<REFERENCE MODIFIED="2012-07-26 13:39:54 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Azima,H.,M.D.,Dorothy Arthurs,R.N. and A. Silver, M.D. The effects of chlordiazepoxide (Librium) in anxiety states.&lt;br&gt;Canadian Psychiatric Journal 1962 (VOl. 7,No.1 44)&lt;/p&gt;" NOTES_MODIFIED="2012-07-26 13:39:54 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Azima H, Arthurs D, Silver A</AU>
<TI>The effects of chlordiazepoxide (librium) in anxiety states: A multi-blind study</TI>
<SO>Canadian Psychiatric Journal</SO>
<YR>1962</YR>
<VL>7</VL>
<PG>44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barbee-1992" MODIFIED="2011-10-10 08:19:37 +0100" MODIFIED_BY="[Empty name]" NAME="Barbee 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-10-10 08:19:37 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Barbee J, Mancuso D, Freed C, Todorov AA. Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia [published erratum appears in Am J Psychiatry 1992 Aug;149(8):1129] [see comments]. American Journal of Psychiatry 1992 Apr;149:506-10&lt;/p&gt;" NOTES_MODIFIED="2011-10-10 08:19:37 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barbee J, Mancuso D, Freed C, Todorov AA</AU>
<TI>Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia [published erratum appears in American Journal of Psychiatry 1992 ;149:1129] [see comments]</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1992</YR>
<VL>149</VL>
<PG>506-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Battaglia-1997" MODIFIED="2012-09-10 16:35:45 +0100" MODIFIED_BY="[Empty name]" NAME="Battaglia 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-09-10 16:35:45 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Battaglia J,Moss S,Rush J, Kang J, Mendoza R, Leedom L, Dubin W, Mc Glynn C, Goodmann L, Haloperidol,Lorazepam,or both for psychotic agitation?A multicenter, prospective, double blind, emergency department study. Am J Emerg. Med. Vol. 15, Nr. 4, 1997&lt;/p&gt;" NOTES_MODIFIED="2012-09-10 16:35:45 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Battaglia J, Moss S, Rush J, Kang J, Mendoza R, Leedom L, et al</AU>
<TI>Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study</TI>
<SO>American Journal of Emergency Medicine</SO>
<YR>1997</YR>
<VL>15</VL>
<PG>335-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carpenter-1999" MODIFIED="2012-09-10 16:35:53 +0100" MODIFIED_BY="[Empty name]" NAME="Carpenter 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-09-10 16:35:53 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Carpenter, T. M.D. ,Buchanan, W. ,M.D., Kirkpatrick,B.,M.D. and Breier,F. M.D. Diazepam Treatment of Early Signs of Exacerbation in Schizophrenia . American Journal of Psychiatry 156:2,1999&lt;/p&gt;" NOTES_MODIFIED="2012-09-10 16:35:53 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter T, Buchanan W , Kirkpatrick B, Breier F</AU>
<TI>Diazepam treatment of early signs of exacerbation in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>156</VL>
<PG>299-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheung-1981" MODIFIED="2012-10-02 11:29:40 +0100" MODIFIED_BY="[Empty name]" NAME="Cheung 1981" YEAR="1981">
<REFERENCE MODIFIED="2012-10-02 11:29:40 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Cheung H. Schizophrenics fully remitted on neuroleptics for 3-5 years--to stop or continue drugs? British Journal of Psychiatry 1981;138:490-494&lt;/p&gt;" NOTES_MODIFIED="2012-10-02 11:29:40 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheung HK</AU>
<TI>Schizophrenics fully remitted on neuroleptics for 3-5 years-To stop or continue drugs?</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1981</YR>
<VL>138</VL>
<PG>490-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chouinard-1993" MODIFIED="2011-10-12 10:54:29 +0100" MODIFIED_BY="[Empty name]" NAME="Chouinard 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-10-12 10:54:29 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Chouinard G, Annable L, Turnier L, Holobow N, Szkrumelak N. A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms [see comments]. Can-J-Psychiatry 1993;38 Suppl 4:S114-21.&lt;/p&gt;" NOTES_MODIFIED="2011-10-12 10:54:29 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Annable L, Turnier L, Holobow N, Szkrumelak N</AU>
<TI>A double-blind randomized clinical trial of rapid tranquilization with i.m. clonazepam and i.m. haloperidol in agitated psychotic patients with manic symptoms</TI>
<SO>Canadian Journal of Psychiatry</SO>
<YR>1993</YR>
<VL>38</VL>
<NO>Suppl 4</NO>
<PG>114-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dorevitch-1999" MODIFIED="2011-10-12 08:29:15 +0100" MODIFIED_BY="[Empty name]" NAME="Dorevitch 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Dorevitch A, Kalian M, Shlafman M, Lerner V. Treatment of long-term tardive dyskinesia with Vitamin E. Biological Psychiatry 1997 ;Vol 41:114-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dorevitch A, Kalian M, Shlafman M, Lerner V</AU>
<TI>Treatment of long-term tardive dyskinesia with Vitamin E</TI>
<SO>Biological Psychiatry</SO>
<YR>1997</YR>
<VL>41</VL>
<PG>114-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-12 08:29:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dorevith A, Katz N, Zemishlany Z, Aizenberg D, Weizman A</AU>
<TI>Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>156</VL>
<PG>142-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Foster-1997" NAME="Foster 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Foster S, Kessel J, Berman ME, Simpson GM. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int-Clin-Psychopharmacol 1997 ;12:175-9&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Foster S, Kessel J, Berman ME, Simpson GM</AU>
<TI>Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1997</YR>
<VL>12</VL>
<PG>175-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garza_x002d_Trevino-1989" MODIFIED="2012-09-10 16:36:08 +0100" MODIFIED_BY="[Empty name]" NAME="Garza-Trevino 1989" YEAR="1989">
<REFERENCE MODIFIED="2012-09-10 16:36:08 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Garza-Trevino ES, Hollister LE, Overall JE, Alexander WF. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation [see comments]. Am-J-Psychiatry 1989 ;146:1598-1601&lt;/p&gt;" NOTES_MODIFIED="2012-09-10 16:36:08 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garza-Trevino ES, Hollister LE, Overall JE, Alexander WF</AU>
<TI>Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>146</VL>
<PG>1598-601</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gundlach-1966" NAME="Gundlach 1966" YEAR="1966">
<REFERENCE NOTES="&lt;p&gt;Gundlach R, Engelhardt DM, Hankoff L, Paley H, Rudorfer L, Bird E. A DOUBLe-blind utpatient study of diazepam (Valium) and placebo. Psychopharmacologia 1966;9:81-92&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gundlach R, Engelhardt DM, Hankoff L, Paley H, Rudorfer L, Bird E</AU>
<TI>A Double-blind outpatient study of diazepam (Valium) and placebo</TI>
<SO>Psychopharmacologia</SO>
<YR>1966</YR>
<VL>9</VL>
<PG>81-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guz-1972" MODIFIED="2011-10-12 08:29:30 +0100" MODIFIED_BY="[Empty name]" NAME="Guz 1972" YEAR="1972">
<REFERENCE MODIFIED="2011-10-12 08:29:30 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Guz I, Moraes R, Sartoretto JN. The therapeutic effects of lorazepam in psychotic patients treated with haloperidol - A double blind study. Current Therapeutic Research 1972 ;14:767-74.&lt;/p&gt;" NOTES_MODIFIED="2011-10-12 08:29:30 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Guz I, Moraes R, Sartoretto JN</AU>
<TI>The therapeutic effects of lorazepam in psychotic patients treated with haloperidol - A double blind study</TI>
<SO>Current Therapeutic Research</SO>
<YR>1972</YR>
<VL>14</VL>
<PG>767-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Guz I. Lorazepam e haloperidol em esquizofrenia. / Lorazepam and haloperidol in the treatment of schizophrenic patients. Jornal Brasileiro de Psiquiatria 1988 ;37:205-207.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guz I</AU>
<TI>Lorazepam and haloperidol in the treatment of schizophrenic patients</TI>
<TO>Lorazepam e haloperidol em esquizofrenia</TO>
<SO>Jornal Brasileiro de Psiquiatria</SO>
<YR>1988</YR>
<VL>37</VL>
<PG>205-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hankoff-1962" MODIFIED="2012-09-10 16:36:23 +0100" MODIFIED_BY="Heather Maxwell" NAME="Hankoff 1962" YEAR="1962">
<REFERENCE MODIFIED="2012-09-10 16:36:23 +0100" MODIFIED_BY="Heather Maxwell" NOTES="&lt;p&gt;Hankoff L.,M.D.,Rudorfer L.,M.D. and PAly H. M., M.D. A two week double blind outpatient evaluation .A reference study of ataraxics.The J new drugs (may-June 1962 :179&lt;/p&gt;" NOTES_MODIFIED="2012-09-10 16:36:23 +0100" NOTES_MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hankoff L, Rudorfer L, Paly HM</AU>
<TI>A reference study of ataraxics. A two-week double blind outpatient evaluation</TI>
<SO>The Journal of New Drugs</SO>
<YR>1962</YR>
<VL>179</VL>
<PG>173-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanlon-1969" MODIFIED="2012-09-10 16:39:10 +0100" MODIFIED_BY="[Empty name]" NAME="Hanlon 1969" YEAR="1969">
<REFERENCE MODIFIED="2012-09-10 16:39:10 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Hanlon T.,Kay Y., Agallianos D.,Berman A,Bethon C,Kolber F, Kurland A. Combined Drug Treatment of Newly Hospitalized Acutly III Psychiatric Patient. Diseases of the Nervous System Feb.1969.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-09-10 16:39:10 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hanlon TE, Kay Y, Agallianos D, Berman A, Bethon C, Kolber F, et al</AU>
<TI>Combined drug treatment of newly hospitalized, acutely ill psychiatric patients</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1969</YR>
<VL>30</VL>
<PG>104-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanlon-1970" MODIFIED="2012-02-14 10:55:08 +0000" MODIFIED_BY="[Empty name]" NAME="Hanlon 1970" YEAR="1970">
<REFERENCE MODIFIED="2012-02-14 10:55:08 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Hanlon T., Kay Y.,Kurland A.. Comparative effects of fluphenazine, fluphenazine-chlordiazepoxide and fluphenazine-imipramine. Diseases of Nervous System March 1970.&lt;/p&gt;" NOTES_MODIFIED="2012-02-14 10:55:08 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hanlon TE, Ota KY, Kurland AA</AU>
<TI>Comparative effects of fluphenazine, fluphenazine-chlordiazepoxide and fluphenazine-imipramine</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1970</YR>
<VL>31</VL>
<PG>171-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hanlon TE, Robert JB, Kurland AA</AU>
<TI>Effects od control techniques on therapeutic outcome in a controlled trial</TI>
<SO>International Pharmacopsychiatry</SO>
<YR>1975</YR>
<VL>10</VL>
<PG>169-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holden-1968" MODIFIED="2011-10-10 07:51:09 +0100" MODIFIED_BY="[Empty name]" NAME="Holden 1968" YEAR="1968">
<REFERENCE NOTES="&lt;p&gt;Holden JM, Holden UP. Weight changes with SCHIZOphrenic psychosis and psychotropic drug therapy. Psychosomatics 1970 Nov-Dec;11:551-61.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holden JMC, Holden UP</AU>
<TI>Weight changes with schizophrenic psychosis and psychotropic drug therapy</TI>
<SO>Psychosomatics</SO>
<YR>1970</YR>
<VL>11</VL>
<PG>551-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-10 07:51:09 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Holden JM, Itil TM, Keskiner A, Fink M. Thioridazine and chlordiazepoxide, alone and combined, in the treatment of chronic SCHIZOphrenia. Compr-Psychiatry 1968 Nov;9:633-43.&lt;/p&gt;" NOTES_MODIFIED="2011-10-10 07:51:09 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Holden JMC, Itil TM, Keskiner A, Fink M</AU>
<TI>Thioridazine and chlordiazepoxide, alone and combined, in the treatment of chronic schizophrenia</TI>
<SO>Comprehensive Psychiatry</SO>
<YR>1968</YR>
<VL>9</VL>
<PG>633-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holden JMC, Itil TM</AU>
<TI>Laboratory changes with chlordiazepoxide and thioridazine, alone and combined</TI>
<SO>Canadian Psychiatric Association Journal</SO>
<YR>1969</YR>
<VL>14</VL>
<PG>299-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kurland-1966" MODIFIED="2011-10-12 08:29:49 +0100" MODIFIED_BY="[Empty name]" NAME="Kurland 1966" YEAR="1966">
<REFERENCE MODIFIED="2011-10-12 08:29:49 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Kurland AA BGMMAD. Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment: side effects and clinical laboratory findings. J-New-Drugs 1966;6:80-95.&lt;/p&gt;" NOTES_MODIFIED="2011-10-12 08:29:49 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kurland AA , Bethon GD, Michaux MH, Agallianos DD</AU>
<TI>Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment: side effects and clinical laboratory findings</TI>
<SO>Journal of New Drugs</SO>
<YR>1966</YR>
<VL>6</VL>
<PG>80-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-10 10:35:21 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Michaux MH KAAD. Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment of newly hospitalized, acutely ill psychiatric patients. Curr-Ther-Res-Clin-Exp 1966;8:Suppl: 117-52.&lt;/p&gt;" NOTES_MODIFIED="2011-10-10 10:35:21 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Michaux MH, Kurland AA, Agallianos DD</AU>
<TI>Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment of newly hospitalized, acutely ill psychiatric patients</TI>
<SO>Current Therapeutic Research Clininical and Experimental</SO>
<YR>1966</YR>
<VL>8</VL>
<NO>Suppl</NO>
<PG>117-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kutcher-1989" MODIFIED="2012-02-21 10:37:25 +0000" MODIFIED_BY="[Empty name]" NAME="Kutcher 1989" YEAR="">
<REFERENCE MODIFIED="2012-02-21 10:37:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kutcher S, Williamson P, MacKenzie S, Marton P, Ehrlich M</AU>
<TI>Successful clonazepam treatment of neuroleptic-induced akathisia in older adolescents and young adults: a double-blind, placebo-controlled study</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1989</YR>
<VL>9</VL>
<PG>403-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lerner-1979" NAME="Lerner 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Lerner Y, Lwow E, Levitin A, Belmaker RH. Acute high-dose parenteral haloperidol treatment of psychosis. Am-J-Psychiatry 1979 Aug;136:1061-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lerner Y, Lwow E, Levitin A, Belmaker RH</AU>
<TI>Acute high-dose parenteral haloperidol treatment of psychosis</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1979</YR>
<VL>136</VL>
<PG>1061-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lingjaerde-1979" MODIFIED="2011-10-10 08:00:56 +0100" MODIFIED_BY="[Empty name]" NAME="Lingjaerde 1979" YEAR="1979">
<REFERENCE MODIFIED="2011-10-10 08:00:56 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Lingjaerde O, Engstrand E, Ellingsen P, et al. Antipsychotic effect of diazepam when given in addition to neuroleptics in chronic psychotic patients - A double-blind clinical trial. Current Therapeutic Research - Clinical and Experimental 1979;26:505-514.&lt;/p&gt;" NOTES_MODIFIED="2011-10-10 08:00:56 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lingjaerde O, Engstrand E, Ellingsen P, Robak OH</AU>
<TI>Antipsychotic effect of diazepam when given in addition to neuroleptics in chronic psychotic patients - A double-blind clinical trial</TI>
<SO>Current Therapeutic Research</SO>
<YR>1979</YR>
<VL>26</VL>
<PG>505-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lingjaerde-1982" NAME="Lingjaerde 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Lingjaerde-O. Effect of the benzodiazepine derivative estazolam in patients with auditory hallucinations. A multicentre double- blind, cross-over study. Acta-Psychiatr-Scand 1982 May;65:339-54.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lingjaerde O</AU>
<TI>Effect of the benzodiazepine derivative estazolam in patients with auditory hallucinations. A multicentre double-blind, cross-over study</TI>
<SO>Acta Psychiatrica Scandinavia</SO>
<YR>1982</YR>
<VL>65</VL>
<PG>339-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-2006" MODIFIED="2011-05-06 08:31:48 +0100" MODIFIED_BY="[Empty name]" NAME="Ma 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-05-06 08:31:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma C</AU>
<TI>The control study of injection of clonazepam into tinggong for auditory hallucination of schizophrenia</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2006</YR>
<VL>12</VL>
<PG>338-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marneros-1979" MODIFIED="2012-02-21 10:37:13 +0000" MODIFIED_BY="[Empty name]" NAME="Marneros 1979" YEAR="1979">
<REFERENCE MODIFIED="2012-02-21 10:37:13 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Marneros,A. Anxiolytische Zusatzbehandlung bei der affekbetonten Schizophrenien . Ein Doppelblindversuch. Therapiewoche 29, 7533-7538(1979)&lt;/p&gt;" NOTES_MODIFIED="2012-02-21 10:37:13 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marneros A</AU>
<TI>Anxiolytische Zusatzbehandlung bei den affektbetonten Schizophrenien. Ein Doppelblindversuch</TI>
<SO>Therapiewoche 29</SO>
<YR>1979</YR>
<VL>44</VL>
<PG>7533-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Merlis-1962" NAME="Merlis 1962" YEAR="1962">
<REFERENCE NOTES="&lt;p&gt;Merlis S TWKW. A double-blind comparison of diazepam, chlordiazepoxide and chlorpromazine in psychotic patients. Journal of Neuropsychiatry 1962;August:S133-S138.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Merlis S, Turner WJ, Krumholz W</AU>
<TI>A double-blind comparison of diazepam, chlordiazepoxide and chlorpromazine in psychotic patients</TI>
<SO>Journal of Neuropsychiatry</SO>
<YR>1962</YR>
<VL>3</VL>
<PG>133-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Minervini-1990" NAME="Minervini 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Minervini MG, Priore P, Farolfi A, Cesana B, Et A. Double blind, controlled study of the efficacy and safety of alpidem in the treatment of anxiety in schizophrenic in patients. Pharmacopsychiatry 1990 Mar;23:102-106.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Minervini MG, Priore P, Farolfi A, Cesana B, Morselli PL</AU>
<TI>Double blind, controlled study of the efficacy and safety of alpidem in the treatment of anxiety in schizophrenic in-patients</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1990</YR>
<VL>23</VL>
<PG>102-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morphy-1986" NAME="Morphy 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Morphy MA. A double-blind comparison of alprazolam and placebo in the treatment of anxious schizophrenic outpatients. CURRENT THERAPEUTIC RESEARCH CLINICAL AND EXPERIMENTAL 1986;40:551-560&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morphy M</AU>
<TI>A double-blind comparison of alprazolam and placebo in the treatment of anxious schizophrenic outpatients</TI>
<SO>Current Therapeutic Research</SO>
<YR>1986</YR>
<VL>40</VL>
<PG>551-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nestoros-1982" MODIFIED="2011-10-10 08:20:36 +0100" MODIFIED_BY="[Empty name]" NAME="Nestoros 1982" YEAR="1982">
<REFERENCE MODIFIED="2011-10-10 08:20:36 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Nestoros JN, Et A. Diazepam in high doses is effective in schizophrenia. Progress in Neuro Psychopharmacology and Biological Psychiatry 1982;6:513-516.&lt;/p&gt;" NOTES_MODIFIED="2011-10-10 08:20:36 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nestoros JN, Suranyi-Cadotte BE, Spees RC, Schwartz G, Vasavan Nair NP</AU>
<TI>Diazepam in high doses is effective in schizophrenia</TI>
<SO>Progress in Neuro- Psychopharmacolgy and Biological Psychiatry</SO>
<YR>1982</YR>
<VL>6</VL>
<PG>513-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nishikawa-1982" NAME="Nishikawa 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Nishikawa T, Tsuda A, Tanaka M, et al. Prophylactic effect of neuroleptics in symptom-free schizophrenics. Psychopharmacology 1982;77:301-304.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nishikawa T, Tsuda A, Tanaka M, Koga I, Uchida Y</AU>
<TI>Prophylactic effect of neuroleptics in symptom-free schizophrenics</TI>
<SO>Psychopharmacology</SO>
<YR>1982</YR>
<VL>77</VL>
<PG>301-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pujalte-1994" MODIFIED="2012-09-10 16:39:25 +0100" MODIFIED_BY="[Empty name]" NAME="Pujalte 1994" YEAR="">
<REFERENCE MODIFIED="2012-09-10 16:39:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pujalte D, Battai T, Hue B, Alric R, Pouget R, Blayac JP, et al</AU>
<TI>A double-blind comparison of clonazepam and placebo in the treatment of neuroleptic-induced akathisia</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1994</YR>
<VL>17</VL>
<PG>236-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stevens-1992" NAME="Stevens 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Stevens A, Stevens I, Mahal A, Gaertner HJ. Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis. Pharmacopsychiatry 1992 Nov;25:273-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stevens A, Stevens I, Mahal A, Gaertner HJ</AU>
<TI>Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1992</YR>
<VL>25</VL>
<PG>273-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TREC_x002d_Rio-2003" MODIFIED="2012-09-10 16:39:35 +0100" MODIFIED_BY="[Empty name]" NAME="TREC-Rio 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-09-10 16:39:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>TREC Collaborative Group</AU>
<TI>Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethiazine</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>708-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2000" MODIFIED="2011-05-05 13:55:24 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-05-05 13:55:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang G, Ji R, Pei G</AU>
<TI>the control study of injection of clonazepam into t´ingkung for refractory auditory hallucination of schizophrenics</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2000</YR>
<VL>6</VL>
<PG>143-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2003" MODIFIED="2011-10-10 08:01:22 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2003" YEAR="">
<REFERENCE MODIFIED="2011-10-10 08:01:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang X, Wang X, Zhou H</AU>
<TI>An efficacy study of risperidone combined with clonazepam injection in the treatment of paranoid schizophrenia</TI>
<SO>Journal of Clinical Psychologic Medicine</SO>
<YR>2003</YR>
<VL>13</VL>
<PG>217-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wyant-1990" NAME="Wyant 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Wyant M, Diamond BI, O'Neal E, Sloan A, Et A. The use of midazolam in acutely agitated psychiatric patients. 29th Annual Meeting of the New Clinical Drug Evaluation Unit (1989, Key Biscayne, Florida). Psychopharmacology Bulletin 1990;26:126-129.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wyant M, Diamond BI, O'Neal E, Sloan A, Borison RL</AU>
<TI>The use of midazolam in acutely agitated psychiatric patients</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1990</YR>
<VL>26</VL>
<PG>126-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xuan-2007" MODIFIED="2011-05-05 14:04:31 +0100" MODIFIED_BY="[Empty name]" NAME="Xuan 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-05-05 14:04:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xuan GH, Chu Y</AU>
<TI>Clinical observation on the effect of risperidone combined with BZD on schizophrenia</TI>
<SO>China Tropical Medicine</SO>
<YR>2007</YR>
<VL>7</VL>
<PG>244</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-10-02 11:35:33 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Adler-1985" MODIFIED="2011-05-22 16:58:30 +0100" MODIFIED_BY="[Empty name]" NAME="Adler 1985" YEAR="1985">
<REFERENCE MODIFIED="2011-05-22 16:58:30 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Adler L, Angrist B, Peselow E, Corwin J, Rotrosen J. Efficacy of propranolol in neuroleptic-induced akathesia. J-Clin-Psychopharmacol 1985 Jun;5:164-6.&lt;/p&gt;" NOTES_MODIFIED="2011-05-22 16:58:30 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adler L, Angrist B, Peselow E, Corwin J, Rotrosen J</AU>
<TI>Efficacy of propranolol in neuroleptic-induced akathisia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1985</YR>
<VL>5</VL>
<PG>164-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alexander-2004" MODIFIED="2012-09-10 16:39:49 +0100" MODIFIED_BY="[Empty name]" NAME="Alexander 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-09-10 16:39:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alexander J, Tharyan P, Adams C, John T, Mol C, Philip J</AU>
<TI>Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2004</YR>
<VL>186</VL>
<PG>63-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Altamura-1987" NAME="Altamura 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Altamura AC, Mauri MC, Mantero M, Brunetti M. Clonazepam/haloperidol combination therapy in schizophrenia: A double blind study. Acta Psychiatrica Scandinavica 1987 ;76:702-6&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Altamura AC, Mauri MC, Mantero M, Brunetti M</AU>
<TI>Clonazepam/haloperidol combination therapy in schizophrenia: A double blind study</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1987</YR>
<VL>76</VL>
<PG>702-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ananth-1979" MODIFIED="2011-10-10 07:51:45 +0100" MODIFIED_BY="[Empty name]" NAME="Ananth 1979" YEAR="1979">
<REFERENCE MODIFIED="2011-10-10 07:51:45 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ananth JV, Sohn JH, Ban TA, Lehmann HE. Doxepin in geriatric patients. Current-Therapeutic-Research 1979 Jan;25:133-138.&lt;/p&gt;" NOTES_MODIFIED="2011-10-10 07:51:45 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ananth JV, Sohn JH, Ban TA, Lehmann HE</AU>
<TI>Doxepin in geriatric patients</TI>
<SO>Current Therapeutic Research</SO>
<YR>1979</YR>
<VL>25</VL>
<PG>133-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bao-2007" MODIFIED="2012-07-26 13:48:08 +0100" MODIFIED_BY="[Empty name]" NAME="Bao 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-07-26 13:48:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bao LY, Wang KM</AU>
<TI>The effectiveness of aripiprazole combined with clonazepam treated with agitation in schizophrenia</TI>
<SO>Medical Journal of Chinese People's Health</SO>
<YR>2007</YR>
<VL>5</VL>
<PG>ni</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bienek-1997" MODIFIED="2011-10-10 08:01:32 +0100" MODIFIED_BY="[Empty name]" NAME="Bienek 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-10-10 08:01:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bienek SA, Ownby RL, Dominguez RA</AU>
<TI>A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation</TI>
<SO>Pharmacotherapy</SO>
<YR>1998</YR>
<VL>18</VL>
<PG>57-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bobruff-1981" MODIFIED="2012-07-26 13:55:13 +0100" MODIFIED_BY="Heather Maxwell" NAME="Bobruff 1981" YEAR="1981">
<REFERENCE MODIFIED="2012-07-26 13:55:13 +0100" MODIFIED_BY="Heather Maxwell" NOTES="&lt;p&gt;Bobruff A, Gardos G, Tarsy D,Rapkin R,Cole J,Moore P. Clonazepam and phenobarbital in tardive dyskinesia. American Journal of Psychiatry 1981 Feb;138:189-93&lt;/p&gt;" NOTES_MODIFIED="2012-07-26 13:55:13 +0100" NOTES_MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bobruff A, Gardos G, Tarsy D, Rapkin R, Cole J, Moore P</AU>
<TI>Clonazepam and phenobarbital in tardive dyskinesia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1981</YR>
<VL>138</VL>
<PG>189-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-1987" NAME="Cohen 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Cohen S,KHan A,Adjunctive Benzodiazepines in acute schizophrenia.Neuropsychobiology 18:9-12(1987)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen S, Khan A</AU>
<TI>Adjunctive benzodiazepines in acute schizophrenia</TI>
<SO>Neuropsychobiology</SO>
<YR>1987</YR>
<VL>18</VL>
<PG>9-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crosse-1974" MODIFIED="2011-10-10 08:01:42 +0100" MODIFIED_BY="[Empty name]" NAME="Crosse 1974" YEAR="1974">
<REFERENCE MODIFIED="2011-10-10 08:01:42 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Crosse B. (Clinical trials of sulpiride (1403 R.D.--Dogmatil): Its advantages prescribed alone or in combination.). Psychologie-Medicale 1974;6:1623-1630.&lt;/p&gt;" NOTES_MODIFIED="2011-10-10 08:01:42 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crosse B</AU>
<TI>Clinical trials of sulpiride (1403 R.D.--Dogmatil): Its advantages prescribed alone or in combination</TI>
<TO>Essais cliniques du sulpiride (1403 R. D. - Dogmatil): Son Intérêt en prescription isolée et en association</TO>
<SO>Psychologie Médicale</SO>
<YR>1974</YR>
<VL>6</VL>
<PG>1623-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Csernansky-1988" MODIFIED="2012-09-10 16:40:03 +0100" MODIFIED_BY="[Empty name]" NAME="Csernansky 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-09-10 16:40:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Csernansky JG, Riney SJ, Lombrozo L, Overall JE, Hollister LE</AU>
<TI>Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative symptoms</TI>
<SO>Archive of General Psychiatry</SO>
<YR>1988</YR>
<VL>45</VL>
<PG>655-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-10 08:20:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Csernansky JG, Tacke U, Rusen D, Hollister LE</AU>
<TI>The effect of benzodiazepines on tardive dyskinesia symptoms</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1988</YR>
<VL>8</VL>
<PG>154</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dubin-1988" MODIFIED="2011-10-10 07:52:09 +0100" MODIFIED_BY="[Empty name]" NAME="Dubin 1988" YEAR="">
<REFERENCE MODIFIED="2011-10-10 07:52:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dubin WR</AU>
<TI>Rapid tranquilization: antipsychotics or benzodiazepines</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1988</YR>
<VL>49</VL>
<PG>5-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ge-Qianrong-2004" MODIFIED="2011-05-11 15:44:25 +0100" MODIFIED_BY="[Empty name]" NAME="Ge Qianrong 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-05-11 15:44:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ge Q, Liang X, Wang X</AU>
<TI>A comparative study of risperidone combining clonazepam and haloperidol in the treatment of patients with schizophrenia</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2004</YR>
<VL>17</VL>
<PG>134-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenfeld-1987" NAME="Greenfeld 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Greenfeld D,Conrad C, Kincare P,Bowers M. B.,Treatment of Catatonia with Low-Dose Lorazepam. Am J Psychiatry 1987;144:1224-1225.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenfeld D, Conrad C, Kincare P, Bowers MB</AU>
<TI>Treatment of catatonia with low-dose lorazepam</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1987</YR>
<VL>144</VL>
<PG>1224-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haas1982" NAME="Haas1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Haas S, Emrich HM, Beckmann H. Analgesic and euphoric effects of high dose diazepam in schizophrenia. Neuropsychobiology 1982 May-Jun;8:123-128.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haas S, Emrich HM, Beckmann H</AU>
<TI>Analgesic and euphoric effects of high dose diazepam in schizophrenia</TI>
<SO>Neuropsychobiology</SO>
<YR>1982</YR>
<VL>8</VL>
<PG>123-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanus-1973" NAME="Hanus 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;Hanus M, Guelfi J. [A new tranquilizer: lorazepam (158 cases)]. Un nouveau tranquillisant: le Lorazepam (158 observations. Therapeutique 1973 May-Jun;49:349-54.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hanus M, Guelfi J</AU>
<TI>A new tranquilizer: lorazepam (158 cases)</TI>
<TO>Un nouveau tranquillisant: le Lorazepam (158 observations)</TO>
<SO>Semaine des Hopitaux (Therapeutique)</SO>
<YR>1973</YR>
<VL>49</VL>
<PG>349-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hartelius-1978" NAME="Hartelius 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Hartelius H, Larsson AK, Lepp M, Malm U, Arvidsson A, Dahlstrom H. A controlled long-term study of flunitrazepam, nitrazepam and placebo, with special regard to withdrawal effects. Acta Psychiatrica Scandinavica 1978 Jul;58:1-15.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hartelius H, Larsson AK, Lepp M, Malm U, Arvidsson A, Dahlstrom H</AU>
<TI>A controlled long-term study of flunitrazepam, nitrazepam and placebo, with special regard to withdrawal effects</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1978</YR>
<VL>58</VL>
<PG>1-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harvey-2004" MODIFIED="2012-09-10 16:40:14 +0100" MODIFIED_BY="[Empty name]" NAME="Harvey 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-09-10 16:40:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey AT, Flockhart D, Gorski JC, Greenblatt DJ, Burke M, Werder S, et al</AU>
<TI>Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>2004</YR>
<VL>44</VL>
<PG>1173-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-03-23 13:56:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-He-2007" MODIFIED="2012-04-23 08:37:44 +0100" MODIFIED_BY="[Empty name]" NAME="He 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-04-23 08:37:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>He W</AU>
<TI>[Title only available in Chinese characters]</TI>
<SO>Modern Medicine and Health</SO>
<YR>2007</YR>
<VL>23</VL>
<PG>527</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hekimian-1967" MODIFIED="2012-09-10 16:40:25 +0100" MODIFIED_BY="Heather Maxwell" NAME="Hekimian 1967" YEAR="1967">
<REFERENCE MODIFIED="2012-09-10 16:40:25 +0100" MODIFIED_BY="Heather Maxwell" NOTES="&lt;p&gt;Hekimian LJ, Friedhoff AJ. A controlled study of placebo, chlordiazepoxide and chlorpromazine with thirty male SCHIZOphrenic patients. Dis-Nerv-Syst 1967 Oct;28:675-8.&lt;/p&gt;" NOTES_MODIFIED="2012-09-10 16:40:25 +0100" NOTES_MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hekimian LJ, Friedhoff AJ</AU>
<TI>A controlled study of placebo, chlordiazepoxide and chlorpromazine with thirty male schizophrenic patients</TI>
<SO>Diseases of Nervous System</SO>
<YR>1967</YR>
<VL>28</VL>
<PG>675-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hesso-1975" NAME="Hesso 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Hesso R, Retterstol N, Torp H. Clinical trial with a new substance (PLP 100-127) in order to asses therapeutic efficacy and dependence creating properties. Behav-Neuropsychiatry 1975 Apr-1976 Mar;7:13-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hesso R, Retterstol N, Torp H</AU>
<TI>Clinical trial with a new substance (PLP 100-127) in order to asses therapeutic efficacy and dependence creating properties</TI>
<SO>Behavioral Neuropsychiatry</SO>
<YR>1975</YR>
<VL>7</VL>
<PG>13-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horiguchi-1992" NAME="Horiguchi 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Horiguchi J, Nishimatsu O. Usefulness of antiparkinsonian drugs during neuroleptic treatment and the effect of clonazepam on akathisia and parkinsonism occurred after antiparkinsonian drug withdrawal: a double-blind study. Jpn-J-Psychiatry-Neurol 1992 Sep;46:733-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horiguchi J, Nishimatsu O</AU>
<TI>Usefulness of antiparkinsonian drugs during neuroleptic treatment and the effect of clonazepam on akathisia and parkinsonism occurred after antiparkinsonian drug withdrawal: a double-blind study</TI>
<SO>Japanese Journal of Psychiatry and Neurology</SO>
<YR>1992</YR>
<VL>46</VL>
<PG>733-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hovens-2005" MODIFIED="2011-05-11 15:50:32 +0100" MODIFIED_BY="[Empty name]" NAME="Hovens 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-05-11 15:50:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hovens JE, Dries PJT, Melman CTM, Wapenaar RJC, Loonen AJM</AU>
<TI>Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2005</YR>
<VL>19</VL>
<PG>51-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hu-2004" MODIFIED="2011-05-11 15:45:48 +0100" MODIFIED_BY="[Empty name]" NAME="Hu 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-05-11 15:45:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hu W</AU>
<TI>Investigation of administering BZD medicament in outpatients with psychosis</TI>
<SO>Heath Psychology Journal</SO>
<YR>2004</YR>
<VL>12</VL>
<PG>43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Itil-1972" MODIFIED="2012-09-10 16:40:38 +0100" MODIFIED_BY="Heather Maxwell" NAME="Itil 1972" YEAR="1972">
<REFERENCE MODIFIED="2012-09-10 16:40:38 +0100" MODIFIED_BY="Heather Maxwell" NOTES="&lt;p&gt;Itil T, Gannon P, Cora R, Polvan N, Akpinar S, Elveris F, Eskazan E. SCH-12,041, a new anti-anxiety agent (quantitative pharmaco-electroencephalography and clinical trials). Behav-Neuropsychiatry 1972 Aug-Sep;4:15-24.&lt;/p&gt;" NOTES_MODIFIED="2012-09-10 16:40:38 +0100" NOTES_MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Itil T, Gannon P, Cora R, Polvan N, Akpinar S, Elveris F, et al</AU>
<TI>SCH-12,041, a new anti-anxiety agent (quantitative pharmaco-electroencephalography and clinical trials)</TI>
<SO>Behavioral Neuropsychiatry</SO>
<YR>1972</YR>
<VL>4</VL>
<PG>15-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jibiki-1994" NAME="Jibiki 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Jibiki I, Yamaguchi N, Momonoi F. Beneficial effect of high-dose clotiazepam on intractable auditory hallucinations in chronic SCHIZOphrenic patients. An open trial. Eur-J-Clin-Pharmacol 1994;46:367-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jibiki I, Yamaguchi N, Momonoi F</AU>
<TI>Beneficial effect of high-dose clotiazepam on intractable auditory hallucinations in chronic schizophrenic patients. An open trial</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1994</YR>
<VL>46</VL>
<PG>367-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jirmeson-1982" MODIFIED="2011-10-10 08:02:01 +0100" MODIFIED_BY="[Empty name]" NAME="Jirmeson 1982" YEAR="1982">
<REFERENCE MODIFIED="2011-10-10 08:02:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jimerson DC, Van Kammen DP, Post RM, Docherty JP, Bunney WE</AU>
<TI>Diazepam in schizophrenia: a preliminary double-blind trial</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1982</YR>
<VL>139</VL>
<PG>489-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jungkunz-1984" NAME="Jungkunz 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Jungkunz G, Nedopil N, Ruther E. Acute effects of the synthetic analogue of methionine enkephalin FK 33-824 in SCHIZOphrenic patients. A double blind trial. Pharmacopsychiatry 1984 May;17:76-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jungkunz G, Nedopil N, Ruther E</AU>
<TI>Acute effects of the synthetic analogue of methionine enkephalin FK 33-824 in schizophrenic patients. A double blind trial</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1984</YR>
<VL>17</VL>
<PG>76-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kang-2006" MODIFIED="2011-05-11 15:59:43 +0100" MODIFIED_BY="[Empty name]" NAME="Kang 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-05-11 15:59:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kang M</AU>
<TI>Clinical study on efficacy of quetiapine combined with clonazepam treated with acute agitation in schizophrenia patients</TI>
<SO>Linchuang Jingshen Yixue Zazhi</SO>
<YR>2006</YR>
<VL>16</VL>
<PG>221-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karson-1982" NAME="Karson 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Karson C, Weinberger D, Bigelow L, Wyatt RJ. Clonazepam treatment of chronic schizophrenia: negative results in a double-blind, placebo-controlled trial. American Journal of Psychiatry 1982 Dec;139:1627-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karson C, Weinberger D, Bigelow L, Wyatt RJ</AU>
<TI>Clonazepam treatment of chronic schizophrenia: negative results in a double-blind, placebo-controlled trial</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1982</YR>
<VL>139</VL>
<PG>1627-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kellner-1975" MODIFIED="2011-10-10 07:52:28 +0100" MODIFIED_BY="[Empty name]" NAME="Kellner 1975" YEAR="">
<REFERENCE MODIFIED="2011-10-10 07:52:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kellner R, Wilson RM, Muldawer MD, Pathak D</AU>
<TI>Anxiety in schizophrenia. The responses to chlordiazepoxide in an intensive design study</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1975</YR>
<VL>32</VL>
<PG>1246-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knott-2006" MODIFIED="2011-03-23 14:04:34 +0000" MODIFIED_BY="[Empty name]" NAME="Knott 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-03-23 14:04:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knott JC, Taylor DM, Castle DJ</AU>
<TI>Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>2006</YR>
<VL>47</VL>
<PG>61-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2004" MODIFIED="2011-05-12 10:04:09 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-05-12 10:04:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li AF</AU>
<TI>[Title only available in Chinese characters]</TI>
<SO>Chinese Journal of Clinical Medicine</SO>
<YR>2004</YR>
<VL>3</VL>
<PG>33-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2007" MODIFIED="2012-09-10 16:40:50 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-09-10 16:40:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li C, Zhu S, Wang H, Chen H, Yu Y, Liu D, et al</AU>
<TI>Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the treatment of schizophrenia with excitement and agitation</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2007</YR>
<VL>19</VL>
<PG>150-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maar-1983" MODIFIED="2011-10-10 10:41:37 +0100" MODIFIED_BY="[Empty name]" NAME="Maar 1983" YEAR="1983">
<REFERENCE MODIFIED="2011-10-10 10:41:37 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Maar S, Schuback G. WIRKUNGSVERGLEICH ZWEIER BENZODIAZEPINE BEI PSYCHOVEGETATIVEN ALLGEMEINNSTORUNGEN Comparison of two benzodiazepines in general psychosomatic disturbances. Therapiewoche 1983;33:1251-1258.&lt;/p&gt;" NOTES_MODIFIED="2011-10-10 10:41:37 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maar S, Schuback G</AU>
<TI>Comparison of two benzodiazepines in general psychosomatic disturbances</TI>
<TO>Wirkungsvergleich zweier Benzodiazepine bei psychovegetativen Allgemeinstörungen</TO>
<SO>Therapiewoche</SO>
<YR>1983</YR>
<VL>33</VL>
<PG>1251-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mei-2006" MODIFIED="2011-05-11 15:56:20 +0100" MODIFIED_BY="[Empty name]" NAME="Mei 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-05-11 15:56:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mei Y, Pan J, Ma P</AU>
<TI>Clinical observation on acute excitation of schizophrenia treated with QIWEI combined with clonazepam</TI>
<SO>Chinese Nursing Research</SO>
<YR>2006</YR>
<VL>20</VL>
<PG>1176-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monroe-1967" NAME="Monroe 1967" YEAR="1967">
<REFERENCE NOTES="&lt;p&gt;Monroe RR, Dale R. Chlordiazepoxide in the treatment of patients with &amp;quot;activated EEG's&amp;quot;. Dis-Nerv-Syst 1967 Jun;28:390-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monroe RR, Dale R</AU>
<TI>Chlordiazepoxide in the treatment of patients with "activated EEG's"</TI>
<SO>Diseases of Nervous System</SO>
<YR>1967</YR>
<VL>28</VL>
<PG>390-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nestros-1983" NAME="Nestros 1983" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nestros JN, Nair NPV, Pulman JR, Schwartz G, Bloom D</AU>
<TI>High doses of diazepam improve neuroleptic-resistant chronic schizophrenic patients</TI>
<SO>Psychopharmacology</SO>
<YR>1983</YR>
<VL>81</VL>
<PG>42-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nobay-2004" MODIFIED="2011-03-23 14:11:06 +0000" MODIFIED_BY="[Empty name]" NAME="Nobay 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-03-23 14:10:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nobay F, Simon BC, Levitt MA, Dresden GM</AU>
<TI>A prospective, double-blind, randomized trial of midazolam versus haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients</TI>
<SO>Academic Emergency Medicine</SO>
<YR>2004</YR>
<VL>11</VL>
<PG>744-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pato-1989" MODIFIED="2011-10-10 08:02:20 +0100" MODIFIED_BY="[Empty name]" NAME="Pato 1989" YEAR="">
<REFERENCE MODIFIED="2011-10-10 08:02:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pato CN, Wolkowitz OM, Rapaport M, Schulz SC, Pickar D</AU>
<TI>Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1989</YR>
<VL>25</VL>
<PG>263-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pecknold-1993" MODIFIED="2011-10-10 08:02:25 +0100" MODIFIED_BY="[Empty name]" NAME="Pecknold 1993" YEAR="">
<REFERENCE MODIFIED="2011-10-10 08:02:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pecknold JC</AU>
<TI>Survey of the adjuvant use of benzodiazepines for treating outpatients with schizophrenia</TI>
<SO>The Journal of Psychiatric Neurosciences</SO>
<YR>1993</YR>
<VL>18</VL>
<PG>82-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qin-2005" MODIFIED="2011-05-11 15:52:10 +0100" MODIFIED_BY="[Empty name]" NAME="Qin 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-05-11 15:52:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qin Y, Kang W, Song L</AU>
<TI>A comparative study of risperidone combining alprazolam and clozapine in the treatment of patients with schizophrenia</TI>
<SO>Heath Psychology Journal</SO>
<YR>2005</YR>
<VL>13</VL>
<PG>444-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Remington-1993" MODIFIED="2011-10-10 07:52:48 +0100" MODIFIED_BY="[Empty name]" NAME="Remington 1993" YEAR="">
<REFERENCE MODIFIED="2011-10-10 07:52:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Remington G, Fornazzari L, Setha R</AU>
<TI>Placebo response in refractory tardive akathisia</TI>
<SO>Canadian Journal of Psychiatry</SO>
<YR>1993</YR>
<VL>38</VL>
<PG>248-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richards-1998" MODIFIED="2011-10-10 08:02:35 +0100" MODIFIED_BY="[Empty name]" NAME="Richards 1998" YEAR="">
<REFERENCE MODIFIED="2011-10-10 08:02:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richards JR, Derlet RW, Duncan DR</AU>
<TI>Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol</TI>
<SO>The Journal of Emergency Medicine</SO>
<YR>1998</YR>
<VL>16</VL>
<PG>567-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruskin-1978" MODIFIED="2011-10-10 08:02:42 +0100" MODIFIED_BY="[Empty name]" NAME="Ruskin 1978" YEAR="">
<REFERENCE MODIFIED="2011-10-10 08:02:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruskin P, Averbush I, Belmaker RH, Dasberg H</AU>
<TI>Benzodiazepind in chronic schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>1979</YR>
<VL>14</VL>
<PG>557-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salam-1988" MODIFIED="2011-10-10 08:02:47 +0100" MODIFIED_BY="[Empty name]" NAME="Salam 1988" YEAR="">
<REFERENCE MODIFIED="2011-10-10 08:02:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salam SA, Kilzieh N</AU>
<TI>Lorazepam treatment of psychogenic catatonia: an update</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1988</YR>
<VL>49</VL>
<PG>16-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saletu-1971" MODIFIED="2011-10-10 07:53:05 +0100" MODIFIED_BY="[Empty name]" NAME="Saletu 1971" YEAR="">
<REFERENCE MODIFIED="2011-10-10 07:53:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saletu B, Saletu M, Itil T</AU>
<TI>Effect of minor and major tranquilizers on somatosensory evoked potentials</TI>
<SO>Psychopharmacologia</SO>
<YR>1971</YR>
<VL>24</VL>
<PG>349-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shafti-2005" MODIFIED="2012-06-19 15:17:38 +0100" MODIFIED_BY="[Empty name]" NAME="Shafti 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-05-12 10:10:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shafti SS, Rey S, Abad A</AU>
<TI>Drug-specific responsiveness of negative symptoms</TI>
<SO>International Journal of Psychosocial Rehabilitation</SO>
<YR>2005</YR>
<VL>10</VL>
<PG>43-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-19 15:17:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shafti SS</AU>
<TI>Rehabilitation of schizophrenia: adjunctive therapy of negative symptoms</TI>
<SO>Iranian Rehabilitation Journal</SO>
<YR>2004</YR>
<VL>2</VL>
<PG>ni</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soldatos-1986" MODIFIED="2011-10-10 07:53:17 +0100" MODIFIED_BY="[Empty name]" NAME="Soldatos 1986" YEAR="">
<REFERENCE MODIFIED="2011-10-10 07:53:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soldatos CR, Sakkas PN, Bergiannaki JD, Stefanis CN</AU>
<TI>Behavioral side effects of triazolam in psychiatric inpatients: report of five cases</TI>
<SO>Drug Intelligence and Clinical Pharmacy</SO>
<YR>1986</YR>
<VL>20</VL>
<PG>294-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sterlin-1971" NAME="Sterlin 1971" YEAR="1971">
<REFERENCE NOTES="&lt;p&gt;Sterlin C, Augustin E, Ban TA, Jarrold L. Doxepin as adjuvant medication in the treatment of chronic schizophrenic patients: a comparative study. Curr-Ther-Res-Clin-Exp 1971 Jan;13:50-2.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sterlin C, Augustin E, Ban TA, Jarrold L</AU>
<TI>Doxepin as adjuvant medication in the treatment of chronic schizophrenic patients: a comparative study</TI>
<SO>Current Therapy Research Clinical and Experimental</SO>
<YR>1971</YR>
<VL>13</VL>
<PG>50-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stonehill-1966" MODIFIED="2011-10-10 08:03:02 +0100" MODIFIED_BY="[Empty name]" NAME="Stonehill 1966" YEAR="">
<REFERENCE MODIFIED="2011-10-10 08:03:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stonehill E, Lee H, Ban TA</AU>
<TI>A comparative study with Benzodiazepines in chronic psychotic patients</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1966</YR>
<VL>27</VL>
<PG>411-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Subramaney-1997" NAME="Subramaney 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Subramaney U, Brook S, Berk M. A prospective randomised double blind controlled study of the efficacy of Lorazepam versus Clothiapine in the control of acutely behaviourally disturbed patients. 10th ECNP (European College of Neuropsychopharmacology) Congress, Vienna, Austria Sep 13 - 17, 1997;&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Subramaney U, Brook S, Berk M</AU>
<SO>A prospective randomised double blind controlled study of the efficacy of Lorazepam versus Clothiapine in the control of acutely behaviourally disturbed patients</SO>
<YR>10th ECNP (European College of Neuropsychopharmacology) Congress, Vienna, Austria Sep 13 - 17, 1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-2007" MODIFIED="2011-05-11 16:01:11 +0100" MODIFIED_BY="[Empty name]" NAME="Tang 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-05-11 16:01:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tang Q, Yang L, Lai G, Zhand J</AU>
<TI>A clinical study of risperidone oral solution combined with clonazepam injection in the treatment of acute excitement phase schizophrenia patient</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2007</YR>
<VL>19</VL>
<PG>153-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TREC_x002d_Vellore-2004" MODIFIED="2011-06-02 13:17:16 +0100" MODIFIED_BY="[Empty name]" NAME="TREC-Vellore 2004" YEAR="">
<REFERENCE MODIFIED="2011-06-02 13:17:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alexander J, Tharyan P, Adams CE, John T, Mol C, Philip J</AU>
<TI>Rapid tranquilisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethiazine</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2004</YR>
<VL>185</VL>
<PG>63-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2004a" MODIFIED="2011-05-20 08:38:47 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2004a" YEAR="2004">
<REFERENCE MODIFIED="2011-05-20 08:38:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang L, Li B, Zhao Z</AU>
<TI>A controlled study of compound diazepam in adjunctive treatment for schizophrenia</TI>
<SO>Journal of Binzhou Medical College</SO>
<YR>2004</YR>
<VL>27</VL>
<PG>111-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2004b" MODIFIED="2012-10-02 11:31:20 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2004b" YEAR="">
<REFERENCE MODIFIED="2012-10-02 11:31:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang G, Cai ZJ, Wang LF</AU>
<TI>A multicenter study of risperidone treatment for acute agitation in patients with schizophrenia</TI>
<SO>Chinese Journal of Psychiatry</SO>
<YR>2004</YR>
<VL>37</VL>
<PG>88-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005" MODIFIED="2012-10-02 11:31:39 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-10-02 11:31:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang DB, Xu SQ, Tang QP, Ying YF, Mei YT, He FX</AU>
<TI>Treatment of 80 cases of schizophrenia manifesting acute erethitic symptoms with quetiapine combined with clonazepam</TI>
<SO>Herald of Medicine</SO>
<YR>2005</YR>
<VL>24</VL>
<PG>687-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-Jian-1995" MODIFIED="2012-09-10 16:41:16 +0100" MODIFIED_BY="[Empty name]" NAME="Wang Jian 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-09-10 16:41:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang J, Wang x, Chen H</AU>
<TI>Clinical controlled study of perphenazine combined with alprazolam in treatment of negative symptoms</TI>
<SO>Chinese Journal of Pharmaco Epidemiology</SO>
<YR>1995</YR>
<VL>4</VL>
<PG>137-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weber-1983" NAME="Weber 1983" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weber SS, Dufresne RL, Becker RE, Mastrati P</AU>
<TI>Diazepam in tardive dyskinesia</TI>
<SO>Drug Intelligence and Clinical Pharmacy</SO>
<YR>1983</YR>
<VL>17</VL>
<PG>523-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weckowicz-1960" MODIFIED="2011-09-30 12:09:33 +0100" MODIFIED_BY="[Empty name]" NAME="Weckowicz 1960" YEAR="1960">
<REFERENCE MODIFIED="2011-09-30 12:09:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weckowicz TE, Ward T</AU>
<TI>Clinical trial of RO 5-0690 and chlorpromazine on disturbed chronic schizophrenic patients</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1960</YR>
<VL>21</VL>
<PG>527-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolkowitz-1986" NAME="Wolkowitz 1986" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolkowitz OM, Pickar D, Doran AR, Breier A, Tarell J, Paul SM</AU>
<TI>Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1986</YR>
<VL>143</VL>
<PG>85-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolkowitz-1988" MODIFIED="2012-10-02 11:35:33 +0100" MODIFIED_BY="[Empty name]" NAME="Wolkowitz 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-10-02 11:35:33 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Wolkowitz OM, Breier A, Doran A, Kelsoe J, Et A. Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients - Preliminary results. Archives of General Psychiatry 1988 Jul;45:664-671.&lt;/p&gt;" NOTES_MODIFIED="2012-10-02 11:35:33 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolkowitz OM, Breier A, Doran A, Kelsoe J et al</AU>
<TI>Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients - Preliminary results</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1988</YR>
<VL>45</VL>
<PG>664-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2006" MODIFIED="2011-05-12 10:02:19 +0100" MODIFIED_BY="[Empty name]" NAME="Wu 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-05-12 10:02:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu Z</AU>
<TI>[Title only available in Chinese characters]</TI>
<SO>Journal of Qiqihar Medical College</SO>
<YR>2006</YR>
<VL>27</VL>
<PG>536-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2003" MODIFIED="2012-10-02 11:33:58 +0100" MODIFIED_BY="[Empty name]" NAME="Yang 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-10-02 11:33:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang X, Wang Z, Ling Z et al</AU>
<TI>A randomly controlled comparison of risperidone added with intramuscular clonazepam in the treatment of excitement of schizophrenia</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2003</YR>
<VL>15</VL>
<PG>98-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-2006" MODIFIED="2011-05-12 10:00:41 +0100" MODIFIED_BY="[Empty name]" NAME="Yu 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-05-12 10:00:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu J</AU>
<TI>[Title only available in Chinese characters]</TI>
<SO>Nervous Diseases and Mental Hygiene</SO>
<YR>2006</YR>
<VL>6</VL>
<PG>129-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2007" MODIFIED="2011-05-11 16:02:54 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-05-11 16:02:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang HS</AU>
<TI>Study of olanzapine combined with clonazepam in treatment of schizophrenia with acute psychomotor excitation</TI>
<SO>Linchuang Jingshen Yixue Zazhi</SO>
<YR>2007</YR>
<VL>17</VL>
<PG>239-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-YingHui-2008" MODIFIED="2011-05-12 09:58:24 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang YingHui 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-05-12 09:58:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang YingHui</AU>
<TI>[Title only available in Chinese characters]</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2008</YR>
<VL>21</VL>
<PG>59-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-09-10 16:45:06 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Davis-2008" MODIFIED="2011-10-10 10:37:04 +0100" MODIFIED_BY="[Empty name]" NAME="Davis 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-10-10 10:37:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davis JM, Wang B, He Y, Jin H, Hu Q, Zhang M</AU>
<TI>The emergency treatment of acutely agitated psychotic schizophrenia patient</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2008</YR>
<VL>11</VL>
<NO>Suppl 1</NO>
<PG>163</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maculans-1964" NAME="Maculans 1964" YEAR="1964">
<REFERENCE NOTES="&lt;p&gt;Maculans GA. Comparison of diazepam, chlorprothixine and chlorpromazine in chronic schizophrenic patients. Diseases of the Nervous System 1964 March;25:164-168.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maculans GA</AU>
<TI>Comparison of diazepam, chlorprothixine and chlorpromazine in chronic schizophrenic patients</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1964</YR>
<VL>25</VL>
<PG>164-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salzman-1991" MODIFIED="2012-09-10 16:45:06 +0100" MODIFIED_BY="Heather Maxwell" NAME="Salzman 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-09-10 16:45:06 +0100" MODIFIED_BY="Heather Maxwell" NOTES="&lt;p&gt;Salzman C, Solomon D, Miyawaki E, Glassman R, Et A. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. Journal of Clinical Psychiatry 1991 Apr;52:177-180.&lt;/p&gt;" NOTES_MODIFIED="2012-09-10 16:45:06 +0100" NOTES_MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salzman C, Solomon D, Miyawaki E, Glassman R, Rood L, Flowers E, et al</AU>
<TI>Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1991</YR>
<VL>52</VL>
<PG>177-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ungvari-1999" NAME="Ungvari 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Ungvari G., Helen F. K. Chiu, Lok Yee Chow, Benjamin S.T. Lau, Wai Kwong Tang. Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study. Psychopharmacology(1999) 142:393-398&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ungvari GS, Chiu HFK, Chow LY, Lau BST, Tang WK</AU>
<TI>Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study</TI>
<SO>Psychopharmacology</SO>
<YR>1999</YR>
<VL>142</VL>
<PG>393-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-10-02 11:34:47 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-10-02 11:34:47 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Adams-2011" MODIFIED="2012-09-10 16:45:17 +0100" MODIFIED_BY="[Empty name]" NAME="Adams 2011" TYPE="BOOK">
<AU>Adams CE, Coutinho E, Duggan L, Leucht S, Tharyan P, Davis JM, et al</AU>
<SO>Cochrane Schizophrenia Group</SO>
<YR>2011</YR>
<PB>The Cochrane Library Chichester</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1996" MODIFIED="2012-09-10 16:45:24 +0100" MODIFIED_BY="[Empty name]" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1989" MODIFIED="2011-05-23 10:30:38 +0100" MODIFIED_BY="[Empty name]" NAME="Andreasen 1989" TYPE="JOURNAL_ARTICLE">
<AU>Andreasen NC</AU>
<TI>Scale for the assessment of negative symptoms</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>155</VL>
<PG>53-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" MODIFIED="2012-09-10 16:45:37 +0100" MODIFIED_BY="[Empty name]" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al</AU>
<TI>Improving the quality of reporting of randomized controlled trials: the CONSORT statement</TI>
<SO>Journal of American Medicale Assosiation</SO>
<YR>1996</YR>
<VL>276</VL>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Benkert-2011" MODIFIED="2012-03-25 11:56:48 +0100" MODIFIED_BY="[Empty name]" NAME="Benkert 2011" TYPE="BOOK">
<AU>Benkert O, Hippius H</AU>
<SO>Kompendium der Psychiatrischen Pharmakotherapie</SO>
<YR>2011</YR>
<EN>8</EN>
<PB>Springer</PB>
<CY>Berlin-Heidelberg-New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" MODIFIED="2012-09-10 16:45:53 +0100" MODIFIED_BY="[Empty name]" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM, Kerry SM. Bland JM, Kerry SM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" MODIFIED="2011-10-10 08:04:08 +0100" MODIFIED_BY="[Empty name]" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<TO>Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite</TO>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<PG>405-11</PG>
<IDENTIFIERS MODIFIED="2011-10-10 08:04:08 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1994" MODIFIED="2011-03-22 10:47:25 +0000" MODIFIED_BY="[Empty name]" NAME="Carpenter 1994" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT, Buchanan RW</AU>
<TI>Schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>681-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cheine-2001" MODIFIED="2011-10-13 08:55:13 +0100" MODIFIED_BY="[Empty name]" NAME="Cheine 2001" TYPE="COCHRANE_REVIEW">
<AU>Cheine M, Ahonen J, Wahlbeck K</AU>
<TI>Beta-blocker supplementation of standard drug treatment for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons</PB>
<IDENTIFIERS MODIFIED="2011-10-13 08:55:13 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-10-13 08:55:13 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000234"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Christison-1991" NAME="Christison 1991" TYPE="JOURNAL_ARTICLE">
<AU>Christison GW, Kirch DG, Wyatt RJ</AU>
<TI>When symptoms persist: choosing among alternative somatic treatments for schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1991</YR>
<VL>17</VL>
<PG>217-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Corrigan-1989" MODIFIED="2011-10-10 08:04:21 +0100" MODIFIED_BY="[Empty name]" NAME="Corrigan 1989" TYPE="JOURNAL_ARTICLE">
<AU>Corrigan JD</AU>
<TI>Development of a scale for assessment of agitation following traumatic brain injury</TI>
<SO>Journal of Clinical and Experimental Neuropsychology</SO>
<YR>1989</YR>
<VL>11</VL>
<PG>261-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" MODIFIED="2012-10-02 11:34:47 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Abstracts of 8th International Cochrane Colloquium</SO>
<YR>2000 Oct 25-28th</YR>
<ED>Cochrane Collaboration</ED>
<CY>Cape Town, South Africa</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" MODIFIED="2011-05-23 10:33:47 +0100" MODIFIED_BY="[Empty name]" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazer LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" MODIFIED="2011-02-17 10:24:03 +0000" MODIFIED_BY="[Empty name]" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997a" MODIFIED="2011-05-23 10:01:30 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997a" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997b" MODIFIED="2011-03-22 11:25:31 +0000" MODIFIED_BY="[Empty name]" NAME="Egger 1997b" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Zellweger-Zähner T, Schneider M, Junker C, Lengeler C, Antes G</AU>
<TI>Language bias in randomised controlled trials published in English and German</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<PG>326-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2011-10-10 08:04:32 +0100" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Essali-2009" MODIFIED="2012-09-27 11:54:12 +0100" MODIFIED_BY="[Empty name]" NAME="Essali 2009" TYPE="COCHRANE_REVIEW">
<AU>Essali A, Al-Haj Haasan N, Li C, Rathbone J</AU>
<TI>Clozapine versus typical neuroleptic medication for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-10-13 08:49:06 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-10-13 08:49:06 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000059.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Falkai-2005" MODIFIED="2011-05-23 10:00:23 +0100" MODIFIED_BY="[Empty name]" NAME="Falkai 2005" TYPE="JOURNAL_ARTICLE">
<AU>Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ, WFSBP Task Force on Treatment Guidelines for Schizophrenia</AU>
<TI>World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia</TI>
<SO>World Journal of Biological Psychiatry</SO>
<YR>2005</YR>
<VL>6</VL>
<PG>132-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Falkai-2006" MODIFIED="2011-05-23 10:00:43 +0100" MODIFIED_BY="[Empty name]" NAME="Falkai 2006" TYPE="JOURNAL_ARTICLE">
<AU>Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ, WFSBP Task Force on Treatment Guidelines for Schizophrenia</AU>
<TI>World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia</TI>
<SO>World Journal of Biological Psychiatry</SO>
<YR>2005</YR>
<VL>7</VL>
<PG>5-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2006" MODIFIED="2011-10-10 08:21:39 +0100" MODIFIED_BY="[Empty name]" NAME="Furukawa 2006" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N</AU>
<TI>Imputing missing standard deviations in meta-analyses can provide accurate results</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gillies-2005" MODIFIED="2012-09-27 11:54:33 +0100" MODIFIED_BY="[Empty name]" NAME="Gillies 2005" TYPE="COCHRANE_REVIEW">
<AU>Gillies D, Beck A, McCloud A, Rathbone J</AU>
<TI>Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<PB>John Wiley and Sons</PB>
<IDENTIFIERS MODIFIED="2011-10-13 08:56:07 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-10-13 08:56:07 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003079.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-GRADE-Profiler" MODIFIED="2011-02-17 10:24:03 +0000" MODIFIED_BY="[Empty name]" NAME="GRADE Profiler" TYPE="COMPUTER_PROGRAM">
<TI>GRADE Profiler</TI>
<YR>2004</YR>
<EN>3.2</EN>
<PB>GRADE Working Group</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" MODIFIED="2012-07-26 14:13:54 +0100" MODIFIED_BY="[Empty name]" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC, Ukoumunne OC, Chinn S</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy W</AU>
<SO>ECDEU Assessment Manual for Psychopharmacology (DOTES: Dosage Record and Treatment Emergent Symptom Scale)</SO>
<YR>1976</YR>
<PB>National Institute of Mental Health</PB>
<CY>Rockville</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2011-06-02 13:19:45 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Honigfeld-1965" MODIFIED="2011-03-24 09:28:50 +0000" MODIFIED_BY="[Empty name]" NAME="Honigfeld 1965" TYPE="JOURNAL_ARTICLE">
<AU>Honigfeld G, Klett CJ</AU>
<TI>The nurses' observation scale for inpatient evaluation. A new scale for measuring improvement in chronic schizophrenia</TI>
<SO>Journal of Clinical Psychology</SO>
<YR>1965</YR>
<VL>21</VL>
<PG>65-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" MODIFIED="2011-02-17 10:24:03 +0000" MODIFIED_BY="[Empty name]" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<TI>Positive and negative syndrome scale (PANSS) manual</TI>
<SO>Positive and negative syndrome scale (PANSS) manual</SO>
<YR>1986</YR>
<PB>North Tonawanda, NY: Multi-Health Systems</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1987" MODIFIED="2011-10-10 08:04:46 +0100" MODIFIED_BY="[Empty name]" NAME="Kay 1987" TYPE="JOURNAL_ARTICLE">
<AU>Kay SR, Fiszbein A</AU>
<TI>The positive and negative symptom scale (PANSS) for schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1987</YR>
<VL>13</VL>
<PG>261-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lehman-2004" MODIFIED="2012-04-20 09:07:13 +0100" MODIFIED_BY="[Empty name]" NAME="Lehman 2004" TYPE="JOURNAL_ARTICLE">
<AU>Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al</AU>
<TI>Practice guideline for the treatment of patients with schizophrenia, second edition</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2004</YR>
<VL>161</VL>
<PG>1-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leon-2006" MODIFIED="2011-09-30 12:46:14 +0100" MODIFIED_BY="[Empty name]" NAME="Leon 2006" TYPE="JOURNAL_ARTICLE">
<AU>Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K</AU>
<TI>Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology</TI>
<SO>Biological Psychiatry</SO>
<YR>2006</YR>
<VL>59</VL>
<PG>1001-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" MODIFIED="2011-05-24 16:09:28 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<PG>231-8</PG>
<IDENTIFIERS MODIFIED="2011-05-24 16:09:28 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005b" MODIFIED="2011-05-24 16:09:48 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of Brief Psychiatric Rating Scale scores</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS MODIFIED="2011-05-24 16:09:48 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2006" MODIFIED="2011-05-24 16:05:08 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2006" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR</AU>
<TI>Linking the PANSS, BPRS, and CGI: clinical implications</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>31</VL>
<PG>2318-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2007a" MODIFIED="2012-09-27 11:57:44 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2007a" TYPE="COCHRANE_REVIEW">
<AU>Leucht S, Kissling W, McGrath J, White P</AU>
<TI>Carbamazepine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2011-10-13 08:54:15 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-10-13 08:54:15 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001258.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2007b" MODIFIED="2012-09-27 11:54:57 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2007b" TYPE="COCHRANE_REVIEW">
<AU>Leucht S, McGrath J, Kissling W</AU>
<TI>Lithium for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons</PB>
<IDENTIFIERS MODIFIED="2011-10-13 08:53:00 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-10-13 08:53:00 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003834.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2009" MODIFIED="2011-05-24 08:22:52 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2009" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Arbter D, Engel RR, Kissling W, Davis JM</AU>
<TI>How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials</TI>
<SO>Molecular Psychiatry</SO>
<YR>2009</YR>
<VL>14</VL>
<PG>429-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2011" MODIFIED="2011-05-24 08:17:06 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2011" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Heres S, Kissling W, Davis JM</AU>
<TI>Evidence-based pharmacotherapy of schizophrenia</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2011</YR>
<VL>14</VL>
<PG>269-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lorr-1962" NAME="Lorr 1962" TYPE="JOURNAL_ARTICLE">
<AU>Lorr M, McNair DM, Klett CJ, Lasky JJ</AU>
<TI>Evidence of ten psychotic symptoms</TI>
<SO>Journal of Consulting Psychology</SO>
<YR>1962</YR>
<VL>26</VL>
<PG>185</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Malamud-1947" MODIFIED="2012-09-10 16:46:15 +0100" MODIFIED_BY="[Empty name]" NAME="Malamud 1947" TYPE="JOURNAL_ARTICLE">
<AU>Malamud W, Sands SL</AU>
<TI>A revision of the psychiatric rating scale</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1947</YR>
<VL>104</VL>
<PG>231-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" MODIFIED="2011-03-24 09:29:12 +0000" MODIFIED_BY="[Empty name]" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marvaha-2004" MODIFIED="2011-09-28 18:30:26 +0100" MODIFIED_BY="[Empty name]" NAME="Marvaha 2004" TYPE="JOURNAL_ARTICLE">
<AU>Marvaha S, Johnson S</AU>
<TI>Schizophrenia and employment ? a review</TI>
<SO>Social Psychiatry and Psychiatric Epidemiology</SO>
<YR>2004</YR>
<VL>39</VL>
<PG>337-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2009" MODIFIED="2012-04-20 09:10:45 +0100" MODIFIED_BY="[Empty name]" NAME="NICE 2009" TYPE="BOOK">
<AU>National Institute for Clinical Excellence (NICE)</AU>
<SO>Core interventions in the treatment and management of schizophrenia in primary and secondary care (update)</SO>
<YR>2009</YR>
<PB>NICE</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The brief psychiatric rating scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>790-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager-_x0028_RevMan_x0029_" MODIFIED="2011-02-17 10:24:03 +0000" MODIFIED_BY="[Empty name]" NAME="Review Manager (RevMan)" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-2010" MODIFIED="2012-04-20 09:27:33 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 2010" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Altman DG, Moher D, CONSORT Group</AU>
<TI>CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials</TI>
<SO>Trials</SO>
<YR>2010</YR>
<VL>11</VL>
<PG>32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schwarz-2008" MODIFIED="2012-09-27 11:55:17 +0100" MODIFIED_BY="[Empty name]" NAME="Schwarz 2008" TYPE="COCHRANE_REVIEW">
<AU>Schwarz C, Volz A, Li C, Leucht S</AU>
<TI>Valproate for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2011-10-13 08:50:51 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-10-13 08:50:51 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004028.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2008" MODIFIED="2011-02-17 10:24:03 +0000" MODIFIED_BY="[Empty name]" NAME="Schünemann 2008" TYPE="BOOK_SECTION">
<AU>Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<PG>359-83</PG>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson M, Angus JW</AU>
<TI>A rating scale for extrapyramidal side effects</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1970</YR>
<VL>212</VL>
<PG>11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tharyan-2005" MODIFIED="2012-09-27 11:55:25 +0100" MODIFIED_BY="[Empty name]" NAME="Tharyan 2005" TYPE="COCHRANE_REVIEW">
<AU>Tharyan P</AU>
<TI>Electroconvulsive therapy for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-10-13 08:52:13 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-10-13 08:52:13 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000076.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tsuang-1978" MODIFIED="2011-09-28 18:30:55 +0100" MODIFIED_BY="[Empty name]" NAME="Tsuang 1978" TYPE="JOURNAL_ARTICLE">
<AU>Tsuang MT</AU>
<TI>Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1978</YR>
<VL>35</VL>
<PG>153-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" MODIFIED="2011-10-10 08:06:02 +0100" MODIFIED_BY="[Empty name]" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<PG>1-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wahlbeck-2001" MODIFIED="2011-05-23 10:27:48 +0100" MODIFIED_BY="[Empty name]" NAME="Wahlbeck 2001" TYPE="JOURNAL_ARTICLE">
<AU>Wahlbeck K, Tuunainen A, Ahokas A, Leucht S</AU>
<TI>Drop-out rates in randomised antipsychotic drug trials</TI>
<SO>Psychopharmacology</SO>
<YR>2001</YR>
<VL>155</VL>
<PG>230-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2001" MODIFIED="2012-09-10 16:46:53 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2001" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>World Health Report 2001. Mental health - new understanding, new hope</SO>
<YR>2001</YR>
<PB>World Health Organization</PB>
<CY>Genf</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xia-2009" MODIFIED="2011-10-10 08:06:10 +0100" MODIFIED_BY="[Empty name]" NAME="Xia 2009" TYPE="JOURNAL_ARTICLE">
<AU>Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al</AU>
<TI>Loss to outcomes stakeholder survey: the LOSS study</TI>
<SO>Psychiatric Bulletin</SO>
<YR>2009</YR>
<VL>33</VL>
<PG>254-7</PG>
<CY>Sao Paulo</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-09-10 16:49:51 +0100" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-Volz-2007" MODIFIED="2012-09-10 16:49:51 +0100" MODIFIED_BY="Heather Maxwell" NAME="Volz 2007" TYPE="COCHRANE_REVIEW">
<AU>Volz A, Khorsand V, Gillies D, Leucht S</AU>
<TI>Benzodiazepines for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-07-26 14:20:43 +0100" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2012-07-26 14:20:43 +0100" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD006391"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-_x003f__x003f__x003f_-2008" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="??? 2008" TYPE="JOURNAL_ARTICLE">
<AU>???</AU>
<TI>[Title only available in Chinese characters]</TI>
<TO>????????????????????????</TO>
<SO>Shandong Archives of Psychiatry [??????]</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>1</NO>
<PG>59-60</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-_x003f__x003f__x003f__x002c_-2002" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="???, 2002" TYPE="JOURNAL_ARTICLE">
<AU>???, ???, ???, ???, ???</AU>
<TI>[only Chinese Title available]</TI>
<TO>??????????????????</TO>
<SO>Strait Pharmaceutical Journal</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>6</NO>
<PG>66-7</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-_x003f__x003f__x003f__x002c_-2003" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="???, 2003" TYPE="JOURNAL_ARTICLE">
<AU>???, ???</AU>
<TI>[only Chinese Title available]</TI>
<TO>??????????????????????</TO>
<SO>Medical Journal of Chinese Civil Administration</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>5</NO>
<PG>293-4</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-_x003f__x003f__x003f__x002c_-2004" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="???, 2004" TYPE="JOURNAL_ARTICLE">
<AU>???, ???</AU>
<TI>[only Chinese Title available]</TI>
<TO>????????????????</TO>
<SO>Journal of the Hainan Medical College</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>6</NO>
<PG>394-5</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-_x003f__x003f__x003f__x002c_-2004a" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="???, 2004a" TYPE="JOURNAL_ARTICLE">
<AU>???, ???</AU>
<TI>[only Chinese Title available]</TI>
<TO>????????????????????</TO>
<SO>Journal of Clinical Psychological Medicine [????????]</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>3</NO>
<PG>163</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-_x003f__x003f__x003f__x002c_-2004b" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="???, 2004b" TYPE="JOURNAL_ARTICLE">
<AU>???, ???, ???, ??</AU>
<TI>[only Chinese Title available]</TI>
<TO>???????????????????????????</TO>
<SO>Chinese Journal of Practical Internal Medicine</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>8</NO>
<PG>496-7</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-_x003f__x003f__x003f__x002c_-2005" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="???, 2005" TYPE="JOURNAL_ARTICLE">
<AU>???, ??, ??</AU>
<TI>[Title only available in Chinese characters]</TI>
<TO>?????????????????????????</TO>
<SO>Medical Journal of the Chinese People's Armed Police Forces</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>12</NO>
<PG>934-5</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-_x003f__x003f__x003f__x002c_-2008" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="???, 2008" TYPE="JOURNAL_ARTICLE">
<AU>???, ???</AU>
<TI>[Title only available in Chinese characters]</TI>
<TO>?-????????????20?</TO>
<SO>Herald of Medicine [????] [????]</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>3</NO>
<PG>304-5</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Alexander-2004" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Alexander 2004" TYPE="JOURNAL_ARTICLE">
<AU>Alexander J, Tharyan P, Adams C, John T, Mol C, Philip J</AU>
<TI>Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v haloperidol plus promethazine</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2004</YR>
<NO>185</NO>
<PG>63-9</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="15231557"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Azima-1962" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Azima 1962" TYPE="JOURNAL_ARTICLE">
<AU>Azima H, Arthurs D, Silver A</AU>
<TI>The effects of chlordiazepoxide (librium) in anxiety states. A multi-blind study</TI>
<SO>Canadian Psychiatric Association Journal</SO>
<YR>1962</YR>
<VL>7</VL>
<PG>44-50</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bao-2007" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Bao 2007" TYPE="JOURNAL_ARTICLE">
<AU>Bao L-Y, Wang K-M</AU>
<TI>The effectiveness of aripirazole combined with clonazepam treated with agitation in schizophrenia</TI>
<TO>?????????????????????????</TO>
<SO>Medical Journal of Chinese People's Health [??????]</SO>
<YR>2007</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Barbee-1992" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Barbee 1992" TYPE="JOURNAL_ARTICLE">
<AU>Barbee JG, Mancuso DM, Freed CR, Todorov AA, ,</AU>
<TI>"Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia": correction</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1992</YR>
<VL>149</VL>
<NO>8</NO>
<PG>1129</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cohen-2009" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Cohen 2009" TYPE="OTHER">
<AU>Cohen B</AU>
<TI>Pentazocine vs lorazepam for bipolar disorder and schizoaffective disorder</TI>
<SO>Stanley Foundation Research Programs</SO>
<YR>2009</YR>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Coutinho-2005" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Coutinho 2005" TYPE="JOURNAL_ARTICLE">
<AU>Coutinho ES, Huf G, Allen MH, Adams CE</AU>
<TI>Physical restraints for agitated patients in psychiatric emergency hospitals in Rio de Janeiro, Brazil: a predictive model</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>220</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Davis-2008" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Davis 2008" TYPE="JOURNAL_ARTICLE">
<AU>Davis JM, Wang B, He Y, Jin H, Hu Q, Zhang M</AU>
<TI>The emergency treatment of acutely agitated psychotic schizophrenia patient</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2008</YR>
<VL>11</VL>
<NO>Suppl 1</NO>
<PG>163</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gaebel-2006" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Gaebel 2006" TYPE="CONFERENCE_PROC">
<AU>Gaebel W, Moeller HJ</AU>
<TI>Measures to prevent relapse in long-term treatment: results from the German Research Network on Schizophrenia</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gattaz-2004" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Gattaz 2004" TYPE="JOURNAL_ARTICLE">
<AU>Gattaz WF, Diehl A, Geuppert MS, Hubrich P, Schmitt A, Linde I, et al</AU>
<TI>Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2004</YR>
<VL>37</VL>
<NO>6</NO>
<PG>279-85</PG>
<CY>Germany</CY>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="15551194"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gazdag-2004" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Gazdag 2004" TYPE="JOURNAL_ARTICLE">
<AU>Gazdag G, Kocsis N, Tolna J, Ivanyi Z</AU>
<TI>Etomidate versus propofol for electroconvulsive therapy in patients with schizophrenia</TI>
<SO>Journal of ECT</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>4</NO>
<PG>225-9</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="15591855"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ge-2004" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Ge 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ge Q, Liang X, Wang X</AU>
<TI>A comparative study of risperidone combining clonazepam and haloperidol in the treatment of patients with schizophrenia</TI>
<SO>Shandong Archives of Psychiatry [??????]</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>3</NO>
<PG>134-6</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ginsberg-2003" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Ginsberg 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ginsberg DL</AU>
<TI>Gabapentin reduces neuroleptic-induced tardive dyskinesia</TI>
<SO>Primary Psychiatry</SO>
<YR>2003</YR>
<VL>10</VL>
<NO>9</NO>
<PG>31-2</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hankoff-1962" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Hankoff 1962" TYPE="JOURNAL_ARTICLE">
<AU>Hankoff LD, Rudorfer L, Paley HM</AU>
<TI>A reference study of ataraxics. A two-week double blind outpatient evaluation</TI>
<SO>Journal of New Drugs</SO>
<YR>1962</YR>
<VL>2</VL>
<PG>173-8</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="13904352"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hanlon-1969" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Hanlon 1969" TYPE="JOURNAL_ARTICLE">
<AU>Hanlon TE, Ota KY, Agallianos DD, Berman SA, Bethon GD, Kobler F, et al</AU>
<TI>Combined drug treatment of newly hospitalized, acutely ill psychiatric patients</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1969</YR>
<VL>30</VL>
<NO>2</NO>
<PG>104-16</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="4388249"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hanlon-1970" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Hanlon 1970" TYPE="JOURNAL_ARTICLE">
<AU>Hanlon TE, Ota KY, Kurland AA</AU>
<TI>Comparative effects of fluphenazine, fluphenazine-chlordiazepoxide and fluphenazine-imipramine</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1970</YR>
<VL>31</VL>
<NO>3</NO>
<PG>171-7</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="4909632"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Harvey-2004" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Harvey 2004" TYPE="JOURNAL_ARTICLE">
<AU>Harvey AT, Flockhart D, Gorski JC, Greenblatt DJ, Burke M, Werder S, et al</AU>
<TI>Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>2004</YR>
<VL>44</VL>
<NO>10</NO>
<PG>1173-84</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="15342619"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-He-2007" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="He 2007" TYPE="JOURNAL_ARTICLE">
<AU>He W, ,</AU>
<TI>[Title only available in Chinese characters]</TI>
<TO>????????????????????</TO>
<SO>Modern Medicine and Health [??????]</SO>
<YR>2007</YR>
<VL>23</VL>
<NO>4</NO>
<PG>527</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hovens-2005" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Hovens 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hovens JE, Dries PJT, Melman CTM, Wapenaar RJC, Loonen AJM</AU>
<TI>Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>1</NO>
<PG>51-7</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="15671129"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hu-2004" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Hu 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hu W</AU>
<TI>Investigation of administering BZD medicament in outpatients with psychosis</TI>
<SO>Heath Psychology Journal</SO>
<YR>2004</YR>
<VL>12</VL>
<NO>1</NO>
<PG>43, 67</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Huf-2002" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Huf 2002" TYPE="OTHER">
<AU>Huf G</AU>
<TI>Rapid safe tranquillisation for acutely disturbed people attending public psychiatric emergency clinics in Rio de janeiro</TI>
<SO>http://www.controlled-trials.com</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kang-2006" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Kang 2006" TYPE="JOURNAL_ARTICLE">
<AU>Kang M-X</AU>
<TI>Clinical study on efficacy of quetiapine combined with clonazepam treated with acute agitation in schizophrenia patients</TI>
<TO>????????????????????????</TO>
<SO>Linchuang Jingshen Yixue Zazhi [????????]</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>4</NO>
<PG>221-2</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Knott-2006" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Knott 2006" TYPE="JOURNAL_ARTICLE">
<AU>Knott JC, Taylor D, Castle DJ</AU>
<TI>Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>2006</YR>
<VL>47</VL>
<NO>1</NO>
<PG>61-7</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Li-2004" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Li 2004" TYPE="JOURNAL_ARTICLE">
<AU>Li AF, ,</AU>
<TI>[Title only available in Chinese characters]</TI>
<TO>?????????????????????</TO>
<SO>Chinese Journal of Clinical Medicine</SO>
<YR>2004</YR>
<VL>3</VL>
<NO>8</NO>
<PG>33-4</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Li-2007" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Li 2007" TYPE="JOURNAL_ARTICLE">
<AU>Li C, Zhu S, Wang H, Chen H, Yu Y, Liu D, et al</AU>
<TI>Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the</TI>
<TO>??????????????????????????????</TO>
<SO>Shanghai Archives of Psychiatry [??????] [??????]</SO>
<YR>2007</YR>
<VL>19</VL>
<NO>3</NO>
<PG>150-2</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Li-2008" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Li 2008" TYPE="JOURNAL_ARTICLE">
<AU>Li W, Yu X, Cui Y</AU>
<TI>A comparative study of olanzapine with small-dose sustained-release tablets of magnesium valproate in treatment of acute phase of schizophrenia</TI>
<TO>??????????????????????????????</TO>
<SO>Shandong Archives of Psychiatry [??????]</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>3</NO>
<PG>178-9</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Liebman-2010" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Liebman 2010" TYPE="JOURNAL_ARTICLE">
<AU>Liebman HM, Woo W</AU>
<TI>The addition of tiagabine to antipsychotic medication in the treatment of recent-onset schizophrenia by modification of developmental pruning of prefrontal circuitry</TI>
<SO>Schizophrenia Research</SO>
<YR>2010</YR>
<VL>117</VL>
<NO>2-3</NO>
<PG>380-1</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ma-2006" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Ma 2006" TYPE="JOURNAL_ARTICLE">
<AU>Ma C</AU>
<TI>The control study of injection of clonazepam into tinggong for auditory hallucination of schizophrenia</TI>
<TO>??????????????????????</TO>
<SO>Journal of Clinical Psychosomatic Diseases [????????]</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>5</NO>
<PG>338-9</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mei-2006" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Mei 2006" TYPE="JOURNAL_ARTICLE">
<AU>Mei Y, Pan J, Ma P, ,</AU>
<TI>Clinical observation on acute excitation of schizophrenia treated with QIWEI combined with clonazepam</TI>
<TO>????????????????????????</TO>
<SO>Chinese Nursing Research [????]</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>5</NO>
<PG>1176-7</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Menzies-2007" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Menzies 2007" TYPE="JOURNAL_ARTICLE">
<AU>Menzies L, Ooi C, Kamath S, Suckling J, McKenna P, Fletcher P, et al</AU>
<TI>Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2007</YR>
<VL>64</VL>
<NO>2</NO>
<PG>156-67</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="17283283"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Migon-2008" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Migon 2008" TYPE="JOURNAL_ARTICLE">
<AU>Migon MN, Coutinho ES, Huf G, Adams CE, Cunha GM, Allen MH</AU>
<TI>Factors associated with the use of physical restraints for agitated patients in psychiatric emergency rooms</TI>
<SO>General Hospital Psychiatry</SO>
<YR>2008</YR>
<VL>30</VL>
<NO>3</NO>
<PG>263-8</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="18433659"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-M_x00f6_ller-2004" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Möller 2004" TYPE="JOURNAL_ARTICLE">
<AU>Möller HJ, Riedel M, Müller N, Fischer W, Kohnen R</AU>
<TI>Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2004</YR>
<VL>37</VL>
<NO>6</NO>
<PG>270-8</PG>
<CY>Germany</CY>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="15551193"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NCT00129441-2005" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00129441 2005" TYPE="OTHER">
<AU>NCT00129441</AU>
<TI>Treatment of cognitive disability in schizophrenia with a gaba-a alpha2/3 receptor agonist</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NCT00159133-2005" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00159133 2005" TYPE="OTHER">
<AU>NCT00159133</AU>
<TI>Prodrome-based early intervention with antipsychotics vs benzodiazepine in patients with first-episode schizophrenia after one year maintenance treatment under further maintenance treatment vs stepwise discontinued drugs</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NCT00179465-2005" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00179465 2005" TYPE="OTHER">
<AU>NCT00179465</AU>
<TI>Addition of tiagabine to second-generation antipsychotics in the treatment of recent-onset schizophrenia by modification of developmental reorganization of the prefrontal cortex</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NCT00374777-2006" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00374777 2006" TYPE="OTHER">
<AU>NCT00374777</AU>
<TI>A double-blind, group-comparison P-III study with zolpidem MR using placebo and nitrazepam in insomnia patients</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NCT00431184-2007" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00431184 2007" TYPE="OTHER">
<AU>NCT00431184</AU>
<TI>Effects of pentazocine versus lorazepam on manic symptoms</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2007</YR>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NCT00499044-2007" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00499044 2007" TYPE="OTHER">
<AU>NCT00499044</AU>
<TI>CDR versus MATRICS cognitive batteries in patients with schizophrenia</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2007</YR>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NCT00645944-2008" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00645944 2008" TYPE="OTHER">
<AU>NCT00645944</AU>
<TI>Randomized, controlled, double blind trial of eszopiclone for insomnia associated with schizophrenia</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2008</YR>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NCT00797277-2008" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00797277 2008" TYPE="JOURNAL_ARTICLE">
<AU>NCT00797277</AU>
<TI>IM olanzapine versus IM haloperidol plus lorazepam for acute agitation in schizophrenia</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2008</YR>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NCT00833547-2009" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00833547 2009" TYPE="OTHER">
<AU>NCT00833547</AU>
<TI>Effects of eszopiclone on sleep-dependent learning in schizophrenia</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2009</YR>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NCT00859872-2009" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00859872 2009" TYPE="OTHER">
<AU>NCT00859872</AU>
<TI>Efficacy and safety of risperidone oral solution combination clonazepam versus haloperidol intramuscular (IM) injection for treatment of acute psychotic agitation in schizophrenia</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2009</YR>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NCT00929370-2009" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00929370 2009" TYPE="OTHER">
<AU>NCT00929370</AU>
<TI>A repeat dose study with GSK1018921 to assess safety, tolerability, pharmacokinetics, pharmacodynamics in healthy volunteers and patients with schizophrenia and to evaluate its effect on pk of midazolam</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2009</YR>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nishimatsu-1991" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Nishimatsu 1991" TYPE="JOURNAL_ARTICLE">
<AU>Nishimatsu O, Horigudchi J, Akita K, Sukegawa T, Toshima Y, Oue M, et al</AU>
<TI>Reevaluation of treatment with neuroleptics and anti-parkinsonian drugs, and double-blind study of clonazepam on neuroleptic-induced akathisia</TI>
<SO>Rinsho Seishin Igaku [Japanese Journal of Clinical Psychiatry]</SO>
<YR>1991</YR>
<VL>20</VL>
<NO>10</NO>
<PG>1583-8</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nobay-2004" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Nobay 2004" TYPE="JOURNAL_ARTICLE">
<AU>Nobay F, Simon BC, Levitt MA, Dresden GM</AU>
<TI>A prospective, double-blind, randomized trial of midazolam versus haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients</TI>
<SO>Academic Emergency Medicine</SO>
<YR>2004</YR>
<VL>11</VL>
<NO>7</NO>
<PG>744-9</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="15231461"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Qin-2005" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Qin 2005" TYPE="JOURNAL_ARTICLE">
<AU>Qin Y, Kang W, Song L</AU>
<TI>A comparative study of risperidone combining alprazolam and clozapine in the treatment of patients with schizophrenia</TI>
<TO>????????????????????????</TO>
<SO>Heath Psychology Journal</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>6</NO>
<PG>444-5</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Qu-1999" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Qu 1999" TYPE="JOURNAL_ARTICLE">
<AU>Qu HF, Zhang Z, Xu B</AU>
<TI>Comparison of the effects of clonazepam and haloperidol in the treatment of psychotic breakdown behavior</TI>
<TO>??????????????????????</TO>
<SO>Health Psychology Journal</SO>
<YR>1999</YR>
<VL>7</VL>
<NO>2</NO>
<PG>134-5</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shafti-2005" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Shafti 2005" TYPE="JOURNAL_ARTICLE">
<AU>Shafti SS, Rey S, Abad A</AU>
<TI>Drug-specific responsiveness of negative symptoms</TI>
<SO>International Journal of Psychosocial Rehabilitation</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>1</NO>
<PG>43-51</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shoja-2004" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Shoja 2004" TYPE="JOURNAL_ARTICLE">
<AU>Shoja Shafti S</AU>
<TI>Rehabilitation of schizophrenia: adjunctive therapy of negative symptoms</TI>
<SO>Iranian Rehabilitation Journal</SO>
<YR>2004</YR>
<VL>2</VL>
<NO>2</NO>
<PG>25-15</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Simpson-2003" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Simpson 2003" TYPE="CONFERENCE_PROC">
<AU>Simpson GM, Morein JD, Reyes-Harde M, Gharabawi G</AU>
<TI>A pragmatic and convenient approach for the management of acute agitation: results from a series of clinical studies</TI>
<SO>Proceedings of the 16th European College of Neuropsychopharmacology Congress; 2003 Sep 20-24; Prague, Czech Republic</SO>
<YR>2003</YR>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Solomon-1990" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Solomon 1990" TYPE="BOOK_SECTION">
<AU>Solomon DA, Miyawaki E, Salzman C</AU>
<TI>Benzodiazepine augmentation of the treatment of disruptive psychotic behavior</TI>
<SO>Progress in Drug Research</SO>
<YR>1990</YR>
<VL>35</VL>
<PG>139-49</PG>
<ED>Jucker E</ED>
<PB>Birkhauser Verlag</PB>
<CY>Basel</CY>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stone-2005" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Stone 2005" TYPE="JOURNAL_ARTICLE">
<AU>Stone WS, Thermenos HW, Tarbox SI, Poldrack RA, Seidman LJ</AU>
<TI>Medial temporal and prefrontal lobe activation during verbal encoding following glucose ingestion in schizophrenia: a pilot fMRI study</TI>
<SO>Neurobiology of Learning and Memory</SO>
<YR>2005</YR>
<VL>83</VL>
<NO>1</NO>
<PG>54-64</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="15607689"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sun-2008" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Sun 2008" TYPE="JOURNAL_ARTICLE">
<AU>Sun Q-X, Guo H, Liu Y, ,</AU>
<TI>Effect of magnesium valproate sustained release tablets on coginiton function in difficult cure sex schizophrenic</TI>
<TO>?????????????????????????</TO>
<SO>????????</SO>
<YR>2008</YR>
<VL>2</VL>
<NO>22</NO>
<PG>25-7</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tandon-2005" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Tandon 2005" TYPE="CONFERENCE_PROC">
<AU>Tandon R, Sitholey P, Katiyar M, Kumar A</AU>
<TI>Short term tolerability of risperidone in children and adolescents with acute and transient psychotic disorders</TI>
<SO>Proceedings of the 8th World Congress of Psychiatry; 2005 Sep 10-15; Cairo, Egypt</SO>
<YR>2005</YR>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tang-2007" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Tang 2007" TYPE="JOURNAL_ARTICLE">
<AU>Tang Q, Yang L, Lai G, Zhand J</AU>
<TI>A clinical study of risperidone oral solution combined with clonazepam injection in the treatment of acute excitement phase schizophrenia patient</TI>
<TO>????????????????????????????</TO>
<SO>Shanghai Archives of Psychiatry [??????] [??????]</SO>
<YR>2007</YR>
<VL>19</VL>
<NO>3</NO>
<PG>153-5</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tharyan-2002" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Tharyan 2002" TYPE="OTHER">
<AU>Tharyan P</AU>
<TI>A randomised controlled trial of intra-muscular lorazepam versus intra-muscular haloperidol+promethazine in the management of psychotic agitations and aggression</TI>
<SO>http://www.controlled-trials.com</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wang-1995" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 1995" TYPE="JOURNAL_ARTICLE">
<AU>Wang J, Wang x, Chen H</AU>
<TI>Clinical controlled study of perphenazine combined with alprazolarn in treatment of negative symptoms</TI>
<SO>Chinese Journal of Pharmaco Epidemiology [????????]</SO>
<YR>1995</YR>
<VL>4</VL>
<NO>3</NO>
<PG>137-9</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wang-2000" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2000" TYPE="JOURNAL_ARTICLE">
<AU>Wang F, Lu Y</AU>
<TI>The control study of clorazepam and artane in akathisia</TI>
<SO>Journal of Clinical Psychosomatic Diseases [????????]</SO>
<YR>2000</YR>
<VL>6</VL>
<NO>1</NO>
<PG>19-20</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wang-2000a" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2000a" TYPE="JOURNAL_ARTICLE">
<AU>Wang G, Ji R, Pei G, ,</AU>
<TI>The control study of injection of clorazepam into t'ingkung for refractory auditory hallucination of schizophrenics</TI>
<SO>Journal of Clinical Psychosomatic Diseases [????????]</SO>
<YR>2000</YR>
<VL>6</VL>
<NO>3</NO>
<PG>143-4</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wang-2004" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2004" TYPE="JOURNAL_ARTICLE">
<AU>Wang G, Cai Z-J, Wang L-F, ,</AU>
<TI>A multicenter study of risperidone treatment for acute agitation in patients with schizophrenia</TI>
<SO>Chinese Journal of Psychiatry</SO>
<YR>2004</YR>
<VL>37</VL>
<NO>2</NO>
<PG>88-91</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wang-2004a" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2004a" TYPE="JOURNAL_ARTICLE">
<AU>Wang L, Li B, Zhao Z</AU>
<TI>A controlled study of compound diazepam in adjunctive treatment for schizophrenia</TI>
<SO>Journal of Binzhou Medical College</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>2</NO>
<PG>111-2</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wang-2005" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wang H</AU>
<TI>Combination of magnesium valproate and anti-psychotics in aggressive behaviors of schizophrenics</TI>
<TO>??????????????????????</TO>
<SO>Journal of Clinical Psychosomatic Diseases [????????]</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>1</NO>
<PG>10-1</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wang-2005a" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Wang D-B, Xu S-Q, Tang Q-P, Ying Y-F, Mei Y-T, He F-X</AU>
<TI>Treatment of 80 cases of schizophrenia manifesting acute erethitic symptoms with quetiapine combined with clonazepam</TI>
<TO>????????????????????80?</TO>
<SO>Herald of Medicine [????] [????]</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>8</NO>
<PG>687-8</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wang-2006" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2006" TYPE="JOURNAL_ARTICLE">
<AU>Wang Honglin</AU>
<TI>Therapeutic effect of risperidone combined with magnesium valproate in aggressive behaviors of schizophrenics</TI>
<TO>????????????????????????</TO>
<SO>Chinese Journal of Health Psychology [?????????]</SO>
<YR>2006</YR>
<VL>14</VL>
<NO>4</NO>
<PG>441-2</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Weckowicz-1960" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Weckowicz 1960" TYPE="JOURNAL_ARTICLE">
<AU>Weckowicz TE, Ward T</AU>
<TI>Clinical trial of RO 5-0690 and chlorpromazine on disturbed chronic schizophrenic patients</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1960</YR>
<VL>21</VL>
<PG>527-8</PG>
<CY>Not Available</CY>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="13783681"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Woo-2009" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Woo 2009" TYPE="OTHER">
<AU>Woo T-U</AU>
<TI>Tiagabine for schizophrenia</TI>
<SO>Stanley Foundation Research Programs</SO>
<YR>2009</YR>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wu-2006" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Wu 2006" TYPE="JOURNAL_ARTICLE">
<AU>Wu Z, ,</AU>
<TI>[Title only available in Chinese characters]</TI>
<TO>????????????????????????????</TO>
<SO>Journal of Qiqihar Medical College [Qiqihar Yixueyuan xuebao][?????????]</SO>
<YR>2006</YR>
<VL>27</VL>
<NO>5</NO>
<PG>536-7</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wu-2006a" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Wu 2006a" TYPE="JOURNAL_ARTICLE">
<AU>Wu Z, ,</AU>
<TI>[Title only available in Chinese characters]</TI>
<TO>????????????????????????????</TO>
<SO>Journal of Qiqihar Medical College [Qiqihar Yixueyuan xuebao][?????????]</SO>
<YR>2006</YR>
<VL>27</VL>
<NO>8</NO>
<PG>913-4</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Xu-2004" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Xu 2004" TYPE="JOURNAL_ARTICLE">
<AU>Xu C, Wang S, Wang H, ,</AU>
<TI>A comparative study of clonazepam and haloperidol in the treatment of patients with excitement of alcohol-caused psychotic disorder</TI>
<SO>Chinese Magazine of Drug Abuse Prevention and Treatment</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>5</NO>
<PG>261-2</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Xuan-2007" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Xuan 2007" TYPE="JOURNAL_ARTICLE">
<AU>Xuan G-H, Chu Y</AU>
<TI>Clinical observation on the effect of risperidone combined with BZD on schizophrenia</TI>
<TO>?????Bzd?????????97?????</TO>
<SO>China Tropical Medicine [??????]</SO>
<YR>2007</YR>
<VL>7</VL>
<NO>2</NO>
<PG>244</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Yu-2006" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Yu 2006" TYPE="JOURNAL_ARTICLE">
<AU>Yu J, ,</AU>
<TI>[Title only available in Chinese characters]</TI>
<TO>????????????????????????</TO>
<SO>Nervous Diseases and Mental Hygiene</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>2</NO>
<PG>129-30</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2007" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2007" TYPE="JOURNAL_ARTICLE">
<AU>Zhang H-S</AU>
<TI>Study of olanzapine combined with clonazepam in treatment of schizophrenia with acute psychomotor excitation</TI>
<TO>????????????????????????????</TO>
<SO>Linchuang Jingshen Yixue Zazhi [????????]</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>4</NO>
<PG>239-40</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2008" MODIFIED="2011-02-21 10:30:43 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2008" TYPE="JOURNAL_ARTICLE">
<AU>Zhang S-L, Wang G-J, Pan S-X</AU>
<TI>Effect of modern electroconvulsive treatment on over-excitement in patients with schizophrenia</TI>
<TO>??????????????????????</TO>
<SO>Medical Journal of Qilu</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>2</NO>
<PG>145-6, 148</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:30:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-10-02 11:25:40 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-10-02 11:25:40 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-10-02 11:04:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Azima-1962">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.<BR/>Blindness: double.<BR/>Design: parallel.<BR/>Duration: mean 3 weeks (no fixed endpoint) (short-term trial duration).</P>
<P>Location: Allan Memorial Hospital, McGill University, Montreal, Canada.<BR/>Setting: not indicated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:43:34 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: neurotic reactions (N = 150), schizophrenia (N = 22)*, psychotic depression (N = 12); diagnostic criteria not indicated.<BR/>History: all with anxiety as target symptom.<BR/>N = 184.<BR/>Age: mean 41 years.<BR/>Sex: 82 M, 102 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:43:39 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chlordiazepoxide: mean dose: 70 mg/d. N = 92 (only 8 participants with schizophrenia).<BR/>2. Placebo. N = 92 (only 14 participants with schizophrenia).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-22 15:41:00 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Global state.</P>
<P>Unable to use:<BR/>Adverse effects (no numbers).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-02 11:04:49 +0100" MODIFIED_BY="[Empty name]">
<P>*only the 22 schizophrenic patients were included in the meta-analytic calculations.<BR/>Main results/conclusion: Benzodiazepine was superior to placebo in terms of anxiety.<BR/>Chlordiazepoxide: 23.4% appreciable improvement<BR/>Placebo: 11.7% appreciable improvement.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-03 15:44:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barbee-1992">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.<BR/>Blindness: double.<BR/>Design: parallel.<BR/>Duration: 72 hours (short-term trial duration).</P>
<P>Location: not indicated.<BR/>Setting: inpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:43:42 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-III-R), acutely psychotic.<BR/>History: not indicated.<BR/>N = 28.<BR/>Age: mean 33.4 years.<BR/>Sex: not indicated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:43:49 +0100" MODIFIED_BY="[Empty name]">
<P>1. Alprazolam: dose 1 mg + haloperidol 5 mg (starting dose). N = 14.<BR/>2. Placebo + haloperidol: dose 5 mg (starting dose). N = 14.</P>
<P>Medication dose was repeated after each rating depending on psychopathology.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-22 15:40:58 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Mental state: BPRS, SANS.<BR/>Still in hospital at the end of the study.<BR/>Use of antiparkinson medication.</P>
<P>Unable to use:<BR/>Adverse effects: SAS (no numbers).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-30 08:28:01 +0100" MODIFIED_BY="[Empty name]">
<P>Main results/conclusion:<BR/>For both groups as a whole the tranquillizing effect was found to be significant for SAPS, the SANS, the BPRS, and BPRS psychotic subscale. There were no significant differences between the two groups on any of these measures, at any of the time points, suggesting that the two treatments had similar overall effects.</P>
<P>The trial was sponsored "in part" by a grant from the manufacturers of alprazolam.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-03 15:44:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Battaglia-1997">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; computer-generated table of random numbers.<BR/>Blindness: double.<BR/>Design: parallel.<BR/>Duration: 24 hours (ultra short-term trial duration).</P>
<P>Location: five sites in the USA: University of Texas Southwestern Medical Center, Dallas; Harbor-UCLA Medical Center, Los Angelas; University of Nebraska Medical Center, Omaha; Albert Einstein Medical Center, Phiadelphia; and Harbor-view Medical Center, Seattle.<BR/>Setting: inpatients (multicentre).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis*: mania (N = 13), psychoactive substance use (N = 16), psychosis NOS (N = 27), schizophrenia (N = 47), schizophreniform disorder (N = 1).<BR/>N = 98.<BR/>Age: mean 34.2 years.<BR/>Sex: 73 M, 25 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:44:17 +0100" MODIFIED_BY="[Empty name]">
<P>1. Lorazepam: dose 2 mg + haloperidol 5 mg. N = 32.<BR/>2. Lorazepam: dose 2 mg. N = 31.<BR/>3. Haloperidol: dose 5 mg. N = 35.</P>
<P>Medication was applied intramuscular; 1-6 injections within 12 hours.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-22 15:40:56 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Mental state: ABS, CGI, MBPRS. Asleep after 12 hours.<BR/>Adverse effects. dryness of mouth, dizziness, movement disorder, total number of adverse effects, use of antiparkinson medication.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-30 08:28:11 +0100" MODIFIED_BY="[Empty name]">
<P>*6 of 98 participants received more than one diagnosis.<BR/>Main results/conclusion:<BR/>Significant mean differences on the ABS (hour 1) and MBPRS (hour 2 and 3) suggest that tranquillization was most rapid in patients receiving the combination treatment.</P>
<P>The trial was sponsored "in part" by a grant from the manufacturers of lorazepam.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-03 15:44:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carpenter-1999">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: stratified randomisation.<BR/>Blindness: double.<BR/>Design: parallel.<BR/>Duration: 4 weeks (followed by a 2-week period of drug taper - single blind) (short-term trial duration).</P>
<P>Location: Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland, Baltimore, USA.<BR/>Setting: outpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:44:21 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia and schizoaffective disorder (DSM-III-R). N = 53.<BR/>History: mean duration of illness: 12.6 years.<BR/>Age: mean 35.6 years.<BR/>Sex: 38 M, 15 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:44:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Diazepam: dose 10 mg tid. N = 15.<BR/>2. Placebo. N = 20.<BR/>3. Fluphenazine: dose 5 mg tid. N = 18.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-22 15:40:54 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Global state: Relapse.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-03 15:44:19 +0100" MODIFIED_BY="[Empty name]">
<P>At the end of the 4-week treatment period, 30% of the placebo-treated and 53% of diazepam-treated participants had not advanced to the next stage of exacerbation.<BR/>There was no statistically significant difference between fluphenazine and diazepam treatment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-02 11:06:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cheung-1981">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.<BR/>Blindness: double.<BR/>Design: parallel.<BR/>Duration: 18 months (long-term trial duration).</P>
<P>Location: South Kwai Chung Psychiatric Centre, Hong Kong.<BR/>Setting: outpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:44:32 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (according to criteria of Parkes).<BR/>History: mean duration of illness: 10.1 years; relapse: 36-60 months prior to study.<BR/>N = 30.<BR/>Age: mean 40.1 years.<BR/>Sex: 12 M, 18 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-02 11:06:12 +0100" MODIFIED_BY="[Empty name]">
<P>1. Benzodiazepines (no further details). N = 15.<BR/>2. Constant dose of antipsychotics: dose (chlorpromazine equivalent =139 +/- 78 mg/d). N = 15.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-07 12:26:51 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Global state: Relapse.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-08 15:47:45 +0100" MODIFIED_BY="[Empty name]">
<P>Females and late-onset patients have a significantly better prognosis than male and early-onset cases.<BR/>The benzodiazepine group had a significantly higher relapse rate than the antipsychotic group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-02 11:09:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chouinard-1993">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.<BR/>Blindness: double.<BR/>Design: parallel.<BR/>Duration: 2 hours (ultra short-term trial duration).</P>
<P>Location: 2 psychiatric hospitals in Montreal, Canada.<BR/>Setting: not indicated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:44:55 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: bipolar disorder (N = 7), chronic schizophrenia (N = 5), schizoaffective disorder (N = 3), brief reactive psychosis (N = 1), all acutely agitated (DSM-III).<BR/>N = 16.<BR/>Age: mean 34.2 years.<BR/>Sex: 10 M, 6 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:45:01 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clonazepam: dose 1-2 mg i.m. at 0, 0.5 and 1 hour + placebo. N = 8.<BR/>2. Haloperidol: dose 5-10 mg i.m. at 0, 0.5 and 1 hour + procyclidine (antiparkinsonian medication). N = 8.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-02 11:09:51 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: CGI Severity Scale, CGI Sedation Scale.</P>
<P>Mental state: Target Manic Symptoms, IMPS Mania Subscale.<BR/>Behaviour: NOSIE subscale.<BR/>Adverse effects: Parkinsonism Total Score*, Tardive Dyskinesia Total Score*.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-30 08:28:40 +0100" MODIFIED_BY="[Empty name]">
<P>*The haloperidol group received antiparkinson medication during the study.<BR/>Both medications produced significant reduction of manic symptoms within two hours of initial treatment; however, haloperidol produced beneficial results more rapidly than clonazepam.</P>
<P>The trial was supported "in part" by a grant from the manufacturers of clonazepam.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-03 15:44:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dorevitch-1999">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; table of random numbers.<BR/>Blindness: double.<BR/>Design: parallel.<BR/>Duration: 2 hours (ultra short-term trial duration).</P>
<P>Location: not indicated.<BR/>Setting: inpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:45:13 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (N = 19), schizoaffective (N = 7) and bipolar disorder (N = 2), acute exacerbation (DSM-IV).<BR/>N = 28.<BR/>Age: 20-60 years.<BR/>Sex: 13 M, 15 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:45:18 +0100" MODIFIED_BY="[Empty name]">
<P>1. Flunitrazepam: dose 1 mg i.m. + antipsychotics. N = 15.<BR/>2. Haloperidol: dose 5 mg i.m. + antipsychotics. N = 13.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early. <BR/>Mental state: OAS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Significantly more rapid onset of sedation in flunitrazepam group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-03 15:44:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Foster-1997">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.<BR/>Blindness: double.<BR/>Design: parallel.<BR/>Duration: 4 hours (ultra short-term trial duration).</P>
<P>Location: not indicated.<BR/>Setting: not indicated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:45:30 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (N = 13), bipolar disorder (N = 13), schizoaffective (N = 4), psychotic disorder NOS (N = 7), acute exacerbation (DSM-III-R).<BR/>N = 37.<BR/>Age: mean 41.8 years.<BR/>Sex: 26 M, 11 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:45:36 +0100" MODIFIED_BY="[Empty name]">
<P>1. Lorazepam: dose 2 mg every 30 min for 4 hours. N = 17.<BR/>2. Haloperidol: dose 5 mg every 30 min for 4 hours. N = 20.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-07 12:28:38 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Global state: CGI.<BR/>Mental state: BPRS.<BR/>Adverse effects: EPS, extreme sedation, use of antiparkinson medication.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-28 09:41:07 +0100" MODIFIED_BY="[Empty name]">
<P>Rapid tranquillisation.<BR/>No differences were found either in the number of doses administered or in the administration route selected.<BR/>Lorazepam may provide an excellent alternative for rapid tranquillisation of the acutely agitated psychotic patient in the emergency room setting.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-03 15:44:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garza_x002d_Trevino-1989">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.<BR/>Blindness: non-blind.<BR/>Design: parallel.<BR/>Duration: 60 minutes (ultra short-term trial duration).</P>
<P>Location: General psychiatric hospital operated by the Department of Psychiatry of the University of Texas Medical School, Houston, USA.<BR/>Setting: not indicated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:45:50 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (N = 16), mania (N = 22), atypical psychotic disorder (N = 16), miscellaneous diagnosis (N = 14), severely agitated.<BR/>N = 68.<BR/>Age: mean 31 years.<BR/>Sex: 41 M, 27 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:45:57 +0100" MODIFIED_BY="[Empty name]">
<P>1. Lorazepam: dose 4 mg i.m. every 30 min + haloperidol 5 mg i.m. every 30 min. N = 24.<BR/>2. Haloperidol: dose 5 mg i.m. every 30 min. N = 21.<BR/>3. Lorazepam: dose 4 mg i.m. every 30 min. N = 23.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-23 11:27:51 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Global state: Global impression.<BR/>Mental state: Tranquillized after 30 minutes and 60 minutes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-13 05:26:45 +0100" MODIFIED_BY="[Empty name]">
<P>These analyses confirmed that the combination treatment was significantly superior to each of the components in producing rapid tranquillization after statistical correction for differences in baseline severity of agitation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-03 15:44:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gundlach-1966">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.<BR/>Blindness: double.<BR/>Design: parallel.<BR/>Duration: 6 weeks (short-term trial duration).</P>
<P>Location: Kings County Psychiatric Hospital Center, Brooklyn, New York, USA.<BR/>Setting: not indicated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:46:16 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: paranoid schizophrenia (N = 22), other schizophrenic types (N = 41), involutions (N = 9), anxiety reactions (N = 18), character disorders (N = 8), other diagnosis (N = 2).<BR/>N = 100.<BR/>Age: mean 40 years.<BR/>Sex: 39 M, 61 F.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 16:16:14 +0100" MODIFIED_BY="[Empty name]">
<P>1. Diazepam: dose 15-40 mg/d. N = 52.<BR/>2. Placebo. N = 48.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-21 17:32:26 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Mental state: anxiety according to TSRS*.<BR/>Adverse effects: autonomic reactions (perspiration, flushing, dryness of mouth etc.), change in energy level, gastric reactions (nausea/vomiting), headache.</P>
<P>Unable to use:<BR/>Mental state: MMPI, MAS (incomplete numbers).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>*Results referred to 39 participants with schizophrenia, who were rated with TSRS.<BR/>63% on diazepam were improved in anxiety as contrasted to 55% of the placebo cases.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-02 11:11:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guz-1972">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.<BR/>Blindness: double.<BR/>Design: parallel.<BR/>Duration: 4 weeks (short-term trial duration).</P>
<P>Location: University of Sao Paulo Psychiatric Clinic, Brazil.<BR/>Setting: inpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:47:31 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (N = 49), dementia (N = 3), maniac-depressive (N = 3), paranoia (N = 2), psychosis with epilepsy (N = 1), phobic neurosis (N = 1), drug dependency (N = 1), acute exacerbation.<BR/>N = 60.<BR/>Age: mean 27 years.<BR/>Sex: not indicated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:47:37 +0100" MODIFIED_BY="[Empty name]">
<P>1. Lorazepam 6 mg/d + 3 mg/d haloperidol. N = 30.<BR/>2. Placebo + 3 mg/d haloperidol. N = 30.</P>
<P>Haloperidol dose could be adjusted weekly.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-09-03 15:44:19 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Mental state: Global impression,<BR/>Adverse effects: anorexia, akathisia, blurring of vision, confusion, depression, diarrhoea, dizziness, dry mouth, excitation, increased salivation, insomnia, parkinsonism, restlessness, somnolence, cardiovascular reactions (tachycardia), tremor, gastric reactions (vomiting).</P>
<P>Unable to use:<BR/>Mental state: HAM-A, TSRS (incomplete numbers).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-02 11:11:15 +0100" MODIFIED_BY="[Empty name]">
<P>The benzodiazepine derivative did have a beneficial effect on some individual symptoms.<BR/>Adverse effects were no more frequent and no more severe in the lorazepam than in the placebo group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-03 15:44:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hankoff-1962">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:20 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.<BR/>Blindness: double.<BR/>Design: parallel.<BR/>Duration: 2 weeks (short-term trial duration).</P>
<P>Location: not indicated.<BR/>Setting: outpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:47:46 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis*: schizophrenia (N = 90), non schizophrenic (N = 44).<BR/>N = 174.<BR/>Age*: 20-71 years.<BR/>Sex*: 70 M, 64 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:48:03 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chlordiazepoxide: dose 10 mg tid. N = 27.<BR/>2. Placebo. N = 95.<BR/>3. Chlorpromazine: dose 50 mg tid. N = 25.<BR/>4. Meprobamate: dose 200 mg tid. N = 27.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-21 17:32:35 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Global state: Global impression.<BR/>Adverse effects: anorexia, ataxia, cardiovascular reactions (palpitations), decreased energy level (retardation), depression, dry mouth, EPS, gastric reactions (nausea), headaches, increased energy level (irritability/nervousness), insomnia.</P>
<P>Unable to use:<BR/>Mental state: Manifest Anxiety Rating Scale, AACL (incomplete numbers).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>*Demographic data is indicated only for completer.<BR/>A decrease in anxiety was indicated.<BR/>A significant difference was noted for only one of the treatment groups, chlorpromazine.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-02 11:12:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hanlon-1969">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:20 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: stratified randomisation.<BR/>Blindness: double.<BR/>Design: parallel.<BR/>Duration: 32 days (short-term trial duration).</P>
<P>Location: not indicated.<BR/>Setting: inpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-02 11:12:00 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (N = 135), not indicated (N = 55) (research psychiatrists´ diagnoses).<BR/>History: 75% of the patients were severely ill with at least one previous hospitalisation.<BR/>N = 190.<BR/>Age: mean 36 years.<BR/>Sex: 60 M, 130 F.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-02 11:12:38 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chlordiazepoxide: mean dose: 29 mg/d + thioridazine 468 mg/d. N = 65.<BR/>2. Placebo + thioridazine: mean dose: 470 mg. N = 61.<BR/>3. Imipramine: mean dose: 75 mg/d + thioridazine 429 mg/d. N = 64.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-02 11:12:41 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Leaving the study early due to adverse effects.<BR/>Leaving the study early due to inefficacy of treatment.<BR/>Global state: Global impression.<BR/>Adverse effects: blurred vision, constipation, drowsiness, dry mouth, headache, insomnia, nasal congestion, palpitation, parkinsonism, vertigo.</P>
<P>Unable to use:<BR/>Global state: CGI (incomplete numbers).<BR/>Mental state: IMPS, SGPG, Group Behavior Scale, MMPI, Depression Index (incomplete numbers).<BR/>Behaviour: NOSIE (incomplete numbers).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-03 15:44:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hanlon-1970">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:20 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: stratified randomisation.<BR/>Blindness: double.<BR/>Design: parallel.<BR/>Duration: 32 days (short-term trial duration).</P>
<P>Location: not indicated.<BR/>Setting: inpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:48:21 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-III-R).<BR/>History: "chronic", acute exacerbation.<BR/>N = 211.<BR/>Age: mean 36.5 years.<BR/>Sex: 57 M, 154 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:48:29 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chlordiazepoxide: mean dose: 37.4 mg/d + fluphenazine 6.6 mg/d. N = 71.<BR/>2. Placebo + fluphenazine: mean dose: 6.6 mg/d. N = 69.<BR/>3. Imipramine: mean dose: 91.8 mg/d + fluphenazine 6.6 mg/d. N = 71.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-09-03 15:44:20 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Leaving the study early due to adverse effects.<BR/>Leaving the study early due to inefficacy of treatment.<BR/>Global state: CGI.</P>
<P>Unable to use:<BR/>Mental state: IMPS, SGPG, Group Behavior Scale, MMPI, WAIS (incomplete numbers).</P>
<P>Behaviour: NOSIE.<BR/>Adverse effects: (incomplete numbers).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-02 11:13:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Holden-1968">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:20 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.<BR/>Blindness: double.<BR/>Design: cross-over.<BR/>Duration: 8 weeks (short-term trial duration).</P>
<P>Location: not indicated.<BR/>Setting: inpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:48:49 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (N = 24); subtypes: hebephrenic schizophrenia (N = 7), paranoid schizophrenia (N = 6), catatonic schizophrenia (N = 1), chronic undifferentiated (N = 8), not indicated (N = 2).<BR/>History: "chronic".<BR/>N = 24.<BR/>Age: mean 33 years.<BR/>Sex: 24 M.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-02 11:13:51 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chlordiazepoxide: mean dose: 1 mg/kg/d. N = 8.<BR/>2. Chlordiazepoxide + thioridazine: mean dose: 0.5 mg/kg/d and 2.5 mg/kg/d. N = 8.<BR/>2. Thioridazine: mean dose: 5 mg/kg/d. N = 8.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-21 17:32:49 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Leaving the study early due to inefficacy of treatment.</P>
<P>Unable to use:<BR/>Global state: CGI, Psychopathologic Cluster Rating (incomplete numbers).<BR/>Adverse effects: (incomplete numbers).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-03 15:44:20 +0100" MODIFIED_BY="[Empty name]">
<P>In global rating, both thioridazine and the combined drug treatments were effective in 20 of 22 participants who completed the study.</P>
<P>The trial was sponsored by the manufacturers of chlordiazepoxide.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-02 11:14:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kurland-1966">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:20 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.<BR/>Blindness: double.<BR/>Design: parallel.<BR/>Duration: 28 days (short-term trial duration).</P>
<P>Location: not indicated.<BR/>Setting: inpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-02 11:14:20 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (N =~163), not indicated (N =~18).<BR/>History: acute exacerbation.<BR/>N = 181.<BR/>Age: mean 39 years.<BR/>Sex: 64 M, 117 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:49:23 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chlordiazepoxide: dose 30 mg/d + chlorpromazine: mean dose: 2.70 mg/lb/d. N = 44.<BR/>2. Placebo + chlorpromazine: mean dose: 2.70 mg/lb/d. N = 40.<BR/>3. Chlorpromazine: mean dose: 2.70 mg/lb/d, + imipramine 75 mg/d. N = 35.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-08 15:21:52 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Leaving the study early due to adverse effects.<BR/>Adverse effects: allergic reactions (skin rash), cardiovascular reactions (vasomotor disturbances), drowsiness, dry mouth, gastrointestinal reactions, increased salivation, insomnia, lactation, movement disorder, sensory disturbances.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-30 08:59:20 +0100" MODIFIED_BY="[Empty name]">
<P>Most common adverse effects for combined drug treatment versus chlorpromazine only.</P>
<P>The trial was sponsored by the manufacturers of chlordiazepoxide.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-03 15:44:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kutcher-1989">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:20 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.<BR/>Blindness: double.<BR/>Design: parallel.<BR/>Duration: 7 days (short-term trial duration).</P>
<P>Location: not indicated.<BR/>Setting: inpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:49:39 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (N = 5), schizoaffective disorder (N = 4), bipolar manic disorder (N = 4), psychotic depression (N = 1), not indicated (N = 1). History: acute phase of psychotic illness and neuroleptic-induced akathisia.<BR/>N = 15.<BR/>Age: mean 18 years.<BR/>Sex: 9 M, 6 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:49:45 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clonazepam: dose 1 mg/d + antipsychotics*. N = 7.<BR/>2. Placebo + antipsychotics*. N = 8.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-21 17:32:57 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Unable to use:<BR/>Adverse effects: akathisia scale (no numbers).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-07 10:17:33 +0100" MODIFIED_BY="[Empty name]">
<P>*Medication was administered in addition to antiparkinsonian agents and lithium.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-02 11:15:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lerner-1979">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:20 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.<BR/>Blindness: double.<BR/>Design: parallel.<BR/>Duration: 24 hours (ultra short-term trial duration).</P>
<P>Location: Eitanim Psychiatric Hospital, Jerusalem, Israel.<BR/>Setting: not indicated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 16:27:00 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis*: paranoid schizophrenia (N = 9), schizoaffective schizophrenia (N = 9), subtypes of schizophrenia (N = 5), paranoid states (N = 2) and mania (N = 5).<BR/>History: acute exacerbation.<BR/>N = 40.<BR/>Age: mean 33 years.<BR/>Sex: not indicated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:50:04 +0100" MODIFIED_BY="[Empty name]">
<P>1. Diazepam: dose 30-40 mg/24 hours. N = 20.<BR/>2. Haloperidol: dose 35 mg/24 hours. N = 20.</P>
<P>Medication was applied intravenous; 3 injection within 24 hours.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-08 15:22:15 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Leaving the study early due to adverse effects.</P>
<P>Global state: CGI** .<BR/>Mental state: BPRS**.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-02 11:15:05 +0100" MODIFIED_BY="[Empty name]">
<P>*Diagnosis of 10 participants was not indicated.<BR/>**Scores of 20 participants were missing. Only the results of 20 participants were analysed (11 in the benzodiazepine group and 9 in the antipsychotic group).<BR/>No significant differences in the clinical response of actively psychotic patients to diazepam or to haloperidol within the first 24 hours of drug treatment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-03 15:44:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lingjaerde-1979">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:20 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.<BR/>Blindness: double.<BR/>Design: cross-over.<BR/>Duration: 3 weeks (short-term trial duration).</P>
<P>Location: 3 psychiatric hospitals in Norway.<BR/>Setting: inpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:50:24 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: hebephrenic schizophrenia (N = 9), paranoid schizophrenia (N = 7), residual schizophrenia (N = 2), undifferentiated schizophrenia (N = 1), reactive paranoid psychosis (N = 3), chronic epileptic psychosis (N = 1).<BR/>History: "chronic".<BR/>N = 23.<BR/>Age: mean 47 years.<BR/>Sex: 19 M, 4 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:50:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Diazepam: dose 15 mg/d + constant dose of antipsychotics. N = 11*.<BR/>2. Placebo + constant dose of antipsychotics. N = 12*.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-21 17:33:03 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Leaving the study early due to adverse effects.<BR/>Leaving the study early due to inefficacy of treatment.</P>
<P>Unable to use:<BR/>Mental state: BPRS (incomplete numbers).<BR/>Behaviour: NOSIE (incomplete numbers).<BR/>Adverse effects: incomplete numbers.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-30 08:29:17 +0100" MODIFIED_BY="[Empty name]">
<P>* More than half of all patients received antiparkinsonian medication.<BR/>This study indicates that diazepam, in a dosage of 15 mg daily, has a beneficial effect when given as an adjunct to neuroleptics in chronic psychotic patients.</P>
<P>The trial was sponsored by the manufacturers of diazepam.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-03 15:44:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lingjaerde-1982">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:20 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.<BR/>Blindness: double.<BR/>Design: cross-over.<BR/>Duration: 3 weeks (short-term trial duration).</P>
<P>Location: 10 psychiatric departments in Denmark and Norway.<BR/>Setting: inpatients and outpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:50:46 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: hebephrenic or simple schizophrenia (N = 24), paranoid schizophrenia (N = 20), unspecified schizophrenia (N = 8), manic-depressive psychosis (N = 3), reactive, paranoid psychosis (N = 3); (ICD-8 diagnosis).<BR/>History: subchronic or chronic.<BR/>N = 58.<BR/>Age: mean 34.7 years (M), 44 years (F).<BR/>Sex: 28 M, 30 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:50:52 +0100" MODIFIED_BY="[Empty name]">
<P>1. Estazolam: dose 6 mg/d + constant dose of antipsychotics*. N = 26.<BR/>2. Placebo + constant dose of antipsychotics*. N = 32.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-21 17:33:07 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Global state: CGI severity scale.<BR/>Adverse effects: dizziness, dryness of mouth, headache, restlessness, somnolence, slight dysarthria, sleep disorder (difficulties going to sleep).</P>
<P>Unable to use:<BR/>Mental state: BPRS, CPRS (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-03 15:44:20 +0100" MODIFIED_BY="[Empty name]">
<P>*Patients received additionally antiparkinsonian agents (N = 22), tricyclic antidepressants (N = 5), antiepileptic (N = 3), and lithium (N = 1).<BR/>Both treatment groups there was a significant improvement during the first 3 weeks period with regard to both, global clinical state and auditory hallucinations.<BR/>It was concluded that estazolam (in addition to antipsychotic compounds) was significantly superior to placebo in terms of the global clinical state.</P>
<P>The trial was sponsored by one of the manufacturers of estazolam.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-03 15:44:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ma-2006">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:20 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.</P>
<P>Blindness: single-blind, the raters did not involved in the study.</P>
<P>Design: parallel.</P>
<P>Duration: 4 weeks (short-term trial duration).</P>
<P>Location: not indicated.</P>
<P>Setting: inpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:51:11 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (CCMD-3) with auditory hallucination.</P>
<P>History: mean duration of illness: 25.2 months (SD = 13.86).</P>
<P>N = 120.</P>
<P>Age: mean 25.55 years (SD = 7.385).</P>
<P>Sex: 76 M, 44 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 16:29:35 +0100" MODIFIED_BY="[Empty name]">
<P>1. Injection of clonazepam into Ting-gong (acupuncture point): dose: 2mg/d (1mg at each acupuncture point, total 14 times) + antipsychotic: dose amount to chlorpromazine dose was 595.35 ±185.60mg/d. N = 60.</P>
<P>2. Antipsychotic: dose: amount to chlorpromazine dose was 583.85 ± 190.80mg/d. N = 60.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-29 09:03:35 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Mental state: 12th item score of the BPRS (hallucination item).</P>
<P>Adverse effects: TESS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-13 05:43:34 +0100" MODIFIED_BY="[Empty name]">
<P>Conclusion: "Injection of clonazepam into Tinggong is safe and effective therapy for auditory hallucination of schizophrenia."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-03 15:44:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marneros-1979">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.<BR/>Blindness: double.<BR/>Design: parallel.<BR/>Duration: 21 days (short-term trial duration).</P>
<P>Location: not indicated.<BR/>Setting: inpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:51:20 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (criteria of K. Schneider).<BR/>History: acute exacerbation.<BR/>N = 20.<BR/>Age: 20-55 years.<BR/>Sex: not indicated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:51:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. Camazepam: dose 40 mg/d + haloperidol 12 mg/d. N = 10.<BR/>2. Placebo + haloperidol: dose 12 mg/d. N = 10.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-21 17:33:14 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Unable to use:<BR/>Global state: CGI (incomplete numbers).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adjunctive treatment with benzodiazepine was significantly better in affective symptoms, like aggression etc.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-03 15:44:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Merlis-1962">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.<BR/>Blindness: double.<BR/>Design: parallel.<BR/>Duration: 4 weeks (proceeded by a 2 week wash-out period) (short-term trial duration).</P>
<P>Location: Center Islip State Hospital, Central Islip, New York, USA.<BR/>Setting: inpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:51:43 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: paranoid schizophrenia (N = 32), hebephrenic schizophrenia (N = 12), catatonic schizophrenia (N = 12), other subtypes (N = 14), psychosis and mental deficiency (N = 5), psychosis and psychopathic personality (N = 5).<BR/>History: "chronic".<BR/>N = 80.<BR/>Age: mean 38 years.<BR/>Sex: 40 M, 40 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:51:53 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chlordiazepoxide: dose 25 mg/d. N = 20.<BR/>2. Diazepam: dose 10 mg/d. N = 20.<BR/>3. Chlorpromazine: dose 50 mg/d. N = 20.<BR/>4. Placebo. N = 20.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-08 15:22:29 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Leaving the study early due to adverse effects.<BR/>Leaving the study early due to inefficacy of treatment.<BR/>Mental state: BPRS - not improved (physicians´ rating), MMS (nurses´rating).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-30 08:29:26 +0100" MODIFIED_BY="[Empty name]">
<P>No significant difference between the groups.</P>
<P>The trial was supported "in part" by the manufacturers of chlordiazepoxide and diazepam.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-03 15:44:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Minervini-1990">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; balanced for each group of six patients.<BR/>Blindness: double.<BR/>Design: parallel.<BR/>Duration: 3 weeks (short-term trial duration).</P>
<P>Location: Psychiatric Department of the "Opera Don Uva" Hospital, Bisceglie, Italy.<BR/>Setting: inpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:52:12 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: disorganized-type schizophrenia (N = 11), catatonic-type schizophrenia (N = 3), paranoid-type schizophrenia (N = 43), undifferentiated-type schizophrenia (N = 9). (DSM-III).<BR/>History: "chronic" without antipsychotic medication and anxiety not related to schizophrenic process.<BR/>N = 66.<BR/>Age: mean 46.5 years.<BR/>Sex: 66 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:52:18 +0100" MODIFIED_BY="[Empty name]">
<P>1. Alpidem: dose 100 mg/d. N = 33.<BR/>2. Placebo. N = 33.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-08 15:22:44 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Leaving the study early due to adverse effects.<BR/>Leaving the study early due to inefficacy of treatment.</P>
<P>Global state: CGI.<BR/>Mental state: BPRS, HAM-A.<BR/>Adverse effects: Gastrointestinal reactions (vomiting), sedation (extreme).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-07 12:34:13 +0100" MODIFIED_BY="[Empty name]">
<P>Alpidem was significantly more effective than placebo in improving HRSA score.<BR/>Considering the results of CGI at day 21, more patients were moderately to markedly improved on alpidem than on placebo.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-03 15:44:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morphy-1986">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.<BR/>Blindness: double.<BR/>Design: parallel.<BR/>Duration: 4 weeks (short-term trial duration).</P>
<P>Location: Buffalo Veterans Administration Medical Center Mental Health Clinic, Buffalo, USA.<BR/>Setting: outpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:52:22 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (N = 30) (DSM-III).<BR/>History: chronic schizophrenic with moderate-to-severe symptoms of anxiety.<BR/>N = 30.<BR/>Age: mean 47 years.<BR/>Sex: 29 M, 1 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:52:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Alprazolam: dose maximum 3 mg/d + constant dose of antipsychotics. N = 15.<BR/>2. Placebo + constant dose of antipsychotics. N = 15.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-21 17:33:32 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Leaving the study early due to adverse effects.<BR/>Leaving the study early due to inefficacy of treatment.</P>
<P>Global state: CGI.<BR/>Mental state: HAM-A.<BR/>
</P>
<P>Unable to use:<BR/>Mental state: Wittenborn Psychiatric Rating Scale, Raskin-Covi Scales (no numbers).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Alprazolam was shown to be more effective than placebo in the relieving symptoms of anxiety.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-03 15:44:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nestoros-1982">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.<BR/>Blindness: double.<BR/>Design: parallel.<BR/>Duration: 1 week (short-term trial duration).</P>
<P>Location: not indicated.<BR/>Setting: inpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:52:36 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (N = 12) (RDC, DSM-III).<BR/>History: "chronic", acute exacerbation.<BR/>N = 12.<BR/>Age: not indicated.<BR/>Sex: not indicated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:52:41 +0100" MODIFIED_BY="[Empty name]">
<P>1. Diazepam: dose 70-400 mg/d. N = 6.<BR/>2. Placebo. N = 6.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-21 17:31:13 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Leaving the study early due to adverse effects.<BR/>Leaving the study early due to inefficacy of treatment.<BR/>Global state: CGI.</P>
<P>Unable to use:<BR/>Mental state: BPRS, SS-PSE, SARS, SCL-90 (incomplete numbers).<BR/>Behaviour: NOSIE (incomplete numbers).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-13 05:46:48 +0100" MODIFIED_BY="[Empty name]">
<P>Within a few hours to a few days from the onset of diazepam treatment both, positive and negative schizophrenic symptoms were dramatically eliminated in 5 out of 6 participants.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-02 11:17:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nishikawa-1982">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.<BR/>Blindness: double.<BR/>Design: cross-over.<BR/>Duration: 3 years (long-term trial duration).</P>
<P>Location: Seiwakai Nishikawa Hospital, Hamada, Japan.<BR/>Setting: outpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:52:44 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-III-R).<BR/>History: "chronic".<BR/>N = 55.<BR/>Age: mean 33.7 years.<BR/>Sex: 37 M, 18 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:52:56 +0100" MODIFIED_BY="[Empty name]">
<P>1. Diazepam: dose 15 mg/d. N = 13.<BR/>2. Haloperidol: dose 3 mg/d. N = 10.<BR/>3. Placebo. N = 10.<BR/>4. Chlorpromazine: dose 75 mg/d. N = 10.<BR/>5. Imipramine: dose 50 mg/d. N = 12.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-02 11:17:37 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Leaving the study early due to inefficacy of treatment.<BR/>Leaving the study early due to adverse effects.<BR/>Global state: relapse.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-06-07 08:41:57 +0100" MODIFIED_BY="[Empty name]">
<P>The drug initially assigned was administered until relapse signs appeared.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-03 15:44:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pujalte-1994">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.<BR/>Blindness: double.<BR/>Design: parallel.<BR/>Duration: 2 weeks (short-term trial duration).</P>
<P>Location: not indicated.<BR/>Setting: not indicated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:53:04 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (N = 10), schizoaffective disorder (N = 2) (DSM-III-R).<BR/>History: neuroleptic induced akathisia.<BR/>N = 12.<BR/>Age: not indicated.<BR/>Sex: 8 M, 4 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:53:09 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clonazepam: dose 0.5-2.5 mg/d + constant antipsychotics*. N = 6.<BR/>2. Placebo + constant antipsychotics*. N = 6.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-26 16:35:20 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Leaving the study early due to adverse effects.<BR/>Leaving the study early due to inefficacy of treatment.<BR/>Adverse effects: drowsiness.</P>
<P>Unable to use:<BR/>Adverse effects: Barnes Rating Scale for Drug Induced Akathisia (skewed data)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-30 08:29:39 +0100" MODIFIED_BY="[Empty name]">
<P>*Patients received anticholinergic agents in a constant dose.</P>
<P>The trial was supported by the manufacturers of clonazepam.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-03 15:44:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stevens-1992">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.<BR/>Blindness: non blind.<BR/>Design: parallel.<BR/>Duration: 28 days (short-term trial duration).</P>
<P>Location: Department of Psychiatry, University of Tübingen, Germany.<BR/>Setting: inpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:53:11 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-III-R).<BR/>History: "chronic".<BR/>N = 61.<BR/>Age: mean ~ 40 years.<BR/>Sex: 33 M, 28 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 16:36:06 +0100" MODIFIED_BY="[Empty name]">
<P>1. Lorazepam: dose 0.05 mg/kg/d + haloperidol 0.5 mg/kg/d. N = 32.<BR/>2. Placebo + haloperidol 0.5 mg/kg/d. N = 29.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-21 17:31:33 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Adverse effects: use of antiparkinson medication at least once.</P>
<P>Unable to use:<BR/>Mental state: BPRS (no usable data).<BR/>Adverse effects: SAS (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-12 10:46:13 +0100" MODIFIED_BY="[Empty name]">
<P>None of the patient treated with lorazepam and haloperidol achieved better BPRS score or subscores, nor did their condition improve faster than in patient treated with haloperidol alone.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-02 11:21:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-TREC_x002d_Rio-2003">
<CHAR_METHODS MODIFIED="2012-10-02 11:21:30 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; table of random numbers.<BR/>Blindness: rater-blinded in terms of the primary outcome.<BR/>Design: parallel.<BR/>Duration: 2 weeks (short-term trial duration).</P>
<P>Location: 3 public psychiatric hospitals in Rio de Janeiro, Brazil.<BR/>Setting: emergency room.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:53:28 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis*: psychosis (N = 219), substance misuse (N = 51), other (N = 30).<BR/>History: acute aggressive or agitated behaviour.<BR/>N = 301.<BR/>Age: mean 38 years.<BR/>Sex: 136 M, 155 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:53:37 +0100" MODIFIED_BY="[Empty name]">
<P>1. Midazolam: dose 15 mg i.m. (N = 124) or midazolam 7.5 mg i.m. (N = 26).<BR/>2. Antipsychotic + promethazine: dose haloperidol 10 mg i.m. (N = 71) or haloperidol 5 mg i.m. (N = 77) + promethazine 25-50 mg i.m.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-26 16:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Leaving the study early due to adverse effects.<BR/>Leaving the study early due to inefficacy of treatment.<BR/>Mental state: tranquillized or asleep after 20, 40, 60 and 120 min., another episode of aggression/agitation after 24 hours, not needing restraints after 120 min., needing a doctor within 24 hours, still in hospital at the end of the study.<BR/>Adverse effects: grand-mal seizure, respiratory depression.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-02 11:21:40 +0100" MODIFIED_BY="[Empty name]">
<P>*Diagnosis of 1 participant is not indicated. According to the authors 150 persons were in the category F20 of ICD-10.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-02 11:22:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2000">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised according to lottery; no further details.</P>
<P>Blindness: non-blind.</P>
<P>Design: parallel.</P>
<P>Duration: 2 weeks (short-term trial duration).</P>
<P>Location: not indicated.</P>
<P>Setting: inpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:53:46 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (CCMD-2-R), refractory auditory hallucinations.</P>
<P>History: mean duration of illness: 12.1 years (SD = 8.31).</P>
<P>N = 90.</P>
<P>Age: mean 38.9 years (SD = 10.355).</P>
<P>Sex: 60 M, 31 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-02 11:22:36 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clonazepam (injected into Ting-gong [acupuncture point]): dose: 2 mg/d (1mg at each acupuncture point) + antipsychotics. N = 45.</P>
<P>2. Antipsychotics. N = 45.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-29 09:02:50 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Mental state: 12th item score of the BPRS (hallucination item).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-03 15:44:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2003">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.<BR/>Blindness: non blind.<BR/>Design: parallel.<BR/>Duration: 8 weeks (short-term trial duration).</P>
<P>Location: not indicated.<BR/>Setting: inpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:53:55 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>History: first episode.<BR/>N = 80.<BR/>Age: unclear.<BR/>Sex: unclear.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:54:00 +0100" MODIFIED_BY="[Empty name]">
<P>1. Risperidone: dose 2-5 mg/d + clonazepam i.m. 2-4 mg/d. N = 40<BR/>2. Risperidone: dose 2-5 mg/d. N = 40</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Mental state: PANSS*<BR/>Adverse effects: TESS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>*usable data only for 2-week treatment.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-03 15:44:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wyant-1990">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.<BR/>Blindness: single.<BR/>Design: parallel.<BR/>Duration: 2 hours (ultra short-term trial duration).</P>
<P>Location: not indicated.<BR/>Setting: inpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:54:08 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: chronic paranoid schizophrenia (N = 5), chronic undifferentiated schizophrenia (N = 10).<BR/>History: "chronic".<BR/>N = 15.<BR/>Age: benzodiazepine group mean age ~35 years, haloperidol group mean age ~43 years.<BR/>Sex: 15 M.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:54:17 +0100" MODIFIED_BY="[Empty name]">
<P>1. Midazolam: dose 5 mg i.m. N = 5.<BR/>2. Haloperidol: dose 10 mg i.m. N = 5.<BR/>3. Sodium amytal: dose 250 mg i.m. N = 5.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-21 17:31:45 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Leaving the study early due to adverse effects.<BR/>Leaving the study early due to inefficacy of treatment.</P>
<P>Unable to use:<BR/>Global state: CGI (incomplete numbers).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-03 15:44:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xuan-2007">
<CHAR_METHODS MODIFIED="2012-09-03 15:44:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised; no further details.</P>
<P>Blindness: non-blind.</P>
<P>Design: parallel.</P>
<P>Duration: 8 weeks (short-term trial duration).</P>
<P>Location: not indicated.</P>
<P>Setting: inpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:54:21 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (CCMD-3);</P>
<P>History: first episode 62 patients; recurrence 35 patients.</P>
<P>N = 97.</P>
<P>Age: mean 30.05 (SD = 9).</P>
<P>Sex: 51 M, 46 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 16:38:52 +0100" MODIFIED_BY="[Empty name]">
<P>1. Risperidone: dose 3.9 ± 1.0 mg/d (2-6 mg/d) [initial dose 0.5-1mg/d, increased to treatment dose within two weeks] + Benzodiazepines (clonazepam or lorazepam or alprazolam). Benzodiazepines dose was not described, it was used in 7-10 days, not beyond 2 weeks. N = 49.</P>
<P>2. Risperidone: dose 3.6 ± 0.9 mg/d (2-6 mg/d) [initial dose 0.5-1 mg/d, increased to treatment dose within two weeks]. N = 48.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-21 17:31:50 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Mental state: BPRS.</P>
<P>Unable to use:</P>
<P>Adverse effects: TESS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<B>General abbreviations:</B>
<BR/>F - females.<BR/>i.m. - intramuscular.<BR/>M - males.<BR/>mg - milligram.<BR/>min - minutes.<BR/>N - number of participants.<BR/>SD - standard deviation.<BR/>tid - three times daily.<BR/>
</P>
<P>
<B>Diagnostic criteria:</B>
<BR/>CCMD-3 - Chinese Classification of Mental Disorders, third revision.<BR/>DSM-II - Diagnostic and Statistical Manual of Mental disorders, second edition.<BR/>DSM-III - Diagnostic and Statistical Manual of Mental disorders, third edition.<BR/>DSM-III-R - Diagnostic and Statistical Manual of Mental disorders, third edition, revised.<BR/>ICD-8/9/10 - International Classification of Diseases, eighth/ninth/tenth revision.<BR/>RDC - Research Diagnostic Criteria.</P>
<P>
<B>Global state scales:</B>
<BR/>CGI - Clinical Global Impression.<BR/>OCR - Overall Clinical Rating.</P>
<P>
<B>Mental state/Behaviour scales:</B>
<BR/>AACL - Affect Adjective Check List.<BR/>ABS - Agitated Behavior Scale.<BR/>BDI - Beck Depression Inventory.<BR/>BPRS - Brief Psychiatric Rating Scale.<BR/>BRMAS - Bech-Rafaelsen Scale for Mania.<BR/>CPRS - Comprehensive Psychopathology Rating Scale.<BR/>HAM-A - Hamilton Rating Scale of Anxiety.<BR/>IMPS - Inpatient Multidimensional Rating Scale.<BR/>MAS - Manifest Anxiety Scale.<BR/>MBPRS - Modified Brief Psychiatric Rating Scale.<BR/>MMPI - Minnesota Multiphasic Personality Inventory.<BR/>MMS - Malamud-Sands Scale.<BR/>MMSE - Mini Mental State Examination.<BR/>MS - Manchester Scale.<BR/>MSM - Murphy Scale for Mania.<BR/>MSRS - Manic State Rating Scale.<BR/>NH - (Modified) New Haven Schizophrenia Index.<BR/>NOSIE - Nurses Observation Scale for Inpatient Evaluation.<BR/>OAS - Overt Aggression Scale.<BR/>PANSS - Positive and Negative Symptoms Scale.<BR/>PIP - Psychotic Inpatient Profile.<BR/>SANS - Scale for Assessment of Negative Symptoms.<BR/>SAPS - Scale for Assessment of Positive Symptoms.<BR/>SARS - Simpson Angus Rating Scale.<BR/>SCI - Structured Clinical Interview.<BR/>SCL-90 - 90 Item Self-Assessment Questionnaire.<BR/>SGPG - Spring Grove Psychiatric Rating Scale.<BR/>SRSS - Self-Rating Symptom Scale.<BR/>SS-PSE - Schizophrenia Subscale of the Present State Examination.<BR/>TSRS - Target Symptom Rating Scale.<BR/>VAS - Visual Analogue Scale.<BR/>WAIS - Wechsler Adult Intelligence Scale.</P>
<P>
<B>Adverse effect scales:</B>
<BR/>AIMS - Abnormal Involuntary Movement Scale.<BR/>BFCRS - Bush-Francis Catatonia Rating Scale.<BR/>BARS - Barnes Akathisia Rating Scale.<BR/>CGI - Clinical Global Impression, side effects.<BR/>EPS - Extrapyramidal side effects.<BR/>EPSE - Extrapyramidal side effects (modified Simpson &amp; Angus Scale).<BR/>FSUCL - Fischers Somatische Symptome or Unerwünschte Effekte Check List.<BR/>MRS - Modified Rogers Scale.<BR/>SAFTEE - Scale for Assessment of Treatment Emergent Events.<BR/>SAS - Simpson and Angus Scale.<BR/>TD - tardive dyskinesia.<BR/>TESS - Treatment Emergent Symptom Scale.<BR/>UKU - UKU Side effect Scale.<BR/>VPAS - Van Putten´s Akinesia Scale.</P>
<P>
<B>Diagnosis:</B>
<BR/>NOS - not otherwise specified.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-09-03 15:44:22 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-10-06 13:38:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Adler-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-06 13:38:43 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: antipsychotics + lorazepam vs. antipsychotics + beta-blockers.<BR/>Outcomes: no usable data in terms of any outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-03 15:44:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alexander-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-03 15:44:22 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: most participants were diagnosed to have mania; only 18.5 % of the patients had schizophrenia.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Altamura-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: clonazepam + haloperidol versus haloperidol + placebo.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ananth-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, double-blind.<BR/>Participants: chronic geriatric patients with psychiatric symptomatology; unclear how many had schizophrenia-like psychoses. <BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-07 08:51:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bao-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-07 08:51:47 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: aripiprazole + clonazepam versus clozapine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-26 14:26:48 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Bienek-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-26 14:26:48 +0100" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised, double-blind.<BR/>Participants: people with bipolar disorder, psychosis not otherwise specified, schizophrenia, brief reactive psychosis, substance-induced psychosis, undifferentiated schizophrenia.<BR/>Interventions: lorazepam versus antipsychotics + lorazepam.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bobruff-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: patients with tardive dyskinesia, no diagnosis given.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cohen-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Crosse-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-23 14:47:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Csernansky-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-23 14:47:42 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: alprazolam + antipsychotics versus placebo + antipsychotics.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dubin-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-07 08:51:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ge-Qianrong-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-07 08:51:31 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: risperidone + clonazepam versus haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Greenfeld-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Haas1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hanus-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hartelius-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: only 39 of 143 participants had schizophrenia; their data were not presented separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-30 14:11:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harvey-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-30 14:11:11 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, partially blinded.<BR/>Participants: people with schizophrenia (mildly symptomatic).<BR/>Interventions: controlled cross-over trial with haloperidol versus lorazepam.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-29 09:02:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-He-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-29 09:02:14 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: risperidone + clonazepam versus clozapine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hekimian-1967">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not adequately randomised, alternate allocation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hesso-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Horiguchi-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with chronic schizophrenia.<BR/>Interventions: antipsychotics + clonazepam versus antipsychotics + antiparkinson medication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-29 09:02:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hovens-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-29 09:02:25 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-29 09:02:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hu-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-29 09:02:31 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Itil-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jibiki-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jirmeson-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jungkunz-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: methionine versus diazepam, no appropriate comparison group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-29 09:01:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kang-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-29 09:01:59 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: quetiapine + clonazepam versus chlorpromazine versus clozapine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-28 11:22:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karson-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-28 11:22:47 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kellner-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: thioridazine or trifluoperazine versus chlordiazepoxide versus placebo.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-29 09:01:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Knott-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-29 09:01:48 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, double-blind.<BR/>Participants: unclear how many patients had schizophrenia or related disorders; no diagnosis given.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-29 09:01:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-29 09:01:54 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: loxapine versus risperidone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-07 08:50:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-07 08:50:44 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised according to hospital admission order/number.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maar-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, double-blind.<BR/>Participants: people with schizophrenia were excluded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-07 08:50:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mei-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-07 08:50:25 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: quetiapine + clonazepam versus haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Monroe-1967">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nestros-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-07 08:49:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nobay-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-07 08:49:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, double-bind.<BR/>Participants: unclear how many patients had schizophrenia or related disorders; no diagnosis given.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-03 07:50:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pato-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-03 07:50:38 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pecknold-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, retrospective survey.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-29 09:01:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qin-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-29 09:01:34 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: risperidone + alprazolam versus clozapine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Remington-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Richards-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, double-blind.<BR/>Participants: only 10 % with schizophrenia-like psychoses.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ruskin-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Salam-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Saletu-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.<BR/>Participants: healthy individuals.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-29 09:01:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shafti-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-29 09:01:28 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear whether randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: alprazolam versus clomipramine versus citalopram versus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Soldatos-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sterlin-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stonehill-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear whether randomised, double-blind, cross-over design.<BR/>Participants: people with psychosis.<BR/>Interventions: diazepam, chlordiazepoxide, LA XIV, LA XVII.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-26 14:28:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Subramaney-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-26 14:28:54 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, double-blind.<BR/>Participants: organic hallucinations (psychoactive substance abuse) (N = 24), schizophrenia (N = 16), bipolar disorders (N = 14).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-29 09:01:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tang-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-29 09:01:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: risperidone + clonazepam versus haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-26 14:29:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-TREC_x002d_Vellore-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-26 14:29:20 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: schizophrenia (N = 37), acute psychosis (N = 22), mania (N = 97), depression (N = 19), substance abuse (N = 10), other (N = 15).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-29 09:01:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2004a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-29 09:01:11 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised according to hospital admission serial number.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-07 08:49:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2004b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-07 08:49:11 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: risperidone + clonazepam versus clozapine versus haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-29 09:00:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-29 09:00:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: quetiapine + clonazepam versus haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-29 09:00:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-Jian-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-29 09:00:50 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised according to hospital admission order/number, stratified randomisation.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weber-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, cross-over design.<BR/>Participants: people with schizophrenia or organic brain syndrome and tardive dyskinesia.<BR/>Interventions: diazepam versus no treatment.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-30 12:10:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weckowicz-1960">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-30 12:10:25 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: study group assignment on the basis of rating.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wolkowitz-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wolkowitz-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-29 09:00:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-29 09:00:42 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: risperidone + clonazepam versus haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yang-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: schizophrenia.<BR/>Interventions: risperidone + clonazepam versus haloperidol versus clozapine (no adequate comparison group).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-29 09:00:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-29 09:00:28 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: risperidone + clonazepam versus haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-29 09:00:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-29 09:00:18 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: olanzapine + clonazepam versus haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-07 08:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-YingHui-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-07 08:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: quetiapine + clonazepam versus haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>Regarding abbreviations see footnotes under the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-09-03 15:44:22 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2012-07-26 14:54:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Davis-2008">
<CHAR_METHODS MODIFIED="2012-04-20 11:14:39 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomisation.<BR/>Blindness: not indicated.<BR/>Design: not indicated.<BR/>Duration: not indicated.<BR/>Setting: not indicated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-03 08:57:48 +0100" MODIFIED_BY="[Empty name]">
<P>acutely agitated schizophrenic patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:54:44 +0100" MODIFIED_BY="[Empty name]">
<P>1. haloperidol 5-15 mg/d. N = 21.</P>
<P>2. clonazepam 2-6 mg/d. N = 20.</P>
<P>3. haloperidol 5-15 mg/d + clonazepam 2-6 mg/d. N = 21.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-08 15:42:03 +0100" MODIFIED_BY="[Empty name]">
<P>BPRS total score, BPRS agitation (primary outcome) and psychosis subscales, CGI at 2, 4, 6 and 24 hours.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-30 09:01:21 +0100" MODIFIED_BY="[Empty name]">
<P>Regarding the BPRS agitation subscale the clonazepam augmentation and haloperidol monotherapy produced equal response rate at 6 and 24 hours, but a better response compared to a monotherapy with clonazepam.</P>
<P>When performing this systematic review, the full publication of the trial results was not yet available.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-09-03 15:44:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maculans-1964">
<CHAR_METHODS MODIFIED="2011-10-06 11:22:58 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomisation.<BR/>Blindness: double.<BR/>Design: cross-over.<BR/>Duration: 3 weeks medication with each drug and 1-week placebo interval between the active drug treatment.<BR/>Setting: inpatient.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-09-03 15:44:22 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: psychotic patients, chronically ill, with histories of long-term hospitalisations and known refractoriness to all therapeutic modalities. paranoid schizophrenia (N = 9), chronic undifferentiated schizophrenia (N = 26), childhood schizophrenia (N = 1), chronic brain syndrome combined with alcohol intoxication (N = 1).<BR/>Age: average 31.5 years.<BR/>Sex: not indicated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-10-06 11:19:13 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chlorprothixene 100 mg.<BR/>2. Chlorpromazine 100 mg.</P>
<P>3. Diazepam 10 mg.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-06 11:28:45 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Global state: Clinical assessment of patient response to each course of therapy ("good", "fair", "poor").</P>
<P>Adverse effects.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-06 11:53:07 +0100" MODIFIED_BY="[Empty name]">
<P>There is no information available regarding the results of the first trial phase up to the point of first cross-over.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-26 14:55:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salzman-1991">
<CHAR_METHODS MODIFIED="2011-10-04 10:08:33 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: implied randomisation.<BR/>Blindness: double.<BR/>Design: parallel.<BR/>Duration: 48 hours.<BR/>Setting: inpatient.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 14:55:11 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: "acute psychotic disruptive behavior" in all participants; schizophrenia (N = 26), bipolar disorder (N = 11), schizoaffective disorder (N = 4), organic mental disorder (N = 6), other including psychotic depression, personality disorder (N = 13).<BR/>Age: mean 30.5 years in the lorazepam group and 37.9 in the haloperidol group.<BR/>Sex: not indicated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-10-04 12:31:51 +0100" MODIFIED_BY="[Empty name]">
<P>1. Lorazepam i.m. 2 mg.<BR/>2. Haloperidol i.m. 5 mg.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-06 13:58:10 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Global state: CGI.</P>
<P>Mental state: BPRS.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-30 09:01:37 +0100" MODIFIED_BY="[Empty name]">
<P>Lorazepam as well as haloperidol were added to ongoing antipsychotic treatment.</P>
<P>When performing this systematic review, the full publication of the trial results was not yet available.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-26 14:55:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ungvari-1999">
<CHAR_METHODS MODIFIED="2011-10-06 11:37:51 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomisation.<BR/>Blindness: double.<BR/>Design: cross-over.<BR/>Duration: 12 weeks (6 weeks each for lorazepam and placebo with a 4-week wash-out period in-between).<BR/>Setting: inpatient.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-13 05:56:30 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia according to DSM-IV. "All subjects were severely disabled chronic patients (duration of illness &gt; 5 years)"<BR/>Age: mean 44.89 years in the lorazepam group and 43.5 in the placebo group.<BR/>Sex: 12 M, 5 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 14:55:16 +0100" MODIFIED_BY="[Empty name]">
<P>1. Lorazepam 6 mg. N = 9 (first phase of the study).<BR/>2. Placebo. N = 9 (first phase of the study).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-08 15:24:32 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Leaving the study early due to adverse effects.</P>
<P>Global state: CGI.<BR/>Mental state: BPRS, HDRS.</P>
<P>Behaviour: NOSIE.<BR/>Adverse effects: AIMS, SAS, BARS, VPAS, BFCRS, MRS.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-06 11:52:56 +0100" MODIFIED_BY="[Empty name]">
<P>There is no information available regarding the results of the first trial phase up to the point of first cross-over.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>Regarding abbreviations see footnotes under the table "Characteristics of included studies". </P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-10-02 11:05:19 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-04-20 11:08:41 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:16:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Azima-1962">
<DESCRIPTION>
<P>Randomly assigned; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:17:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barbee-1992">
<DESCRIPTION>
<P>Randomly assigned; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:18:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Battaglia-1997">
<DESCRIPTION>
<P>Participants were "sequentially assigned on the basis of a computer-generated table of random numbers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:18:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-1999">
<DESCRIPTION>
<P>&#8220;A stratified randomization procedure was used to assign drug treatment to balance study groups on gender, prior social function, and past duration of hospital care.&#8221; No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:19:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheung-1981">
<DESCRIPTION>
<P>Randomly assigned; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:19:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1993">
<DESCRIPTION>
<P>Randomly assigned; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:20:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dorevitch-1999">
<DESCRIPTION>
<P>&#8220;Patients were assigned by a table of random numbers.&#8221; No further details. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:21:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Foster-1997">
<DESCRIPTION>
<P>Randomly assigned; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:21:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garza_x002d_Trevino-1989">
<DESCRIPTION>
<P>Randomly assigned; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:22:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gundlach-1966">
<DESCRIPTION>
<P>Randomly assigned; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:22:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guz-1972">
<DESCRIPTION>
<P>Randomly assigned; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:23:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hankoff-1962">
<DESCRIPTION>
<P>Randomly assigned; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:23:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hanlon-1969">
<DESCRIPTION>
<P>Randomly assigned &#8220;within sex&#8221;; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:24:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hanlon-1970">
<DESCRIPTION>
<P>Randomly assigned &#8220;within sex&#8221;; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:24:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Holden-1968">
<DESCRIPTION>
<P>Randomly assigned; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:24:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kurland-1966">
<DESCRIPTION>
<P>Randomly assigned; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:25:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kutcher-1989">
<DESCRIPTION>
<P>Randomly assigned; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:25:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lerner-1979">
<DESCRIPTION>
<P>Randomly assigned; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:27:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lingjaerde-1979">
<DESCRIPTION>
<P>Randomly assigned; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:28:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lingjaerde-1982">
<DESCRIPTION>
<P>Randomly assigned; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:28:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ma-2006">
<DESCRIPTION>
<P>Randomly assigned; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-07 10:39:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marneros-1979">
<DESCRIPTION>
<P>No randomisation mentioned in the publication, but the trial was described as &#8220;double-blind.&#8221; Thus it was implied that the study was randomised.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:29:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Merlis-1962">
<DESCRIPTION>
<P>Randomly assigned; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 11:07:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Minervini-1990">
<DESCRIPTION>
<P>Randomly assigned; &#8220;Randomisation was balanced for each group of six patients.&#8221; No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 11:08:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morphy-1986">
<DESCRIPTION>
<P>Randomly assigned; &#8220;randomization was forced so that in each consecutive group of six patients, three patients received alprazolam and three patients received placebo.&#8221; No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:32:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nestoros-1982">
<DESCRIPTION>
<P>Randomly assigned; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:32:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nishikawa-1982">
<DESCRIPTION>
<P>Randomly assigned; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:33:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pujalte-1994">
<DESCRIPTION>
<P>Randomly assigned; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:58:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stevens-1992">
<DESCRIPTION>
<P>Randomly assigned; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:59:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TREC_x002d_Rio-2003">
<DESCRIPTION>
<P>Randomly assigned; &#8220;In Britain one collaborator used Microsoft Excel to generate even random numbers less than 10. These block sizes were than applied to a table of random numbers.&#8221; Comment: Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:59:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2000">
<DESCRIPTION>
<P>randomised according to lottery; allocated by acupuncturist; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 15:00:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2003">
<DESCRIPTION>
<P>Randomly assigned; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 15:01:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wyant-1990">
<DESCRIPTION>
<P>Randomly assigned; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 15:01:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Xuan-2007">
<DESCRIPTION>
<P>Randomly assigned; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-05-20 08:39:46 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:16:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Azima-1962">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:17:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barbee-1992">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 15:19:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Battaglia-1997">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:18:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-1999">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:19:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheung-1981">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:19:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1993">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:20:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dorevitch-1999">
<DESCRIPTION>
<P>No further details. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:21:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Foster-1997">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:21:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garza_x002d_Trevino-1989">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:22:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gundlach-1966">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:22:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guz-1972">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:23:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hankoff-1962">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:23:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hanlon-1969">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:24:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hanlon-1970">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:24:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Holden-1968">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:24:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kurland-1966">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:25:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kutcher-1989">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:25:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lerner-1979">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:27:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lingjaerde-1979">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:28:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lingjaerde-1982">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:28:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ma-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:28:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marneros-1979">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:29:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Merlis-1962">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:30:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Minervini-1990">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:31:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morphy-1986">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:32:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nestoros-1982">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:32:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nishikawa-1982">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:33:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pujalte-1994">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:58:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stevens-1992">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:58:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TREC_x002d_Rio-2003">
<DESCRIPTION>
<P>&#8220;To help ensure concealment of allocation, [one collaborator] produced a table of allocation sequence independent of block size. He sent these tables to a Brazilian colleague independent of the TREC team, who ensured that the correct drug was in the consecutively numbered local pack before it was sealed. These packs were constructed of cardboard, were identical, and were sealed firmly with tape, across which the consecutive number was written.&#8221; Comment: Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:59:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2000">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 15:00:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2003">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 15:01:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wyant-1990">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 15:01:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Xuan-2007">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-03-28 13:25:42 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-10-02 11:05:10 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-10-02 11:05:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Azima-1962">
<DESCRIPTION>
<P>&#8220;Multi-blind&#8221;; &#8220;identical placebos&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 14:17:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barbee-1992">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;; &#8220;identically appearing placebo tablet&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 14:18:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Battaglia-1997">
<DESCRIPTION>
<P>"Double-blind". "The emergency department psychiatrist who treated and rated the patient remained blinded to the identity of the patient&#8217;s medication throughout treatment." The non-blinding of others is unlikely to introduce bias. The "syringes containing the study drug were prepared by a non-blinded nurse or hospital pharmacist and delivered to the emergency department as needed."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 14:18:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-1999">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 14:19:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheung-1981">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 05:24:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chouinard-1993">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;. &#8220;To ensure double-blind conditions, the clonazepam group received procyclidine placebo with each dose.&#8221; The nurse administering the drugs i.m. injections &#8220;was not blind to the treatment allocations&#8221;, but this was unlikely to introduce bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 14:20:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dorevitch-1999">
<DESCRIPTION>
<P>&#8220;Double-blind&#8220;; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 14:21:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Foster-1997">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;; no further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-09-03 15:44:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Garza_x002d_Trevino-1989">
<DESCRIPTION>
<P>Non-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-09-03 15:44:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gundlach-1966">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;. &#8220;Placebo was matched in appearance.&#8221; &#8220;The psychiatrists, social workers and other personnel dealing with the patients did not have access the code indicating which patients were treated with diazepam and which with placebo.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 14:22:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guz-1972">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 14:23:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hankoff-1962">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;; &#8220;All the drugs and their placebos were administered in pink No. 2 capsules.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 14:23:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hanlon-1969">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 14:24:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hanlon-1970">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 14:24:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Holden-1968">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;. &#8220;The drugs were prepared in identical capsules.&#8221; Comment: Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 14:25:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kurland-1966">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;; &#8220;Chlordiazepoxide, imipramine, and placebo were dispensed from the pharmacy in identical opaque white capsules, so that neither patients nor research personnel knew which of theses medications was being administered.&#8221; Comment: Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 14:25:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kutcher-1989">
<DESCRIPTION>
<P>&#8220;Double blind&#8221;; tablets were &#8220;identical in appearance&#8221; Comment: Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 14:25:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lerner-1979">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 14:27:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lingjaerde-1979">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;. &#8220;Tablets of identical appearance.&#8221; Comment: Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 14:28:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lingjaerde-1982">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;. &#8220;Similar-looking placebo tablets&#8221; Comment: Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-07 12:48:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ma-2006">
<DESCRIPTION>
<P>Single-blind; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 14:28:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marneros-1979">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 14:29:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Merlis-1962">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;. &#8220;Capsules of identical appearance, identified on the ward only by code letter.&#8221; Comment: Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-26 16:31:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Minervini-1990">
<DESCRIPTION>
<P>&#8220;Alpidem tablets of 50 mg and placebo tablets were identical in size and appearance.&#8221; Comment: Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 14:31:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morphy-1986">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 14:32:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nestoros-1982">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;; &#8220;matched tablets&#8221;. Comment: Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-06 18:17:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nishikawa-1982">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;. &#8220;Drug appearance, with respect to powder colour, taste and volume, was made identical by adding a kind of stomachics.&#8221; Comment: Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 14:33:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pujalte-1994">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;; &#8220;identical appearance&#8221; of the study medication. Comment: Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 14:58:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stevens-1992">
<DESCRIPTION>
<P>&#8220;The study design was open.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 14:59:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-TREC_x002d_Rio-2003">
<DESCRIPTION>
<P>&#8220;Open treatment.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-13 05:51:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2000">
<DESCRIPTION>
<P>Non-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 15:00:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2003">
<DESCRIPTION>
<P>Not double-blind; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 15:01:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wyant-1990">
<DESCRIPTION>
<P>&#8220;Single-blind&#8221;; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-18 15:02:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Xuan-2007">
<DESCRIPTION>
<P>Non-blind; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-10-02 11:05:12 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-10-02 11:05:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Azima-1962">
<DESCRIPTION>
<P>&#8220;Multi-blind&#8221;; &#8220;evaluation of drug effects is made by different members of the research team and the final conclusion is the result of pooling of the multiple observations&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:17:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barbee-1992">
<DESCRIPTION>
<P>Two investigators administered the scales and were blind to each other&#8217;s ratings and the drug assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:18:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Battaglia-1997">
<DESCRIPTION>
<P>"Double-blind". "The emergency department psychiatrist who treated and rated the patient remained blinded to the identity of the patient&#8217;s medication throughout treatment." The non-blinding of others is unlikely to introduce bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:18:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-1999">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:19:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheung-1981">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:20:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chouinard-1993">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;. The evaluating psychiatrist was blind to treatment allocations.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:20:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dorevitch-1999">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;; &#8221;All ratings were completed by the same rater, who was blind to the study medications.&#8221; Comment: Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:21:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Foster-1997">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;. &#8220;All raters were unaware of the specific medication received by the patient.&#8221;  Raters were trained by the first author of the trial, and &#8220;periodic calibration training sessions were conducted to control for rater drift. Initial training was continued until raters agreed on item scores at least 90% of the time.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-09-03 15:44:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Garza_x002d_Trevino-1989">
<DESCRIPTION>
<P>Non-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 05:27:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gundlach-1966">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:22:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guz-1972">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:23:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hankoff-1962">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:23:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hanlon-1969">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:24:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hanlon-1970">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:24:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Holden-1968">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:24:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kurland-1966">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:25:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kutcher-1989">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;, &#8220;Akathisia ratings were repeated blind to the patient&#8217;s medication status.&#8221; Comment: Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:25:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lerner-1979">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;; clinical ratings &#8220;were performed by consensus of two physicians unaware of the treatment administered.&#8221; Comment: Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:27:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lingjaerde-1979">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;. No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:28:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lingjaerde-1982">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:28:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ma-2006">
<DESCRIPTION>
<P>Single-blinded, the raters did not involved in the study. Comment: Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:28:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marneros-1979">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:29:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Merlis-1962">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;. No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:30:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Minervini-1990">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:31:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morphy-1986">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:32:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nestoros-1982">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:32:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nishikawa-1982">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 14:33:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pujalte-1994">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;. &#8220;The patients were all examined by the same independent psychiatrist, who was unaware of the medication dose.&#8221; Comment. Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 05:49:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stevens-1992">
<DESCRIPTION>
<P>The mean outcome (BPRS) was rated &#8220;by raters ignorant of the patient&#8217;s current medication.&#8221; Thus, the study was single-blinded concerning the main-outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-04-21 07:37:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TREC_x002d_Rio-2003">
<DESCRIPTION>
<P>The ratings of the primary outcome were performed by raters &#8220;blind to the allocated treatment, and unknown to the clinicians looking after the patient.&#8221; Comment: Probably done. Thus, concerning the main-outcome (tranquillised or asleep by 20 minutes), the study was single-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-13 05:51:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2000">
<DESCRIPTION>
<P>Non-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 15:00:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2003">
<DESCRIPTION>
<P>Not double-blind; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 15:01:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wyant-1990">
<DESCRIPTION>
<P>&#8220;Single-blind&#8221;; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-18 15:02:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Xuan-2007">
<DESCRIPTION>
<P>Non-blind; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-07-26 16:44:24 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 05:57:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Azima-1962">
<DESCRIPTION>
<P>No participant left the trial early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 05:57:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barbee-1992">
<DESCRIPTION>
<P>No participant left the trial early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 05:57:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Battaglia-1997">
<DESCRIPTION>
<P>No participant left the trial early. "Data for two patients were excluded from the efficacy analysis because of receiving antipsychotic medication shortly before entering the study." Due to the low attrition the risk of bias might be rather low.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 05:57:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carpenter-1999">
<DESCRIPTION>
<P>No participant left the trial early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-07-26 16:43:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cheung-1981">
<DESCRIPTION>
<P>Two participants left the trial early in the benzodiazepine group, the total number of patients leaving the trial early is rather low (6.7%). The analysis was based on completer data, but due to the low attrition the risk of bias might be rather low. Additionally, the trial authors provided a worst-case-scenario analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-07-26 16:11:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chouinard-1993">
<DESCRIPTION>
<P>One participant left the trial early in the benzodiazepine group; the total number of patients leaving the trial early is rather low (6.25%). The trial authors did not provide any information how they considered with the drop-out in the analysis, but due to the low attrition the risk of bias might be rather low.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 05:57:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dorevitch-1999">
<DESCRIPTION>
<P>No participant left the trial early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 05:57:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Foster-1997">
<DESCRIPTION>
<P>No participant left the trial early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 05:57:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garza_x002d_Trevino-1989">
<DESCRIPTION>
<P>No participant left the trial early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-07-26 16:17:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gundlach-1966">
<DESCRIPTION>
<P>The attrition was high (32.7% in the benzodiazepine group and 37.5% in the placebo group).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 05:57:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guz-1972">
<DESCRIPTION>
<P>No participant left the trial early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-07-26 16:19:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hankoff-1962">
<DESCRIPTION>
<P>With 23.2% the attrition was rather high. The authors provided a completer analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-07-26 16:43:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hanlon-1969">
<DESCRIPTION>
<P>The attrition was rather low in the thioridazine plus placebo group (4.9%) but moderate in the thioridazine plus chlordiazepoxide group (16.9%), overall 11.1%. The trial authors provided a modified completer-analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-07-26 16:24:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hanlon-1970">
<DESCRIPTION>
<P>With 7.1% the overall attrition was rather low (8.5% in the fluphenazine plus chlordiazepoxide group and 5.8% in the fluphenazine plus placebo group). The trial authors provided a modified completer-analysis, but due to the low attrition the risk of bias might be rather low.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-07-26 16:25:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Holden-1968">
<DESCRIPTION>
<P>The attrition was rather low (8.3%). The analysis was based on completer data, but due to the low attrition the risk of bias might be rather low.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-07-26 16:44:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kurland-1966">
<DESCRIPTION>
<P>The attrition was rather low in the chlordiazepoxide plus chlorpromazine group (6.8%) and moderate in the chlorpromazine plus placebo group (12.5%), overall 9.5%.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-07-26 16:26:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kutcher-1989">
<DESCRIPTION>
<P>One of 15 participants left the trial early (7.1%). The analysis was based on completer data, but due to the low attrition the risk of bias might be rather low.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-05-18 14:26:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lerner-1979">
<DESCRIPTION>
<P>The attrition was very high (50%). 4 patients were not rated &#8220;because the raters were unavailable.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 08:11:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lingjaerde-1979">
<DESCRIPTION>
<P>No drop-outs; but the data for one participant regarding the BPRS and for two participants regarding the NOSIE scale were missing. Due to the low attrition the risk of bias might be rather low.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-07-26 16:29:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lingjaerde-1982">
<DESCRIPTION>
<P>The attrition was moderate (12.1%). It was not clearly indicated which analysis-method was applied.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 05:57:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ma-2006">
<DESCRIPTION>
<P>No participant left the trial early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 05:44:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marneros-1979">
<DESCRIPTION>
<P>Three patients in the camazepame group left the trial early (30%) and no participant in the placebo group; the total number of patients leaving the trial early is moderate (15%). The trial authors provided the individual patient data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 05:58:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Merlis-1962">
<DESCRIPTION>
<P>No participant left the trial early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 05:58:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Minervini-1990">
<DESCRIPTION>
<P>No participant left the trial early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-07-26 16:32:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morphy-1986">
<DESCRIPTION>
<P>One alprazolam-treated patient (6.7%) was dropped from the study early in the protocol and the data were not available for the analyses. Due to the low attrition the risk of bias might be rather low.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 05:58:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nestoros-1982">
<DESCRIPTION>
<P>No participant left the trial early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-05-18 14:32:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nishikawa-1982">
<DESCRIPTION>
<P>Regarding the outcomes of interest for this review in the case of cross-over-studies (only data up to the point of the first cross-over were used), there was no risk of bias due to the attrition: &#8220;the treatments with the first allocated drugs were performed in all patients.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 05:48:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pujalte-1994">
<DESCRIPTION>
<P>No participant left the trial early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-07-26 16:36:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stevens-1992">
<DESCRIPTION>
<P>The attrition was moderate in the haloperidol plus lorazepam group (18.75%) and in the haloperidol plus placebo group (20.7%), overall 19.7%. The trial authors provided a completer-analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-07-26 16:44:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TREC_x002d_Rio-2003">
<DESCRIPTION>
<P>With 2% the overall attrition was rather low (0.7% in the midazolam group and 3.3% in the haloperidol plus promethazine group). Due to the low attrition the risk of bias might be rather low.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 05:51:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2000">
<DESCRIPTION>
<P>No participant left the trial early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 05:51:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2003">
<DESCRIPTION>
<P>No participant left the trial early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 05:51:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wyant-1990">
<DESCRIPTION>
<P>No participant left the trial early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-10-13 05:52:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Xuan-2007">
<DESCRIPTION>
<P>No participant left the trial early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-04-20 10:17:30 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 10:11:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Azima-1962">
<DESCRIPTION>
<P>The outcomes that are of interest in the review have been reported in the pre-specific way. The adverse effects were not fully addressed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-08 15:20:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Barbee-1992">
<DESCRIPTION>
<P>The outcomes that are of interest in the review were not fully addressed (Simpson and Angus Scale). The adverse effects were not fully addressed (only the five most frequent).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:18:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Battaglia-1997">
<DESCRIPTION>
<P>The outcomes that are of interest in the review have been reported in the pre-specific way.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-08 15:21:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Carpenter-1999">
<DESCRIPTION>
<P>The outcomes that are of interest in the review were not fully addressed. The trial authors did not provide raw data of the BPRS total score or the CGI. Reporting on adverse effects was incomplete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 10:13:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheung-1981">
<DESCRIPTION>
<P>The outcomes that are of interest in the review have been reported in the pre-specific way. The adverse effects were not fully addressed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-08 15:21:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chouinard-1993">
<DESCRIPTION>
<P>The outcomes that are of interest in the review have been reported in the pre-specific way with the exception of adverse effects, which were not fully addressed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:20:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dorevitch-1999">
<DESCRIPTION>
<P>The outcomes that are of interest in the review were not fully addressed (e.g. SDs are missing). Adverse effects were not fully addressed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-08 15:21:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Foster-1997">
<DESCRIPTION>
<P>The outcomes that are of interest in the review have been reported in the pre-specific way with the exception of adverse effects, which were not fully addressed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 10:17:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garza_x002d_Trevino-1989">
<DESCRIPTION>
<P>The outcomes that are of interest in the review have been reported in the pre-specific way. No information regarding adverse effects available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:22:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gundlach-1966">
<DESCRIPTION>
<P>The outcomes that are of interest in the review were not fully addressed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:22:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Guz-1972">
<DESCRIPTION>
<P>The outcomes that are of interest in the review were not fully addressed (e.g. SDs are missing).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:23:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hankoff-1962">
<DESCRIPTION>
<P>The outcomes that are of interest in the review were not fully addressed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:23:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hanlon-1969">
<DESCRIPTION>
<P>The outcomes that are of interest in the review were not fully addressed (e.g. SDs are missing).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:24:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hanlon-1970">
<DESCRIPTION>
<P>The outcomes that are of interest in the review were not fully addressed (e.g. SDs are missing).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:24:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Holden-1968">
<DESCRIPTION>
<P>The outcomes of interest for this review were not fully addressed (e.g. no raw data regarding the BPRS were provided; SDs were missing).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:25:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kurland-1966">
<DESCRIPTION>
<P>The outcomes that are of interest in the review have been reported in the pre-specific way.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 15:29:23 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kutcher-1989">
<DESCRIPTION>
<P>The outcomes that are of interest in the review were not fully addressed (akathisia scale).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:26:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lerner-1979">
<DESCRIPTION>
<P>The outcomes that are of interest in the review were not fully addressed (SDs were missing).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:27:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lingjaerde-1979">
<DESCRIPTION>
<P>The outcomes that are of interest in the review were not fully addressed (e.g. the SDs were missing).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 05:41:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lingjaerde-1982">
<DESCRIPTION>
<P>The outcomes that are of interest in the review were not fully addressed (incomplete numbers).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:28:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ma-2006">
<DESCRIPTION>
<P>The outcomes that are of interest in the review have been reported in the pre-specific way.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:28:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Marneros-1979">
<DESCRIPTION>
<P>The outcomes that are of interest in the review were not fully addressed. The adverse effects were not fully addressed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-08 15:22:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Merlis-1962">
<DESCRIPTION>
<P>The outcomes that are of interest in the review were not fully addressed. The trial authors did not provide raw data of the BPRS score or the MMS. Reporting on adverse effects was incomplete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:30:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Minervini-1990">
<DESCRIPTION>
<P>The outcomes have been reported in the pre-specific way.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:31:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Morphy-1986">
<DESCRIPTION>
<P>The outcomes of interest for this review were not fully addressed (e.g. no raw data regarding the BPRS were provided). The adverse effects were not fully addressed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-08 15:23:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nestoros-1982">
<DESCRIPTION>
<P>The outcomes that are of interest in the review were not fully addressed. The trial authors did not provide raw data of the BPRS score, the SCL-90, the SARS and the SS-PSE. Reporting on adverse effects was incomplete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-08 15:23:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nishikawa-1982">
<DESCRIPTION>
<P>The outcomes that are of interest in the review have been reported in the pre-specific way with the exception of adverse effects, which were not fully addressed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-08 15:23:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pujalte-1994">
<DESCRIPTION>
<P>The outcomes that are of interest in the review have been reported in the pre-specific way. Reporting on adverse effects was incomplete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-08 15:23:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stevens-1992">
<DESCRIPTION>
<P>The outcomes that are of interest in the review were not fully addressed. The trial authors did not provide raw data of the BPRS score (only relative scores). Reporting on adverse effects was incomplete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-08 15:23:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TREC_x002d_Rio-2003">
<DESCRIPTION>
<P>The outcomes that are of interest in the review have been reported in the pre-specific way with the exception of adverse effects, which were not fully addressed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 05:51:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2000">
<DESCRIPTION>
<P>The outcomes that are of interest in the review were not fully addressed. PANSS total score was assessed but no data were provided in the publication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 15:00:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2003">
<DESCRIPTION>
<P>The outcomes that are of interest in the review were not fully addressed (usable data only for 2-week treatment).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-08 15:24:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wyant-1990">
<DESCRIPTION>
<P>The outcomes that are of interest in the review were not fully addressed (CGI). The adverse effects were not addressed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 15:01:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Xuan-2007">
<DESCRIPTION>
<P>The outcomes that are of interest in the review were not fully addressed (TESS score).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-10-02 11:05:19 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-02 11:05:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Azima-1962">
<DESCRIPTION>
<P>&#8220;In the present study, in conjunction with Librium, 3 tranquillizers, 2 anti-depressants, 4 placebos, were investigated in the unit.&#8221;</P>
<P>No fixed endpoint for the study (mean three weeks; range: 5 days to 3 months).</P>
<P>The majority of participants were treatment-resistant.</P>
<P>Regarding this review the main focus on the anti-anxiety effect of the medication to judge improvement could be a possible risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:17:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barbee-1992">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-06 15:06:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Battaglia-1997">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:18:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-1999">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-06 15:06:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheung-1981">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 10:13:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chouinard-1993">
<DESCRIPTION>
<P>&#8220;Of the 16 patients, 12 (6 in each group) were receiving neuroleptics at study entry.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 10:15:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dorevitch-1999">
<DESCRIPTION>
<P>Antipsychotic drug treatment in both study groups additionally to flunitrazepam and haloperidol. Four patients were taking additional medications including mood stabilizers and lorazepam.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 05:26:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Foster-1997">
<DESCRIPTION>
<P>Baseline-imbalance regarding the diagnosis randomised to the both different treatment groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 10:16:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garza_x002d_Trevino-1989">
<DESCRIPTION>
<P>Baseline-imbalance concerning sex-distribution.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 05:28:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gundlach-1966">
<DESCRIPTION>
<P>The drop-out rate mentioned in the text differs from the drop-out rate presented in the tables of the publication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:22:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guz-1972">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 10:20:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hankoff-1962">
<DESCRIPTION>
<P>&#8220;Certain variations in the composition of the groups emerged.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:23:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hanlon-1969">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:24:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hanlon-1970">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 11:01:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Holden-1968">
<DESCRIPTION>
<P>Cross-over study design.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:24:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kurland-1966">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-06 15:10:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kutcher-1989">
<DESCRIPTION>
<P>&#8220;All patients continued on their routine medications (neuroleptics and others) over the duration of the trial.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:25:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lerner-1979">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-03 15:44:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lingjaerde-1979">
<DESCRIPTION>
<P>Additionally to the study medication the participants received further their previous medication which contains two different antipsychotic agents in 11 participants.</P>
<P>Cross-over study design.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 11:04:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lingjaerde-1982">
<DESCRIPTION>
<P>The difference in mean age at baseline was statistically significant. Some patients received no antipsychotic agent, whereas other participants received one or more antipsychotics during the trial.</P>
<P>Cross-over study design.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:28:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ma-2006">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:28:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marneros-1979">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-06 18:16:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Merlis-1962">
<DESCRIPTION>
<P>&#8220;Neither of the two psychiatrists had had previous experience with the BPRS-Scale.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 05:45:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Minervini-1990">
<DESCRIPTION>
<P>The main focus of this investigated trial was on the anti-anxiety effect of the additional benzodiazepine medication. This can be judge as a possible risk of bias. &#8220;The patients were all chronic institutionalised schizophrenics whose anxiety was not directly linked to the schizophrenic process.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 11:09:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morphy-1986">
<DESCRIPTION>
<P>The main focus of this investigated trial was on the anti-anxiety effect of the additional benzodiazepine medication. This can be judged as a possible risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-06 15:10:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nestoros-1982">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 11:11:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nishikawa-1982">
<DESCRIPTION>
<P>Cross-over study design.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-06 15:10:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pujalte-1994">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:58:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stevens-1992">
<DESCRIPTION>
<P>&#8220;to avoid bias introduced by group differences in entry scores that did not reach significance or violated homogeneity of variance, the comparison was based on improvement calculated as the quotient of actual score/initial score.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:59:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TREC_x002d_Rio-2003">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 14:59:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2000">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 15:00:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2003">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 15:01:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wyant-1990">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-18 15:01:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Xuan-2007">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2012-10-02 11:29:03 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2012-04-30 08:30:26 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2011-06-04 10:23:15 +0100" MODIFIED_BY="Grade Profiler">BENZODIAZEPINES AS SOLE TREATMENT versus PLACEBO AS SOLE TREATMENT for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Benzodiazepines as sole treatment versus placebo as sole treatment for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with schizophrenia</P>
<P>
<B>Setting:</B> inpatients and outpatients<BR/>
<B>Intervention:</B> benzodiazepines as sole treatment versus placebo as sole treatment<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>B</B>enzodiazepines as sole treatment versus placebo as sole treatment</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>No clinically important response to treatment - short term</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>667 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>447 per 1000</B>
<BR/>(293 to 680)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 0.67 </B>
<BR/>(0.44 to 1.02)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>382<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Leaving the study early due to any reason (overall acceptability of treatment)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 0.89 </B>
<BR/>(0.57 to 1.38)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>440<BR/>(8 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Leaving the study early due to adverse effects (overall tolerability of treatment)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>161<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>6,7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Number of participants tranquillised at endpoint of the study (Desired sedation/tranquillisation)</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>No included trial provided data for that outcome.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes<SUP>8</SUP>. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Serious study limitations: High risk of bias regarding outcome data reporting in <LINK REF="STD-Merlis-1962" TYPE="STUDY">Merlis 1962</LINK> and attrition in two trials (<LINK REF="STD-Gundlach-1966" TYPE="STUDY">Gundlach 1966</LINK>; <LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK>).<BR/>
<SUP>2</SUP> Substancial level of heterogeneity.<BR/>
<SUP>3</SUP> Serious imprecision: The 95% confidence interval around the pooled risk ratio includes both "no effect" and "appreciable benefit". Downgraded by 1.<BR/>
<SUP>4</SUP> High risk of bias regarding outcome data reporting in <LINK REF="STD-Merlis-1962" TYPE="STUDY">Merlis 1962</LINK> and attrition in two trials (<LINK REF="STD-Gundlach-1966" TYPE="STUDY">Gundlach 1966</LINK>; <LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK>). <LINK REF="STD-Nishikawa-1982" TYPE="STUDY">Nishikawa 1982</LINK> used a cross-over design.<BR/>
<SUP>5</SUP> Serious imprecision: The 95% confidence interval around the pooled risk ratio and the best estimate of effect includes both "no effect" and "appreciable benefit". Downgraded by 1.<BR/>
<SUP>6</SUP> <LINK REF="STD-Merlis-1962" TYPE="STUDY">Merlis 1962</LINK> was characterised by incomplete outcome data reporting and Nishikawa used a cross-over study design.<BR/>
<SUP>7</SUP> There were only few studies included that were characterised by a small sample size; one of these used a cross-over design (<LINK REF="STD-Nishikawa-1982" TYPE="STUDY">Nishikawa 1982</LINK>) and another one reported outcome data incompletely (<LINK REF="STD-Merlis-1962" TYPE="STUDY">Merlis 1962</LINK>).</P>
<P>
<SUP>8</SUP> The basis for the assumed risk was the risk in the pooled control group of the relevant studies.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2012-10-02 11:29:03 +0100" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2011-06-04 10:23:24 +0100" MODIFIED_BY="Grade Profiler">BENZODIAZEPINES versus ANTIPSYCHOTICS for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Benzodiazepines versus antipsychotics for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with schizophrenia</P>
<P>
<B>Setting:</B> inpatients and outpatients<BR/>
<B>Intervention:</B> benzodiazepine monotherapy versus antipsychotic monotherapy<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>B</B>enzodiazepines versus antipsychotics</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>No clinically important response to treatment - ultra short term (at 60 minutes)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>286 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>174 per 1000</B>
<BR/>(57 to 532)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 0.61 </B>
<BR/>(0.2 to 1.86)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>44<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>No clinically important response to treatment - ultra short term (at 12 hours)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>514 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>386 per 1000</B>
<BR/>(226 to 668)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 0.75 </B>
<BR/>(0.44 to 1.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>66<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>No clinically important response to treatment - short term</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>150 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>222 per 1000</B>
<BR/>(96 to 519)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 1.48 </B>
<BR/>(0.64 to 3.46)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>112<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Leaving the study early due to any reason (overall acceptability of treatment)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 0.73 </B>
<BR/>(0.45 to 1.18)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>738<BR/>(13 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>5,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Leaving the study early due to adverse effects (overall tolerability of treatment)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 13 </B>
<BR/>(0.78 to 216.39)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>444<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>7,8</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Desired sedation - ultra short term - asleep at 12 hours</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>514 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>386 per 1000</B>
<BR/>(226 to 668)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 0.75 </B>
<BR/>(0.44 to 1.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>66<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>8</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes<SUP>10</SUP>. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> The trial was not blinded.<BR/>
<SUP>2</SUP> Serious imprecision: The 95% confidence interval around the risk ratio includes both "no effect" and "appreciable benefit". Downgraded by 1.<BR/>
<SUP>3</SUP> Both trials were characterised by incomplete outcome data reporting.<BR/>
<SUP>4</SUP> Serious imprecision: The 95% confidence interval around the pooled risk ratio and the best estimate of effect includes both "no effect" and "appreciable harm". Downgraded by 1.<BR/>
<SUP>5</SUP> Two trials were non-blinded (<LINK REF="STD-Garza_x002d_Trevino-1989" TYPE="STUDY">Garza-Trevino 1989</LINK>; <LINK REF="STD-TREC_x002d_Rio-2003" TYPE="STUDY">TREC-Rio 2003</LINK>); <LINK REF="STD-Lerner-1979" TYPE="STUDY">Lerner 1979</LINK>,<LINK REF="STD-Merlis-1962" TYPE="STUDY">Merlis 1962</LINK> and <LINK REF="STD-Hankoff-1962" TYPE="STUDY">Hankoff 1962</LINK> reported outcome data incomplete and Nishikawa used a cross-over study design.<BR/>
<SUP>6</SUP> Serious imprecision: The 95% confidence interval around the best estimate of effect includes both "no effect" and "appreciable benefit". Downgraded by 1.<BR/>
<SUP>7</SUP> <LINK REF="STD-TREC_x002d_Rio-2003" TYPE="STUDY">TREC-Rio 2003</LINK> was not blinded, <LINK REF="STD-Lerner-1979" TYPE="STUDY">Lerner 1979</LINK> and <LINK REF="STD-Merlis-1962" TYPE="STUDY">Merlis 1962</LINK> reported outcome data incompletely and <LINK REF="STD-Nishikawa-1982" TYPE="STUDY">Nishikawa 1982</LINK> used a cross-over trial design.<BR/>
<SUP>8</SUP> Serious imprecision: The 95% confidence interval of the risk ratio includes both "no effect" and appreciable harm". Downgraded by 1.<BR/>
<SUP>9</SUP> Both included studies were conducted as open trials.</P>
<P>
<SUP>10</SUP> The basis for the assumed risk was the risk in the pooled control group of the relevant studies.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2012-04-30 08:10:28 +0100" MODIFIED_BY="[Empty name]" NO="3" READONLY="YES">
<TITLE MODIFIED="2011-06-06 07:54:31 +0100" MODIFIED_BY="Grade Profiler">ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS versus PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Adjunctive benzodiazepines + antipsychotics versus placebo/no adjunctive treatment + antipsychotics for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with schizophrenia</P>
<P>
<B>Setting:</B> inpatients and outpatients<BR/>
<B>Intervention:</B> adjunctive benzodiazepines + antipsychotics versus placebo/no adjunctive treatment + antipsychotics<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>A</B>djunctive benzodiazepines + antipsychotics versus placebo/no adjunctive treatment + antipsychotics</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>No clinically important response to treatment - ultra short term (at 60 minutes)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>286 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>20 per 1000</B>
<BR/>(0 to 323)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 0.07 </B>
<BR/>(0 to 1.13)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>45<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>No clinically important response to treatment - ultra short term (at 12 hours)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>514 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>437 per 1000</B>
<BR/>(262 to 725)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 0.85 </B>
<BR/>(0.51 to 1.41)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>67<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>No clinically important response to treatment - short term (3 weeks or longer)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>307 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>267 per 1000</B>
<BR/>(150 to 473)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 0.87 </B>
<BR/>(0.49 to 1.54)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>511<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Leaving the study early due to any reason (overall acceptability of treatment)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 1.36 </B>
<BR/>(0.81 to 2.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1185<BR/>(19 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>5,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Leaving the study early due to adverse effects (overall tolerability of treatment) - short term </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 3.24 </B>
<BR/>(0.68 to 15.45)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>415<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>7,8</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Desired sedation - ultra short term - tranquillised at 60 minutes</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>714 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>992 per 1000</B>
<BR/>(757 to 1000)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 1.39 </B>
<BR/>(1.06 to 1.83)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>45<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Desired sedation - ultra short term - asleep at 12 hours</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>514 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>437 per 1000</B>
<BR/>(262 to 725)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 0.85 </B>
<BR/>(0.51 to 1.41)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>67<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>9</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes<SUP>10</SUP>. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> The study was not double-blinded.<BR/>
<SUP>2</SUP> Serious imprecision: The 95% confidence interval of the risk ratio includes both "no effect" and "appreciable benefit". Downgraded by 1.<BR/>
<SUP>3</SUP> <LINK REF="STD-Xuan-2007" TYPE="STUDY">Xuan 2007</LINK> was not blinded and <LINK REF="STD-Lingjaerde-1982" TYPE="STUDY">Lingjaerde 1982</LINK> used a cross-over study design.<BR/>
<SUP>4</SUP> Serious imprecision: The 95% confidence interval of the pooled risk ratio includes both "no effect" and "appreciable benefit". Downgraded by 1.<BR/>
<SUP>5</SUP> Five studies were not blinded und three used a cross-over design.<BR/>
<SUP>6</SUP> Serious imprecision: The 95% confidence interval of the pooled risk ratio includes both "no effect" and "appreciable harm". Downgraded by 1.<BR/>
<SUP>7</SUP> One study used a cross-over-design and three were characterised by selective reporting.<BR/>
<SUP>8</SUP> Serious imprecision: The 95% confidence interval of the pooled risk ratio and best estimate of effect includes both "no effect" and "appreciable harm". Downgraded by 1.<BR/>
<SUP>9</SUP> Serious imprecision: The 95% confidence interval of the risk ratio includes both "no effect" and "appreciable harm". Downgraded by 1.</P>
<P>
<SUP>10</SUP> The basis for the assumed risk was the risk in the pooled control group of the relevant studies.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-04-23 11:40:59 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-04-23 11:39:36 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>BENZODIAZEPINES AS SOLE TREATMENT versus PLACEBO AS SOLE TREATMENT</NAME>
<DICH_OUTCOME CHI2="13.291346016038494" CI_END="1.0158211263854995" CI_START="0.4409719233215638" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6692896203086457" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="112" I2="62.381537626312905" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.006817240759989522" LOG_CI_START="-0.3555890611777131" LOG_EFFECT_SIZE="-0.17438591020886177" METHOD="MH" MODIFIED="2012-04-23 11:39:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.020796285577849627" P_Q="1.0" P_Z="0.059264499760957504" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.14965862732116977" TOTALS="YES" TOTAL_1="166" TOTAL_2="216" WEIGHT="100.0" Z="1.886226048460704">
<NAME>No clinically important response to treatment - short term</NAME>
<GROUP_LABEL_1>Benzodiazepines</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.377282176976943" CI_START="0.5558955258395225" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.13902292743874523" LOG_CI_START="-0.25500682139411873" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="0.23145502494313788" STUDY_ID="STD-Azima-1962" TOTAL_1="8" TOTAL_2="14" VAR="0.053571428571428575" WEIGHT="22.298659175995873"/>
<DICH_DATA CI_END="1.4341142204885133" CI_START="0.6446879891497157" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="24" LOG_CI_END="0.15658374223304564" LOG_CI_START="-0.19065042083060627" LOG_EFFECT_SIZE="-0.017033339298780342" MODIFIED="2011-05-25 08:03:52 +0100" MODIFIED_BY="[Empty name]" ORDER="249" O_E="0.0" SE="0.20396706622041733" STUDY_ID="STD-Gundlach-1966" TOTAL_1="52" TOTAL_2="48" VAR="0.041602564102564105" WEIGHT="23.694078850673154"/>
<DICH_DATA CI_END="1.3214942600548643" CI_START="0.2917420752108864" EFFECT_SIZE="0.6209150326797386" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="34" LOG_CI_END="0.12106528110230146" LOG_CI_START="-0.5350009321598035" LOG_EFFECT_SIZE="-0.20696782552875104" MODIFIED="2011-05-25 08:03:54 +0100" MODIFIED_BY="[Empty name]" ORDER="526" O_E="0.0" SE="0.38537654125029236" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="95" VAR="0.1485150785460383" WEIGHT="15.198381552415844"/>
<DICH_DATA CI_END="2.533730058636853" CI_START="0.39467503516850566" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.40376034366137825" LOG_CI_START="-0.4037603436613783" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-24 05:54:58 +0100" MODIFIED_BY="[Empty name]" ORDER="247" O_E="0.0" SE="0.47434164902525694" STUDY_ID="STD-Merlis-1962" TOTAL_1="40" TOTAL_2="20" VAR="0.22500000000000003" WEIGHT="12.095698377667063"/>
<DICH_DATA CI_END="0.5912770228464836" CI_START="0.23783268174875655" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="32" LOG_CI_END="-0.22820899745086837" LOG_CI_START="-0.6237284670936939" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="525" O_E="0.0" SE="0.23233009432114626" STUDY_ID="STD-Minervini-1990" TOTAL_1="33" TOTAL_2="33" VAR="0.05397727272727272" WEIGHT="22.254218188392088"/>
<DICH_DATA CI_END="1.2400965730172222" CI_START="0.03225555240643706" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.0934555073359019" LOG_CI_START="-1.4913955160079393" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="524" O_E="0.0" SE="0.9309493362512627" STUDY_ID="STD-Nestoros-1982" TOTAL_1="6" TOTAL_2="6" VAR="0.8666666666666666" WEIGHT="4.458963854855982"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.011301415328758065" CI_END="1.379316806022723" CI_START="0.569113606777928" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8859954640769915" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.13966402781875234" LOG_CI_START="-0.2448010308423382" LOG_EFFECT_SIZE="-0.05256850151179295" METHOD="MH" MODIFIED="2011-06-03 14:37:40 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9153378943486309" P_Q="1.0" P_Z="0.5919738902394454" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="194" TOTAL_2="246" WEIGHT="100.0" Z="0.5359778079348301">
<NAME>Leaving the study early - any reason</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.011301415328758065" CI_END="1.379316806022723" CI_START="0.569113606777928" DF="1" EFFECT_SIZE="0.8859954640769915" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="41" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.13966402781875234" LOG_CI_START="-0.2448010308423382" LOG_EFFECT_SIZE="-0.05256850151179295" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9153378943486309" P_Z="0.5919738902394454" STUDIES="7" TAU2="0.0" TOTAL_1="181" TOTAL_2="236" WEIGHT="100.0" Z="0.5359778079348301">
<NAME>short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="514" O_E="0.0" SE="0.0" STUDY_ID="STD-Azima-1962" TOTAL_1="8" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="509" O_E="0.0" SE="0.0" STUDY_ID="STD-Carpenter-1999" TOTAL_1="15" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4875050297308898" CI_START="0.5109403217448859" EFFECT_SIZE="0.8717948717948718" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.17245844289179918" LOG_CI_START="-0.2916298228602874" LOG_EFFECT_SIZE="-0.05958568998424408" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="508" O_E="0.0" SE="0.2726077445767411" STUDY_ID="STD-Gundlach-1966" TOTAL_1="52" TOTAL_2="48" VAR="0.0743149824032177" WEIGHT="68.62977524498656"/>
<DICH_DATA CI_END="2.023017697142493" CI_START="0.41645379982127606" EFFECT_SIZE="0.9178743961352657" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="23" LOG_CI_END="0.3059996819491106" LOG_CI_START="-0.38043317095728824" LOG_EFFECT_SIZE="-0.03721674450408881" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="511" O_E="0.0" SE="0.40321405569464114" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="95" VAR="0.16258157470972115" WEIGHT="31.37022475501344"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="510" O_E="0.0" SE="0.0" STUDY_ID="STD-Merlis-1962" TOTAL_1="40" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="513" O_E="0.0" SE="0.0" STUDY_ID="STD-Minervini-1990" TOTAL_1="33" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="512" O_E="0.0" SE="0.0" STUDY_ID="STD-Nestoros-1982" TOTAL_1="6" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>long term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="515" O_E="0.0" SE="0.0" STUDY_ID="STD-Nishikawa-1982" TOTAL_1="13" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-10-13 08:58:30 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="92" TOTAL_2="69" WEIGHT="0.0" Z="0.0">
<NAME>Leaving the study early due to adverse effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-10-13 08:58:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="3" TAU2="0.0" TOTAL_1="79" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="516" O_E="0.0" SE="0.0" STUDY_ID="STD-Merlis-1962" TOTAL_1="40" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="517" O_E="0.0" SE="0.0" STUDY_ID="STD-Minervini-1990" TOTAL_1="33" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="518" O_E="0.0" SE="0.0" STUDY_ID="STD-Nestoros-1982" TOTAL_1="6" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-10-13 08:58:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>long term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="519" O_E="0.0" SE="0.0" STUDY_ID="STD-Nishikawa-1982" TOTAL_1="13" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-10-13 08:58:36 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="92" TOTAL_2="69" WEIGHT="0.0" Z="0.0">
<NAME>Leaving the study early due to inefficacy of treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-10-13 08:58:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="3" TAU2="0.0" TOTAL_1="79" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="520" O_E="0.0" SE="0.0" STUDY_ID="STD-Merlis-1962" TOTAL_1="40" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="521" O_E="0.0" SE="0.0" STUDY_ID="STD-Minervini-1990" TOTAL_1="33" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="522" O_E="0.0" SE="0.0" STUDY_ID="STD-Nestoros-1982" TOTAL_1="6" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-10-13 08:58:36 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>long term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="523" O_E="0.0" SE="0.0" STUDY_ID="STD-Nishikawa-1982" TOTAL_1="13" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.373278953505702" CI_END="1.7419644040569264" CI_START="0.4085738466311334" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8436356424784627" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="24" I2="81.38938981852846" I2_Q="36.37937255811245" ID="CMP-001.05" LOG_CI_END="0.24103927622870375" LOG_CI_START="-0.38872943659564946" LOG_EFFECT_SIZE="-0.0738450801834728" METHOD="MH" MODIFIED="2011-05-23 11:53:48 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.020447574945734126" P_Q="0.20994334441638074" P_Z="0.6457740697988079" Q="1.5718172552029945" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2287083954881707" TOTALS="YES" TOTAL_1="28" TOTAL_2="30" WEIGHT="100.0" Z="0.4596408003375881">
<NAME>Global state: 1. Relapse</NAME>
<GROUP_LABEL_1>Benzodiazepines</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2298681412779253" CI_START="0.36137568697619343" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.08985855161411156" LOG_CI_START="-0.44204106972547413" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.19437822071607125" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="20" WEIGHT="41.935687540357975" Z="1.2977355572174842">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.2298681412779253" CI_START="0.36137568697619343" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="0.08985855161411156" LOG_CI_START="-0.44204106972547413" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="528" O_E="0.0" SE="0.31244047052046187" STUDY_ID="STD-Carpenter-1999" TOTAL_1="15" TOTAL_2="20" VAR="0.09761904761904759" WEIGHT="41.935687540357975"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.177841444676015" CI_START="0.8490107089711609" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.07108683176105288" LOG_CI_START="-0.0710868317610529" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="10" WEIGHT="58.06431245964202" Z="0.0">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.177841444676015" CI_START="0.8490107089711609" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.07108683176105288" LOG_CI_START="-0.0710868317610529" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="529" O_E="0.0" SE="0.08351351372386966" STUDY_ID="STD-Nishikawa-1982" TOTAL_1="13" TOTAL_2="10" VAR="0.0069745069745069666" WEIGHT="58.06431245964202"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.037574179633735424" CI_END="1.4914844970526822" CI_START="0.5741071454140186" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9253496134068349" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.17361874353149426" LOG_CI_START="-0.24100704781176127" LOG_EFFECT_SIZE="-0.033694152140133486" METHOD="MH" MODIFIED="2011-05-24 10:35:37 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.8463007698100771" P_Q="0.8488356546974819" P_Z="0.7500684994298291" Q="0.036330016122599104" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="80" TOTAL_2="40" WEIGHT="200.0" Z="0.3185490438032254">
<NAME>Mental state: 1. General - various scales (unimproved or worse) - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.533730058636853" CI_START="0.39467503516850566" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.40376034366137825" LOG_CI_START="-0.4037603436613783" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-24 10:35:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="20" WEIGHT="100.0" Z="0.0">
<NAME>BPRS</NAME>
<DICH_DATA CI_END="2.533730058636853" CI_START="0.39467503516850566" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.40376034366137825" LOG_CI_START="-0.4037603436613783" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-24 10:35:31 +0100" MODIFIED_BY="[Empty name]" ORDER="530" O_E="0.0" SE="0.47434164902525694" STUDY_ID="STD-Merlis-1962" TOTAL_1="40" TOTAL_2="20" VAR="0.22500000000000003" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.936555764770062E-31" CI_END="1.5697596999295993" CI_START="0.5160025448712481" DF="0" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" I2="100.0" ID="CMP-001.06.02" LOG_CI_END="0.19583317535063458" LOG_CI_START="-0.2873481564719848" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2011-05-24 10:35:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.7104744600430752" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="20" WEIGHT="100.0" Z="0.37121895079662665">
<NAME>MMS</NAME>
<DICH_DATA CI_END="1.5697596999295993" CI_START="0.5160025448712481" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.19583317535063458" LOG_CI_START="-0.2873481564719848" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2011-05-24 10:35:37 +0100" MODIFIED_BY="[Empty name]" ORDER="531" O_E="0.0" SE="0.28382310609877337" STUDY_ID="STD-Merlis-1962" TOTAL_1="40" TOTAL_2="20" VAR="0.08055555555555556" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-12.592929283706251" CI_START="-22.607070716293766" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-17.60000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2011-06-07 08:11:21 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="5.6055481886715776E-12" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="33" UNITS="" WEIGHT="100.00000000000001" Z="6.889330724978956">
<NAME>Mental state: 2. General mean BPRS at 3 weeks (high=poor) - short term</NAME>
<GROUP_LABEL_1>Benzodiazepines</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-12.592929283706251" CI_START="-22.607070716293766" EFFECT_SIZE="-17.60000000000001" ESTIMABLE="YES" MEAN_1="49.3" MEAN_2="66.9" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="532" SD_1="9.6" SD_2="11.1" SE="2.554674859226441" STUDY_ID="STD-Minervini-1990" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.153888658301622" CI_START="0.6259279035383108" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1611111111111112" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.3332232494099629" LOG_CI_START="-0.20347568739446692" LOG_EFFECT_SIZE="0.06487378100774797" METHOD="MH" MODIFIED="2011-06-07 08:12:19 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.6356258034138295" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="19" WEIGHT="100.0" Z="0.4738234626406852">
<NAME>Mental state: 3a. Specific - anxiety TSRS at 6 weeks (unimproved or worse) - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.153888658301622" CI_START="0.6259279035383108" EFFECT_SIZE="1.1611111111111112" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.3332232494099629" LOG_CI_START="-0.20347568739446692" LOG_EFFECT_SIZE="0.06487378100774797" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="533" O_E="0.0" SE="0.315259612181506" STUDY_ID="STD-Gundlach-1966" TOTAL_1="20" TOTAL_2="19" VAR="0.09938862307283358" WEIGHT="100.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.09" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="9" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mental state: 3b. Specific - anxiety mean HAM-A at 3 weeks (skewed data) - short term</NAME>
<TR>
<TH>
<P>Invervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="29" STUDY_ID="STD-Minervini-1990">
<TR>
<TD>
<P>Benzodiazepine<BR/>
</P>
</TD>
<TD>
<P>7.60</P>
</TD>
<TD>
<P>6.90</P>
</TD>
<TD>
<P>33</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>31.40</P>
</TD>
<TD>
<P>8.50</P>
</TD>
<TD>
<P>33</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.042421139604376" CI_START="1.0220680681406846" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4448160535117056" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.3101452968833551" LOG_CI_START="0.009479820097609828" LOG_EFFECT_SIZE="0.15981255849048243" METHOD="MH" MODIFIED="2011-06-03 09:50:27 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.037200463926133465" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="48" WEIGHT="100.0" Z="2.083557196303934">
<NAME>Adverse effects: 1. total number of participants with adverse effects - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.042421139604376" CI_START="1.0220680681406846" EFFECT_SIZE="1.4448160535117056" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="23" LOG_CI_END="0.3101452968833551" LOG_CI_START="0.009479820097609828" LOG_EFFECT_SIZE="0.15981255849048243" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="535" O_E="0.0" SE="0.17661238938206014" STUDY_ID="STD-Gundlach-1966" TOTAL_1="52" TOTAL_2="48" VAR="0.03119193608324043" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="27" TOTAL_2="95" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 2. Anorexia - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="536" O_E="0.0" SE="0.0" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="95" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.934889550046154" CI_START="0.7468508258814052" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.5949325464844889" LOG_CI_START="-0.12676613441775306" LOG_EFFECT_SIZE="0.23408320603336796" METHOD="MH" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.20357576433825664" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="48" WEIGHT="100.0" Z="1.2714299342698023">
<NAME>Adverse effects: 3. Autonomic reaction (flushing, dryness of mouth etc) - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.934889550046154" CI_START="0.7468508258814052" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.5949325464844889" LOG_CI_START="-0.12676613441775306" LOG_EFFECT_SIZE="0.23408320603336796" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="537" O_E="0.0" SE="0.42392937762806343" STUDY_ID="STD-Gundlach-1966" TOTAL_1="52" TOTAL_2="48" VAR="0.17971611721611722" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="27" TOTAL_2="95" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 4. Cardiovascular reactions - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="538" O_E="0.0" SE="0.0" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="95" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="27" TOTAL_2="95" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 5. Depression - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="539" O_E="0.0" SE="0.0" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="95" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="27" TOTAL_2="95" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 6. Dryness of mouth - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="540" O_E="0.0" SE="0.0" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="95" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.76716047488833" CI_END="3.3536213248812663" CI_START="1.3607516125315895" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1362222790834546" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="27" I2="37.06945642373672" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.5255140225518266" LOG_CI_START="0.13377885764144007" LOG_EFFECT_SIZE="0.32964644009663335" METHOD="MH" MODIFIED="2011-06-03 09:22:25 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.1896627108804666" P_Q="0.49755827343665293" P_Z="9.715705613774435E-4" Q="0.4601406612866662" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.21562088802532026" TOTALS="SUB" TOTAL_1="158" TOTAL_2="286" WEIGHT="200.0" Z="3.2986323827683055">
<NAME>Adverse effects: 7. Energy level change - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.2727635425497397" CI_END="22.78207839675737" CI_START="0.016849323697655315" DF="1" EFFECT_SIZE="0.6195664721499422" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="69.44478307097856" ID="CMP-001.16.01" LOG_CI_END="1.3575933420024393" LOG_CI_START="-1.773417526262726" LOG_EFFECT_SIZE="-0.2079120921301434" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07043893311606297" P_Z="0.7946327926305758" STUDIES="2" TAU2="4.699373610256596" TOTAL_1="79" TOTAL_2="143" WEIGHT="100.0" Z="0.26029945578007074">
<NAME>Increased energy level (Insomnia, tension etc.)</NAME>
<DICH_DATA CI_END="1.8591338760360403" CI_START="0.005676030723711033" EFFECT_SIZE="0.10272536687631027" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2693106643981896" LOG_CI_START="-2.2459552624213903" LOG_EFFECT_SIZE="-0.9883222990116003" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="542" O_E="0.0" SE="1.4774796561809622" STUDY_ID="STD-Gundlach-1966" TOTAL_1="52" TOTAL_2="48" VAR="2.1829461344286143" WEIGHT="49.148414093779586"/>
<DICH_DATA CI_END="54.41774181231837" CI_START="0.22749882947835473" EFFECT_SIZE="3.5185185185185186" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.7357405157826304" LOG_CI_START="-0.6430208335229095" LOG_EFFECT_SIZE="0.5463598411298605" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="541" O_E="0.0" SE="1.397296191640659" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="95" VAR="1.9524366471734893" WEIGHT="50.851585906220414"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.030916207367808198" CI_END="3.432526174157717" CI_START="1.38285350692087" DF="1" EFFECT_SIZE="2.1786878751972885" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="22" I2="0.0" ID="CMP-001.16.02" LOG_CI_END="0.5356138575617935" LOG_CI_START="0.140776175405299" LOG_EFFECT_SIZE="0.3381950164835462" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8604274979577513" P_Z="7.862726677291373E-4" STUDIES="2" TAU2="0.0" TOTAL_1="79" TOTAL_2="143" WEIGHT="100.00000000000001" Z="3.357582530818115">
<NAME>Decreased energy level (sleepiness, motor inhibition)</NAME>
<DICH_DATA CI_END="3.580401198390179" CI_START="1.2673597156009992" EFFECT_SIZE="2.1301775147928996" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="13" LOG_CI_END="0.5539316938183407" LOG_CI_START="0.10289989848888684" LOG_EFFECT_SIZE="0.32841579615361377" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="543" O_E="0.0" SE="0.26493830921991574" STUDY_ID="STD-Gundlach-1966" TOTAL_1="52" TOTAL_2="48" VAR="0.07019230769230769" WEIGHT="76.63424282318296"/>
<DICH_DATA CI_END="6.007319715755223" CI_START="0.9159176287102742" EFFECT_SIZE="2.345679012345679" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.7786807461629893" LOG_CI_START="-0.0381435820146308" LOG_EFFECT_SIZE="0.37026858207417923" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="544" O_E="0.0" SE="0.47980665371716874" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="95" VAR="0.23021442495126707" WEIGHT="23.36575717681706"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.2312754206801975" CI_END="3.3673868444360116" CI_START="0.29400094502131596" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9949949319049494" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="10.365166869883497" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.5272930108797418" LOG_CI_START="-0.5316512736120496" LOG_EFFECT_SIZE="-0.0021791313661537947" METHOD="MH" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.327706530482354" P_Q="1.0" P_Z="0.9935638858270568" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.16168652100770867" TOTALS="YES" TOTAL_1="112" TOTAL_2="176" WEIGHT="99.99999999999999" Z="0.008066560361658258">
<NAME>Adverse effects: 8. Gastrointestinal reactions - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5901218455331994" CI_START="0.21054045960325174" EFFECT_SIZE="0.7384615384615385" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4133201948140804" LOG_CI_START="-0.676664433348617" LOG_EFFECT_SIZE="-0.13167211926726832" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="547" O_E="0.0" SE="0.6402623660936956" STUDY_ID="STD-Gundlach-1966" TOTAL_1="52" TOTAL_2="48" VAR="0.4099358974358975" WEIGHT="67.68807640982108"/>
<DICH_DATA CI_END="9.201496957624006" CI_START="0.026071849260412002" EFFECT_SIZE="0.4897959183673469" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.963858486861863" LOG_CI_START="-1.5838281634956786" LOG_EFFECT_SIZE="-0.30998483831690765" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="546" O_E="0.0" SE="1.496523749672331" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="95" VAR="2.2395833333333335" WEIGHT="16.113150243080625"/>
<DICH_DATA CI_END="130.41470314078393" CI_START="0.375724506669344" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.115326557139312" LOG_CI_START="-0.4251304771107986" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="545" O_E="0.0" SE="1.4922770373836491" STUDY_ID="STD-Minervini-1990" TOTAL_1="33" TOTAL_2="33" VAR="2.226890756302521" WEIGHT="16.198773347098285"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.07941924099657628" CI_END="2.809779209282098" CI_START="0.20262259258282705" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.754536114423998" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.44867219465320834" LOG_CI_START="-0.6933121320901525" LOG_EFFECT_SIZE="-0.12231996871847205" METHOD="MH" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.7780859943683958" P_Q="1.0" P_Z="0.6745801011752511" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="79" TOTAL_2="143" WEIGHT="99.99999999999999" Z="0.4198704442152101">
<NAME>Adverse effects: 9. Headache - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.935570892374437" CI_START="0.16326975515168995" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.46769257280609106" LOG_CI_START="-0.7870942585411149" LOG_EFFECT_SIZE="-0.1597008428675119" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="548" O_E="0.0" SE="0.7370679960283384" STUDY_ID="STD-Gundlach-1966" TOTAL_1="52" TOTAL_2="48" VAR="0.5432692307692306" WEIGHT="82.82861174427438"/>
<DICH_DATA CI_END="27.284931090176777" CI_START="0.047869736033521716" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.4359228612823034" LOG_CI_START="-1.3199389673269297" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="549" O_E="0.0" SE="1.6188068798611261" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="95" VAR="2.6205357142857144" WEIGHT="17.1713882557256"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="27.284931090176777" CI_START="0.047869736033521716" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="1.4359228612823034" LOG_CI_START="-1.3199389673269297" LOG_EFFECT_SIZE="0.05799194697768673" METHOD="MH" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="1.0" P_Q="1.0" P_Z="0.9342590284845106" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="95" WEIGHT="100.0" Z="0.08248753713968521">
<NAME>Adverse effects: 10. Insomnia - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="27.284931090176777" CI_START="0.047869736033521716" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.4359228612823034" LOG_CI_START="-1.3199389673269297" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="550" O_E="0.0" SE="1.6188068798611261" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="95" VAR="2.6205357142857144" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.14847297823206032" CI_END="49.738525196236395" CI_START="1.3464539298661975" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="8.183558682884932" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="1.69669290380018" LOG_CI_START="0.12919149822492768" LOG_EFFECT_SIZE="0.9129422010125537" METHOD="MH" MODIFIED="2012-04-22 16:23:22 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.6999990756240702" P_Q="1.0" P_Z="0.022428040129736294" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="62" TOTAL_2="204" WEIGHT="100.0" Z="2.2830395272209283">
<NAME>Adverse effects: 11. Movement disorders - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.14847297823206032" CI_END="49.738525196236395" CI_START="1.3464539298661975" DF="1" EFFECT_SIZE="8.183558682884932" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-001.20.01" LOG_CI_END="1.69669290380018" LOG_CI_START="0.12919149822492768" LOG_EFFECT_SIZE="0.9129422010125537" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6999990756240702" P_Z="0.022428040129736294" STUDIES="2" TAU2="0.0" TOTAL_1="35" TOTAL_2="109" WEIGHT="100.0" Z="2.2830395272209283">
<NAME>Ataxia</NAME>
<DICH_DATA CI_END="110.11428639259826" CI_START="0.22703684343796882" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.041843668644446" LOG_CI_START="-0.6439036599724087" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="552" O_E="0.0" SE="1.5776212754932308" STUDY_ID="STD-Azima-1962" TOTAL_1="8" TOTAL_2="14" VAR="2.4888888888888885" WEIGHT="34.06321008056187"/>
<DICH_DATA CI_END="97.42576586691094" CI_START="1.1436374361031498" EFFECT_SIZE="10.555555555555555" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.988673828480288" LOG_CI_START="0.0582883632187578" LOG_EFFECT_SIZE="1.0234810958495228" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="551" O_E="0.0" SE="1.133917977856786" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="95" VAR="1.2857699805068226" WEIGHT="65.93678991943813"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.20.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="95" WEIGHT="0.0" Z="0.0">
<NAME>EPS</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="553" O_E="0.0" SE="0.0" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="95" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="61.7381697935959" CI_START="0.14577691612966426" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="1.7905537508292086" LOG_CI_START="-0.8363112413898837" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" MODIFIED="2011-06-07 08:12:38 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="1.0" P_Q="1.0" P_Z="0.4764758426845581" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0" Z="0.7119821370942423">
<NAME>Adverse effects: 12. Sedation (extreme) - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="554" O_E="0.0" SE="0.0" STUDY_ID="STD-Minervini-1990" TOTAL_1="33" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="61.7381697935959" CI_START="0.14577691612966426" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7905537508292086" LOG_CI_START="-0.8363112413898837" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="555" O_E="0.0" SE="1.5430334996209192" STUDY_ID="STD-Nestoros-1982" TOTAL_1="6" TOTAL_2="6" VAR="2.380952380952381" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.29134601603849" CI_END="0.8348508241385075" CI_START="0.5159892899996568" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6563338205538831" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="112" I2="62.3815376263129" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="-0.07839111977546558" LOG_CI_START="-0.28735931260209413" LOG_EFFECT_SIZE="-0.18287521618877983" METHOD="MH" MODIFIED="2012-04-22 16:23:13 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.020796285577849294" P_Q="1.0" P_Z="6.025519174609758E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="166" TOTAL_2="216" WEIGHT="100.0" Z="3.4304631010744977">
<NAME>Sensitivity analysis (no clinically important response to treatment) - use of fixed-effects model</NAME>
<GROUP_LABEL_1>Benzodiazepines</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.377282176976943" CI_START="0.5558955258395225" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.13902292743874523" LOG_CI_START="-0.25500682139411873" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2011-09-30 14:07:07 +0100" MODIFIED_BY="[Empty name]" ORDER="929" O_E="0.0" SE="0.23145502494313788" STUDY_ID="STD-Azima-1962" TOTAL_1="8" TOTAL_2="14" VAR="0.053571428571428575" WEIGHT="9.444781467928063"/>
<DICH_DATA CI_END="1.4341142204885133" CI_START="0.6446879891497157" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="24" LOG_CI_END="0.15658374223304564" LOG_CI_START="-0.19065042083060627" LOG_EFFECT_SIZE="-0.017033339298780342" MODIFIED="2011-09-30 14:07:07 +0100" MODIFIED_BY="[Empty name]" ORDER="930" O_E="0.0" SE="0.20396706622041733" STUDY_ID="STD-Gundlach-1966" TOTAL_1="52" TOTAL_2="48" VAR="0.041602564102564105" WEIGHT="27.012074998274265"/>
<DICH_DATA CI_END="1.3214942600548643" CI_START="0.2917420752108864" EFFECT_SIZE="0.6209150326797386" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="34" LOG_CI_END="0.12106528110230146" LOG_CI_START="-0.5350009321598035" LOG_EFFECT_SIZE="-0.20696782552875104" MODIFIED="2011-09-30 14:07:07 +0100" MODIFIED_BY="[Empty name]" ORDER="931" O_E="0.0" SE="0.38537654125029236" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="95" VAR="0.1485150785460383" WEIGHT="16.28644181406038"/>
<DICH_DATA CI_END="2.533730058636853" CI_START="0.39467503516850566" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.40376034366137825" LOG_CI_START="-0.4037603436613783" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-09-30 14:07:07 +0100" MODIFIED_BY="[Empty name]" ORDER="932" O_E="0.0" SE="0.47434164902525694" STUDY_ID="STD-Merlis-1962" TOTAL_1="40" TOTAL_2="20" VAR="0.22500000000000003" WEIGHT="7.214763621333939"/>
<DICH_DATA CI_END="0.5912770228464836" CI_START="0.23783268174875655" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="32" LOG_CI_END="-0.22820899745086837" LOG_CI_START="-0.6237284670936939" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2011-09-30 14:07:07 +0100" MODIFIED_BY="[Empty name]" ORDER="927" O_E="0.0" SE="0.23233009432114626" STUDY_ID="STD-Minervini-1990" TOTAL_1="33" TOTAL_2="33" VAR="0.05397727272727272" WEIGHT="34.6308653824029"/>
<DICH_DATA CI_END="1.2400965730172222" CI_START="0.03225555240643706" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.0934555073359019" LOG_CI_START="-1.4913955160079393" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2011-09-30 14:07:07 +0100" MODIFIED_BY="[Empty name]" ORDER="928" O_E="0.0" SE="0.9309493362512627" STUDY_ID="STD-Nestoros-1982" TOTAL_1="6" TOTAL_2="6" VAR="0.8666666666666666" WEIGHT="5.4110727160004535"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-04-23 11:40:05 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>BENZODIAZEPINES versus ANTIPSYCHOTICS</NAME>
<DICH_OUTCOME CHI2="0.6406025555068257" CI_END="1.1430571807378473" CI_START="0.5903877634293392" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8214907013519165" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.058067956255100715" LOG_CI_START="-0.2288626524217827" LOG_EFFECT_SIZE="-0.08539734808334098" METHOD="MH" MODIFIED="2012-04-23 11:39:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7259303493600855" P_Q="0.74460995910246" P_Z="0.2433463297780124" Q="0.5897895649512712" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="77" TOTAL_2="77" WEIGHT="300.0" Z="1.166663447935338">
<NAME>No clinically important response to treatment - ultra short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4260886230791563" CI_START="0.5845698364767296" DF="0" EFFECT_SIZE="0.9130434782608695" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.15414651522012718" LOG_CI_START="-0.2331635977874745" LOG_EFFECT_SIZE="-0.039508541283673634" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.689258087825201" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="21" WEIGHT="100.0" Z="0.3998621022126237">
<NAME>Unimproved or worse at 30 minutes</NAME>
<DICH_DATA CI_END="1.4260886230791563" CI_START="0.5845698364767296" EFFECT_SIZE="0.9130434782608695" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.15414651522012718" LOG_CI_START="-0.2331635977874745" LOG_EFFECT_SIZE="-0.039508541283673634" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="579" O_E="0.0" SE="0.22750787759664504" STUDY_ID="STD-Garza_x002d_Trevino-1989" TOTAL_1="23" TOTAL_2="21" VAR="0.05175983436853002" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8624499491236017" CI_START="0.19893710279289573" DF="0" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.2700846104879784" LOG_CI_START="-0.701284211166688" LOG_EFFECT_SIZE="-0.21559980033935483" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3842752024025484" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="21" WEIGHT="100.0" Z="0.8700461334950897">
<NAME>Unimproved or worse at 60 minutes</NAME>
<DICH_DATA CI_END="1.8624499491236017" CI_START="0.19893710279289573" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.2700846104879784" LOG_CI_START="-0.701284211166688" LOG_EFFECT_SIZE="-0.21559980033935483" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="580" O_E="0.0" SE="0.5705868541931665" STUDY_ID="STD-Garza_x002d_Trevino-1989" TOTAL_1="23" TOTAL_2="21" VAR="0.3255693581780538" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3014672400440466" CI_START="0.4353082942865892" DF="0" EFFECT_SIZE="0.7526881720430108" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="0.11443324071482025" LOG_CI_START="-0.36120305779417694" LOG_EFFECT_SIZE="-0.12338490853967829" MODIFIED="2011-05-24 10:40:56 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.30921561951834686" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="35" WEIGHT="100.0" Z="1.016869308467901">
<NAME>Unimproved or worse at 12 hours</NAME>
<DICH_DATA CI_END="1.3014672400440466" CI_START="0.4353082942865892" EFFECT_SIZE="0.7526881720430108" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.11443324071482025" LOG_CI_START="-0.36120305779417694" LOG_EFFECT_SIZE="-0.12338490853967829" MODIFIED="2011-05-24 10:40:56 +0100" MODIFIED_BY="[Empty name]" ORDER="581" O_E="0.0" SE="0.27939111618183443" STUDY_ID="STD-Battaglia-1997" TOTAL_1="31" TOTAL_2="35" VAR="0.0780593958013313" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8300616481182821" CI_END="3.4571758744412975" CI_START="0.6356531103469281" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4824184961086297" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.5387214736576758" LOG_CI_START="-0.1967798235996711" LOG_EFFECT_SIZE="0.1709708250290023" METHOD="MH" MODIFIED="2012-04-23 11:40:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.36225477099093206" P_Q="1.0" P_Z="0.36218676492083357" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="45" WEIGHT="100.0" Z="0.9112061684010755">
<NAME>No clinically important response to treatment - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.190441200779986" CI_START="0.38695836203868794" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5038507450680781" LOG_CI_START="-0.4123357639467279" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2011-05-24 13:47:58 +0100" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="0.5381724905916594" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="25" VAR="0.2896296296296297" WEIGHT="64.44646510570584"/>
<DICH_DATA CI_END="10.344133602427869" CI_START="0.6042071999662749" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.0146941211552538" LOG_CI_START="-0.21881410381117877" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2011-05-24 13:47:58 +0100" MODIFIED_BY="[Empty name]" ORDER="253" O_E="0.0" SE="0.7245688373094719" STUDY_ID="STD-Merlis-1962" TOTAL_1="40" TOTAL_2="20" VAR="0.5249999999999999" WEIGHT="35.55353489429417"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.741918646929731" CI_END="1.1811352494623055" CI_START="0.4507926321368426" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7296897066662781" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.0722996306635061" LOG_CI_START="-0.3460231907813478" LOG_EFFECT_SIZE="-0.13686178005892083" METHOD="MH" MODIFIED="2011-06-03 14:38:30 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5871384258757624" P_Q="0.4210541966275603" P_Z="0.19967627121276074" Q="1.7299890753201208" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="373" TOTAL_2="365" WEIGHT="100.0" Z="1.2824744241733355">
<NAME>Leaving the study early - any reason</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.118389256930419" CI_END="1.3639709472286317" CI_START="0.33230975503935595" DF="2" EFFECT_SIZE="0.6732465011824011" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" I2="5.588645077532483" ID="CMP-002.03.01" LOG_CI_END="0.1348051198859549" LOG_CI_START="-0.47845690970660415" LOG_EFFECT_SIZE="-0.17182589491032463" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3467351361116153" P_Z="0.2720739248217616" STUDIES="7" TAU2="0.051870955842664664" TOTAL_1="255" TOTAL_2="259" WEIGHT="66.7432611766672" Z="1.098299093649566">
<NAME>ultra short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="560" O_E="0.0" SE="0.0" STUDY_ID="STD-Battaglia-1997" TOTAL_1="31" TOTAL_2="35" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.140168426766256" CI_START="0.015561413186640009" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8537084563073322" LOG_CI_START="-1.8079509657466573" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="561" O_E="0.0" SE="1.563471919941143" STUDY_ID="STD-Chouinard-1993" TOTAL_1="8" TOTAL_2="8" VAR="2.444444444444444" WEIGHT="2.4701205492750535"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="562" O_E="0.0" SE="0.0" STUDY_ID="STD-Foster-1997" TOTAL_1="17" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="556" O_E="0.0" SE="0.0" STUDY_ID="STD-Garza_x002d_Trevino-1989" TOTAL_1="23" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.5301313618884815" CI_START="0.4374928220392194" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.18472871663091092" LOG_CI_START="-0.3590290680687112" LOG_EFFECT_SIZE="-0.08715017571890014" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="557" O_E="0.0" SE="0.3194060143770026" STUDY_ID="STD-Lerner-1979" TOTAL_1="20" TOTAL_2="20" VAR="0.102020202020202" WEIGHT="59.185066626194356"/>
<DICH_DATA CI_END="1.6803951182954717" CI_START="0.023489685583327008" EFFECT_SIZE="0.1986754966887417" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.2254114112018158" LOG_CI_START="-1.6291227963488297" LOG_EFFECT_SIZE="-0.701855692573507" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="558" O_E="0.0" SE="1.0893625736076313" STUDY_ID="STD-TREC_x002d_Rio-2003" TOTAL_1="151" TOTAL_2="150" VAR="1.186710816777042" WEIGHT="5.088074001197792"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="559" O_E="0.0" SE="0.0" STUDY_ID="STD-Wyant-1990" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2054227060692696" CI_END="1.5631642746695942" CI_START="0.27403912785734263" DF="1" EFFECT_SIZE="0.6544984144581338" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.19400462090696793" LOG_CI_START="-0.5621874233134565" LOG_EFFECT_SIZE="-0.1840914012032443" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6503789554393018" P_Z="0.3399378663116166" STUDIES="4" TAU2="0.0" TOTAL_1="90" TOTAL_2="71" WEIGHT="30.602641041449957" Z="0.9542880515063927">
<NAME>short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="564" O_E="0.0" SE="0.0" STUDY_ID="STD-Carpenter-1999" TOTAL_1="15" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.7218024707367026" CI_START="0.2800861856200107" EFFECT_SIZE="0.6944444444444444" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.23598332668229594" LOG_CI_START="-0.5527083108727953" LOG_EFFECT_SIZE="-0.15836249209524966" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="566" O_E="0.0" SE="0.4632813719864307" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="25" VAR="0.2146296296296296" WEIGHT="28.1325204921749"/>
<DICH_DATA CI_END="7.140168426766256" CI_START="0.015561413186640009" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8537084563073322" LOG_CI_START="-1.8079509657466573" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="565" O_E="0.0" SE="1.563471919941143" STUDY_ID="STD-Holden-1968" TOTAL_1="8" TOTAL_2="8" VAR="2.444444444444444" WEIGHT="2.4701205492750535"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="563" O_E="0.0" SE="0.0" STUDY_ID="STD-Merlis-1962" TOTAL_1="40" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="96.12715085961011" CI_START="0.26007220412172094" DF="0" EFFECT_SIZE="4.999999999999998" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-002.03.03" LOG_CI_END="1.982846070323241" LOG_CI_START="-0.5849060616512036" LOG_EFFECT_SIZE="0.6989700043360186" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.28595065344202364" STUDIES="2" TAU2="0.0" TOTAL_1="28" TOTAL_2="35" WEIGHT="2.6540977818828413" Z="1.0670469456247629">
<NAME>long term</NAME>
<DICH_DATA CI_END="96.12715085961011" CI_START="0.260072204121721" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.982846070323241" LOG_CI_START="-0.5849060616512035" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="568" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Cheung-1981" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="2.6540977818828413"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="567" O_E="0.0" SE="0.0" STUDY_ID="STD-Nishikawa-1982" TOTAL_1="13" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="216.3886995962606" CI_START="0.7810019669017899" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="2.3352345769930722" LOG_CI_START="-0.10734787237939857" LOG_EFFECT_SIZE="1.1139433523068367" METHOD="MH" MODIFIED="2011-10-13 08:58:45 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.07382620228436418" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="229" TOTAL_2="215" WEIGHT="100.0" Z="1.7876889698442948">
<NAME>Leaving the study early due to adverse effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="216.3886995962606" CI_START="0.7810019669017899" DF="0" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="2.3352345769930722" LOG_CI_START="-0.10734787237939857" LOG_EFFECT_SIZE="1.1139433523068367" MODIFIED="2011-10-13 08:58:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.07382620228436418" STUDIES="3" TAU2="0.0" TOTAL_1="176" TOTAL_2="175" WEIGHT="100.0" Z="1.7876889698442948">
<NAME>ultra short term</NAME>
<DICH_DATA CI_END="216.3886995962606" CI_START="0.7810019669017899" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3352345769930722" LOG_CI_START="-0.10734787237939857" LOG_EFFECT_SIZE="1.1139433523068367" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="571" O_E="0.0" SE="1.4347850217395144" STUDY_ID="STD-Lerner-1979" TOTAL_1="20" TOTAL_2="20" VAR="2.058608058608059" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="570" O_E="0.0" SE="0.0" STUDY_ID="STD-TREC_x002d_Rio-2003" TOTAL_1="151" TOTAL_2="150" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="569" O_E="0.0" SE="0.0" STUDY_ID="STD-Wyant-1990" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-10-13 08:58:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="572" O_E="0.0" SE="0.0" STUDY_ID="STD-Merlis-1962" TOTAL_1="40" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-10-13 08:58:45 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>long term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="573" O_E="0.0" SE="0.0" STUDY_ID="STD-Nishikawa-1982" TOTAL_1="13" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.140168426766256" CI_START="0.015561413186640009" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.8537084563073322" LOG_CI_START="-1.8079509657466573" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" MODIFIED="2011-10-13 08:58:54 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.4822584525845881" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="217" TOTAL_2="203" WEIGHT="100.0" Z="0.7026747808233531">
<NAME>Leaving the study early due to inefficacy of treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-10-13 08:58:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="156" TOTAL_2="155" WEIGHT="0.0" Z="0.0">
<NAME>ultra short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.0" STUDY_ID="STD-TREC_x002d_Rio-2003" TOTAL_1="151" TOTAL_2="150" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="575" O_E="0.0" SE="0.0" STUDY_ID="STD-Wyant-1990" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.140168426766256" CI_START="0.015561413186640009" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="0.8537084563073322" LOG_CI_START="-1.8079509657466573" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-10-13 08:58:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4822584525845881" STUDIES="2" TAU2="0.0" TOTAL_1="48" TOTAL_2="28" WEIGHT="100.0" Z="0.7026747808233531">
<NAME>short term</NAME>
<DICH_DATA CI_END="7.140168426766256" CI_START="0.015561413186640009" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8537084563073322" LOG_CI_START="-1.8079509657466573" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="576" O_E="0.0" SE="1.563471919941143" STUDY_ID="STD-Holden-1968" TOTAL_1="8" TOTAL_2="8" VAR="2.444444444444444" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="0.0" STUDY_ID="STD-Merlis-1962" TOTAL_1="40" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.05.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-10-13 08:58:54 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>long term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="578" O_E="0.0" SE="0.0" STUDY_ID="STD-Nishikawa-1982" TOTAL_1="13" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.013164986711107203" CI_END="-0.28954163170754244" CI_START="-1.0258011225935366" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6576713771505395" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.9086521800774028" P_Q="0.9086521800774028" P_Z="4.626191023016775E-4" Q="0.013164986711107203" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="34" TOTAL_2="40" UNITS="" WEIGHT="200.0" Z="3.5015160519744333">
<NAME>Global state: 2a. Mean CGI severity score - ultra short term (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.2458883872435766" CI_START="-1.0941116127564232" DF="0" EFFECT_SIZE="-0.6699999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.01" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0019595342926944097" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="20" WEIGHT="100.00000000000001" Z="3.0962978379845074">
<NAME>Mean CGI severity score at 1 hour</NAME>
<CONT_DATA CI_END="-0.2458883872435766" CI_START="-1.0941116127564232" EFFECT_SIZE="-0.6699999999999999" ESTIMABLE="YES" MEAN_1="4.88" MEAN_2="5.55" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="583" SD_1="0.7" SD_2="0.6" SE="0.21638745206634488" STUDY_ID="STD-Foster-1997" TOTAL_1="17" TOTAL_2="20" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.12135911085540885" CI_START="-1.36135911085541" DF="0" EFFECT_SIZE="-0.6200000000000006" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.02" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.10118795467544162" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="20" WEIGHT="100.0" Z="1.6391215169834694">
<NAME>Mean CGI severity score at 4 hours</NAME>
<CONT_DATA CI_END="0.12135911085540885" CI_START="-1.36135911085541" EFFECT_SIZE="-0.6200000000000006" ESTIMABLE="YES" MEAN_1="3.53" MEAN_2="4.15" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="584" SD_1="1.23" SD_2="1.04" SE="0.37825139477212616" STUDY_ID="STD-Foster-1997" TOTAL_1="17" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-002.07" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="7" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Global state: 2b. Mean CGI severity score - ultra short term (skewed data)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.07.01" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>Mean CGI severity score at 2 hours</NAME>
<OTHER_DATA MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="87" STUDY_ID="STD-Chouinard-1993">
<TR>
<TD>
<P>Benzodiazepines<BR/>
</P>
</TD>
<TD>
<P>2.20</P>
</TD>
<TD>
<P>1.30</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>Antipsychotics</P>
</TD>
<TD>
<P>2.60</P>
</TD>
<TD>
<P>1.30</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.07.02" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="2" STUDIES="1">
<NAME>Mean CGI severity score at 4 hours</NAME>
<OTHER_DATA MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="88" STUDY_ID="STD-Lerner-1979">
<TR>
<TD>
<P>Benzodiazepines</P>
</TD>
<TD>
<P>0.90</P>
</TD>
<TD>
<P>0.67</P>
</TD>
<TD>
<P>11</P>
</TD>
</TR>
<TR>
<TD>
<P>Antipsychotics</P>
</TD>
<TD>
<P>0.50</P>
</TD>
<TD>
<P>0.05</P>
</TD>
<TD>
<P>9</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.07.03" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="3" STUDIES="1">
<NAME>Mean CGI severity score at 24 hours</NAME>
<OTHER_DATA MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="89" STUDY_ID="STD-Lerner-1979">
<TR>
<TD>
<P>Benzodiazepines<BR/>
</P>
</TD>
<TD>
<P>0.40</P>
</TD>
<TD>
<P>0.83</P>
</TD>
<TD>
<P>20</P>
</TD>
</TR>
<TR>
<TD>
<P>Antipsychotics</P>
</TD>
<TD>
<P>1.0</P>
</TD>
<TD>
<P>0.83</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="4.448886920214621" CI_END="2.22340241175275" CI_START="0.7234209849512604" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2682491721476432" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="28" I2="55.04493515192521" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.347018072409928" LOG_CI_START="-0.14060889740416124" LOG_EFFECT_SIZE="0.10320458750288336" METHOD="MH" MODIFIED="2011-10-04 09:46:13 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.10812768477619938" P_Q="0.34650137438559825" P_Z="0.4067426986004645" Q="0.8862289869827363" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.13432069168451113" TOTALS="YES" TOTAL_1="43" TOTAL_2="53" WEIGHT="100.0" Z="0.8296394049823922">
<NAME>Global state: 3. Relapse</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.659293404009396" CI_START="0.4252412492540737" DF="0" EFFECT_SIZE="0.84" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" I2="0.0" ID="CMP-002.08.01" LOG_CI_END="0.21992318679335063" LOG_CI_START="-0.3713646146695873" LOG_EFFECT_SIZE="-0.07572071393811836" MODIFIED="2011-05-20 07:46:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.615675531527677" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="18" WEIGHT="32.18000171593845" Z="0.5019886148003831">
<NAME>short term (by 4 weeks)</NAME>
<DICH_DATA CI_END="1.659293404009396" CI_START="0.4252412492540737" EFFECT_SIZE="0.84" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.21992318679335063" LOG_CI_START="-0.3713646146695873" LOG_EFFECT_SIZE="-0.07572071393811836" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="588" O_E="0.0" SE="0.3473253815011518" STUDY_ID="STD-Carpenter-1999" TOTAL_1="15" TOTAL_2="18" VAR="0.12063492063492062" WEIGHT="32.18000171593845"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.059190489669914" CI_END="11.039321671840526" CI_START="0.37033385577300854" DF="1" EFFECT_SIZE="2.021938317518919" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="18" I2="83.49614520776558" ID="CMP-002.08.02" LOG_CI_END="1.0429423883182443" LOG_CI_START="-0.43140658310775604" LOG_EFFECT_SIZE="0.30576790260524417" MODIFIED="2011-05-20 07:46:44 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.013834168098653454" P_Z="0.4162404499429593" STUDIES="2" TAU2="1.2832615992526777" TOTAL_1="28" TOTAL_2="35" WEIGHT="67.81999828406154" Z="0.8129609588359372">
<NAME>long term (by 1 year or longer)</NAME>
<DICH_DATA CI_END="15.809332971372681" CI_START="1.012060409441219" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.1989135465316223" LOG_CI_START="0.005206436124302438" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="589" O_E="0.0" SE="0.7011894655987544" STUDY_ID="STD-Cheung-1981" TOTAL_1="15" TOTAL_2="15" VAR="0.4916666666666667" WEIGHT="13.106450046431702"/>
<DICH_DATA CI_END="1.5680751139820313" CI_START="0.960539666548587" EFFECT_SIZE="1.2272727272727273" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.195366862434247" LOG_CI_START="-0.0174846957606849" LOG_EFFECT_SIZE="0.08894108333678108" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="590" O_E="0.0" SE="0.12503005891590885" STUDY_ID="STD-Nishikawa-1982" TOTAL_1="13" TOTAL_2="20" VAR="0.015632515632515637" WEIGHT="54.713548237629844"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0934395595760797" CI_END="2.2990470367496867" CI_START="0.7192208180237338" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2858936544077628" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="10" I2="8.545470918603469" I2_Q="1.1070929080888494" ID="CMP-002.09" LOG_CI_END="0.36154785669418793" LOG_CI_START="-0.14313775033213955" LOG_EFFECT_SIZE="0.10920505318102419" METHOD="MH" MODIFIED="2011-06-07 08:13:52 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.2957108439280093" P_Q="0.31461703033717536" P_Z="0.39632482895169296" Q="1.0111948666557038" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0294594166996807" TOTALS="SUB" TOTAL_1="80" TOTAL_2="40" WEIGHT="200.0" Z="0.8482031909953921">
<NAME>Mental state: 1. General (various scales) - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.344133602427869" CI_START="0.6042071999662749" DF="0" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" I2="0.0" ID="CMP-002.09.01" LOG_CI_END="1.0146941211552538" LOG_CI_START="-0.21881410381117877" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2060142928927411" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="20" WEIGHT="100.0" Z="1.264601352821908">
<NAME>BPRS (unimproved or worse)</NAME>
<DICH_DATA CI_END="10.344133602427869" CI_START="0.6042071999662749" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.0146941211552538" LOG_CI_START="-0.21881410381117877" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="591" O_E="0.0" SE="0.7245688373094719" STUDY_ID="STD-Merlis-1962" TOTAL_1="40" TOTAL_2="20" VAR="0.5249999999999999" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.126679617367301" CI_START="0.5951178492822375" DF="0" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" I2="0.0" ID="CMP-002.09.02" LOG_CI_END="0.32770206870402196" LOG_CI_START="-0.22539702380925936" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7169571049402728" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="20" WEIGHT="100.0" Z="0.3625285344789697">
<NAME>MMS (unimproved or worse)</NAME>
<DICH_DATA CI_END="2.126679617367301" CI_START="0.5951178492822375" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" LOG_CI_END="0.32770206870402196" LOG_CI_START="-0.22539702380925936" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="592" O_E="0.0" SE="0.32489314482696546" STUDY_ID="STD-Merlis-1962" TOTAL_1="40" TOTAL_2="20" VAR="0.10555555555555556" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="5.027174737960765" CI_END="4.602535285839797" CI_START="-1.5632312180157235" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="1.5196520339120367" ESTIMABLE="YES" I2="40.32433411660309" I2_Q="40.32433411660309" ID="CMP-002.10" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.16981824059596218" P_Q="0.16981824059596218" P_Z="0.33397959152678647" Q="5.027174737960765" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="6.9648141712855125" TOTALS="SUB" TOTAL_1="96" TOTAL_2="110" UNITS="" WEIGHT="400.0" Z="0.9661291109996358">
<NAME>Mental state: 2a. General - BPRS - ultra short term (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.128733705496296" CI_START="-10.648733705496305" DF="0" EFFECT_SIZE="-3.260000000000005" ESTIMABLE="YES" I2="0.0" ID="CMP-002.10.01" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3871704474732157" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="20" WEIGHT="100.0" Z="0.8647601665286171">
<NAME>Mean BPRS score at 1hour</NAME>
<CONT_DATA CI_END="4.128733705496296" CI_START="-10.648733705496305" EFFECT_SIZE="-3.260000000000005" ESTIMABLE="YES" MEAN_1="52.12" MEAN_2="55.38" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="593" SD_1="11.2" SD_2="11.69" SE="3.7698313661769753" STUDY_ID="STD-Foster-1997" TOTAL_1="17" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.135300520288545" CI_START="-9.59530052028854" DF="0" EFFECT_SIZE="-1.7299999999999969" ESTIMABLE="YES" I2="0.0" ID="CMP-002.10.02" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6663950481341603" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="20" WEIGHT="100.0" Z="0.43110084408191146">
<NAME>Mean BPRS score at 4 hours</NAME>
<CONT_DATA CI_END="6.135300520288545" CI_START="-9.59530052028854" EFFECT_SIZE="-1.7299999999999969" ESTIMABLE="YES" MEAN_1="38.56" MEAN_2="40.29" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="594" SD_1="9.85" SD_2="14.42" SE="4.012982168207696" STUDY_ID="STD-Foster-1997" TOTAL_1="17" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="11.317382168541737" CI_START="0.6826178314582636" DF="0" EFFECT_SIZE="6.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.10.03" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.026996116740980826" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="35" WEIGHT="100.0" Z="2.2115739539679136">
<NAME>Mean MBPRS at 1 hour</NAME>
<CONT_DATA CI_END="11.317382168541737" CI_START="0.6826178314582636" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="39.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="595" SD_1="11.0" SD_2="11.0" SE="2.7129999380011918" STUDY_ID="STD-Battaglia-1997" TOTAL_1="31" TOTAL_2="35" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.317382168541736" CI_START="-4.317382168541736" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.10.04" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.7124291324773101" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="35" WEIGHT="100.0" Z="0.36859565899465224">
<NAME>Mean MBPRS at 12 hours</NAME>
<CONT_DATA CI_END="6.317382168541736" CI_START="-4.317382168541736" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="33.0" MEAN_2="32.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="596" SD_1="11.0" SD_2="11.0" SE="2.7129999380011918" STUDY_ID="STD-Battaglia-1997" TOTAL_1="31" TOTAL_2="35" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-002.11" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="11" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Mental state: 2b . General - BPRS - ultra short term (skewed data)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.11.01" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>Mean BPRS score at 4 hours</NAME>
<OTHER_DATA MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="99" STUDY_ID="STD-Lerner-1979">
<TR>
<TD>
<P>Benzodiazepines<BR/>
</P>
</TD>
<TD>
<P>11.40</P>
</TD>
<TD>
<P>4.20</P>
</TD>
<TD>
<P>11</P>
</TD>
</TR>
<TR>
<TD>
<P>Antipsychotics</P>
</TD>
<TD>
<P>3.80</P>
</TD>
<TD>
<P>5.20</P>
</TD>
<TD>
<P>9</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.11.02" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="2" STUDIES="1">
<NAME>Mean BPRS score at 12-24 hours</NAME>
<OTHER_DATA MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="100" STUDY_ID="STD-Lerner-1979">
<TR>
<TD>
<P>Benzodiazepines<BR/>
</P>
</TD>
<TD>
<P>6.30</P>
</TD>
<TD>
<P>6.80</P>
</TD>
<TD>
<P>20</P>
</TD>
</TR>
<TR>
<TD>
<P>Antipsychotics</P>
</TD>
<TD>
<P>8.0</P>
</TD>
<TD>
<P>8.30</P>
</TD>
<TD>
<P>20</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-002.12" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="12" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Mental state: 3a. Specific -mania - ultra short term (skewed data)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.12.01" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>Mean IMPS subscore</NAME>
<OTHER_DATA MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="101" STUDY_ID="STD-Chouinard-1993">
<TR>
<TD>
<P>Benzodiazepines<BR/>
</P>
</TD>
<TD>
<P>10.0</P>
</TD>
<TD>
<P>7.20</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>Antipsychotics</P>
</TD>
<TD>
<P>7.40</P>
</TD>
<TD>
<P>3.80</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="16.221099611794692" CI_END="1.1299615373565377" CI_START="1.046968771537504" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0876738677796778" ESTIMABLE="YES" EVENTS_1="600" EVENTS_2="534" I2="63.01113892650485" I2_Q="65.00073773356682" ID="CMP-002.13" LOG_CI_END="0.05306366083022799" LOG_CI_START="0.019933727952764192" LOG_EFFECT_SIZE="0.03649869439149614" METHOD="MH" MODIFIED="2011-06-07 08:14:24 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.01261518376581916" P_Q="0.01389115589689538" P_Z="1.5707952141023733E-5" Q="14.286015407802928" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.005497658338903762" TOTALS="SUB" TOTAL_1="681" TOTAL_2="677" WEIGHT="600.0" Z="4.318519252945902">
<NAME>Mental state: 3b. Specific - sedation - ultra short term (high=better)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4935901058936116" CI_START="1.162958037805947" DF="0" EFFECT_SIZE="1.317946364172841" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="101" I2="0.0" ID="CMP-002.13.01" LOG_CI_END="0.17423142801946315" LOG_CI_START="0.06556404466989056" LOG_EFFECT_SIZE="0.11989773634467683" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.5250603076388586E-5" STUDIES="1" TAU2="0.0" TOTAL_1="151" TOTAL_2="150" WEIGHT="100.0" Z="4.325037335397841">
<NAME>Tranquilized or asleep at 20 minutes</NAME>
<DICH_DATA CI_END="1.4935901058936116" CI_START="1.162958037805947" EFFECT_SIZE="1.317946364172841" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="101" LOG_CI_END="0.17423142801946315" LOG_CI_START="0.06556404466989056" LOG_EFFECT_SIZE="0.11989773634467683" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="600" O_E="0.0" SE="0.06383175889176189" STUDY_ID="STD-TREC_x002d_Rio-2003" TOTAL_1="151" TOTAL_2="150" VAR="0.004074493443216022" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5891526471701924" CI_START="0.5322481990988648" DF="0" EFFECT_SIZE="1.173913043478261" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" I2="0.0" ID="CMP-002.13.02" LOG_CI_END="0.4131576556374333" LOG_CI_START="-0.27388579935464435" LOG_EFFECT_SIZE="0.06963592814139448" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6911403911445657" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="21" WEIGHT="100.00000000000001" Z="0.39730794375655965">
<NAME>Tranquilized or asleep at 30 minutes</NAME>
<DICH_DATA CI_END="2.5891526471701924" CI_START="0.5322481990988648" EFFECT_SIZE="1.173913043478261" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.4131576556374333" LOG_CI_START="-0.27388579935464435" LOG_EFFECT_SIZE="0.06963592814139448" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="601" O_E="0.0" SE="0.40357272638229796" STUDY_ID="STD-Garza_x002d_Trevino-1989" TOTAL_1="23" TOTAL_2="21" VAR="0.16287094547964112" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2294089411228208" CI_START="1.037832128647311" DF="0" EFFECT_SIZE="1.1295663319803462" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="124" I2="0.0" ID="CMP-002.13.03" LOG_CI_END="0.08969636728994912" LOG_CI_START="0.016127111221364235" LOG_EFFECT_SIZE="0.052911739255656676" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.004813584534306466" STUDIES="1" TAU2="0.0" TOTAL_1="151" TOTAL_2="150" WEIGHT="100.0" Z="2.8192511068422985">
<NAME>Tranquilized or asleep at 40 minutes</NAME>
<DICH_DATA CI_END="1.2294089411228208" CI_START="1.037832128647311" EFFECT_SIZE="1.1295663319803462" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="124" LOG_CI_END="0.08969636728994912" LOG_CI_START="0.016127111221364235" LOG_EFFECT_SIZE="0.052911739255656676" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="602" O_E="0.0" SE="0.043214945188377644" STUDY_ID="STD-TREC_x002d_Rio-2003" TOTAL_1="151" TOTAL_2="150" VAR="0.0018675314876344844" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.22520817337448884" CI_END="1.153946578504304" CI_START="0.9982597601258909" DF="1" EFFECT_SIZE="1.0732839487553139" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="146" I2="0.0" ID="CMP-002.13.04" LOG_CI_END="0.062185703795605" LOG_CI_START="-7.564349547162264E-4" LOG_EFFECT_SIZE="0.030714634420444427" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6350999057872537" P_Z="0.055766679430785684" STUDIES="2" TAU2="0.0" TOTAL_1="174" TOTAL_2="171" WEIGHT="100.00000000000001" Z="1.9128545186932662">
<NAME>Tranquilized or asleep at 60 minutes</NAME>
<DICH_DATA CI_END="1.6073010257977196" CI_START="0.8321667886807013" EFFECT_SIZE="1.1565217391304348" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="15" LOG_CI_END="0.20609722187831236" LOG_CI_START="-0.07978962065136419" LOG_EFFECT_SIZE="0.0631538006134741" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="604" O_E="0.0" SE="0.16793134646462599" STUDY_ID="STD-Garza_x002d_Trevino-1989" TOTAL_1="23" TOTAL_2="21" VAR="0.02820093712542225" WEIGHT="4.847241477398086"/>
<DICH_DATA CI_END="1.151661466797839" CI_START="0.9926574844066018" EFFECT_SIZE="1.06920782569132" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="131" LOG_CI_END="0.061324836111159756" LOG_CI_START="-0.0032005785869048133" LOG_EFFECT_SIZE="0.029062128762127465" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="603" O_E="0.0" SE="0.03790254799959717" STUDY_ID="STD-TREC_x002d_Rio-2003" TOTAL_1="151" TOTAL_2="150" VAR="0.0014366031448617674" WEIGHT="95.15275852260193"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0994031866867062" CI_START="0.9773237291598531" DF="0" EFFECT_SIZE="1.0365678088108263" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="138" I2="0.0" ID="CMP-002.13.05" LOG_CI_END="0.04115699146038878" LOG_CI_START="-0.009961556547338886" LOG_EFFECT_SIZE="0.015597717456524931" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.23166493564889545" STUDIES="1" TAU2="0.0" TOTAL_1="151" TOTAL_2="150" WEIGHT="100.0" Z="1.196081095699319">
<NAME>Tranquilized or asleep at 120 minutes</NAME>
<DICH_DATA CI_END="1.0994031866867062" CI_START="0.9773237291598531" EFFECT_SIZE="1.0365678088108263" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="138" LOG_CI_END="0.04115699146038878" LOG_CI_START="-0.009961556547338886" LOG_EFFECT_SIZE="0.015597717456524931" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="605" O_E="0.0" SE="0.03002728814063285" STUDY_ID="STD-TREC_x002d_Rio-2003" TOTAL_1="151" TOTAL_2="150" VAR="9.016380330805901E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3014672400440466" CI_START="0.4353082942865892" DF="0" EFFECT_SIZE="0.7526881720430108" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" I2="0.0" ID="CMP-002.13.06" LOG_CI_END="0.11443324071482025" LOG_CI_START="-0.36120305779417694" LOG_EFFECT_SIZE="-0.12338490853967829" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.30921561951834686" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="35" WEIGHT="100.0" Z="1.016869308467901">
<NAME>Asleep at 12 hours</NAME>
<DICH_DATA CI_END="1.3014672400440466" CI_START="0.4353082942865892" EFFECT_SIZE="0.7526881720430108" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.11443324071482025" LOG_CI_START="-0.36120305779417694" LOG_EFFECT_SIZE="-0.12338490853967829" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="606" O_E="0.0" SE="0.27939111618183443" STUDY_ID="STD-Battaglia-1997" TOTAL_1="31" TOTAL_2="35" VAR="0.0780593958013313" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.184641306532983" CI_START="-0.9846413065329829" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.14" MODIFIED="2011-06-07 08:14:42 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.8566018181711409" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="8" UNITS="" WEIGHT="100.0" Z="0.1807015805810504">
<NAME>Mental state: 3c. Specific - sedation, mean CGI sedation score - ultra short term (at 2 hours) (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.184641306532983" CI_START="-0.9846413065329829" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="3.3" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="607" SD_1="1.4" SD_2="0.7" SE="0.5533985905294664" STUDY_ID="STD-Chouinard-1993" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-002.15" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="15" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Behaviour: 1. General - mean modified NOSIE score - ultra short term (at 2 hours)(skewed data)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="110" STUDY_ID="STD-Chouinard-1993">
<TR>
<TD>
<P>Benzodiazepines<BR/>
</P>
</TD>
<TD>
<P>1.30</P>
</TD>
<TD>
<P>1.60</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>Antipsychotics</P>
</TD>
<TD>
<P>1.70</P>
</TD>
<TD>
<P>1.60</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="3.645510495575063" CI_END="1.2241605736710994" CI_START="0.7177108920269892" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9373331197145206" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="86" I2="45.13799912446805" I2_Q="44.54795723433921" ID="CMP-002.16" LOG_CI_END="0.0878383881407759" LOG_CI_START="-0.1440504628364816" LOG_EFFECT_SIZE="-0.028106037347852802" METHOD="MH" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.16158001731301408" P_Q="0.16474446833520173" P_Z="0.6347057146645827" Q="3.606720149971678" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.05822484512430354" TOTALS="SUB" TOTAL_1="453" TOTAL_2="450" WEIGHT="300.0" Z="0.47511401016284177">
<NAME>Behaviour: 2a. Specific - aggression - ultra short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.584036164830836E-31" CI_END="1.2247330017787268" CI_START="0.5483970375802272" DF="0" EFFECT_SIZE="0.8195364238410596" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="40" I2="100.0" ID="CMP-002.16.01" LOG_CI_END="0.0880414205432036" LOG_CI_START="-0.2609048999183298" LOG_EFFECT_SIZE="-0.0864317396875631" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.3315778084355444" STUDIES="1" TAU2="0.0" TOTAL_1="151" TOTAL_2="150" WEIGHT="99.99999999999999" Z="0.9709407262681787">
<NAME>Needing restraints within 120 min.</NAME>
<DICH_DATA CI_END="1.2247330017787268" CI_START="0.5483970375802272" EFFECT_SIZE="0.8195364238410596" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="40" LOG_CI_END="0.0880414205432036" LOG_CI_START="-0.2609048999183298" LOG_EFFECT_SIZE="-0.0864317396875631" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="609" O_E="0.0" SE="0.20497279595124873" STUDY_ID="STD-TREC_x002d_Rio-2003" TOTAL_1="151" TOTAL_2="150" VAR="0.04201384708007225" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6178098984214109" CI_START="0.7763852468309294" DF="0" EFFECT_SIZE="1.1207335710646968" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="39" I2="0.0" ID="CMP-002.16.02" LOG_CI_END="0.20892748827932905" LOG_CI_START="-0.10992272583492904" LOG_EFFECT_SIZE="0.04950238122220001" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5428030644927001" STUDIES="1" TAU2="0.0" TOTAL_1="151" TOTAL_2="150" WEIGHT="100.0" Z="0.608579703256629">
<NAME>Any episode of aggression at 24 hours</NAME>
<DICH_DATA CI_END="1.6178098984214109" CI_START="0.7763852468309294" EFFECT_SIZE="1.1207335710646968" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="39" LOG_CI_END="0.20892748827932905" LOG_CI_START="-0.10992272583492904" LOG_EFFECT_SIZE="0.04950238122220001" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="610" O_E="0.0" SE="0.18729419410473008" STUDY_ID="STD-TREC_x002d_Rio-2003" TOTAL_1="151" TOTAL_2="150" VAR="0.03507911514534031" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3441100999098503" CI_START="0.05993185089246506" DF="0" EFFECT_SIZE="0.2838221381267738" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" I2="0.0" ID="CMP-002.16.03" LOG_CI_END="0.1284348444803724" LOG_CI_START="-1.2223423096559003" LOG_EFFECT_SIZE="-0.5469537325877639" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.11245633687562592" STUDIES="1" TAU2="0.0" TOTAL_1="151" TOTAL_2="150" WEIGHT="100.0" Z="1.5872486646655557">
<NAME>Use of additional tranquilising drugs at 120 minutes</NAME>
<DICH_DATA CI_END="1.3441100999098505" CI_START="0.05993185089246509" EFFECT_SIZE="0.28382213812677387" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.12843484448037246" LOG_CI_START="-1.2223423096559" LOG_EFFECT_SIZE="-0.5469537325877638" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="611" O_E="0.0" SE="0.7934531867943972" STUDY_ID="STD-TREC_x002d_Rio-2003" TOTAL_1="151" TOTAL_2="150" VAR="0.6295679596341847" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.06793137991485099" CI_END="7.259956989536291" CI_START="-0.259956989536291" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="3.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.17" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.7943728516012917" P_Q="0.7943728516012917" P_Z="0.06808324860818442" Q="0.06793137991485099" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="62" TOTAL_2="70" UNITS="" WEIGHT="200.0" Z="1.8244554299373">
<NAME>Behaviour: 2b. Specific - aggression - ultra short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.317382168541737" CI_START="-1.3173821685417364" DF="0" EFFECT_SIZE="4.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.17.01" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.14037859695892507" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="35" WEIGHT="100.0" Z="1.474382635978609">
<NAME>Mean ABS after 1 hour</NAME>
<CONT_DATA CI_END="9.317382168541737" CI_START="-1.3173821685417364" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="32.0" MEAN_2="28.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="612" SD_1="11.0" SD_2="11.0" SE="2.7129999380011918" STUDY_ID="STD-Battaglia-1997" TOTAL_1="31" TOTAL_2="35" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.317382168541737" CI_START="-2.3173821685417364" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.17.02" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.26881875064740357" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="35" WEIGHT="100.0" Z="1.1057869769839568">
<NAME>Mean ABS after 12 hours</NAME>
<CONT_DATA CI_END="8.317382168541737" CI_START="-2.3173821685417364" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="19.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="613" SD_1="11.0" SD_2="11.0" SE="2.7129999380011918" STUDY_ID="STD-Battaglia-1997" TOTAL_1="31" TOTAL_2="35" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1843751256350439" CI_START="0.7726067772623959" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9565857247976454" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="81" I2="0.0" I2_Q="0.0" ID="CMP-002.18" LOG_CI_END="0.07348927771685525" LOG_CI_START="-0.1120414865681703" LOG_EFFECT_SIZE="-0.019276104425657525" METHOD="MH" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.6838103818951673" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="151" TOTAL_2="150" WEIGHT="100.0" Z="0.40726906485957054">
<NAME>Service use: 1. Still in hospital - short term (after 2 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1843751256350439" CI_START="0.7726067772623959" EFFECT_SIZE="0.9565857247976454" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="81" LOG_CI_END="0.07348927771685525" LOG_CI_START="-0.1120414865681703" LOG_EFFECT_SIZE="-0.019276104425657525" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="614" O_E="0.0" SE="0.1089816893331189" STUDY_ID="STD-TREC_x002d_Rio-2003" TOTAL_1="151" TOTAL_2="150" VAR="0.01187700860990044" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9837963432223625" CI_END="1.174648471142531" CI_START="0.44824324304182334" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7256226568534418" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-002.19" LOG_CI_END="0.06990791776983943" LOG_CI_START="-0.3484862484066458" LOG_EFFECT_SIZE="-0.13928916531840316" METHOD="MH" MODIFIED="2011-06-07 08:15:45 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.3212635699114841" P_Q="0.32168470978152397" P_Z="0.19189357370047744" Q="0.9820854391322233" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="60" WEIGHT="100.0" Z="1.304997868185186">
<NAME>Adverse effects: 1. total number of participants with adverse-effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6564058775300605" CI_START="0.475089286665682" DF="0" EFFECT_SIZE="0.8870967741935484" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" I2="0.0" ID="CMP-002.19.01" LOG_CI_END="0.2191667628677371" LOG_CI_START="-0.3232247628757571" LOG_EFFECT_SIZE="-0.052029000004010034" MODIFIED="2011-05-19 16:20:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7069022053392452" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="35" WEIGHT="59.50390253353628" Z="0.37601976181213287">
<NAME>ultra short term</NAME>
<DICH_DATA CI_END="1.6564058775300605" CI_START="0.475089286665682" EFFECT_SIZE="0.8870967741935484" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.2191667628677371" LOG_CI_START="-0.3232247628757571" LOG_EFFECT_SIZE="-0.052029000004010034" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="615" O_E="0.0" SE="0.3186034671030821" STUDY_ID="STD-Battaglia-1997" TOTAL_1="31" TOTAL_2="35" VAR="0.10150816925010474" WEIGHT="59.50390253353628"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1514110143573244" CI_START="0.25337029517452303" DF="0" EFFECT_SIZE="0.5401234567901234" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" I2="0.0" ID="CMP-002.19.02" LOG_CI_END="0.06123037958474688" LOG_CI_START="-0.5962443026253824" LOG_EFFECT_SIZE="-0.2675069615203177" MODIFIED="2011-05-19 16:21:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.11073403844104705" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="25" WEIGHT="40.49609746646372" Z="1.5949025091919726">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.1514110143573244" CI_START="0.25337029517452303" EFFECT_SIZE="0.5401234567901234" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.06123037958474688" LOG_CI_START="-0.5962443026253824" LOG_EFFECT_SIZE="-0.2675069615203177" MODIFIED="2011-05-19 16:21:14 +0100" MODIFIED_BY="[Empty name]" ORDER="791" O_E="0.0" SE="0.3862038828823956" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="25" VAR="0.14915343915343912" WEIGHT="40.49609746646372"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.6896336884404715" CI_START="0.009347756127233712" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.18571428571428572" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.20" LOG_CI_END="0.566983250986734" LOG_CI_START="-2.029292626401574" LOG_EFFECT_SIZE="-0.7311546877074201" METHOD="MH" MODIFIED="2011-05-22 16:06:45 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="1.0" P_Q="1.0" P_Z="0.2696290555812896" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="25" WEIGHT="100.0" Z="1.1039172435524995">
<NAME>Adverse effects: 2. Anorexia - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6896336884404715" CI_START="0.009347756127233712" EFFECT_SIZE="0.18571428571428572" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.566983250986734" LOG_CI_START="-2.029292626401574" LOG_EFFECT_SIZE="-0.7311546877074201" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="617" O_E="0.0" SE="1.5250653021507559" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="25" VAR="2.325824175824176" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.6896336884404715" CI_START="0.009347756127233712" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.18571428571428572" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.21" LOG_CI_END="0.566983250986734" LOG_CI_START="-2.029292626401574" LOG_EFFECT_SIZE="-0.7311546877074201" METHOD="MH" MODIFIED="2011-05-22 16:06:45 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="1.0" P_Q="1.0" P_Z="0.2696290555812896" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="25" WEIGHT="100.0" Z="1.1039172435524995">
<NAME>Adverse effects: 3.Cardiovascular reactions - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6896336884404715" CI_START="0.009347756127233712" EFFECT_SIZE="0.18571428571428572" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.566983250986734" LOG_CI_START="-2.029292626401574" LOG_EFFECT_SIZE="-0.7311546877074201" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="618" O_E="0.0" SE="1.5250653021507559" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="25" VAR="2.325824175824176" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.12449510137492734" CI_END="1.3130533538396179" CI_START="0.25763187899469386" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5816222165374921" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-002.22" LOG_CI_END="0.11828237331519446" LOG_CI_START="-0.5890003990184496" LOG_EFFECT_SIZE="-0.23535901285162752" METHOD="MH" MODIFIED="2011-05-22 16:06:45 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.7242094867112551" P_Q="0.7252500840136189" P_Z="0.19209206585608335" Q="0.12351781352015537" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="54" TOTAL_2="50" WEIGHT="200.0" Z="1.3044151693503558">
<NAME>Adverse effects: 4. Change in energy level - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3043551024046978" CI_START="0.2366241943927941" DF="0" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" ID="CMP-002.22.01" LOG_CI_END="0.11539584141153876" LOG_CI_START="-0.6259408516181507" LOG_EFFECT_SIZE="-0.25527250510330607" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.17708293031073374" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="25" WEIGHT="100.0" Z="1.3497913187085688">
<NAME>Decreased energy level</NAME>
<DICH_DATA CI_END="1.3043551024046978" CI_START="0.2366241943927941" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.11539584141153876" LOG_CI_START="-0.6259408516181507" LOG_EFFECT_SIZE="-0.25527250510330607" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="619" O_E="0.0" SE="0.4354648431614539" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="25" VAR="0.18962962962962962" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.026374384632664" CI_START="0.06112333784852388" DF="0" EFFECT_SIZE="0.9259259259259259" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-002.22.02" LOG_CI_END="1.1469454266781303" LOG_CI_START="-1.2137929376520293" LOG_EFFECT_SIZE="-0.0334237554869497" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9557408943848755" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="25" WEIGHT="100.0" Z="0.055499040446256476">
<NAME>Increased energy level</NAME>
<DICH_DATA CI_END="14.02637438463267" CI_START="0.06112333784852386" EFFECT_SIZE="0.9259259259259259" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1469454266781303" LOG_CI_START="-1.2137929376520296" LOG_EFFECT_SIZE="-0.0334237554869497" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="620" O_E="0.0" SE="1.3867094010509062" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="25" VAR="1.922962962962963" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.6896336884404715" CI_START="0.009347756127233712" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.18571428571428572" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.23" LOG_CI_END="0.566983250986734" LOG_CI_START="-2.029292626401574" LOG_EFFECT_SIZE="-0.7311546877074201" METHOD="MH" MODIFIED="2011-05-22 16:06:45 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="1.0" P_Q="1.0" P_Z="0.2696290555812896" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="25" WEIGHT="100.0" Z="1.1039172435524995">
<NAME>Adverse effects: 5. Depression - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6896336884404715" CI_START="0.009347756127233712" EFFECT_SIZE="0.18571428571428572" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.566983250986734" LOG_CI_START="-2.029292626401574" LOG_EFFECT_SIZE="-0.7311546877074201" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="621" O_E="0.0" SE="1.5250653021507559" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="25" VAR="2.325824175824176" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.190912313458027" CI_START="0.24556643664456068" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1290322580645162" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.24" LOG_CI_END="0.7152436927002788" LOG_CI_START="-0.6098309916682728" LOG_EFFECT_SIZE="0.052706350516002996" METHOD="MH" MODIFIED="2011-05-22 16:06:46 +0100" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="1.0" P_Q="1.0" P_Z="0.8760964059857753" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="35" WEIGHT="100.0" Z="0.155919587003713">
<NAME>Adverse effects: 6. Dizziness - ultra short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.190912313458027" CI_START="0.24556643664456068" EFFECT_SIZE="1.1290322580645162" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7152436927002788" LOG_CI_START="-0.6098309916682728" LOG_EFFECT_SIZE="0.052706350516002996" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="622" O_E="0.0" SE="0.7783554288235607" STUDY_ID="STD-Battaglia-1997" TOTAL_1="31" TOTAL_2="35" VAR="0.605837173579109" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0767093924660096" CI_END="5.332407349104358" CI_START="0.34823909398369557" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.362700518824331" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="7.124428652964614" I2_Q="5.915042897020862" ID="CMP-002.25" LOG_CI_END="0.7269233182945023" LOG_CI_START="-0.4581224757564512" LOG_EFFECT_SIZE="0.13440042126902554" METHOD="MH" MODIFIED="2011-06-07 08:16:08 +0100" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.29943528215609516" P_Q="0.3025620952196675" P_Z="0.656627994476718" Q="1.0628691671777737" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.11755694001213784" TOTALS="YES" TOTAL_1="58" TOTAL_2="60" WEIGHT="100.0" Z="0.44457351187050387">
<NAME>Adverse effects: 7. Dryness of mouth</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.23872042167959" CI_START="0.4891571397728431" DF="0" EFFECT_SIZE="1.881720430107527" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-002.25.01" LOG_CI_END="0.8596618033632805" LOG_CI_START="-0.3105516030985617" LOG_EFFECT_SIZE="0.27455510013235934" MODIFIED="2011-05-19 16:19:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.35773360753231154" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="35" WEIGHT="82.1199585093569" Z="0.9196922630688719">
<NAME>ultra short term</NAME>
<DICH_DATA CI_END="7.23872042167959" CI_START="0.4891571397728431" EFFECT_SIZE="1.881720430107527" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8596618033632805" LOG_CI_START="-0.3105516030985617" LOG_EFFECT_SIZE="0.27455510013235934" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="623" O_E="0.0" SE="0.6873891476054708" STUDY_ID="STD-Battaglia-1997" TOTAL_1="31" TOTAL_2="35" VAR="0.47250384024577574" WEIGHT="82.1199585093569"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.264937143867087" CI_START="0.013187311433658885" DF="0" EFFECT_SIZE="0.30952380952380953" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.25.02" LOG_CI_END="0.8612318611406103" LOG_CI_START="-1.8798437373227375" LOG_EFFECT_SIZE="-0.5093059380910637" MODIFIED="2011-05-19 16:19:24 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4664037930680467" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="25" WEIGHT="17.8800414906431" Z="0.7283427690432733">
<NAME>short term</NAME>
<DICH_DATA CI_END="7.264937143867087" CI_START="0.013187311433658885" EFFECT_SIZE="0.30952380952380953" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8612318611406103" LOG_CI_START="-1.8798437373227375" LOG_EFFECT_SIZE="-0.5093059380910637" MODIFIED="2011-05-19 16:19:21 +0100" MODIFIED_BY="[Empty name]" ORDER="789" O_E="0.0" SE="1.6101213750804138" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="25" VAR="2.5924908424908426" WEIGHT="17.8800414906431"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.26" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-05-22 16:06:46 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="27" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 8. Gastric reactions - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="625" O_E="0.0" SE="0.0" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.6896336884404715" CI_START="0.009347756127233712" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.18571428571428572" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.27" LOG_CI_END="0.566983250986734" LOG_CI_START="-2.029292626401574" LOG_EFFECT_SIZE="-0.7311546877074201" METHOD="MH" MODIFIED="2011-05-22 16:06:46 +0100" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="1.0" P_Q="1.0" P_Z="0.2696290555812896" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="25" WEIGHT="100.0" Z="1.1039172435524995">
<NAME>Adverse effects: 9. Headaches - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6896336884404715" CI_START="0.009347756127233712" EFFECT_SIZE="0.18571428571428572" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.566983250986734" LOG_CI_START="-2.029292626401574" LOG_EFFECT_SIZE="-0.7311546877074201" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="626" O_E="0.0" SE="1.5250653021507559" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="25" VAR="2.325824175824176" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.28" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-05-22 16:06:46 +0100" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="27" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 10. Insomnia - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="627" O_E="0.0" SE="0.0" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.9069381726030326" CI_END="0.8602747001912786" CI_START="0.22897148986644136" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4438224642773315" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-002.29" LOG_CI_END="-0.0653628490728866" LOG_CI_START="-0.6402185899941887" LOG_EFFECT_SIZE="-0.3527907195335377" METHOD="MH" MODIFIED="2012-04-22 16:22:34 +0100" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="0.7904318688967737" P_Q="0.7963178057457297" P_Z="0.01614276257229043" Q="3.8550109081219093" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="274" TOTAL_2="300" WEIGHT="800.0" Z="2.405671736904045">
<NAME>Adverse effects: 11a. Movement disorders</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="23.70740186889787" CI_START="0.21507440533542027" DF="0" EFFECT_SIZE="2.2580645161290325" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-002.29.01" LOG_CI_END="1.3748839615771888" LOG_CI_START="-0.6674112692172205" LOG_EFFECT_SIZE="0.3537363461799842" MODIFIED="2011-05-20 07:49:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4971681050808824" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="35" WEIGHT="100.0" Z="0.6789522769104042">
<NAME>Ataxia - ultra short term</NAME>
<DICH_DATA CI_END="23.70740186889787" CI_START="0.21507440533542027" EFFECT_SIZE="2.2580645161290325" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3748839615771888" LOG_CI_START="-0.6674112692172205" LOG_EFFECT_SIZE="0.3537363461799842" MODIFIED="2011-05-20 07:49:17 +0100" MODIFIED_BY="[Empty name]" ORDER="248" O_E="0.0" SE="1.199654328093073" STUDY_ID="STD-Battaglia-1997" TOTAL_1="31" TOTAL_2="35" VAR="1.4391705069124425" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.776649361264728" CI_START="0.034307489541650554" DF="0" EFFECT_SIZE="0.30864197530864196" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-002.29.02" LOG_CI_END="0.4435210399654002" LOG_CI_START="-1.4646110603786247" LOG_EFFECT_SIZE="-0.5105450102066121" MODIFIED="2011-05-20 07:49:55 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.29425795697191726" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="25" WEIGHT="100.0" Z="1.048826579995361">
<NAME>Ataxia - short term</NAME>
<DICH_DATA CI_END="2.776649361264728" CI_START="0.034307489541650554" EFFECT_SIZE="0.30864197530864196" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4435210399654002" LOG_CI_START="-1.4646110603786247" LOG_EFFECT_SIZE="-0.5105450102066121" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="628" O_E="0.0" SE="1.1208462411483104" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="25" VAR="1.2562962962962962" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.238890452044345" CI_START="0.020998279642272525" DF="0" EFFECT_SIZE="0.16129032258064513" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" ID="CMP-002.29.03" LOG_CI_END="0.09303290591115465" LOG_CI_START="-1.6778162849076623" LOG_EFFECT_SIZE="-0.792391689498254" MODIFIED="2011-05-20 07:49:23 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.0794257789794843" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="35" WEIGHT="100.0" Z="1.7540275943512833">
<NAME>Dystonia - ultra short term</NAME>
<DICH_DATA CI_END="1.238890452044345" CI_START="0.020998279642272525" EFFECT_SIZE="0.16129032258064516" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.09303290591115465" LOG_CI_START="-1.6778162849076623" LOG_EFFECT_SIZE="-0.7923916894982539" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="630" O_E="0.0" SE="1.0402055805318415" STUDY_ID="STD-Battaglia-1997" TOTAL_1="31" TOTAL_2="35" VAR="1.0820276497695853" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.993813525573719" CI_START="0.008627485116229242" DF="0" EFFECT_SIZE="0.1607142857142857" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-002.29.04" LOG_CI_END="0.47622474612846594" LOG_CI_START="-2.0641157812622173" LOG_EFFECT_SIZE="-0.7939455175668756" MODIFIED="2011-05-20 07:49:23 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.22053192400000843" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="35" WEIGHT="100.0" Z="1.2251149822944767">
<NAME>Parkinsonism - ultra short term</NAME>
<DICH_DATA CI_END="2.993813525573719" CI_START="0.008627485116229242" EFFECT_SIZE="0.16071428571428573" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.47622474612846594" LOG_CI_START="-2.0641157812622173" LOG_EFFECT_SIZE="-0.7939455175668755" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="631" O_E="0.0" SE="1.492208600677703" STUDY_ID="STD-Battaglia-1997" TOTAL_1="31" TOTAL_2="35" VAR="2.226686507936508" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8728458967100807" CI_START="0.11092779473570388" DF="0" EFFECT_SIZE="0.5645161290322581" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-002.29.05" LOG_CI_END="0.45831233048083414" LOG_CI_START="-0.9549596207767906" LOG_EFFECT_SIZE="-0.2483236451479782" MODIFIED="2011-05-20 07:49:23 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.49097181637478404" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="35" WEIGHT="100.0" Z="0.6887639715295256">
<NAME>Slight dysarthria - ultra short term</NAME>
<DICH_DATA CI_END="2.8728458967100807" CI_START="0.11092779473570388" EFFECT_SIZE="0.5645161290322581" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.45831233048083414" LOG_CI_START="-0.9549596207767906" LOG_EFFECT_SIZE="-0.2483236451479782" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="632" O_E="0.0" SE="0.8301629399777145" STUDY_ID="STD-Battaglia-1997" TOTAL_1="31" TOTAL_2="35" VAR="0.6891705069124424" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.926850467224469" CI_START="0.053768601333855075" DF="0" EFFECT_SIZE="0.5645161290322581" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.29.06" LOG_CI_END="0.7728239702492266" LOG_CI_START="-1.2694712605451828" LOG_EFFECT_SIZE="-0.2483236451479782" MODIFIED="2011-05-20 07:49:23 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.6336285387470226" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="35" WEIGHT="100.0" Z="0.4766258997827888">
<NAME>Tremor - ultra short term</NAME>
<DICH_DATA CI_END="5.926850467224469" CI_START="0.053768601333855075" EFFECT_SIZE="0.5645161290322581" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7728239702492266" LOG_CI_START="-1.2694712605451828" LOG_EFFECT_SIZE="-0.2483236451479782" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="633" O_E="0.0" SE="1.199654328093073" STUDY_ID="STD-Battaglia-1997" TOTAL_1="31" TOTAL_2="35" VAR="1.4391705069124425" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.29.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-05-20 07:49:22 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>EPS - ultra short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="634" O_E="0.0" SE="0.0" STUDY_ID="STD-Foster-1997" TOTAL_1="17" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6896336884404715" CI_START="0.009347756127233712" DF="0" EFFECT_SIZE="0.18571428571428572" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-002.29.08" LOG_CI_END="0.566983250986734" LOG_CI_START="-2.029292626401574" LOG_EFFECT_SIZE="-0.7311546877074201" MODIFIED="2011-05-20 07:49:22 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.2696290555812896" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="25" WEIGHT="100.0" Z="1.1039172435524995">
<NAME>EPS - short term</NAME>
<DICH_DATA CI_END="3.6896336884404715" CI_START="0.009347756127233712" EFFECT_SIZE="0.18571428571428572" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.566983250986734" LOG_CI_START="-2.029292626401574" LOG_EFFECT_SIZE="-0.7311546877074201" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="635" O_E="0.0" SE="1.5250653021507559" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="25" VAR="2.325824175824176" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4688075456257228" CI_START="0.17142839926190268" DF="0" EFFECT_SIZE="0.5017921146953405" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" I2="0.0" ID="CMP-002.29.09" LOG_CI_END="0.16696489494049815" LOG_CI_START="-0.7659172301312173" LOG_EFFECT_SIZE="-0.29947616759535955" MODIFIED="2011-05-20 07:49:22 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.2082525273789544" STUDIES="2" TAU2="0.0" TOTAL_1="48" TOTAL_2="55" WEIGHT="100.0" Z="1.258385142002508">
<NAME>Use of antiparkinson medication - ultra short term</NAME>
<DICH_DATA CI_END="1.4688075456257228" CI_START="0.17142839926190268" EFFECT_SIZE="0.5017921146953405" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.16696489494049815" LOG_CI_START="-0.7659172301312173" LOG_EFFECT_SIZE="-0.29947616759535955" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="636" O_E="0.0" SE="0.5479795781081203" STUDY_ID="STD-Battaglia-1997" TOTAL_1="31" TOTAL_2="35" VAR="0.30028161802355346" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="637" O_E="0.0" SE="0.0" STUDY_ID="STD-Foster-1997" TOTAL_1="17" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-002.30" MODIFIED="2012-04-22 16:22:42 +0100" MODIFIED_BY="[Empty name]" NO="30" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Adverse effects: 11b. Movement disorders - ultra short term (skewed data)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.30.01" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>Mean Parkinson Total Score at 2 hours</NAME>
<OTHER_DATA MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="140" STUDY_ID="STD-Chouinard-1993">
<TR>
<TD>
<P>Benzodiazepines<BR/>
</P>
</TD>
<TD>
<P>6.50</P>
</TD>
<TD>
<P>4.90</P>
</TD>
<TD>
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>Antipsychotics</P>
</TD>
<TD>
<P>8.50</P>
</TD>
<TD>
<P>4.90</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.30.02" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="2" STUDIES="1">
<NAME>Mean Tardive Dyskinesia Total Score</NAME>
<OTHER_DATA MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="141" STUDY_ID="STD-Chouinard-1993">
<TR>
<TD>
<P>Benzodiazepines</P>
</TD>
<TD>
<P>3.0</P>
</TD>
<TD>
<P>2.0</P>
</TD>
<TD>
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>Antipsychotics</P>
</TD>
<TD>
<P>0.90</P>
</TD>
<TD>
<P>2.0</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="72.57983850384156" CI_START="0.12237514815956214" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.9802631578947367" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.31" LOG_CI_END="1.860815997524382" LOG_CI_START="-0.9123067693882637" LOG_EFFECT_SIZE="0.4742546140680593" METHOD="MH" MODIFIED="2011-05-22 16:06:46 +0100" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="1.0" P_Q="1.0" P_Z="0.5026160710730098" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="151" TOTAL_2="150" WEIGHT="100.0" Z="0.670379237562705">
<NAME>Adverse effects: 12. Respiratory depression - ultra short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="72.57983850384156" CI_START="0.12237514815956214" EFFECT_SIZE="2.9802631578947367" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.860815997524382" LOG_CI_START="-0.9123067693882637" LOG_EFFECT_SIZE="0.4742546140680593" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="640" O_E="0.0" SE="1.6289460404635736" STUDY_ID="STD-TREC_x002d_Rio-2003" TOTAL_1="151" TOTAL_2="150" VAR="2.653465202741954" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.358349677163112" CI_START="0.3327709434506947" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7647058823529411" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.32" LOG_CI_END="0.971199268685308" LOG_CI_START="-0.47785460200253105" LOG_EFFECT_SIZE="0.2466723333413885" METHOD="MH" MODIFIED="2011-05-22 16:06:46 +0100" MODIFIED_BY="[Empty name]" NO="32" P_CHI2="1.0" P_Q="1.0" P_Z="0.50458752460135" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="20" WEIGHT="100.0" Z="0.667289048545982">
<NAME>Adverse effects: 13. Sedation (extreme) - ultra short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.358349677163112" CI_START="0.3327709434506947" EFFECT_SIZE="1.7647058823529411" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.971199268685308" LOG_CI_START="-0.47785460200253105" LOG_EFFECT_SIZE="0.2466723333413885" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="641" O_E="0.0" SE="0.8511814165743802" STUDY_ID="STD-Foster-1997" TOTAL_1="17" TOTAL_2="20" VAR="0.7245098039215685" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.064426500426842" CI_START="0.013597238684395798" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.331140350877193" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.33" LOG_CI_END="0.9065734880850574" LOG_CI_START="-1.8665492788275886" LOG_EFFECT_SIZE="-0.4799878953712655" METHOD="MH" MODIFIED="2011-05-22 16:06:46 +0100" MODIFIED_BY="[Empty name]" NO="33" P_CHI2="1.0" P_Q="1.0" P_Z="0.49746520145296536" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="151" TOTAL_2="150" WEIGHT="100.0" Z="0.6784834765827692">
<NAME>Adverse effects: 14. Seizure - ultra short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.064426500426842" CI_START="0.013597238684395798" EFFECT_SIZE="0.33114035087719296" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9065734880850574" LOG_CI_START="-1.8665492788275886" LOG_EFFECT_SIZE="-0.47998789537126557" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="642" O_E="0.0" SE="1.6289460404635736" STUDY_ID="STD-TREC_x002d_Rio-2003" TOTAL_1="151" TOTAL_2="150" VAR="2.653465202741954" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6406025555068257" CI_END="1.1148982152252997" CI_START="0.5610091110034159" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7908653846153847" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-002.34" LOG_CI_END="0.047235220223853534" LOG_CI_START="-0.2510300855773903" LOG_EFFECT_SIZE="-0.1018974326767684" METHOD="MH" MODIFIED="2012-04-22 16:22:10 +0100" MODIFIED_BY="[Empty name]" NO="34" P_CHI2="0.7259303493600855" P_Q="0.74460995910246" P_Z="0.18051244824486254" Q="0.5897895649512711" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="77" TOTAL_2="77" WEIGHT="300.0" Z="1.3391788738355372">
<NAME>Sensitivity analysis (no clinically important response to treatment, ultra short term) - use of a fixed-effects model</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4260886230791563" CI_START="0.5845698364767296" DF="0" EFFECT_SIZE="0.9130434782608695" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="0.0" ID="CMP-002.34.01" LOG_CI_END="0.15414651522012718" LOG_CI_START="-0.2331635977874745" LOG_EFFECT_SIZE="-0.039508541283673634" MODIFIED="2011-09-30 14:17:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.689258087825201" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="21" WEIGHT="100.0" Z="0.3998621022126237">
<NAME>Unimproved or worse at 30 minutes</NAME>
<DICH_DATA CI_END="1.4260886230791563" CI_START="0.5845698364767296" EFFECT_SIZE="0.9130434782608695" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.15414651522012718" LOG_CI_START="-0.2331635977874745" LOG_EFFECT_SIZE="-0.039508541283673634" MODIFIED="2011-09-30 14:17:23 +0100" MODIFIED_BY="[Empty name]" ORDER="933" O_E="0.0" SE="0.22750787759664504" STUDY_ID="STD-Garza_x002d_Trevino-1989" TOTAL_1="23" TOTAL_2="21" VAR="0.05175983436853002" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8624499491236017" CI_START="0.19893710279289573" DF="0" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-002.34.02" LOG_CI_END="0.2700846104879784" LOG_CI_START="-0.701284211166688" LOG_EFFECT_SIZE="-0.21559980033935483" MODIFIED="2011-09-30 14:17:23 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3842752024025484" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="21" WEIGHT="100.0" Z="0.8700461334950897">
<NAME>Unimproved or worse at 60 minutes</NAME>
<DICH_DATA CI_END="1.8624499491236017" CI_START="0.19893710279289573" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.2700846104879784" LOG_CI_START="-0.701284211166688" LOG_EFFECT_SIZE="-0.21559980033935483" MODIFIED="2011-09-30 14:17:23 +0100" MODIFIED_BY="[Empty name]" ORDER="934" O_E="0.0" SE="0.5705868541931665" STUDY_ID="STD-Garza_x002d_Trevino-1989" TOTAL_1="23" TOTAL_2="21" VAR="0.3255693581780538" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3014672400440466" CI_START="0.4353082942865892" DF="0" EFFECT_SIZE="0.7526881720430108" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" I2="0.0" ID="CMP-002.34.03" LOG_CI_END="0.11443324071482025" LOG_CI_START="-0.36120305779417694" LOG_EFFECT_SIZE="-0.12338490853967829" MODIFIED="2011-09-30 14:17:23 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.30921561951834686" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="35" WEIGHT="100.0" Z="1.016869308467901">
<NAME>Unimproved or worse at 12 hours</NAME>
<DICH_DATA CI_END="1.3014672400440466" CI_START="0.4353082942865892" EFFECT_SIZE="0.7526881720430108" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.11443324071482025" LOG_CI_START="-0.36120305779417694" LOG_EFFECT_SIZE="-0.12338490853967829" MODIFIED="2011-09-30 14:17:23 +0100" MODIFIED_BY="[Empty name]" ORDER="935" O_E="0.0" SE="0.27939111618183443" STUDY_ID="STD-Battaglia-1997" TOTAL_1="31" TOTAL_2="35" VAR="0.0780593958013313" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8300616481182821" CI_END="3.6703222430140876" CI_START="0.6822103813020531" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5823817292006526" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="7" I2="0.0" I2_Q="100.0" ID="CMP-002.35" LOG_CI_END="0.5647041956469537" LOG_CI_START="-0.16608167615129402" LOG_EFFECT_SIZE="0.19931125974782982" METHOD="MH" MODIFIED="2012-04-22 16:22:19 +0100" MODIFIED_BY="[Empty name]" NO="35" P_CHI2="0.36225477099093206" P_Q="0.0" P_Z="0.285023020976905" Q="1.672264533555432E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="45" WEIGHT="99.99999999999999" Z="1.0691035661589838">
<NAME>Sensitivity analysis (no clinically important response to treatment, short term) - use of a fixed-effects model</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.190441200779986" CI_START="0.38695836203868794" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5038507450680781" LOG_CI_START="-0.4123357639467279" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2011-09-30 14:17:29 +0100" MODIFIED_BY="[Empty name]" ORDER="936" O_E="0.0" SE="0.5381724905916594" STUDY_ID="STD-Hankoff-1962" TOTAL_1="27" TOTAL_2="25" VAR="0.2896296296296297" WEIGHT="66.06851549755301"/>
<DICH_DATA CI_END="10.344133602427869" CI_START="0.6042071999662749" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.0146941211552538" LOG_CI_START="-0.21881410381117877" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2011-09-30 14:17:29 +0100" MODIFIED_BY="[Empty name]" ORDER="937" O_E="0.0" SE="0.7245688373094719" STUDY_ID="STD-Merlis-1962" TOTAL_1="40" TOTAL_2="20" VAR="0.5249999999999999" WEIGHT="33.93148450244698"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2012-04-23 11:40:59 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS versus PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS</NAME>
<DICH_OUTCOME CHI2="6.1844437138928114" CI_END="0.9519340491003796" CI_START="0.41344281233709823" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6273518075366503" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="38" I2="67.66079388018078" I2_Q="64.01020218652802" ID="CMP-003.01" LOG_CI_END="-0.02139313890957524" LOG_CI_START="-0.3835845538358291" LOG_EFFECT_SIZE="-0.20248884637270215" METHOD="MH" MODIFIED="2012-04-23 11:40:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.045401001030535126" P_Q="0.06212762841244979" P_Z="0.028415788104323873" Q="5.557130413362159" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.4182949122992839" TOTALS="SUB" TOTAL_1="80" TOTAL_2="77" WEIGHT="300.0" Z="2.1914978092032773">
<NAME>No clinically important response to treatment - ultra short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.3132158019282495E-31" CI_END="0.7987104962617081" CI_START="0.17606504566821463" DF="0" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" I2="100.0" ID="CMP-003.01.01" LOG_CI_END="-0.09761060824489459" LOG_CI_START="-0.7543268562996677" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.011003110345656642" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="21" WEIGHT="100.0" Z="2.5426000232728296">
<NAME>Unimproved or worse at 30 minutes</NAME>
<DICH_DATA CI_END="0.7987104962617081" CI_START="0.17606504566821463" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="-0.09761060824489459" LOG_CI_START="-0.7543268562996677" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="671" O_E="0.0" SE="0.3857583749052298" STUDY_ID="STD-Garza_x002d_Trevino-1989" TOTAL_1="24" TOTAL_2="21" VAR="0.1488095238095238" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.13430331773508" CI_START="0.004039703004536443" DF="0" EFFECT_SIZE="0.06769230769230769" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.05472920235631467" LOG_CI_START="-2.393650562669651" LOG_EFFECT_SIZE="-1.1694606801566683" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.06115945257453507" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="21" WEIGHT="100.0" Z="1.8723409229110966">
<NAME>Unimproved or worse at 60 minutes</NAME>
<DICH_DATA CI_END="1.13430331773508" CI_START="0.004039703004536443" EFFECT_SIZE="0.06769230769230769" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.05472920235631467" LOG_CI_START="-2.393650562669651" LOG_EFFECT_SIZE="-1.1694606801566683" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="672" O_E="0.0" SE="1.4381903936515528" STUDY_ID="STD-Garza_x002d_Trevino-1989" TOTAL_1="24" TOTAL_2="21" VAR="2.0683916083916083" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.413738242373146" CI_START="0.5118918171116655" DF="0" EFFECT_SIZE="0.8506944444444444" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="0.15036900605468123" LOG_CI_START="-0.29082181284407804" LOG_EFFECT_SIZE="-0.07022640339469839" MODIFIED="2011-05-24 10:41:41 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5326582949796707" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="35" WEIGHT="100.0" Z="0.6239532443623902">
<NAME>Unimproved or worse at 12 hours</NAME>
<DICH_DATA CI_END="1.413738242373146" CI_START="0.5118918171116655" EFFECT_SIZE="0.8506944444444444" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="0.15036900605468123" LOG_CI_START="-0.29082181284407804" LOG_EFFECT_SIZE="-0.07022640339469839" MODIFIED="2011-05-24 10:41:41 +0100" MODIFIED_BY="[Empty name]" ORDER="673" O_E="0.0" SE="0.25915767095090664" STUDY_ID="STD-Battaglia-1997" TOTAL_1="32" TOTAL_2="35" VAR="0.06716269841269841" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.53524723556784" CI_END="1.540743174546165" CI_START="0.48682608043687586" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8660681039180341" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="71" I2="67.81512438017378" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.1877302524932515" LOG_CI_START="-0.31262616362517076" LOG_EFFECT_SIZE="-0.06244795556595964" METHOD="MH" MODIFIED="2012-04-23 11:40:59 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.008304177032240956" P_Q="1.0" P_Z="0.6246758776442269" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.32039723628302297" TOTALS="YES" TOTAL_1="256" TOTAL_2="255" WEIGHT="99.99999999999999" Z="0.4892342333368636">
<NAME>No clinically important response to treatment - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9171435836951519" CI_START="0.12114909059653102" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.03756266790137051" LOG_CI_START="-0.9166798415379545" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-05-23 11:48:48 +0100" MODIFIED_BY="[Empty name]" ORDER="247" O_E="0.0" SE="0.5163977794943222" STUDY_ID="STD-Guz-1972" TOTAL_1="30" TOTAL_2="30" VAR="0.26666666666666666" WEIGHT="14.714610571461515"/>
<DICH_DATA CI_END="3.1973524021921604" CI_START="1.0186752720983236" EFFECT_SIZE="1.8047337278106508" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="13" LOG_CI_END="0.504790505490647" LOG_CI_START="0.008035763975577523" LOG_EFFECT_SIZE="0.2564131347331123" MODIFIED="2011-05-23 11:48:48 +0100" MODIFIED_BY="[Empty name]" ORDER="248" O_E="0.0" SE="0.29179619414158015" STUDY_ID="STD-Hanlon-1969" TOTAL_1="65" TOTAL_2="61" VAR="0.08514501891551073" WEIGHT="21.30090416407536"/>
<DICH_DATA CI_END="2.3107662619202203" CI_START="0.6756385245378359" EFFECT_SIZE="1.2494969818913482" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.36375601804851554" LOG_CI_START="-0.17028559516201935" LOG_EFFECT_SIZE="0.0967352114432481" MODIFIED="2011-05-23 11:48:48 +0100" MODIFIED_BY="[Empty name]" ORDER="249" O_E="0.0" SE="0.3136986871484882" STUDY_ID="STD-Hanlon-1970" TOTAL_1="71" TOTAL_2="69" VAR="0.09840686631868506" WEIGHT="20.626389901156926"/>
<DICH_DATA CI_END="1.868396809676368" CI_START="0.5956492021337781" EFFECT_SIZE="1.054945054945055" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.27146911705016397" LOG_CI_START="-0.22500943561321432" LOG_EFFECT_SIZE="0.023229840718474823" MODIFIED="2011-05-24 06:17:13 +0100" MODIFIED_BY="[Empty name]" ORDER="250" O_E="0.0" SE="0.2916339594429399" STUDY_ID="STD-Lingjaerde-1982" TOTAL_1="26" TOTAL_2="32" VAR="0.0850503663003663" WEIGHT="21.3058769059814"/>
<DICH_DATA CI_END="0.6188101004315442" CI_START="0.013355410333725814" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.20844260621073604" LOG_CI_START="-1.8743427641057142" LOG_EFFECT_SIZE="-1.041392685158225" MODIFIED="2011-05-23 11:48:48 +0100" MODIFIED_BY="[Empty name]" ORDER="251" O_E="0.0" SE="0.9785579990862869" STUDY_ID="STD-Morphy-1986" TOTAL_1="15" TOTAL_2="15" VAR="0.9575757575757575" WEIGHT="6.759467339277381"/>
<DICH_DATA CI_END="2.5817540249927142" CI_START="0.37168535705099137" EFFECT_SIZE="0.9795918367346939" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.41191486276500283" LOG_CI_START="-0.42982454807085574" LOG_EFFECT_SIZE="-0.008954842652926454" MODIFIED="2011-06-02 14:24:20 +0100" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="0.4944418966022663" STUDY_ID="STD-Xuan-2007" TOTAL_1="49" TOTAL_2="48" VAR="0.2444727891156462" WEIGHT="15.292751118047399"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.020500571173331" CI_END="2.297649122938228" CI_START="0.8084292051686766" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3628964209408791" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="22" I2="0.29201010619538764" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.36128370772626917" LOG_CI_START="-0.09235800562866212" LOG_EFFECT_SIZE="0.13446285104880348" METHOD="MH" MODIFIED="2011-06-07 08:17:40 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.42674855867161376" P_Q="1.0" P_Z="0.24527755446254196" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0017636858018604067" TOTALS="YES" TOTAL_1="597" TOTAL_2="588" WEIGHT="100.0" Z="1.161896437455839">
<NAME>Leaving the study early any reason</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="3" TAU2="0.0" TOTAL_1="71" TOTAL_2="69" WEIGHT="0.0" Z="0.0">
<NAME>ultra short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="643" O_E="0.0" SE="0.0" STUDY_ID="STD-Battaglia-1997" TOTAL_1="32" TOTAL_2="35" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="645" O_E="0.0" SE="0.0" STUDY_ID="STD-Dorevitch-1999" TOTAL_1="15" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="644" O_E="0.0" SE="0.0" STUDY_ID="STD-Garza_x002d_Trevino-1989" TOTAL_1="24" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.020500571173331" CI_END="2.297649122938228" CI_START="0.8084292051686766" DF="7" EFFECT_SIZE="1.3628964209408791" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="22" I2="0.29201010619538764" ID="CMP-003.03.02" LOG_CI_END="0.36128370772626917" LOG_CI_START="-0.09235800562866212" LOG_EFFECT_SIZE="0.13446285104880348" MODIFIED="2011-05-24 12:03:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.42674855867161376" P_Z="0.24527755446254196" STUDIES="16" TAU2="0.0017636858018604067" TOTAL_1="526" TOTAL_2="519" WEIGHT="100.0" Z="1.161896437455839">
<NAME>short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="646" O_E="0.0" SE="0.0" STUDY_ID="STD-Barbee-1992" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="648" O_E="0.0" SE="0.0" STUDY_ID="STD-Guz-1972" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="11.747350841359477" CI_START="1.0079427797889493" EFFECT_SIZE="3.4410256410256412" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="1.0699399393995428" LOG_CI_START="0.0034358782134053965" LOG_EFFECT_SIZE="0.5366879088064741" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="647" O_E="0.0" SE="0.6264697648209832" STUDY_ID="STD-Hanlon-1969" TOTAL_1="65" TOTAL_2="61" VAR="0.392464366234858" WEIGHT="18.01165600699292"/>
<DICH_DATA CI_END="4.942577789785508" CI_START="0.4299426103234983" EFFECT_SIZE="1.4577464788732395" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6939535132732643" LOG_CI_START="-0.3665895111255417" LOG_EFFECT_SIZE="0.1636820010738613" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="651" O_E="0.0" SE="0.6229682223044967" STUDY_ID="STD-Hanlon-1970" TOTAL_1="71" TOTAL_2="69" VAR="0.3880894060012247" WEIGHT="18.213784143024935"/>
<DICH_DATA CI_END="7.140168426766256" CI_START="0.015561413186640009" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8537084563073322" LOG_CI_START="-1.8079509657466573" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="652" O_E="0.0" SE="1.563471919941143" STUDY_ID="STD-Holden-1968" TOTAL_1="8" TOTAL_2="8" VAR="2.444444444444444" WEIGHT="2.90273749555289"/>
<DICH_DATA CI_END="2.137578681188118" CI_START="0.13918582916987907" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.32992210944789796" LOG_CI_START="-0.8564049789970608" LOG_EFFECT_SIZE="-0.26324143477458145" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="653" O_E="0.0" SE="0.6968544041663657" STUDY_ID="STD-Kurland-1966" TOTAL_1="44" TOTAL_2="40" VAR="0.4856060606060606" WEIGHT="14.56943134843068"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-24 12:03:57 +0100" MODIFIED_BY="[Empty name]" ORDER="654" O_E="0.0" SE="0.0" STUDY_ID="STD-Lingjaerde-1979" TOTAL_1="11" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.685740012565781" CI_START="0.4027923834074037" EFFECT_SIZE="1.641025641025641" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8251494842362991" LOG_CI_START="-0.39491875032152307" LOG_EFFECT_SIZE="0.21511536695738795" MODIFIED="2011-05-24 06:18:52 +0100" MODIFIED_BY="[Empty name]" ORDER="655" O_E="0.0" SE="0.7166741204144286" STUDY_ID="STD-Lingjaerde-1982" TOTAL_1="26" TOTAL_2="32" VAR="0.5136217948717948" WEIGHT="13.777454600216952"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 16:10:33 +0100" MODIFIED_BY="[Empty name]" ORDER="783" O_E="0.0" SE="0.0" STUDY_ID="STD-Ma-2006" TOTAL_1="60" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="120.15725297777159" CI_START="0.4077989366906108" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.079749990979728" LOG_CI_START="-0.3895539109512146" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="656" O_E="0.0" SE="1.4504813352456845" STUDY_ID="STD-Marneros-1979" TOTAL_1="10" TOTAL_2="10" VAR="2.103896103896104" WEIGHT="3.372197206943292"/>
<DICH_DATA CI_END="68.25874292736694" CI_START="0.13185124152633113" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.87991577648491" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="657" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Morphy-1986" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="2.791780814717686"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="658" O_E="0.0" SE="0.0" STUDY_ID="STD-Pujalte-1994" TOTAL_1="6" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.497903375393569" CI_START="0.3287913658271901" EFFECT_SIZE="0.90625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.39757563486077435" LOG_CI_START="-0.48307959570267417" LOG_EFFECT_SIZE="-0.04275198042094989" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="649" O_E="0.0" SE="0.517301241746667" STUDY_ID="STD-Stevens-1992" TOTAL_1="32" TOTAL_2="29" VAR="0.26760057471264365" WEIGHT="26.360958384120654"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 16:10:40 +0100" MODIFIED_BY="[Empty name]" ORDER="784" O_E="0.0" SE="0.0" STUDY_ID="STD-Wang-2000" TOTAL_1="45" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="650" O_E="0.0" SE="0.0" STUDY_ID="STD-Wang-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 16:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="785" O_E="0.0" SE="0.0" STUDY_ID="STD-Xuan-2007" TOTAL_1="49" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.09614164194110231" CI_END="15.45392579141281" CI_START="0.6777424988232256" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.2363223390912115" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="1.189038822464639" LOG_CI_START="-0.16893528044273157" LOG_EFFECT_SIZE="0.5100517710109538" METHOD="MH" MODIFIED="2011-06-07 08:17:48 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.9530662896629847" P_Q="1.0" P_Z="0.14093572292311107" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="212" TOTAL_2="203" WEIGHT="99.99999999999999" Z="1.472315413514966">
<NAME>Leaving the study early due to adverse effects - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="26.341299044628926" CI_START="0.30091114789422635" EFFECT_SIZE="2.8153846153846156" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4206371887731697" LOG_CI_START="-0.5215617225980219" LOG_EFFECT_SIZE="0.44953773308757394" MODIFIED="2011-06-06 07:08:54 +0100" MODIFIED_BY="[Empty name]" ORDER="659" O_E="0.0" SE="1.1408572545791025" STUDY_ID="STD-Hanlon-1969" TOTAL_1="65" TOTAL_2="61" VAR="1.301555275325767" WEIGHT="48.887244927117656"/>
<DICH_DATA CI_END="99.45994496606356" CI_START="0.23758711351218584" EFFECT_SIZE="4.861111111111111" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9976482145891328" LOG_CI_START="-0.6241771187511184" LOG_EFFECT_SIZE="0.6867355479190071" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="660" O_E="0.0" SE="1.5400731790487738" STUDY_ID="STD-Hanlon-1970" TOTAL_1="71" TOTAL_2="69" VAR="2.371825396825397" WEIGHT="26.827207270905593"/>
<DICH_DATA CI_END="65.23744012964735" CI_START="0.11452183127148555" EFFECT_SIZE="2.7333333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8144969112986467" LOG_CI_START="-0.941111715970538" LOG_EFFECT_SIZE="0.43669259766405427" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="661" O_E="0.0" SE="1.618658148140615" STUDY_ID="STD-Kurland-1966" TOTAL_1="44" TOTAL_2="40" VAR="2.6200542005420053" WEIGHT="24.285547801976744"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-24 06:20:03 +0100" MODIFIED_BY="[Empty name]" ORDER="251" O_E="0.0" SE="0.0" STUDY_ID="STD-Lingjaerde-1979" TOTAL_1="11" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="663" O_E="0.0" SE="0.0" STUDY_ID="STD-Morphy-1986" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="664" O_E="0.0" SE="0.0" STUDY_ID="STD-Pujalte-1994" TOTAL_1="6" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3486424178384078" CI_END="3.4158472992981066" CI_START="0.16736326202923776" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7561000903348003" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.5334984479202171" LOG_CI_START="-0.7763398680214024" LOG_EFFECT_SIZE="-0.12142071005059264" METHOD="MH" MODIFIED="2011-06-07 08:18:22 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.7176162837777003" P_Q="1.0" P_Z="0.7163259502166163" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="176" TOTAL_2="171" WEIGHT="100.0" Z="0.3633734267505565">
<NAME>Leaving the study early due to inefficacy of treatment - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.543210375357778" CI_START="0.012998605949484718" EFFECT_SIZE="0.31313131313131315" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.877556220082767" LOG_CI_START="-1.8861032216093214" LOG_EFFECT_SIZE="-0.5042735007632773" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="667" O_E="0.0" SE="1.6233872363848025" STUDY_ID="STD-Hanlon-1969" TOTAL_1="65" TOTAL_2="61" VAR="2.635386119257087" WEIGHT="22.462926225421008"/>
<DICH_DATA CI_END="15.23141940682358" CI_START="0.06200705528221281" EFFECT_SIZE="0.971830985915493" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.182740376863771" LOG_CI_START="-1.207558892827411" LOG_EFFECT_SIZE="-0.012409257981819953" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="668" O_E="0.0" SE="1.404073623188812" STUDY_ID="STD-Hanlon-1970" TOTAL_1="71" TOTAL_2="69" VAR="1.971422739334558" WEIGHT="30.028305340716823"/>
<DICH_DATA CI_END="7.140168426766256" CI_START="0.015561413186640009" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8537084563073322" LOG_CI_START="-1.8079509657466573" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="669" O_E="0.0" SE="1.563471919941143" STUDY_ID="STD-Holden-1968" TOTAL_1="8" TOTAL_2="8" VAR="2.444444444444444" WEIGHT="24.21756162506066"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-24 06:20:45 +0100" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="0.0" STUDY_ID="STD-Lingjaerde-1979" TOTAL_1="11" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="68.25874292736694" CI_START="0.13185124152633113" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.87991577648491" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="665" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Morphy-1986" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="23.291206808801512"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="666" O_E="0.0" SE="0.0" STUDY_ID="STD-Pujalte-1994" TOTAL_1="6" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-003.06" MODIFIED="2011-05-24 06:23:57 +0100" MODIFIED_BY="[Empty name]" NO="6" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Global state: 2. Mean CGI severity score - short term (high=poor)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-05-24 06:23:57 +0100" MODIFIED_BY="[Empty name]" ORDER="190" STUDY_ID="STD-Lingjaerde-1982">
<TR>
<TD>
<P>Adjunctive benzodiazepines + antipsychotics<BR/>
</P>
</TD>
<TD>
<P>4.60</P>
</TD>
<TD>
<P>5.16</P>
</TD>
<TD>
<P>22</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo/no adjunctive treatment</P>
</TD>
<TD>
<P>4.55</P>
</TD>
<TD>
<P>4.30</P>
</TD>
<TD>
<P>29</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="2.9332732756569886" CI_END="1.6068113110596387" CI_START="-4.212953450866994" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.3030710699036778" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.07" MODIFIED="2011-06-07 08:18:43 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.40202811106015235" P_Q="0.40202811106015235" P_Z="0.38011241129770434" Q="2.9332732756569886" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="92" TOTAL_2="98" UNITS="" WEIGHT="400.0" Z="0.8776892093699648">
<NAME>Mental state: 1. General - ultra short term (various scales)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.6380720627708767" CI_START="-8.858072062770876" DF="0" EFFECT_SIZE="-3.1099999999999994" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.01" MODIFIED="2011-05-24 10:50:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.28894429432980373" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="14" WEIGHT="100.0" Z="1.060440426869182">
<NAME>Mean BPRS score after 1 hour (high = poor)</NAME>
<CONT_DATA CI_END="2.6380720627708767" CI_START="-8.858072062770876" EFFECT_SIZE="-3.1099999999999994" ESTIMABLE="YES" MEAN_1="31.46" MEAN_2="34.57" MODIFIED="2011-05-24 10:50:16 +0100" MODIFIED_BY="[Empty name]" ORDER="262" SD_1="7.37" SD_2="8.13" SE="2.932743717798355" STUDY_ID="STD-Barbee-1992" TOTAL_1="14" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5073019995046897" CI_START="-9.50730199950469" DF="0" EFFECT_SIZE="-4.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.02" MODIFIED="2011-05-24 10:49:21 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.15458013535265988" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="35" WEIGHT="100.0" Z="1.4235384111612748">
<NAME>Mean MBPRS after 1 hour (high = poor)</NAME>
<CONT_DATA CI_END="1.5073019995046897" CI_START="-9.50730199950469" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="35.0" MEAN_2="39.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="680" SD_1="11.0" SD_2="12.0" SE="2.809899591495346" STUDY_ID="STD-Battaglia-1997" TOTAL_1="32" TOTAL_2="35" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.2731383528901254" CI_START="-3.2731383528901254" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.03" MODIFIED="2011-05-24 10:49:20 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.45725367767877" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="35" WEIGHT="100.0" Z="0.7433766585949062">
<NAME>Mean MBPRS after 12 hours (high = poor)</NAME>
<CONT_DATA CI_END="7.2731383528901254" CI_START="-3.2731383528901254" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="34.0" MEAN_2="32.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="681" SD_1="11.0" SD_2="11.0" SE="2.6904261478700464" STUDY_ID="STD-Battaglia-1997" TOTAL_1="32" TOTAL_2="35" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.283924412580875" CI_START="-7.263924412580879" DF="0" EFFECT_SIZE="0.00999999999999801" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.04" MODIFIED="2011-05-24 10:51:05 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.9978500971110812" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="14" WEIGHT="100.0" Z="0.002694506944765247">
<NAME>Mean BPRS score after 24 hours (high = poor)</NAME>
<CONT_DATA CI_END="7.283924412580875" CI_START="-7.263924412580879" EFFECT_SIZE="0.00999999999999801" ESTIMABLE="YES" MEAN_1="24.86" MEAN_2="24.85" MODIFIED="2011-05-24 10:51:05 +0100" MODIFIED_BY="[Empty name]" ORDER="263" SD_1="11.91" SD_2="7.14" SE="3.711254119951522" STUDY_ID="STD-Barbee-1992" TOTAL_1="14" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="11.084725901140693" CI_END="0.8972080521135812" CI_START="-3.8658840329367656" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.484337990411592" ESTIMABLE="YES" I2="63.91430843059121" I2_Q="63.91430843059121" ID="CMP-003.08" MODIFIED="2011-06-07 08:18:57 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.025628159097684344" P_Q="0.025628159097684344" P_Z="0.22186652052483313" Q="11.084725901140693" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="15.505372669587299" TOTALS="SUB" TOTAL_1="149" TOTAL_2="145" UNITS="" WEIGHT="500.0" Z="1.221579994735932">
<NAME>Mental state: 1. General - short term (various scales)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.863557230567177" CI_START="-3.863557230567177" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.01" MODIFIED="2011-05-24 10:49:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5037992548439967" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="14" WEIGHT="100.0" Z="0.6685238695454734">
<NAME>Mean BPRS score at 2 days (high = poor)</NAME>
<CONT_DATA CI_END="7.863557230567177" CI_START="-3.863557230567177" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="21.25" MEAN_2="19.25" MODIFIED="2011-05-24 10:49:05 +0100" MODIFIED_BY="[Empty name]" ORDER="261" SD_1="10.0" SD_2="5.03" SE="2.991665804483229" STUDY_ID="STD-Barbee-1992" TOTAL_1="14" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="13.299755876790982" CI_START="0.3202441232090161" DF="0" EFFECT_SIZE="6.809999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.02" MODIFIED="2011-05-19 16:12:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.03971696357178366" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="14" WEIGHT="99.99999999999999" Z="2.0566805575000595">
<NAME>Mean BPRS score at 3 days (high = poor)</NAME>
<CONT_DATA CI_END="13.299755876790982" CI_START="0.3202441232090161" EFFECT_SIZE="6.809999999999999" ESTIMABLE="YES" MEAN_1="27.11" MEAN_2="20.3" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="682" SD_1="10.59" SD_2="6.43" SE="3.3111607804946157" STUDY_ID="STD-Barbee-1992" TOTAL_1="14" TOTAL_2="14" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.1468494198699819" CI_START="-12.54684941986996" DF="0" EFFECT_SIZE="-6.199999999999989" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.03" MODIFIED="2011-05-19 16:12:22 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.0555415483231974" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="1.9146155675452075">
<NAME>Mean PANSS at 2 weeks (high = poor)</NAME>
<CONT_DATA CI_END="0.1468494198699819" CI_START="-12.54684941986996" EFFECT_SIZE="-6.199999999999989" ESTIMABLE="YES" MEAN_1="70.4" MEAN_2="76.6" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="683" SD_1="16.3" SD_2="12.4" SE="3.2382479830920916" STUDY_ID="STD-Wang-2003" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.929783601298482" CI_START="-14.929783601298482" DF="0" EFFECT_SIZE="-4.5" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.04" MODIFIED="2011-05-19 16:12:23 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.3977538411446717" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="29" WEIGHT="100.0" Z="0.8456395901955431">
<NAME>Mean percentage BPRS reduction at 28 days (low = poor)</NAME>
<CONT_DATA CI_END="5.929783601298482" CI_START="-14.929783601298482" EFFECT_SIZE="-4.5" ESTIMABLE="YES" MEAN_1="64.1" MEAN_2="68.6" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="684" SD_1="22.9" SD_2="18.6" SE="5.3214159461945645" STUDY_ID="STD-Stevens-1992" TOTAL_1="32" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.1432746737549322" CI_START="-6.543274673754931" DF="0" EFFECT_SIZE="-3.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.05" MODIFIED="2011-05-19 16:12:56 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.060659327132923234" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="48" WEIGHT="100.0" Z="1.875970526670497">
<NAME>Mean BPRS at 8 weeks (high = poor)</NAME>
<CONT_DATA CI_END="0.1432746737549322" CI_START="-6.543274673754931" EFFECT_SIZE="-3.1999999999999993" ESTIMABLE="YES" MEAN_1="30.8" MEAN_2="34.0" MODIFIED="2011-05-19 16:12:56 +0100" MODIFIED_BY="[Empty name]" ORDER="786" SD_1="6.2" SD_2="10.1" SE="1.705783728745148" STUDY_ID="STD-Xuan-2007" TOTAL_1="49" TOTAL_2="48" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-003.09" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="9" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Mental state: 2a. Specific - anxiety - short term (skewed data)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-003.09.01" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>Summary of mean HAM-A score at 4 weeks</NAME>
<OTHER_DATA MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="200" STUDY_ID="STD-Morphy-1986">
<TR>
<TD>
<P>Adjunctive benzodiazepines + antipsychotics</P>
</TD>
<TD>
<P>0.96</P>
</TD>
<TD>
<P>0.65</P>
</TD>
<TD>
<P>13</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo/no adjunctive treatment + antipsychotics</P>
</TD>
<TD>
<P>1.29</P>
</TD>
<TD>
<P>0.38</P>
</TD>
<TD>
<P>15</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-003.09.02" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="2" STUDIES="1">
<NAME>Hamilton Anxiety Score (total difference from baseline to 4 weeks)</NAME>
<OTHER_DATA MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="201" STUDY_ID="STD-Guz-1972">
<TR>
<TD>
<P>Adjunctive benzodiazepines + antipsychotics</P>
</TD>
<TD>
<P>15.47</P>
</TD>
<TD>
<P>11.23</P>
</TD>
<TD>
<P>30</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo/no adjunctive treatment + antipsychotics</P>
</TD>
<TD>
<P>12.5</P>
</TD>
<TD>
<P>11.23</P>
</TD>
<TD>
<P>30</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-003.10" MODIFIED="2011-05-24 10:54:02 +0100" MODIFIED_BY="[Empty name]" NO="10" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mental state: 2b. Specific - negative symptoms (SANS score at endpoint) - short term (skewed data)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-05-24 10:54:02 +0100" MODIFIED_BY="[Empty name]" ORDER="202" STUDY_ID="STD-Barbee-1992">
<TR>
<TD>
<P>Benzodiazepines + antipsychotics<BR/>
</P>
</TD>
<TD>
<P>23.31</P>
</TD>
<TD>
<P>11.66</P>
</TD>
<TD>
<P>14</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo + antipsychotics</P>
</TD>
<TD>
<P>20.92</P>
</TD>
<TD>
<P>11.47</P>
</TD>
<TD>
<P>14</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="5.61642924646571" CI_END="1.6788368778934635" CI_START="1.065584093433354" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.337513316775795" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="40" I2="64.39018614436291" I2_Q="64.31809596216891" ID="CMP-003.11" LOG_CI_END="0.22500850050236" LOG_CI_START="0.027587728919243024" LOG_EFFECT_SIZE="0.12629811471080146" METHOD="MH" MODIFIED="2011-06-03 09:33:41 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.06031262854238795" P_Q="0.060655788914100506" P_Z="0.01215068254699402" Q="5.605082054700715" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.09986029223306732" TOTALS="SUB" TOTAL_1="80" TOTAL_2="77" WEIGHT="300.0" Z="2.507737703215911">
<NAME>Mental state: 3. Specific - sedation - ultra short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.299041289561695" CI_START="1.177588131635773" DF="0" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="7" I2="0.0" ID="CMP-003.11.01" LOG_CI_END="0.6333716162597592" LOG_CI_START="0.07099341996296582" LOG_EFFECT_SIZE="0.3521825181113625" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.014096012668492029" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="21" WEIGHT="100.0" Z="2.454807302374897">
<NAME>Tranquilized at 30 minutes</NAME>
<DICH_DATA CI_END="4.299041289561695" CI_START="1.177588131635773" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="7" LOG_CI_END="0.6333716162597592" LOG_CI_START="0.07099341996296582" LOG_EFFECT_SIZE="0.3521825181113625" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="688" O_E="0.0" SE="0.33034373632170494" STUDY_ID="STD-Garza_x002d_Trevino-1989" TOTAL_1="24" TOTAL_2="21" VAR="0.10912698412698413" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8336952031938554" CI_START="1.0551324209907722" DF="0" EFFECT_SIZE="1.3909677419354838" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="15" I2="0.0" ID="CMP-003.11.02" LOG_CI_END="0.26332714890662945" LOG_CI_START="0.02330696778218968" LOG_EFFECT_SIZE="0.14331705834440958" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.01925250043442901" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="21" WEIGHT="100.0" Z="2.3406054558357017">
<NAME>Tranquilized at 60 minutes</NAME>
<DICH_DATA CI_END="1.8336952031938554" CI_START="1.0551324209907722" EFFECT_SIZE="1.3909677419354838" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="15" LOG_CI_END="0.26332714890662945" LOG_CI_START="0.02330696778218968" LOG_EFFECT_SIZE="0.14331705834440958" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="689" O_E="0.0" SE="0.1409890425115542" STUDY_ID="STD-Garza_x002d_Trevino-1989" TOTAL_1="24" TOTAL_2="21" VAR="0.019877910108324834" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.413738242373146" CI_START="0.5118918171116655" DF="0" EFFECT_SIZE="0.8506944444444444" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" I2="0.0" ID="CMP-003.11.03" LOG_CI_END="0.15036900605468123" LOG_CI_START="-0.29082181284407804" LOG_EFFECT_SIZE="-0.07022640339469839" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5326582949796707" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="35" WEIGHT="100.0" Z="0.6239532443623902">
<NAME>Asleep at 12 hours</NAME>
<DICH_DATA CI_END="1.413738242373146" CI_START="0.5118918171116655" EFFECT_SIZE="0.8506944444444444" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="0.15036900605468123" LOG_CI_START="-0.29082181284407804" LOG_EFFECT_SIZE="-0.07022640339469839" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="690" O_E="0.0" SE="0.25915767095090664" STUDY_ID="STD-Battaglia-1997" TOTAL_1="32" TOTAL_2="35" VAR="0.06716269841269841" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="15" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>Behaviour: 1. Specific -aggression - ultra short term (needing restraints within 120 minutes)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="691" O_E="0.0" SE="0.0" STUDY_ID="STD-Dorevitch-1999" TOTAL_1="15" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.6216849636116936" CI_END="2.2286718874634697" CI_START="-5.22867188746347" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.13" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.43042203677967106" P_Q="0.43042203677967106" P_Z="0.43042183827006564" Q="0.6216849636116936" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="64" TOTAL_2="70" UNITS="" WEIGHT="200.0" Z="0.7884700144023826">
<NAME>Behaviour: 2. Specific - aggression - ultra short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.2731383528901254" CI_START="-8.273138352890125" DF="0" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.13.01" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.26482259170756484" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="35" WEIGHT="100.0" Z="1.1150649878923593">
<NAME>Mean ABS at 1 hour (high = poor)</NAME>
<CONT_DATA CI_END="2.2731383528901254" CI_START="-8.273138352890125" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="25.0" MEAN_2="28.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="692" SD_1="11.0" SD_2="11.0" SE="2.6904261478700464" STUDY_ID="STD-Battaglia-1997" TOTAL_1="32" TOTAL_2="35" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.2731383528901254" CI_START="-5.2731383528901254" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.13.02" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="35" WEIGHT="100.0" Z="0.0">
<NAME>Mean ABS at 12 hours (high = poor)</NAME>
<CONT_DATA CI_END="5.2731383528901254" CI_START="-5.2731383528901254" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="19.0" MEAN_2="19.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="693" SD_1="11.0" SD_2="11.0" SE="2.6904261478700464" STUDY_ID="STD-Battaglia-1997" TOTAL_1="32" TOTAL_2="35" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5018371111820334" CI_START="0.5393394489782468" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-003.14" LOG_CI_END="0.17662283176869495" LOG_CI_START="-0.26813781289004524" LOG_EFFECT_SIZE="-0.045757490560675115" METHOD="MH" MODIFIED="2011-05-24 10:54:58 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.6867373020058279" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="14" WEIGHT="100.0" Z="0.40328673230819473">
<NAME>Service use: 1. Still in hospital - short term (at 3 days)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5018371111820334" CI_START="0.5393394489782468" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.17662283176869495" LOG_CI_START="-0.26813781289004524" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2011-05-24 10:54:58 +0100" MODIFIED_BY="[Empty name]" ORDER="694" O_E="0.0" SE="0.261254604273242" STUDY_ID="STD-Barbee-1992" TOTAL_1="14" TOTAL_2="14" VAR="0.06825396825396826" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1133799012442496" CI_END="1.5327972057550547" CI_START="0.5435682901886434" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.912786917269417" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-003.15" LOG_CI_END="0.18548470002891926" LOG_CI_START="-0.2647458863725332" LOG_EFFECT_SIZE="-0.03963059317180694" METHOD="MH" MODIFIED="2011-05-23 09:15:36 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.7363285417435355" P_Q="0.7383097076842422" P_Z="0.7300617803507319" Q="0.11161788137322907" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="75" WEIGHT="100.00000000000001" Z="0.3450433517790431">
<NAME>Adverse effects: 1. total number of participants with adverse-effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6096140589770664" CI_START="0.4588214090863147" DF="0" EFFECT_SIZE="0.859375" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" I2="0.0" ID="CMP-003.15.01" LOG_CI_END="0.20672175668441697" LOG_CI_START="-0.3383563256637036" LOG_EFFECT_SIZE="-0.06581728448964333" MODIFIED="2011-05-23 08:27:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6359814206501624" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="35" WEIGHT="68.22641509433963" Z="0.47332487339874574">
<NAME>ultra short term</NAME>
<DICH_DATA CI_END="1.6096140589770664" CI_START="0.4588214090863147" EFFECT_SIZE="0.859375" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.20672175668441697" LOG_CI_START="-0.3383563256637036" LOG_EFFECT_SIZE="-0.06581728448964333" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="695" O_E="0.0" SE="0.32018156375130935" STUDY_ID="STD-Battaglia-1997" TOTAL_1="32" TOTAL_2="35" VAR="0.10251623376623377" WEIGHT="68.22641509433963"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.605949526548887" CI_START="0.4142213920422803" DF="0" EFFECT_SIZE="1.0389610389610389" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-003.15.02" LOG_CI_END="0.4159659998057362" LOG_CI_START="-0.38276747616681284" LOG_EFFECT_SIZE="0.016599261819461673" MODIFIED="2011-05-19 15:57:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9350730662508375" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="40" WEIGHT="31.773584905660382" Z="0.0814638582575543">
<NAME>short term</NAME>
<DICH_DATA CI_END="2.605949526548887" CI_START="0.41422139204228026" EFFECT_SIZE="1.0389610389610389" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4159659998057362" LOG_CI_START="-0.3827674761668129" LOG_EFFECT_SIZE="0.016599261819461673" MODIFIED="2011-05-19 15:56:17 +0100" MODIFIED_BY="[Empty name]" ORDER="752" O_E="0.0" SE="0.4691799975807474" STUDY_ID="STD-Kurland-1966" TOTAL_1="44" TOTAL_2="40" VAR="0.22012987012987012" WEIGHT="31.773584905660382"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.6408801933394384" CI_START="-0.4208801933394395" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6099999999999994" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.16" MODIFIED="2011-06-07 08:19:42 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.24614480874875821" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="60" UNITS="" WEIGHT="100.0" Z="1.159764285213852">
<NAME>Adverse effects: 2. TESS score - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.6408801933394384" CI_START="-0.4208801933394395" EFFECT_SIZE="0.6099999999999994" ESTIMABLE="YES" MEAN_1="6.56" MEAN_2="5.95" MODIFIED="2011-05-19 15:54:35 +0100" MODIFIED_BY="[Empty name]" ORDER="748" SD_1="2.81" SD_2="2.95" SE="0.5259689471188707" STUDY_ID="STD-Ma-2006" TOTAL_1="60" TOTAL_2="60" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.8698689779204765" CI_START="0.01411854649967386" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.17" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" MODIFIED="2011-05-23 09:37:45 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.49584060533880536" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>Adverse effects: 3. Anorexia - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="697" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Guz-1972" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.747402764426775" CI_START="0.24001645309697386" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3636363636363635" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.18" LOG_CI_END="0.889156134232018" LOG_CI_START="-0.6197589864371057" LOG_EFFECT_SIZE="0.13469857389745618" METHOD="MH" MODIFIED="2011-06-07 08:20:31 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.72639419743841" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="40" WEIGHT="100.00000000000001" Z="0.34992604950615014">
<NAME>Adverse effects: 4. Allergic reaction - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.747402764426775" CI_START="0.24001645309697386" EFFECT_SIZE="1.3636363636363635" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.889156134232018" LOG_CI_START="-0.6197589864371057" LOG_EFFECT_SIZE="0.13469857389745618" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="698" O_E="0.0" SE="0.8863442111313531" STUDY_ID="STD-Kurland-1966" TOTAL_1="44" TOTAL_2="40" VAR="0.7856060606060605" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.004477683753358" CI_END="9.041520824079887" CI_START="0.10156048308812522" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9582594756875077" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.4457723477366431" I2_Q="0.0" ID="CMP-003.19" LOG_CI_END="0.9562414868862509" LOG_CI_START="-0.9932752420046164" LOG_EFFECT_SIZE="-0.01851687755918278" METHOD="MH" MODIFIED="2011-06-07 08:21:21 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.3162297214692843" P_Q="1.0" P_Z="0.9702998524530687" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.011691690656420842" TOTALS="YES" TOTAL_1="74" TOTAL_2="70" WEIGHT="100.0" Z="0.03723221512726787">
<NAME>Adverse effects: 5. Blurred vision - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="700" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Guz-1972" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="50.17065448620602"/>
<DICH_DATA CI_END="7.248604458849704" CI_START="0.012724647919053953" EFFECT_SIZE="0.3037037037037037" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8602544018593217" LOG_CI_START="-1.8953542254098628" LOG_EFFECT_SIZE="-0.5175499117752707" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="699" O_E="0.0" SE="1.618658148140615" STUDY_ID="STD-Kurland-1966" TOTAL_1="44" TOTAL_2="40" VAR="2.6200542005420053" WEIGHT="49.82934551379398"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.22350148126667063" CI_END="12.111666904055964" CI_START="0.19392273144584307" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5325558810029571" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.20" LOG_CI_END="1.0832039183218107" LOG_CI_START="-0.712371280334028" LOG_EFFECT_SIZE="0.1854163189938914" METHOD="MH" MODIFIED="2011-05-23 09:37:59 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.63638483783131" P_Q="1.0" P_Z="0.6856369044085102" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="70" WEIGHT="100.0" Z="0.40478316658201113">
<NAME>Adverse effects: 6. Cardiovascular reactions - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="702" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-Guz-1972" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="57.54076895607666"/>
<DICH_DATA CI_END="65.23744012964735" CI_START="0.11452183127148555" EFFECT_SIZE="2.7333333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8144969112986467" LOG_CI_START="-0.941111715970538" LOG_EFFECT_SIZE="0.43669259766405427" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="701" O_E="0.0" SE="1.618658148140615" STUDY_ID="STD-Kurland-1966" TOTAL_1="44" TOTAL_2="40" VAR="2.6200542005420053" WEIGHT="42.459231043923346"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.21" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-06-07 08:21:51 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="44" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 7. Chills - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="703" O_E="0.0" SE="0.0" STUDY_ID="STD-Kurland-1966" TOTAL_1="44" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.8698689779204765" CI_START="0.01411854649967386" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.22" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" MODIFIED="2011-05-23 09:38:09 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="1.0" P_Q="1.0" P_Z="0.49584060533880536" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>Adverse effects: 8. Confusion - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="704" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Guz-1972" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.259760455310136" CI_START="0.0655318281652329" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.23" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2011-05-23 09:38:13 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.0">
<NAME>Adverse effects: 9. Depression - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="705" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-Guz-1972" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="70.82882080128432" CI_START="0.12706691849706483" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.24" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" MODIFIED="2011-05-23 09:38:18 +0100" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="1.0" P_Q="1.0" P_Z="0.49584060533880536" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>Adverse effects: 10. Diarrhoea - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="706" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Guz-1972" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.0649420881770992" CI_END="4.370062802999185" CI_START="0.8820281625021427" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9632927606825057" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" I2="2.1188683606000565" I2_Q="39.24914021829158" ID="CMP-003.25" LOG_CI_END="0.6404876783434207" LOG_CI_START="-0.0545175479475288" LOG_EFFECT_SIZE="0.292985065197946" METHOD="MH" MODIFIED="2011-06-07 08:22:18 +0100" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.3817206052363472" P_Q="0.19949511332481118" P_Z="0.0984372913323245" Q="1.6460672385431683" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.02033798060965013" TOTALS="YES" TOTAL_1="124" TOTAL_2="133" WEIGHT="100.0" Z="1.6524772881512115">
<NAME>Adverse effects: 11. Dizziness</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.087469507620745" CI_START="0.13007657348550183" DF="0" EFFECT_SIZE="0.7291666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-003.25.01" LOG_CI_END="0.6114545258588145" LOG_CI_START="-0.8858009119094377" LOG_EFFECT_SIZE="-0.1371731930253116" MODIFIED="2011-05-19 16:00:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7194979951271216" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="35" WEIGHT="20.994858813283244" Z="0.35912979334336603">
<NAME>ultra short term</NAME>
<DICH_DATA CI_END="4.087469507620745" CI_START="0.13007657348550183" EFFECT_SIZE="0.7291666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6114545258588145" LOG_CI_START="-0.8858009119094377" LOG_EFFECT_SIZE="-0.1371731930253116" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="708" O_E="0.0" SE="0.87949525567902" STUDY_ID="STD-Battaglia-1997" TOTAL_1="32" TOTAL_2="35" VAR="0.7735119047619047" WEIGHT="20.994858813283244"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4241918906407" CI_END="6.149818507816681" CI_START="1.082224141574532" DF="2" EFFECT_SIZE="2.5798220976379507" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" I2="0.0" ID="CMP-003.25.02" LOG_CI_END="0.7888622991548008" LOG_CI_START="0.03431721767239126" LOG_EFFECT_SIZE="0.411589758413596" MODIFIED="2011-05-24 06:26:18 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4906148857435775" P_Z="0.03249686836760232" STUDIES="3" TAU2="0.0" TOTAL_1="92" TOTAL_2="98" WEIGHT="79.00514118671676" Z="2.1382449443877163">
<NAME>short term</NAME>
<DICH_DATA CI_END="9.602236874559962" CI_START="0.017285638521392088" EFFECT_SIZE="0.4074074074074074" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9823724152392092" LOG_CI_START="-1.7623145732407337" LOG_EFFECT_SIZE="-0.3899710790007623" MODIFIED="2011-05-24 06:26:18 +0100" MODIFIED_BY="[Empty name]" ORDER="254" O_E="0.0" SE="1.6122427234528303" STUDY_ID="STD-Lingjaerde-1982" TOTAL_1="26" TOTAL_2="32" VAR="2.599326599326599" WEIGHT="6.362175673162889"/>
<DICH_DATA CI_END="7.7319789505847645" CI_START="1.1639969608711023" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.8882906630418067" LOG_CI_START="0.0659518463975182" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-05-19 15:59:15 +0100" MODIFIED_BY="[Empty name]" ORDER="756" O_E="0.0" SE="0.48304589153964794" STUDY_ID="STD-Ma-2006" TOTAL_1="60" TOTAL_2="60" VAR="0.23333333333333334" WEIGHT="65.70221127195718"/>
<DICH_DATA CI_END="61.7381697935959" CI_START="0.14577691612966426" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7905537508292086" LOG_CI_START="-0.8363112413898837" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-05-19 15:59:15 +0100" MODIFIED_BY="[Empty name]" ORDER="755" O_E="0.0" SE="1.5430334996209192" STUDY_ID="STD-Pujalte-1994" TOTAL_1="6" TOTAL_2="6" VAR="2.380952380952381" WEIGHT="6.940754241596676"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.376969506605776" CI_END="2.046957068228084" CI_START="0.13428948424790316" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5242945822435602" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.26" LOG_CI_END="0.31110873410013856" LOG_CI_START="-0.8719579941214153" LOG_EFFECT_SIZE="-0.2804246300106384" METHOD="MH" MODIFIED="2011-06-07 08:22:32 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.5392298901041267" P_Q="0.5405969130893291" P_Z="0.35281228615072235" Q="0.37443511894854875" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="75" WEIGHT="100.0" Z="0.9291482248428055">
<NAME>Adverse effects: 12. Drowsiness</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.087469507620745" CI_START="0.13007657348550183" DF="0" EFFECT_SIZE="0.7291666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-003.26.01" LOG_CI_END="0.6114545258588145" LOG_CI_START="-0.8858009119094377" LOG_EFFECT_SIZE="-0.1371731930253116" MODIFIED="2011-05-19 16:00:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7194979951271216" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="35" WEIGHT="62.43479403455753" Z="0.35912979334336603">
<NAME>ultra short term</NAME>
<DICH_DATA CI_END="4.087469507620745" CI_START="0.13007657348550183" EFFECT_SIZE="0.7291666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6114545258588145" LOG_CI_START="-0.8858009119094377" LOG_EFFECT_SIZE="-0.1371731930253116" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="711" O_E="0.0" SE="0.87949525567902" STUDY_ID="STD-Battaglia-1997" TOTAL_1="32" TOTAL_2="35" VAR="0.7735119047619047" WEIGHT="62.43479403455753"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7965157245879086" CI_START="0.03283634836995915" DF="0" EFFECT_SIZE="0.30303030303030304" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-003.26.02" LOG_CI_END="0.44661726567483706" LOG_CI_START="-1.4836451454306119" LOG_EFFECT_SIZE="-0.5185139398778875" MODIFIED="2011-05-19 16:01:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.2923478988314847" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="40" WEIGHT="37.56520596544248" Z="1.0529849639051054">
<NAME>short term</NAME>
<DICH_DATA CI_END="2.7965157245879086" CI_START="0.03283634836995915" EFFECT_SIZE="0.30303030303030304" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.44661726567483706" LOG_CI_START="-1.4836451454306119" LOG_EFFECT_SIZE="-0.5185139398778875" MODIFIED="2011-05-19 16:00:37 +0100" MODIFIED_BY="[Empty name]" ORDER="758" O_E="0.0" SE="1.133845695236376" STUDY_ID="STD-Kurland-1966" TOTAL_1="44" TOTAL_2="40" VAR="1.2856060606060606" WEIGHT="37.56520596544248"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6853486500727942" CI_END="6.974032545886952" CI_START="0.3799581139203867" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6278329928326796" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.27" LOG_CI_END="0.8434839697772865" LOG_CI_START="-0.4202642767933945" LOG_EFFECT_SIZE="0.21160984649194597" METHOD="MH" MODIFIED="2011-10-13 10:02:10 +0100" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.7098694422241738" P_Q="0.40954126824714876" P_Z="0.511581552272145" Q="0.6801330604406218" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="137" WEIGHT="100.00000000000001" Z="0.6563770577308049">
<NAME>Adverse effects: 13. Dryness of mouth</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="29.965403637219076" CI_START="0.359301069087791" DF="0" EFFECT_SIZE="3.28125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-003.27.01" LOG_CI_END="1.4766201320654186" LOG_CI_START="-0.4445414905653545" LOG_EFFECT_SIZE="0.5160393207500321" MODIFIED="2011-05-19 16:01:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.292375891923211" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="35" WEIGHT="43.27064082179362" Z="1.0529238887164256">
<NAME>ultra short term</NAME>
<DICH_DATA CI_END="29.965403637219076" CI_START="0.359301069087791" EFFECT_SIZE="3.28125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4766201320654186" LOG_CI_START="-0.4445414905653545" LOG_EFFECT_SIZE="0.5160393207500321" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="714" O_E="0.0" SE="1.128499847036722" STUDY_ID="STD-Battaglia-1997" TOTAL_1="32" TOTAL_2="35" VAR="1.2735119047619048" WEIGHT="43.27064082179362"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.002337910414277316" CI_END="6.581672792524188" CI_START="0.13818878084699635" DF="1" EFFECT_SIZE="0.9536840877003052" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-003.27.02" LOG_CI_END="0.8183362875704058" LOG_CI_START="-0.859527214660985" LOG_EFFECT_SIZE="-0.020595463545289617" MODIFIED="2011-10-13 10:02:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9614357722656508" P_Z="0.9616234845014144" STUDIES="3" TAU2="0.0" TOTAL_1="100" TOTAL_2="102" WEIGHT="56.729359178206394" Z="0.04811638937254668">
<NAME>short term</NAME>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 16:01:33 +0100" MODIFIED_BY="[Empty name]" ORDER="763" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-Guz-1972" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="28.50293597236067"/>
<DICH_DATA CI_END="14.058470058579275" CI_START="0.05878635993447888" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1479380602805238" LOG_CI_START="-1.2307234305969739" LOG_EFFECT_SIZE="-0.04139268515822506" MODIFIED="2011-05-19 16:01:33 +0100" MODIFIED_BY="[Empty name]" ORDER="761" O_E="0.0" SE="1.3972375343057197" STUDY_ID="STD-Kurland-1966" TOTAL_1="44" TOTAL_2="40" VAR="1.9522727272727274" WEIGHT="28.22642320584572"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-10-13 10:02:10 +0100" MODIFIED_BY="[Empty name]" ORDER="255" O_E="0.0" SE="0.0" STUDY_ID="STD-Lingjaerde-1982" TOTAL_1="26" TOTAL_2="32" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.8698689779204765" CI_START="0.01411854649967386" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.28" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" MODIFIED="2011-05-23 09:38:41 +0100" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="1.0" P_Q="1.0" P_Z="0.49584060533880536" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>Adverse effects: 14. Excitation - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="716" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Guz-1972" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.248604458849704" CI_START="0.012724647919053953" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3037037037037037" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.29" LOG_CI_END="0.8602544018593217" LOG_CI_START="-1.8953542254098628" LOG_EFFECT_SIZE="-0.5175499117752707" METHOD="MH" MODIFIED="2011-05-23 09:38:52 +0100" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="1.0" P_Q="1.0" P_Z="0.4615914867279396" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="40" WEIGHT="99.99999999999999" Z="0.7362287788209354">
<NAME>Adverse effects: 15. Gastrointestinal reactions - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.248604458849704" CI_START="0.012724647919053953" EFFECT_SIZE="0.3037037037037037" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8602544018593217" LOG_CI_START="-1.8953542254098628" LOG_EFFECT_SIZE="-0.5175499117752707" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="717" O_E="0.0" SE="1.618658148140615" STUDY_ID="STD-Kurland-1966" TOTAL_1="44" TOTAL_2="40" VAR="2.6200542005420053" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8258975497708292" CI_END="14.931206378388163" CI_START="0.04124041518193708" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7847095961003122" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="45.23241459382476" I2_Q="0.0" ID="CMP-003.30" LOG_CI_END="1.17409489830179" LOG_CI_START="-1.3846769711693983" LOG_EFFECT_SIZE="-0.10529103643380405" METHOD="MH" MODIFIED="2011-06-07 08:23:31 +0100" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="0.17661303911865756" P_Q="1.0" P_Z="0.8718560841878003" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="2.045217233663418" TOTALS="YES" TOTAL_1="70" TOTAL_2="72" WEIGHT="100.0" Z="0.16130131940820475">
<NAME>Adverse effects: 16. Headache - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6847560641029866" CI_START="0.009011434595382995" EFFECT_SIZE="0.18222222222222223" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5664087422573171" LOG_CI_START="-2.045206065040571" LOG_EFFECT_SIZE="-0.739398661391627" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="719" O_E="0.0" SE="1.5340754655085709" STUDY_ID="STD-Kurland-1966" TOTAL_1="44" TOTAL_2="40" VAR="2.3533875338753387" WEIGHT="51.3598088249754"/>
<DICH_DATA CI_END="86.42013187103964" CI_START="0.1555707466925288" EFFECT_SIZE="3.6666666666666665" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.936614924678534" LOG_CI_START="-0.8080720638014088" LOG_EFFECT_SIZE="0.5642714304385625" MODIFIED="2011-05-24 06:29:05 +0100" MODIFIED_BY="[Empty name]" ORDER="256" O_E="0.0" SE="1.6122427234528303" STUDY_ID="STD-Lingjaerde-1982" TOTAL_1="26" TOTAL_2="32" VAR="2.599326599326599" WEIGHT="48.6401911750246"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6916561940581674" CI_END="14.90955867951992" CI_START="0.2617844473875105" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9756240987874651" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.31" LOG_CI_END="1.1734647885981442" LOG_CI_START="-0.5820561584514938" LOG_EFFECT_SIZE="0.29570431507332523" METHOD="MH" MODIFIED="2011-05-23 09:39:02 +0100" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="0.4056020171103224" P_Q="1.0" P_Z="0.509072615173088" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="70" WEIGHT="100.0" Z="0.6602824176958277">
<NAME>Adverse effects: 17. Increased salivation - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="99.95416281504153" CI_START="0.25011464551267176" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9998008859974516" LOG_CI_START="-0.6018608773254143" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="721" O_E="0.0" SE="1.5282289982092807" STUDY_ID="STD-Guz-1972" TOTAL_1="30" TOTAL_2="30" VAR="2.335483870967742" WEIGHT="45.531332820381294"/>
<DICH_DATA CI_END="14.058470058579275" CI_START="0.05878635993447888" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1479380602805238" LOG_CI_START="-1.2307234305969739" LOG_EFFECT_SIZE="-0.04139268515822506" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="720" O_E="0.0" SE="1.3972375343057197" STUDY_ID="STD-Kurland-1966" TOTAL_1="44" TOTAL_2="40" VAR="1.9522727272727274" WEIGHT="54.4686671796187"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.165926702848663" CI_END="5.438430165383165" CI_START="0.41410009225177613" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5006846548125996" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.32" LOG_CI_END="0.7354735561502672" LOG_CI_START="-0.38289467274699923" LOG_EFFECT_SIZE="0.17628944170163405" METHOD="MH" MODIFIED="2011-06-07 08:24:13 +0100" MODIFIED_BY="[Empty name]" NO="32" P_CHI2="0.6837577860203746" P_Q="1.0" P_Z="0.5366399747632934" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="70" WEIGHT="100.00000000000001" Z="0.6179019533317159">
<NAME>Adverse effects: 18. Insomnia - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.454794518074456" CI_START="0.32591104429087336" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.736778395374003" LOG_CI_START="-0.4869009221574032" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="722" O_E="0.0" SE="0.7187952884282608" STUDY_ID="STD-Guz-1972" TOTAL_1="30" TOTAL_2="30" VAR="0.5166666666666666" WEIGHT="83.52844615318158"/>
<DICH_DATA CI_END="65.23744012964735" CI_START="0.11452183127148555" EFFECT_SIZE="2.7333333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8144969112986467" LOG_CI_START="-0.941111715970538" LOG_EFFECT_SIZE="0.43669259766405427" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="723" O_E="0.0" SE="1.618658148140615" STUDY_ID="STD-Kurland-1966" TOTAL_1="44" TOTAL_2="40" VAR="2.6200542005420053" WEIGHT="16.471553846818438"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.248604458849704" CI_START="0.012724647919053953" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3037037037037037" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.33" LOG_CI_END="0.8602544018593217" LOG_CI_START="-1.8953542254098628" LOG_EFFECT_SIZE="-0.5175499117752707" METHOD="MH" MODIFIED="2011-05-23 09:39:16 +0100" MODIFIED_BY="[Empty name]" NO="33" P_CHI2="1.0" P_Q="1.0" P_Z="0.4615914867279396" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="40" WEIGHT="99.99999999999999" Z="0.7362287788209354">
<NAME>Adverse effects: 19. Lactation - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.248604458849704" CI_START="0.012724647919053953" EFFECT_SIZE="0.3037037037037037" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8602544018593217" LOG_CI_START="-1.8953542254098628" LOG_EFFECT_SIZE="-0.5175499117752707" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="724" O_E="0.0" SE="1.618658148140615" STUDY_ID="STD-Kurland-1966" TOTAL_1="44" TOTAL_2="40" VAR="2.6200542005420053" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.761510841282549" CI_END="0.8448736939937785" CI_START="0.5805612778016576" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7003577309961208" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="82" I2="5.5336281754625825" I2_Q="0.0" ID="CMP-003.34" LOG_CI_END="-0.07320821188058074" LOG_CI_START="-0.23615193405356724" LOG_EFFECT_SIZE="-0.154680072967074" METHOD="MH" MODIFIED="2012-04-22 16:22:55 +0100" MODIFIED_BY="[Empty name]" NO="34" P_CHI2="0.3908516180235201" P_Q="0.6334860919999896" P_Z="1.98333437160023E-4" Q="7.952405225468306" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.02238855998323777" TOTALS="SUB" TOTAL_1="507" TOTAL_2="520" WEIGHT="1100.0" Z="3.7211298244388953">
<NAME>Adverse effects: 20. Movement disorders</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="29.965403637219076" CI_START="0.359301069087791" DF="0" EFFECT_SIZE="3.28125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-003.34.01" LOG_CI_END="1.4766201320654186" LOG_CI_START="-0.4445414905653545" LOG_EFFECT_SIZE="0.5160393207500321" MODIFIED="2011-05-24 06:32:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.292375891923211" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="35" WEIGHT="100.0" Z="1.0529238887164256">
<NAME>Ataxia - ultra short term</NAME>
<DICH_DATA CI_END="29.965403637219076" CI_START="0.359301069087791" EFFECT_SIZE="3.28125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4766201320654186" LOG_CI_START="-0.4445414905653545" LOG_EFFECT_SIZE="0.5160393207500321" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="727" O_E="0.0" SE="1.128499847036722" STUDY_ID="STD-Battaglia-1997" TOTAL_1="32" TOTAL_2="35" VAR="1.2735119047619048" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.7086562974712898" CI_START="0.11983975024794952" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-003.34.02" LOG_CI_END="0.569216586623787" LOG_CI_START="-0.9213991047351494" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2011-05-24 06:32:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6433114807050054" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.00000000000001" Z="0.46307378587542436">
<NAME>Ataxia - short term</NAME>
<DICH_DATA CI_END="3.7086562974712898" CI_START="0.11983975024794946" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.569216586623787" LOG_CI_START="-0.9213991047351496" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2011-05-19 16:03:34 +0100" MODIFIED_BY="[Empty name]" ORDER="766" O_E="0.0" SE="0.8755950357709131" STUDY_ID="STD-Guz-1972" TOTAL_1="30" TOTAL_2="30" VAR="0.7666666666666666" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3957256886632718" CI_START="0.06996808240559668" DF="0" EFFECT_SIZE="0.3125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" I2="0.0" ID="CMP-003.34.03" LOG_CI_END="0.14480007186451077" LOG_CI_START="-1.155100028504323" LOG_EFFECT_SIZE="-0.5051499783199059" MODIFIED="2011-05-24 06:32:17 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.1276810305222708" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="35" WEIGHT="100.0" Z="1.5233105436599028">
<NAME>Dystonia - ultra short term</NAME>
<DICH_DATA CI_END="1.3957256886632718" CI_START="0.06996808240559668" EFFECT_SIZE="0.3125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.14480007186451077" LOG_CI_START="-1.155100028504323" LOG_EFFECT_SIZE="-0.5051499783199059" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="728" O_E="0.0" SE="0.7635677535659257" STUDY_ID="STD-Battaglia-1997" TOTAL_1="32" TOTAL_2="35" VAR="0.5830357142857142" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.966232699790958" CI_START="0.013947761168717392" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-003.34.04" LOG_CI_END="0.9012529883348099" LOG_CI_START="-1.8554954977741351" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-05-24 10:58:24 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.4974944815935268" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="0.6784372823427343">
<NAME>Dystonia - short term</NAME>
<DICH_DATA CI_END="7.966232699790958" CI_START="0.013947761168717392" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9012529883348099" LOG_CI_START="-1.8554954977741351" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-05-20 07:56:09 +0100" MODIFIED_BY="[Empty name]" ORDER="249" O_E="0.0" SE="1.6193277068654826" STUDY_ID="STD-Kurland-1966" TOTAL_1="44" TOTAL_2="44" VAR="2.6222222222222222" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3199520029520615" CI_START="0.03222828158130432" DF="0" EFFECT_SIZE="0.27343749999999994" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-003.34.05" LOG_CI_END="0.36547899994749733" LOG_CI_START="-1.4917628505426828" LOG_EFFECT_SIZE="-0.5631419252975928" MODIFIED="2011-05-24 06:32:17 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.2346060069506799" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="35" WEIGHT="100.0" Z="1.188577450455921">
<NAME>Parkinsonism - ultra short term</NAME>
<DICH_DATA CI_END="2.3199520029520624" CI_START="0.03222828158130432" EFFECT_SIZE="0.2734375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3654789999474975" LOG_CI_START="-1.4917628505426828" LOG_EFFECT_SIZE="-0.5631419252975928" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="730" O_E="0.0" SE="1.0909530564733625" STUDY_ID="STD-Battaglia-1997" TOTAL_1="32" TOTAL_2="35" VAR="1.1901785714285715" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5785011367192963" CI_END="1.6013837427413025" CI_START="0.04153329264554206" DF="1" EFFECT_SIZE="0.2578967615637853" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-003.34.06" LOG_CI_END="0.2044954152329835" LOG_CI_START="-1.3816036378497674" LOG_EFFECT_SIZE="-0.588554111308392" MODIFIED="2011-05-24 06:32:17 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.44690055897822023" P_Z="0.14578875655523862" STUDIES="2" TAU2="0.0" TOTAL_1="74" TOTAL_2="70" WEIGHT="100.0" Z="1.4545685010975706">
<NAME>Parkinsonism - short term</NAME>
<DICH_DATA CI_END="1.9774190029426781" CI_START="0.006243329812231785" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.29609870339830113" LOG_CI_START="-2.204583722276951" LOG_EFFECT_SIZE="-0.9542425094393249" MODIFIED="2011-05-19 16:03:34 +0100" MODIFIED_BY="[Empty name]" ORDER="769" O_E="0.0" SE="1.4689132354192893" STUDY_ID="STD-Guz-1972" TOTAL_1="30" TOTAL_2="30" VAR="2.1577060931899643" WEIGHT="40.229397442464474"/>
<DICH_DATA CI_END="4.8235043133041575" CI_START="0.042834328908561196" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6833626712179824" LOG_CI_START="-1.368208032862395" LOG_EFFECT_SIZE="-0.3424226808222062" MODIFIED="2011-05-19 16:03:34 +0100" MODIFIED_BY="[Empty name]" ORDER="771" O_E="0.0" SE="1.2051027870155837" STUDY_ID="STD-Kurland-1966" TOTAL_1="44" TOTAL_2="40" VAR="1.4522727272727274" WEIGHT="59.77060255753552"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.678865612928433E-32" CI_END="3.387339582036292" CI_START="0.19865519277276888" DF="0" EFFECT_SIZE="0.8203125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="100.0" ID="CMP-003.34.07" LOG_CI_END="0.5298587370083374" LOG_CI_START="-0.701900078164198" LOG_EFFECT_SIZE="-0.0860206705779303" MODIFIED="2011-05-24 06:32:17 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Z="0.7842762161054695" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="35" WEIGHT="100.0" Z="0.27375069564265603">
<NAME>Slight dysarthria - ultra short term</NAME>
<DICH_DATA CI_END="3.387339582036292" CI_START="0.19865519277276888" EFFECT_SIZE="0.8203125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5298587370083374" LOG_CI_START="-0.701900078164198" LOG_EFFECT_SIZE="-0.0860206705779303" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="733" O_E="0.0" SE="0.7235412253368184" STUDY_ID="STD-Battaglia-1997" TOTAL_1="32" TOTAL_2="35" VAR="0.5235119047619047" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.34.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-05-24 06:32:59 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Slight dysarthria - short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-24 06:32:59 +0100" MODIFIED_BY="[Empty name]" ORDER="257" O_E="0.0" SE="0.0" STUDY_ID="STD-Lingjaerde-1982" TOTAL_1="26" TOTAL_2="32" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.7463656017629745" CI_START="0.05204546427279967" DF="0" EFFECT_SIZE="0.546875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.34.09" LOG_CI_END="0.7593932537090307" LOG_CI_START="-1.283617112976254" LOG_EFFECT_SIZE="-0.2621119296336115" MODIFIED="2011-05-24 06:32:17 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.6150242686100811" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="35" WEIGHT="99.99999999999999" Z="0.5029146698199923">
<NAME>Tremor - ultra short term</NAME>
<DICH_DATA CI_END="5.7463656017629745" CI_START="0.05204546427279967" EFFECT_SIZE="0.546875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7593932537090307" LOG_CI_START="-1.283617112976254" LOG_EFFECT_SIZE="-0.2621119296336115" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="735" O_E="0.0" SE="1.2000744024553525" STUDY_ID="STD-Battaglia-1997" TOTAL_1="32" TOTAL_2="35" VAR="1.4401785714285715" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6113995451271035" CI_START="0.0248231421691539" DF="0" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-003.34.10" LOG_CI_END="0.20720323671350532" LOG_CI_START="-1.6051432453855428" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2011-05-24 06:32:17 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.1305838145818064" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.5118036736394114">
<NAME>Tremor - short term</NAME>
<DICH_DATA CI_END="1.6113995451271035" CI_START="0.0248231421691539" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.20720323671350532" LOG_CI_START="-1.6051432453855428" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2011-05-19 16:03:34 +0100" MODIFIED_BY="[Empty name]" ORDER="774" O_E="0.0" SE="1.064581294844754" STUDY_ID="STD-Guz-1972" TOTAL_1="30" TOTAL_2="30" VAR="1.133333333333333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2294046057296408" CI_START="0.10811819503926214" DF="0" EFFECT_SIZE="0.3645833333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" I2="0.0" ID="CMP-003.34.11" LOG_CI_END="0.08969483578924842" LOG_CI_START="-0.9661012131678338" LOG_EFFECT_SIZE="-0.4382031886892928" MODIFIED="2011-05-24 06:32:17 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Z="0.1037482096098662" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="35" WEIGHT="100.0" Z="1.6269476829166196">
<NAME>Use of antiparkinson medication - ultra short term</NAME>
<DICH_DATA CI_END="1.2294046057296408" CI_START="0.10811819503926214" EFFECT_SIZE="0.3645833333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.08969483578924842" LOG_CI_START="-0.9661012131678338" LOG_EFFECT_SIZE="-0.4382031886892928" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="738" O_E="0.0" SE="0.6201798254321208" STUDY_ID="STD-Battaglia-1997" TOTAL_1="32" TOTAL_2="35" VAR="0.38462301587301584" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9705468297586993" CI_END="0.9011605153276897" CI_START="0.6051351591647682" DF="2" EFFECT_SIZE="0.738460501229298" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="40" I2="0.0" ID="CMP-003.34.12" LOG_CI_END="-0.04519784530037166" LOG_CI_START="-0.2181476132423344" LOG_EFFECT_SIZE="-0.13167272927135307" MODIFIED="2011-05-24 06:32:17 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.615528928609067" P_Z="0.0028415478547310132" STUDIES="3" TAU2="0.0" TOTAL_1="111" TOTAL_2="104" WEIGHT="100.0" Z="2.9843787614048436">
<NAME>Use of antiparkinson medication - short term</NAME>
<DICH_DATA CI_END="1.2413090390636161" CI_START="0.24864233288872747" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.09387991788191366" LOG_CI_START="-0.6044249280885257" LOG_EFFECT_SIZE="-0.25527250510330607" MODIFIED="2011-05-19 16:03:34 +0100" MODIFIED_BY="[Empty name]" ORDER="778" O_E="0.0" SE="0.410187723187772" STUDY_ID="STD-Barbee-1992" TOTAL_1="14" TOTAL_2="14" VAR="0.16825396825396827" WEIGHT="6.1340859289894"/>
<DICH_DATA CI_END="5.044163637879916" CI_START="0.04364995479913513" EFFECT_SIZE="0.46923076923076923" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7027891670912743" LOG_CI_START="-1.3600162016834139" LOG_EFFECT_SIZE="-0.32861351729606975" MODIFIED="2011-05-19 16:03:34 +0100" MODIFIED_BY="[Empty name]" ORDER="776" O_E="0.0" SE="1.211702084669509" STUDY_ID="STD-Hanlon-1969" TOTAL_1="65" TOTAL_2="61" VAR="1.4682219419924338" WEIGHT="0.7029484232899541"/>
<DICH_DATA CI_END="0.9279897907334036" CI_START="0.6142703713268423" EFFECT_SIZE="0.7550077041602465" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="29" LOG_CI_END="-0.03245680163947453" LOG_CI_START="-0.2116404319042365" LOG_EFFECT_SIZE="-0.12204861677185556" MODIFIED="2011-05-19 16:03:34 +0100" MODIFIED_BY="[Empty name]" ORDER="777" O_E="0.0" SE="0.10525335139079595" STUDY_ID="STD-Stevens-1992" TOTAL_1="32" TOTAL_2="29" VAR="0.011078267978994367" WEIGHT="93.16296564772064"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5845481551731051" CI_END="3.3636165832121945" CI_START="0.39945371944846586" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1591415595011039" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.35" LOG_CI_END="0.5268064849601867" LOG_CI_START="-0.3985335306239807" LOG_EFFECT_SIZE="0.06413647716810297" METHOD="MH" MODIFIED="2011-06-07 08:24:31 +0100" MODIFIED_BY="[Empty name]" NO="35" P_CHI2="0.4445352307727616" P_Q="1.0" P_Z="0.7858564507586694" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="62" WEIGHT="100.0" Z="0.27169512444655197">
<NAME>Adverse effects: 21. Restlessness - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1005692822786637" CI_START="0.3225214175072657" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.491441440109722" LOG_CI_START="-0.49144144010972196" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="742" O_E="0.0" SE="0.5773502691896258" STUDY_ID="STD-Guz-1972" TOTAL_1="30" TOTAL_2="30" VAR="0.33333333333333337" WEIGHT="88.6337543053961"/>
<DICH_DATA CI_END="86.42013187103964" CI_START="0.1555707466925288" EFFECT_SIZE="3.6666666666666665" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.936614924678534" LOG_CI_START="-0.8080720638014088" LOG_EFFECT_SIZE="0.5642714304385625" MODIFIED="2011-05-24 06:33:59 +0100" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="1.6122427234528303" STUDY_ID="STD-Lingjaerde-1982" TOTAL_1="26" TOTAL_2="32" VAR="2.599326599326599" WEIGHT="11.366245694603906"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.058470058579275" CI_START="0.05878635993447888" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.36" LOG_CI_END="1.1479380602805238" LOG_CI_START="-1.2307234305969739" LOG_EFFECT_SIZE="-0.04139268515822506" METHOD="MH" MODIFIED="2011-05-23 09:39:47 +0100" MODIFIED_BY="[Empty name]" NO="36" P_CHI2="1.0" P_Q="1.0" P_Z="0.9456158416403186" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="40" WEIGHT="100.0" Z="0.06821329764211068">
<NAME>Adverse effects: 22. Sensory disturbances - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.058470058579275" CI_START="0.05878635993447888" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1479380602805238" LOG_CI_START="-1.2307234305969739" LOG_EFFECT_SIZE="-0.04139268515822506" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="743" O_E="0.0" SE="1.3972375343057197" STUDY_ID="STD-Kurland-1966" TOTAL_1="44" TOTAL_2="40" VAR="1.9522727272727274" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.7419788060767594E-33" CI_END="9.602236874559962" CI_START="0.017285638521392088" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4074074074074074" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="100.0" I2_Q="0.0" ID="CMP-003.37" LOG_CI_END="0.9823724152392092" LOG_CI_START="-1.7623145732407337" LOG_EFFECT_SIZE="-0.3899710790007623" METHOD="MH" MODIFIED="2011-06-07 08:24:52 +0100" MODIFIED_BY="[Empty name]" NO="37" P_CHI2="0.0" P_Q="1.0" P_Z="0.5775603190614632" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="32" WEIGHT="100.00000000000001" Z="0.5569518659590526">
<NAME>Adverse effects: 23. Sleep disorder - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.602236874559962" CI_START="0.017285638521392088" EFFECT_SIZE="0.4074074074074074" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9823724152392092" LOG_CI_START="-1.7623145732407337" LOG_EFFECT_SIZE="-0.3899710790007623" MODIFIED="2011-05-24 06:36:51 +0100" MODIFIED_BY="[Empty name]" ORDER="259" O_E="0.0" SE="1.6122427234528303" STUDY_ID="STD-Lingjaerde-1982" TOTAL_1="26" TOTAL_2="32" VAR="2.599326599326599" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.31454894086647167" CI_END="10.39831008041358" CI_START="1.0448598613629698" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.2961760919329084" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.38" LOG_CI_END="1.0169627640693488" LOG_CI_START="0.019058045932232297" LOG_EFFECT_SIZE="0.5180104050007904" METHOD="MH" MODIFIED="2011-10-04 09:34:46 +0100" MODIFIED_BY="[Empty name]" NO="38" P_CHI2="0.574902212434387" P_Q="1.0" P_Z="0.04186828220902508" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="62" WEIGHT="100.0" Z="2.0348270109672986">
<NAME>Adverse effects: 24. Somnolence - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="129.92776744614594" CI_START="0.3771326250203609" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1137019760147355" LOG_CI_START="-0.423505895986222" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="746" O_E="0.0" SE="1.490368463394884" STUDY_ID="STD-Guz-1972" TOTAL_1="30" TOTAL_2="30" VAR="2.2211981566820276" WEIGHT="15.469135785120368"/>
<DICH_DATA CI_END="10.019427896092964" CI_START="0.8231214268115338" EFFECT_SIZE="2.871794871794872" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="1.0008429242594428" LOG_CI_START="-0.084536092972078" LOG_EFFECT_SIZE="0.4581534156436824" MODIFIED="2011-05-24 06:37:27 +0100" MODIFIED_BY="[Empty name]" ORDER="260" O_E="0.0" SE="0.6375570074345805" STUDY_ID="STD-Lingjaerde-1982" TOTAL_1="26" TOTAL_2="32" VAR="0.40647893772893773" WEIGHT="84.53086421487963"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="70.82882080128432" CI_START="0.12706691849706483" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.39" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" MODIFIED="2011-05-23 09:40:04 +0100" MODIFIED_BY="[Empty name]" NO="39" P_CHI2="1.0" P_Q="1.0" P_Z="0.49584060533880536" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>Adverse effects: 25. Vomitting - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-05-19 15:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="747" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Guz-1972" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.560895451441564" CI_END="1.6231540050656477" CI_START="0.41345325049153714" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8192058956347598" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="64" I2="74.29453843140216" I2_Q="0.0" ID="CMP-003.40" LOG_CI_END="0.2103597276987738" LOG_CI_START="-0.38357358937952535" LOG_EFFECT_SIZE="-0.0866069308403758" METHOD="MH" MODIFIED="2012-04-22 16:21:33 +0100" MODIFIED_BY="[Empty name]" NO="40" P_CHI2="0.003668707662863091" P_Q="1.0" P_Z="0.5675922606272064" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.40998624405549383" TOTALS="YES" TOTAL_1="207" TOTAL_2="207" WEIGHT="99.99999999999999" Z="0.5716010884646497">
<NAME>Sensitivity analysis (no clinically important response to treatment, ultra short term) - exclusion of studies which were not double-blind-effects model</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9171435836951519" CI_START="0.12114909059653102" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.03756266790137051" LOG_CI_START="-0.9166798415379545" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-09-30 14:20:29 +0100" MODIFIED_BY="[Empty name]" ORDER="942" O_E="0.0" SE="0.5163977794943222" STUDY_ID="STD-Guz-1972" TOTAL_1="30" TOTAL_2="30" VAR="0.26666666666666666" WEIGHT="17.988072349978165"/>
<DICH_DATA CI_END="3.1973524021921604" CI_START="1.0186752720983236" EFFECT_SIZE="1.8047337278106508" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="13" LOG_CI_END="0.504790505490647" LOG_CI_START="0.008035763975577523" LOG_EFFECT_SIZE="0.2564131347331123" MODIFIED="2011-09-30 14:20:29 +0100" MODIFIED_BY="[Empty name]" ORDER="938" O_E="0.0" SE="0.29179619414158015" STUDY_ID="STD-Hanlon-1969" TOTAL_1="65" TOTAL_2="61" VAR="0.08514501891551073" WEIGHT="24.582736789549735"/>
<DICH_DATA CI_END="2.3107662619202203" CI_START="0.6756385245378359" EFFECT_SIZE="1.2494969818913482" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.36375601804851554" LOG_CI_START="-0.17028559516201935" LOG_EFFECT_SIZE="0.0967352114432481" MODIFIED="2011-09-30 14:20:29 +0100" MODIFIED_BY="[Empty name]" ORDER="939" O_E="0.0" SE="0.3136986871484882" STUDY_ID="STD-Hanlon-1970" TOTAL_1="71" TOTAL_2="69" VAR="0.09840686631868506" WEIGHT="23.941476124519358"/>
<DICH_DATA CI_END="1.868396809676368" CI_START="0.5956492021337781" EFFECT_SIZE="1.054945054945055" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.27146911705016397" LOG_CI_START="-0.22500943561321432" LOG_EFFECT_SIZE="0.023229840718474823" MODIFIED="2011-09-30 14:20:29 +0100" MODIFIED_BY="[Empty name]" ORDER="940" O_E="0.0" SE="0.2916339594429399" STUDY_ID="STD-Lingjaerde-1982" TOTAL_1="26" TOTAL_2="32" VAR="0.0850503663003663" WEIGHT="24.587437089034385"/>
<DICH_DATA CI_END="0.6188101004315442" CI_START="0.013355410333725814" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.20844260621073604" LOG_CI_START="-1.8743427641057142" LOG_EFFECT_SIZE="-1.041392685158225" MODIFIED="2011-09-30 14:20:29 +0100" MODIFIED_BY="[Empty name]" ORDER="941" O_E="0.0" SE="0.9785579990862869" STUDY_ID="STD-Morphy-1986" TOTAL_1="15" TOTAL_2="15" VAR="0.9575757575757575" WEIGHT="8.900277646918347"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.1844437138928114" CI_END="0.8018235500669627" CI_START="0.35041296033336644" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5300654335494569" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="38" I2="67.66079388018078" I2_Q="64.01020218652805" ID="CMP-003.41" LOG_CI_END="-0.09592119239338893" LOG_CI_START="-0.4554198394412457" LOG_EFFECT_SIZE="-0.2756705159173173" METHOD="MH" MODIFIED="2012-04-22 16:21:41 +0100" MODIFIED_BY="[Empty name]" NO="41" P_CHI2="0.045401001030535126" P_Q="0.06212762841244979" P_Z="0.0026481645543329014" Q="5.55713041336216" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="80" TOTAL_2="77" WEIGHT="300.0" Z="3.0058765852634313">
<NAME>Sensitivity analysis (no clinically important response to treatment, ultra short term) - use of a fixed-effects model</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.3132158019282495E-31" CI_END="0.798710496261708" CI_START="0.17606504566821463" DF="0" EFFECT_SIZE="0.37499999999999994" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" I2="100.0" ID="CMP-003.41.01" LOG_CI_END="-0.09761060824489465" LOG_CI_START="-0.7543268562996677" LOG_EFFECT_SIZE="-0.4259687322722812" MODIFIED="2011-09-30 14:20:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.01100311034565663" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="21" WEIGHT="100.0" Z="2.54260002327283">
<NAME>Unimproved or worse at 30 minutes</NAME>
<DICH_DATA CI_END="0.7987104962617081" CI_START="0.17606504566821463" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="-0.09761060824489459" LOG_CI_START="-0.7543268562996677" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2011-09-30 14:20:34 +0100" MODIFIED_BY="[Empty name]" ORDER="944" O_E="0.0" SE="0.3857583749052298" STUDY_ID="STD-Garza_x002d_Trevino-1989" TOTAL_1="24" TOTAL_2="21" VAR="0.1488095238095238" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.13430331773508" CI_START="0.004039703004536443" DF="0" EFFECT_SIZE="0.06769230769230769" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" I2="0.0" ID="CMP-003.41.02" LOG_CI_END="0.05472920235631467" LOG_CI_START="-2.393650562669651" LOG_EFFECT_SIZE="-1.1694606801566683" MODIFIED="2011-09-30 14:20:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.06115945257453507" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="21" WEIGHT="100.0" Z="1.8723409229110966">
<NAME>Unimproved or worse at 60 minutes</NAME>
<DICH_DATA CI_END="1.13430331773508" CI_START="0.004039703004536443" EFFECT_SIZE="0.06769230769230769" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.05472920235631467" LOG_CI_START="-2.393650562669651" LOG_EFFECT_SIZE="-1.1694606801566683" MODIFIED="2011-09-30 14:20:34 +0100" MODIFIED_BY="[Empty name]" ORDER="945" O_E="0.0" SE="1.4381903936515528" STUDY_ID="STD-Garza_x002d_Trevino-1989" TOTAL_1="24" TOTAL_2="21" VAR="2.0683916083916083" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.413738242373146" CI_START="0.5118918171116655" DF="0" EFFECT_SIZE="0.8506944444444444" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" I2="0.0" ID="CMP-003.41.03" LOG_CI_END="0.15036900605468123" LOG_CI_START="-0.29082181284407804" LOG_EFFECT_SIZE="-0.07022640339469839" MODIFIED="2011-09-30 14:20:34 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5326582949796707" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="35" WEIGHT="100.0" Z="0.6239532443623902">
<NAME>Unimproved or worse at 12 hours</NAME>
<DICH_DATA CI_END="1.413738242373146" CI_START="0.5118918171116655" EFFECT_SIZE="0.8506944444444444" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="0.15036900605468123" LOG_CI_START="-0.29082181284407804" LOG_EFFECT_SIZE="-0.07022640339469839" MODIFIED="2011-09-30 14:20:34 +0100" MODIFIED_BY="[Empty name]" ORDER="946" O_E="0.0" SE="0.25915767095090664" STUDY_ID="STD-Battaglia-1997" TOTAL_1="32" TOTAL_2="35" VAR="0.06716269841269841" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.535247235567844" CI_END="1.2747199714500892" CI_START="0.716377376608638" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9556048079923274" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="71" I2="67.8151243801738" I2_Q="0.0" ID="CMP-003.42" LOG_CI_END="0.105414790094596" LOG_CI_START="-0.14485813774367928" LOG_EFFECT_SIZE="-0.019721673824541625" METHOD="MH" MODIFIED="2012-04-22 16:21:48 +0100" MODIFIED_BY="[Empty name]" NO="42" P_CHI2="0.008304177032241289" P_Q="1.0" P_Z="0.7574029668543981" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="256" TOTAL_2="255" WEIGHT="100.0" Z="0.3088929413566113">
<NAME>Sensitivity analysis (no clinically important response to treatment, short term) - use of a fixed-effects model</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9171435836951519" CI_START="0.12114909059653102" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.03756266790137051" LOG_CI_START="-0.9166798415379545" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-09-30 14:20:39 +0100" MODIFIED_BY="[Empty name]" ORDER="951" O_E="0.0" SE="0.5163977794943222" STUDY_ID="STD-Guz-1972" TOTAL_1="30" TOTAL_2="30" VAR="0.26666666666666666" WEIGHT="17.085112513697595"/>
<DICH_DATA CI_END="3.1973524021921604" CI_START="1.0186752720983236" EFFECT_SIZE="1.8047337278106508" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="13" LOG_CI_END="0.504790505490647" LOG_CI_START="0.008035763975577523" LOG_EFFECT_SIZE="0.2564131347331123" MODIFIED="2011-09-30 14:20:39 +0100" MODIFIED_BY="[Empty name]" ORDER="947" O_E="0.0" SE="0.29179619414158015" STUDY_ID="STD-Hanlon-1969" TOTAL_1="65" TOTAL_2="61" VAR="0.08514501891551073" WEIGHT="19.096455124437128"/>
<DICH_DATA CI_END="2.3107662619202203" CI_START="0.6756385245378359" EFFECT_SIZE="1.2494969818913482" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.36375601804851554" LOG_CI_START="-0.17028559516201935" LOG_EFFECT_SIZE="0.0967352114432481" MODIFIED="2011-09-30 14:20:39 +0100" MODIFIED_BY="[Empty name]" ORDER="948" O_E="0.0" SE="0.3136986871484882" STUDY_ID="STD-Hanlon-1970" TOTAL_1="71" TOTAL_2="69" VAR="0.09840686631868506" WEIGHT="20.21738314120882"/>
<DICH_DATA CI_END="1.868396809676368" CI_START="0.5956492021337781" EFFECT_SIZE="1.054945054945055" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.27146911705016397" LOG_CI_START="-0.22500943561321432" LOG_EFFECT_SIZE="0.023229840718474823" MODIFIED="2011-09-30 14:20:39 +0100" MODIFIED_BY="[Empty name]" ORDER="949" O_E="0.0" SE="0.2916339594429399" STUDY_ID="STD-Lingjaerde-1982" TOTAL_1="26" TOTAL_2="32" VAR="0.0850503663003663" WEIGHT="17.87063492812047"/>
<DICH_DATA CI_END="0.6188101004315442" CI_START="0.013355410333725814" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.20844260621073604" LOG_CI_START="-1.8743427641057142" LOG_EFFECT_SIZE="-1.041392685158225" MODIFIED="2011-09-30 14:20:39 +0100" MODIFIED_BY="[Empty name]" ORDER="950" O_E="0.0" SE="0.9785579990862869" STUDY_ID="STD-Morphy-1986" TOTAL_1="15" TOTAL_2="15" VAR="0.9575757575757575" WEIGHT="15.661353137556128"/>
<DICH_DATA CI_END="2.5817540249927142" CI_START="0.37168535705099137" EFFECT_SIZE="0.9795918367346939" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.41191486276500283" LOG_CI_START="-0.42982454807085574" LOG_EFFECT_SIZE="-0.008954842652926454" MODIFIED="2011-09-30 14:20:39 +0100" MODIFIED_BY="[Empty name]" ORDER="952" O_E="0.0" SE="0.4944418966022663" STUDY_ID="STD-Xuan-2007" TOTAL_1="49" TOTAL_2="48" VAR="0.2444727891156462" WEIGHT="10.069061154979853"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-10-02 11:05:20 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-06-19 13:39:52 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-10-02 11:05:20 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION/>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2012-10-02 11:05:20 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION/>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2012-09-03 15:44:22 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2011-02-17 10:26:41 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-02-17 10:26:38 +0000" MODIFIED_BY="[Empty name]">Previous search methods</TITLE>
<APPENDIX_BODY MODIFIED="2011-02-17 10:26:41 +0000" MODIFIED_BY="[Empty name]">
<P>1. Electronic searching<BR/>1.1 We searched Cochrane Schizophrenia Group's Register of Trials (August 1998**) using the phrase:</P>
<P>[and (benzodiazepine* or alprazolam* or bromazepam* or neo* or brotizolam* or chlordiazepoxid* or clobazam* or clotiazepam* or diazepam* or dikaliumclorazepat* or flunitrazepam* or flurazepam* or loprazolam* or lorazepam* or lormetazepam* or medazepam* or metaclazepam* or midazolam* or nitrazepam* or nordazepam* or oxazepam* or prazepam* or temazepam* or triazolam*]</P>
<P>1.2 We searched Biological Abstracts (1980 - August 1998) using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and (benzodiazepine* or alprazolam* or bromazepam* or neo* or brotizolam* or chlordiazepoxid* or clobazam* or clotiazepam* or diazepam* or dikaliumclorazepat* or flunitrazepam* or flurazepam* or loprazolam* or lorazepam* or lormetazepam* or medazepam* or metaclazepam* or midazolam* or nitrazepam* or nordazepam* or oxazepam* or prazepam* or temazepam* or triazolam*]</P>
<P>1.3 We searched the Cochrane Library (issue 3, 1998) using the Phrase:</P>
<P>[and (benzodiazepine* or alprazolam* or bromazepam* or neo* or brotizolam* or chlordiazepoxid* or clobazam* or clotiazepam* or diazepam* or dikaliumclorazepat* or flunitrazepam* or flurazepam* or loprazolam* or lorazepam* or lormetazepam* or medazepam* or metaclazepam* or midazolam* or nitrazepam* or nordazepam* or oxazepam* or prazepam* or temazepam* or triazolam*]<BR/>
<BR/>1.4 We searched EMBASE (1980 - August 1998) using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and schizophrenia (see Group search strategy)<BR/>combined with the phrase:</P>
<P>[and (benzodiazepine* or alprazolam* or bromazepam* or neo* or brotizolam* or chlordiazepoxid* or clobazam* or clotiazepam* or diazepam* or dikaliumclorazepat* or flunitrazepam* or flurazepam* or loprazolam* or lorazepam* or lormetazepam* or medazepam* or metaclazepam* or midazolam* or nitrazepam* or nordazepam* or oxazepam* or prazepam* or temazepam* or triazolam*]</P>
<P>1.5 We searched MEDLINE (1966 - August 1998) using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and schizophrenia (see Group search strategy)<BR/>combined with the phrase:</P>
<P>[and (benzodiazepine* or alprazolam* or bromazepam* or neo* or brotizolam* or chlordiazepoxid* or clobazam* or clotiazepam* or diazepam* or dikaliumclorazepat* or flunitrazepam* or flurazepam* or loprazolam* or lorazepam* or lormetazepam* or medazepam* or metaclazepam* or midazolam* or nitrazepam* or nordazepam* or oxazepam* or prazepam* or temazepam* or triazolam*]</P>
<P>1.6 We searched PsycLIT (1886 - August 1998) using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and (benzodiazepine* or alprazolam* or bromazepam* or neo* or brotizolam* or chlordiazepoxid* or clobazam* or clotiazepam* or diazepam* or dikaliumclorazepat* or flunitrazepam* or flurazepam* or loprazolam* or lorazepam* or lormetazepam* or medazepam* or metaclazepam* or midazolam* or nitrazepam* or nordazepam* or oxazepam* or prazepam* or temazepam* or triazolam*]</P>
<P>1.7 We searched PSYNDEX (1974 - August 1998) using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and schizophrenia (see Group search<BR/>strategy) combined with the phrase:</P>
<P>[and (benzodiazepine* or alprazolam* or bromazepam* or neo* or brotizolam* or chlordiazepoxid* or clobazam* or clotiazepam* or diazepam* or dikaliumclorazepat* or flunitrazepam* or flurazepam* or loprazolam* or lorazepam* or lormetazepam* or medazepam* or metaclazepam* or midazolam* or nitrazepam* or nordazepam* or oxazepam* or prazepam* or temazepam* or triazolam*]</P>
<P>**The search was repeated twice - for the last time in March 2005 - due to a delay in summarising the results. For these updates we only searched the Cochrane Schizophrenia Group's Register of Trials.</P>
<P>2. Reference lists<BR/>We search all references of articles selected for inclusion for further relevant trials.</P>
<P>3. Personal contact<BR/>We contacted the first authors of included studies identified from the first search for further relevant studies.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-09-03 15:44:22 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-02-17 10:31:04 +0000" MODIFIED_BY="[Empty name]">Previous methods: data collection and analyses</TITLE>
<APPENDIX_BODY MODIFIED="2012-09-03 15:44:22 +0100" MODIFIED_BY="[Empty name]">
<P>[For definitions of terms used in this, and other sections, please refer to the Glossary]</P>
<P>1. Study selection<BR/>We inspected all study citations identified by the searches independently, and the full reports of the studies of agreed relevance were obtained. Where agreement could not be reached, we acquired the full report for more detailed scrutiny. If the disagreement could not be resolved from published information, we added the article to those awaiting assessment and the authors of the study were contacted for clarification.</P>
<P>2. Quality assessment<BR/>The methodological quality of the trials included in this review was assessed using the criteria described in the Cochrane Handbook. These criteria are based on the evidence of a strong relationship between allocation concealment and the potential for bias in the results (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>) and are defined as below:</P>
<P>A. Low risk of bias (adequate allocation concealment)<BR/>B. Moderate risk of bias (some doubt about the results)<BR/>C. High risk of bias (inadequate allocation concealment)</P>
<P>For the purpose of the analysis in this review, trials were included if they met the criteria A or B.</P>
<P>3. Data extraction<BR/>Anja Volz and/or Vesal Khors and/or Donna Gillies independently extracted the data from included studies and the data were checked by Stefan Leucht. Again, any disagreements were discussed, the decisions documented and, if necessary, the authors of the studies were contacted for clarification. Justification for excluding references from the review were documented.</P>
<P>4. Data management<BR/>4.1 Intention-to-treat<BR/>For studies that did not specify the reasons for people leaving the study early ('dropped out'), the reviewers assumed that these people had no change in the clinical outcome variables. Wahlbeck and colleagues highlighted the problem of high drop-out rates in randomised controlled antipsychotic drug trials (<LINK REF="REF-Wahlbeck-2001" TYPE="REFERENCE">Wahlbeck 2001</LINK>). As there is no consensus on the level of drop-out that makes results meaningless, all trials were included in the main analysis. We performed a sensitivity analysis excluding those trials with a greater than 50% drop-out rate to test whether this procedure significantly changed the results of the primary outcomes. When insufficient data were provided to identify the original group size (prior to drop-outs), the authors were contacted and the trials were allocated to the 'awaiting assessment' list.</P>
<P>4.2 Cross-over design<BR/>We expected that some trials would use a crossover design. In order to exclude the potential additive effect in the second or later stages on these trials, only data from the first stage were analysed.</P>
<P>4.3 Cluster trials<BR/>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) - whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated - causing type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>, <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Secondly, RevMan does not currently support meta-analytic pooling of clustered dichotomous data, even when these are correctly analysed by the authors of primary studies, since the 'design effect' (a statistical correction for clustering) cannot be incorporated.</P>
<P>Where clustering was not accounted for in primary studies, we presented the data in a table, with a (*) symbol - to indicate the presence of a probable unit of analysis error. Subsequent versions of this review will seek to contact first authors of studies to seek intra-class correlation co-efficients of their clustered data and to adjust for this using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, then we also presented these data as if from a non-cluster randomised study, but adjusted for the clustering effect. We have sought statistical advice from the MRC Biostatistics Unit, Cambridge, UK. Dr Julian Higgins advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intraclass correlation co-efficient (ICC) [Design effect = 1+(m-1)*ICC]. Should the ICC not be reported it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>). Where cluster studies were appropriately analysed taking into account intra-class correlation coefficients and relevant data documented in the report, synthesis with other studies was possible using the generic inverse variance technique.</P>
<P>4.4 Data types<BR/>Outcomes are assessed using continuous (for example changes on a behaviour scale), categorical (for example, one of three categories on a behaviour scale, such as 'little change', 'moderate change' or 'much change') or dichotomous measures (for example, either 'no important changes' or 'important changes' in a person's behaviour). Currently RevMan does not support categorical data so they could not be analysed as such.</P>
<P>4.4.1 Dichotomous data: Where possible efforts were made to convert outcome measures to dichotomous data. This may be done by identifying cut off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. If authors of studies used predefined cut off points for determining clinical effectiveness then, where appropriate, we used these.</P>
<P>For dichotomous outcomes, we calculated the relative risk (RR) with a 95% confidence interval (CI) based on a random effects model. If the overall results were statistically significant, the Number Needed to Treat (NNT) or the Number Needed to Harm (NNH) were calculated as the inverse of the risk reduction. It has been shown that RR is more intuitive than odds ratios (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) and that odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). This misinterpretation then leads to an overestimate of the impression of the effect. We therefore chose the relative risk as an effect size measure.</P>
<P>4.4.2 Continuous data<BR/>4.4.2.1 Normal distribution: Continuous data on outcomes in trials relevant to mental health issues are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data the following standards were applied. When a scale starts from zero, the standard deviation, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution - <LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). Endpoint scores on scales often have a finite start and end point and this rule can be applied. When continuous data were presented on a scale which includes a possibility of negative values (such as change on a scale) it is impossible to tell whether data are non-normally distributed (skewed) or not. It is thus preferable to use scale endpoint data, which typically cannot have negative values. If endpoint data were not available, we chose to use change data, because the statistics used in Metaview are rather robust towards skewness. If a scale starts from a positive value (such as PANSS, which can have values from 30-210) the calculation described above should be modified to take the scale starting point into account. In these cases skewness is present if 2SD&gt;(S-Smin), where S is the mean score and Smin is the minimum score.</P>
<P>4.4.2.2 Intention-to-treat versus completer analyses: in the case of continuous data it was supposed that in many cases an intention-to-treat analysis would not be available, so that the data had to be analysed as they were presented in the original publications.</P>
<P>4.4.2.3 Summary statistic: for continuous outcomes, a weighted mean difference (MD) between groups was estimated using a random effects model. Whenever possible we took the opportunity to make direct comparisons between trials that used the same measurement instrument to quantify specific outcomes. Where continuous data was presented from different scales rating the same effect, both sets of data were presented and the general direction of effect inspected.</P>
<P>4.4.2.4 Rating scales: a wide range of instruments are available to measure mental health outcomes. These instruments vary in quality and many are not valid, or even ad hoc. For outcome instruments some minimum standards have to be set. Continuous data from rating scales were included only if the measuring instrument had been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>), the instrument was either a self report or completed by an independent rater or relative (not the therapist), and the instrument could be considered a global assessment of an area of functioning. However, as it was expected that therapists would frequently also be the rater, such data were commented on with 'prone to bias'.</P>
<P>4.5 Data display<BR/>Whenever possible data were entered into RevMan in such a way that the area to the left of the line of no effect indicated a favourable outcome for benzodiazepine alone or benzodiazepine augmentation.</P>
<P>5. Heterogeneity<BR/>We assessed heterogeneity by visual inspection of the graphs and supplemented this procedure using the I-squared statistic. This measure provides an estimate of the percentage of variability due to heterogeneity rather than chance alone. Where the I-squared estimate was greater than or equal to 75%, we interpreted this as indicating the presence of high levels of heterogeneity. In such cases we investigated the reasons for heterogeneity.<BR/>
<BR/>6. Publication bias<BR/>Data from all included trials were entered into a funnel graph (trial effect versus trial size or 'precision') in an attempt to investigate the likelihood of overt publication bias. A formal test of funnel plot asymmetry (suggesting potential publication bias) was not undertaken (<LINK REF="REF-Egger-1997a" TYPE="REFERENCE">Egger 1997a</LINK>).</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;34 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;38 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 citations were additional references to primary publications of a trial and 6 citations of the update search had been already included&lt;/p&gt;" WIDTH="297">
<FLOWCHARTBOX TEXT="&lt;p&gt;116 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;262 citations were screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;182 citations identified through initial database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;80 further references identified through the update database searching&lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;146 citations were clearly not relevant and excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;65 full-text articles excluded with reasons:&lt;/p&gt;&lt;p&gt;lack of adequate randomisation (N=26)&lt;br&gt;it was not only the medication with benzodiazepines that was randomised (N=15)&lt;br&gt;less than 50% of the participants had schizophrenia and/or schizophrenia-like psychoses (N=7)&lt;br&gt;no diagnoses were indicated (N=4)&lt;br&gt;no inclusion of a placebo or non-intervention group (N=3)&lt;br&gt;no information regarding the numbers of participants in each group (N=3)&lt;br&gt;case reports (N=3)&lt;br&gt;cross-over design without providing data separately for the first cross-over phase (N=2)&lt;br&gt;reviews (N=2)&lt;/p&gt;" WIDTH="556"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;4 studies are awaiting assessment&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>